Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors

ABSTRACT

Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington&#39;s Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/334,520, filed May 13, 2010, which is hereby incorporated by reference.

FIELD OF THE INVENTION

Provided herein are certain heteroaryloxyheterocyclyl compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

BACKGROUND

Neurotransmitters and hormones, as well as other types of extracellular signals such as light and odors, create intracellular signals by altering the amounts of cyclic nucleotide monophosphates (cAMP and cGMP) within cells. These intracellular messengers alter the functions of many intracellular proteins. Cyclic AMP regulates the activity of cAMP-dependent protein kinase (PKA). PKA phosphorylates and regulates the function of many types of proteins, including ion channels, enzymes, and transcription factors. Downstream mediators of cGMP signaling also include kinases and ion channels. In addition to actions mediated by kinases, cAMP and cGMP bind directly to some cell proteins and directly regulate their activities.

Cyclic nucleotides are produced from the actions of adenylyl cyclase and guanylyl cyclase, which convert ATP to cAMP and GTP to cGMP. Extracellular signals, often through the actions of G protein-coupled receptors, regulate the activities of the cyclases. Alternatively, the amount of cAMP and cGMP may be altered by regulating the activities of the enzymes that degrade cyclic nucleotides. Cell homeostasis is maintained by the rapid degradation of cyclic nucleotides after stimulus-induced increases. The enzymes that degrade cyclic nucleotides are called 3′,5′-cyclic nucleotide-specific phosphodiesterases (PDEs).

Eleven PDE gene families (PDE1-PDE11) have been identified based on their distinct amino acid sequences, catalytic and regulatory characteristics, and sensitivity to small molecule inhibitors. These families are coded for by 21 genes; and further multiple splice variants are transcribed from many of these genes. Expression patterns of each of the gene families are distinct. PDEs differ with respect to their affinity for cAMP and cGMP. Activities of different PDEs are regulated by different signals. For example, PDE1 is stimulated by Ca²⁺/calmodulin. PDE2 activity is stimulated by cGMP. PDE3 is inhibited by cGMP. PDE4 is cAMP specific and is specifically inhibited by rolipram. PDES is cGMP-specific. PDE6 is expressed in retina.

PDE10 sequences were identified by using bioinformatics and sequence information from other PDE gene families (Fujishige et al., J. Biol. Chem. 274:18438-18445, 1999; Loughney et al., Gene 234:109-117, 1999; Soderling et al., Proc. Natl. Acad. Sci. USA 96:7071-7076, 1999). The PDE10 gene family is distinguished based on its amino acid sequence, functional properties and tissue distribution. The human PDE10 gene is large, over 200 kilobases, with up to 24 exons coding for each of the splice variants. The amino acid sequence is characterized by two GAF domains (which bind cGMP), a catalytic region, and alternatively spliced N and C termini. Numerous splice variants are possible because at least three alternative exons encode N termini and two exons encode C-termini. PDE10A1 is a 779 amino acid protein that hydrolyzes both cAMP and cGMP. The K_(m) values for cAMP and cGMP are 0.05 and 3.0 micromolar, respectively. In addition to human variants, several variants with high homology have been isolated from both rat and mouse tissues and sequence banks.

PDE10 RNA transcripts were initially detected in human testis and brain. Subsequent immunohistochemical analysis revealed that the highest levels of PDE10 are expressed in the basal ganglia. Specifically, striatal neurons in the olfactory tubercle, caudate nucleus and nucleus accumbens are enriched in PDE10. Western blots did not reveal the expression of PDE10 in other brain tissues, although immunoprecipitation of the PDE10 complex was possible in hippocampal and cortical tissues. This suggests that the expression level of PDE10 in these other tissues is 100-fold less than in striatal neurons. Expression in hippocampus is limited to the cell bodies, whereas PDE10 is expressed in terminals, dendrites and axons of striatal neurons.

The tissue distribution of PDE10 indicates that PDE10 inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDE10 enzyme, for example, in neurons that comprise the basal ganglia and therefore would be useful in treating a variety of neuropsychiatric conditions involving the basal ganglia such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive compulsive disorder, and the like.

Noninvasive, nuclear imaging techniques can be used to obtain basic and diagnostic information about the physiology and biochemistry of a variety of living subjects including experimental animals, normal humans and patients. These techniques rely on the use of sophisticated imaging instrumentation that is capable of detecting radiation emitted from radiotracers administered to such living subjects. The information obtained can be reconstructed to provide planar and tomographic images that reveal distribution of the radiotracer as a function of time. Use of appropriately designed radiotracers can result in images which contain information on the structure, function and most importantly, the physiology and biochemistry of the subject. Much of this information cannot be obtained by other means. The radiotracers used in these studies are designed to have defined behaviors in vivo which permit the determination of specific information concerning the physiology or biochemistry of the subject or the effects that various diseases or drugs have on the physiology or biochemistry of the subject. Currently, radiotracers are available for obtaining useful information concerning such things as cardiac function, myocardial blood flow, lung perfusion, liver function, brain blood flow, regional brain glucose and oxygen metabolism.

Compounds of the invention can be labeled with either positron or gamma emitting radionuclides. For imaging, the most commonly used positron emitting (PET) radionuclides are ¹¹C, ¹⁸F, ¹⁵O, ¹³N, ⁷⁶Br, ⁷⁷Br, ¹²³I, or ¹²⁵I, wherein ¹¹C, ¹⁸F, ¹²³I, or ¹²⁵I are preferred, all of which are accelerator produced. In the two decades, one of the most active areas of nuclear medicine research has been the development of receptor imaging radiotracers. These tracers bind with high affinity and specificity to selective receptors and neuroreceptors. For example, Johnson and Johnson has synthesized and evaluated ¹⁸F-JNJ41510417 as a selective and high-affinity radioligand for in vivo brain imaging of PDE10A using PET (The Journal of Nuclear Medicine; Vol. 51; No. 10; October 2010).

SUMMARY OF THE INVENTION

The present invention comprises a new class of heteroaryloxyheterocyclyl compounds useful in the treatment of diseases, such as PDE10-mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of PDE10-mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.

The compounds of the invention are represented by the following general structure:

or a pharmaceutically acceptable salt thereof, wherein W, m, p, q, R², R^(4a), R^(4b), X¹, X², X³, X⁴, and X⁵ are defined below.

Other compounds of the invention are represented by the following general structure:

or a pharmaceutically acceptable salt thereof, wherein m, p, q, R¹, R², R^(4a), R^(4b), X¹, X², X³, and X⁴ are defined below.

Other compounds of the invention are represented by the following general structure:

or a pharmaceutically acceptable salt thereof, wherein m, p, q, Ring D, R², R^(4a), R^(4b), X¹, X², X³, and X⁴ are defined below.

Other compounds of the invention are represented by the following general structure:

or a pharmaceutically acceptable salt thereof, wherein m, p, q, R^(1a)R^(2a), R^(4a), R^(4b), X¹, X², X³, and X⁴ are defined below.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the current invention relates to compounds of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

X¹ is N or CR⁶;

X² is N or CR⁶;

X³ is N or CR³;

X⁴ is N or CR⁶;

X⁵ is N or CR⁶;

1 to 2 of X¹, X², X³, X⁴ and X⁵ are N;

the ring containing X¹, X², X³, X⁴, and X⁵ can be fused to ring A, ring B, or ring C; each having the formula:

wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms; and is substituted by 0, 1, or 2 R¹⁰ groups;

W is —O—; —NH—; or —NC₁₋₆alk; —CH₂—; —CH(CH₃)—; or C(CH₃)₂—;

m is 0, 1, 2, 3, or 4;

each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6;

the ring containing p and q contains 0 or 1 double bond;

R¹ is halo, C₁₋₈alk, C₁₋₄haloalk, —OR^(c), —N(R^(a))C(═O)R^(b), —C(═O)R^(a), —C(═O)R^(c), —C(═O)—R^(a), —NR^(a)R^(c), —N(R^(c))C(═O)R^(b), —N(R^(a))C(═O)R^(c), —C(═O)NR^(a)R^(b), —C(═O)NR^(a)R^(c), or C₀₋₄alk-L¹; wherein said C₁₋₈alk group is substituted by 0, 1, 2 or 3 groups which are halo, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk;

R² is —C(═O)R⁵ or -L²;

each of R³ and R⁶ is independently R¹, H, halo, CN, OH, OC₁₋₄alk, C₁₋₄alk, or C₁₋₄haloalk; wherein 1 or 2 of R³ and R⁶ must be R¹;

R^(4a) is H, C₁₋₄alk, or C₁₋₄haloalk;

each R^(4b) is independently F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk, or C₁₋₄haloalk;

R⁵ is H, C₁₋₈alk, or C₀₋₈alk-L³;

R^(a) is independently H or R^(b);

R^(b) is independently phenyl, benzyl, or C₁₋₆alk, wherein said phenyl, benzyl, and C₁₋₆alk are being substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk;

R^(c) is C₀₋₄alk-L⁴; and

each of L¹, L², L³, and L⁴ is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring; each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; each L¹, L², L³, and L⁴ is independently substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₁₋₆alkNR^(a)R^(a), —OC₁₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₁₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a), or oxo.

In one embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, W is —O—.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), or —C₁₋₆alkOR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), or —C₁₋₆alkOR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), or —C₁₋₆alkOR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is azepanyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, morpholinyl, piperidinyl, piperazinyl, dihydropyranyl dihydropyridyl, tetrahydropyranyl, benzothiazolinyl, quinolinyl, or quinazolinyl; each R¹ is independently substituted by 0, 1, or 2 R⁷ groups which are independently F, Cl, Br, methyl, methoxy, —CN, —C(═O)CH₃, —C(═O)OC(CH₃)₃, —C(═O)NH(CH₃), —C(═O)N(CH₃)₂, —NH₂, —CH₂OH, or —CH₂CH₂OH.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R³ is R¹ or H.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R³ is H.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the ring containing X¹, X², X³, X⁴, and X⁵ is pyrimidyl, pyrazinyl, piridazinyl, pyridinyl, quinoxalinyl, or quinolinyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the ring containing X¹, X², X³, X⁴, and X⁵ is

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof,

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of said Ring A, Ring B, and Ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic which are fused phenyl, cyclobutyl, cyclopentyl, or cyclohexyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R¹⁰ groups which are oxo, C₁₋₆alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of said Ring A, Ring B, and Ring C is a fused 5-membered-saturated, -partially saturated, or -unsaturated-heterocyclic ring which are fused furanyl, thiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, or isothiazolyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R¹⁰ groups which are oxo, C₁₋₆alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of said Ring A, Ring B, and Ring C is a fused 6-membered-saturated, -partially saturated, or -unsaturated-heterocyclic ring which are fused pyranyl, pyridinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, pyridazinyl, pyrazinyl, or piperazinyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R¹⁰ groups which are oxo, C₁₋₆alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of p and q is independently 1.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of p and q is independently 2.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the ring containing p and q contains 0 or 1 double bond.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the sum of p and q is 3; and the ring containing p and q contains 0 or 1 double bond.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, m is 0.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is —C(═O)—O—R^(b), —C(═O)NR^(a)R^(b), —OR²⁰, or —C(═O)NR^(a)R^(c).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(4a) is H or C₁₋₄alk; and m is 0.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R⁵ is C₁₋₈alk or C₀₋₈alk-L³.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each R⁶ is independently H.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(a) is H or C₁₋₆alk substituted by 0 or 1 —OH, —OC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(c) is a carbon-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom which is O or S, which is substituted by 0 or 1 R⁷ groups which are independently F, C₁₋₆alk, C₁₋₄haloalk, or —OR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(c) is a nitrogen-linked saturated, partially-saturated, or unsaturated 4-, 5-, 6- or 7-membered ring heterocycle containing 0, 1 or 2 nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle is substituted by 0, 1, 2 or 3 R⁷ groups which are independently oxo, F, Cl, Br, Cl, C₁₋₄alk, C₁₋₄haloalk, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof,

wherein each R² is substituted by 0, 1 or 2 R⁷ groups.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R² is —C(═O)R⁵ wherein R⁵ is: H, C₁₋₈alk, C₀₋₈alk-phenyl, C₀₋₈alk-benzimidazolyl, C₀₋₈alk-pyrimidinyl, C₀₋₈alk-pyridinyl, C₀₋₈alk-imidazolyl, C₀₋₈alk-benzthiazolyl, C₀₋₈alk-pyrrolyl, C₀₋₈alk-quinolinyl, C₀₋₈alk-quinazolinyl, C₀₋₈alk-pyrrolyl, or C₀₋₈alk-indolyl; wherein each R⁵ is substituted by 0, 1 or 2 R⁷ groups.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, W is —O—; R¹ is azepanyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, morpholinyl, piperidinyl, piperazinyl, dihydropyranyl dihydropyridyl, tetrahydropyranyl, benzothiazolinyl, quinolinyl, or quinazolinyl; each R¹ is independently substituted by 0, 1, or 2 R⁷ groups which are independently F, Cl, Br, methyl, methoxy, —CN, —C(═O)CH₃, —C(═O)OC(CH₃)₃, —C(═O)NH(CH₃), —C(═O)N(CH₃)₂, —NH₂, —CH₂OH, or —CH₂CH₂OH; R² is benzamidazolyl, quinolinyl, or quinazolinyl; each of p and q is independently 1 or 2; and R³ is R¹ or H.

Another aspect of the current invention relates to compounds of formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

each of X¹, X², and X³ is independently N or CR³; and X⁴ is N; wherein no more than one of X¹, X², and X³ are N; and wherein any adjacent X¹, X², and X³ may optionally form an optionally substituted-saturated, -partially saturated, or -unsaturated-heterocyclic or -heteroaryl ring fused to the ring containing X¹, X², X³, and X⁴;

m is 1, 2, 3, or 4;

each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6;

R¹ is C₂₋₈alk, C₁₋₄haloalk, —OR^(c), —N(R^(a))C(═O)R^(b), —C(═O)R^(a), —C(═O)R^(c), —C(═O)—O—R^(b), —NR^(a)R^(c), —N(R^(c))C(═O)R^(b), —N(R^(a))C(═O)R^(c), —C(═O)NR^(a)R^(b), —C(═O)NR^(a)R^(c), or C₀₋₄alk-L¹; wherein said C₂₋₈alk group is substituted by 0, 1, 2 or 3 groups selected from halo, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk;

R² is —C(═O)R⁵ or -L²;

R³ is H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk or C₁₋₄haloalk;

R^(4a) is H, C₁₋₄alk or C₁₋₄haloalk;

each R^(4b) is independently H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk, or C₁₋₄haloalk;

R⁵ is H, C₁₋₈alk, or C₀₋₈alk-L³;

R^(a) is independently H or R^(b);

R^(b) is independently phenyl, benzyl, or C₁₋₆alk, wherein said phenyl, benzyl, and C₁₋₆alk are being substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk;

R^(c) is C₀₋₄alk-L⁴; and

each of L¹, L², L³, and L⁴ is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; wherein each L¹, L², L³, and L⁴ is independently substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, X¹ is N or C, and each of X² and X³ is C.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, X¹ and X² form an optionally substituted 5- to 6-membered-saturated, -partially saturated, or -unsaturated-heterocyclic or -heteroaryl ring fused to the ring containing X¹, X², X³, and X⁴.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, X² and X³ form an optionally substituted 5- to 6-membered-saturated, -partially saturated, or -unsaturated-heterocyclic or -heteroaryl ring fused to the ring containing X¹, X², X³, and X⁴.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group:

wherein each of Y¹, Y², Y³, M¹, M², M³, and M⁴ is independently CR⁷ or a heteroatom selected from S, O, or NR⁸; wherein no more than one of Y¹, Y², Y³, M¹, M², M³, and M⁴ are N; wherein R⁷ is H, halo, C₁₋₄alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk; and R⁸ is H, C₁₋₄alk, or C₁₋₃haloalk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, m is 1.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, p is 0, 1, or 2.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, q is 0, 1, or 2.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is —C(═O)—O—R^(b), —C(═O)NR^(a)R^(b), —OR^(c), or —C(═O)NR^(a)R^(c).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —NR^(a)R^(a), —NR^(a)R^(c), or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —NR^(a)R^(a), —NR^(a)R^(c), or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —NR^(a)R^(c), R^(c) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is not methyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, pyrazolyl, morpholinyl, pyrimidyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, or quinolinyl, all of which are substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), CN, —C(═O)R^(b), —C(═O)OR^(a), —SR^(a), or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is C₂₋₆alk substituted by 0, 1, 2 or 3 groups selected from halo, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R¹ is:

wherein the dotted bond is an optional double bond.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R³ is independently H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk or C₁₋₄haloalk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R³ is H, C₁₋₄alk, or C₁₋₄haloalk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(4a) is H or C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of R^(4a) and R^(4b) is H.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R⁵ is C₁₋₈alk or C₀₋₈alk-L³.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R⁶ is H.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(a) is H or C₁₋₆alk substituted by 0 or 1-OH, —OC₁₋₄alk, —OC(═O)Cl_(—)4alk, or —N(C₁₋₄alk)C₁₋₄alk.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(c) is a carbon-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O or S, which is substituted by 0 or 1 R⁷ groups selected from F, C₁₋₆alk, C₁₋₄haloalk, or —OR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(c) is a nitrogen-linked saturated, partially-saturated, or unsaturated 4-, 5-, 6- or 7-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle being substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁, C₁₋₄alk, C₁₋₄haloalk, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —N(C₁₋₄alk)C₁₋₄alk, or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R^(c) is a C₀₋₄alk-saturated, partially-saturated or unsaturated 3-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0 or 1 R⁷ groups selected from F, C₁₋₆alk, C₁₋₄haloalk, or —OR^(a).

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R² is —C(═O)R⁵.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R² is —C(═O)R⁵ or -L²; wherein each of said R⁵ or -L² is independently:

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of said R⁵ or -L² is:

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, R² is —C(═O)R⁵ wherein R⁵ is: H, C₁₋₈alk, C₀₋₈alk-phenyl, C₀₋₈alk-benzimidazolyl, C₀₋₈alk-pyrimidinyl, C₀₋₈alk-pyridinyl, C₀₋₈alk-imidazolyl, C₀₋₈alk-benzthiazolyl, C₀₋₈alk-pyrrolyl, C₀₋₈alk-quinolinyl, C₀₋₈alk-pyrrolyl, or C₀₋₈alk-indolyl.

Another aspect of the current invention relates to compounds of formula (III):

or any pharmaceutically-acceptable salt thereof, wherein:

Ring D is -L¹;

each of X¹, X², and X³ is independently N or CR³; and X⁴ is N; wherein no more than one of X¹, X², and X³ are N; and wherein any adjacent X¹, X², and X³ may optionally form an optionally substituted-saturated, -partially saturated, or -unsaturated-heterocyclic or -heteroaryl ring fused to the ring containing X¹, X², X³, and X⁴;

m is 1, 2, 3, or 4;

each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6;

R² is —C(═O)R⁵ or -L²;

R³ is H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk or C₁₋₄haloalk;

R^(4a) is H, C₁₋₄alk, or C₁₋₄haloalk;

each R^(4b) is independently H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk, or C₁₋₄haloalk;

R⁵ is H, C₁₋₈alk, or C₀₋₈alk-L³;

R^(a) is independently H or R^(b);

R^(b) is independently phenyl, benzyl, or C₁₋₆alk, wherein said phenyl, benzyl, and C₁₋₆alk are being substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk; and

each of L¹, L², L³, and L⁴ is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; wherein each L¹, L², L³, and L⁴ is independently substituted by 0, 1, 2 or 3 R⁶ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is azetidinyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is pyrrolidinyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is piperidinyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, the group

is azepanyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is a carbon-linked saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; independently substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is a carbon-linked-saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; independently substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is a nitrogen-linked saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; independently substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is a nitrogen-linked-saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; independently substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, or cycloheptyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, pyrazolyl, morpholinyl, pyrimidyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, or tetrahydrothiopyranyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is oxaspiro[3.5]nonyl, azepanyl, oxepanyl, or quinolinyl.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, ring D is cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, pyrazolyl, morpholinyl, pyrimidyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, or quinolinyl, all of which are substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), CN, —C(═O)R^(b), —C(═O)OR^(a), —NR^(a)R^(a), —SR^(a), or oxo.

In another embodiment of compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, each of X₁, X₂, and X₃ is C; the group

is piperidinyl; and R² is —C(═O)R⁵; wherein R⁵ is phenyl or pyridinyl; wherein said R⁵ is being substituted by 0, 1, 2 or 3 R⁷ groups selected from F, Cl, Br, C₁, C₁₋₄alk, C₁₋₄haloalk, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk.

Another aspect of the current invention relates to compounds of formula (IV):

or a pharmaceutically-acceptable salt thereof, wherein:

each of X¹, X², and X³ is independently N or CR³; and X⁴ is N; wherein no more than one of X¹, X², and X³ are N; and wherein any adjacent X¹, X², and X³ may optionally form an optionally substituted-saturated, -partially saturated, or -unsaturated-heterocyclic or -heteroaryl ring fused to the ring containing X¹, X², X³, and X⁴;

m is 1, 2, 3, or 4;

each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6;

R^(1a) is F, Cl, Br, I, —OR^(a), or —C(═O)—O—R^(b);

R^(2a) is —C(═O)OR⁶;

R³ is H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk or C₁₋₄haloalk;

R^(4a) is H, C₁₋₄alk or C₁₋₄haloalk;

each R^(4b) is independently H, F, Cl, Br, CN, OH, OC₁₋₄alk, C₁₋₄alk, or C₁₋₄haloalk;

R⁵ is H, C₁₋₈alk, or C₀₋₈alk-L³;

R^(a) is independently H or R^(b);

R^(b) is independently phenyl, benzyl, or C₁₋₆alk, wherein said phenyl, benzyl, and C₁₋₆alk are being substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alk, C₁₋₃haloalk, —OH, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, —OC(═O)C₁₋₄alk, or —N(C₁₋₄alk)C₁₋₄alk; and

L³ is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O or S; wherein each L¹, L², L³, and L⁴ is independently substituted by 0, 1, 2 or 3 R² groups selected from F, Cl, Br, C₁₋₆alk, C₁₋₄haloalk, —OR^(a), —OC₁₋₄haloalk, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkNR^(a)R^(a), —OC₂₋₆alkOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkNR^(a)R^(a), —NR^(a)C₂₋₆alkOR^(a), —C₁₋₆alkNR^(a)R^(a), —C₁₋₆alkOR^(a), —C₁₋₆alkN(R^(a))C(═O)R^(b), —C₁₋₆alkOC(═O)R^(b), —C₁₋₆alkC(═O)NR^(a)R^(a), —C₁₋₆alkC(═O)OR^(a) or oxo; provided that the compound is not

In another embodiment of the compound of formula (III), R² is —C(═O)OR⁵ wherein R⁵ is H, C₁₋₈alk, C₀₋₈alk-phenyl, C₀₋₈alk-benzimidazolyl, C₀₋₈alk-pyrimidinyl, C₀₋₈alk-pyridinyl, C₀₋₈alk-imidazolyl, C₀₋₈alk-benzthiazolyl, C₀₋₈alk-pyrrolyl, C₀₋₈alk-quinolinyl, C₀₋₈alk-pyrrolyl, or C₀₋₈alk-indolyl.

Another aspect of the invention relates to a method of treating conditions that may be treated with PDE10 inhibitors comprising the step of administering to a patient in need thereof a therapeutically effective amount of any one of the above compounds, or a pharmaceutically acceptable salt thereof.

In one embodiment of the method, said conditions is psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, or compulsions with pallidal disease.

In another embodiment of the method, said condition is schizophrenia, Huntington's disease, bipolar disorder, or obsessive-compulsive disorder.

In another embodiment of the method, said condition is schizophrenia.

Another aspect of the invention relates to a pharmaceutical composition comprising any one of the above compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable excipient.

Another aspect of the invention relates to the use of any one of the above compounds, or a pharmaceutically acceptable salt thereof, as a medicament.

Another aspect of the invention relates to the use of any one of the above compounds, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of schizophrenia, bipolar disorder, or obsessive-compulsive disorder.

Another aspect of the invention relates to a compound, or a pharmaceutically acceptable salt thereof, which is listed below:

-   1H-Benzo[d]imidazol-2-yl)(4-(3-(pyridine-4-yl)pyrazin-2-yloxy)piperidin-1-yl)methanone; -   1-(4-(3-(1-(1H-Benzo[d]imidazol-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(3-(2-(1-picolinoylazetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R) and     (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-(pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)methanone; -   (R) and     (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (1H-benzo[d]imidazol-2-yl)(3-((3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)methanone; -   benzyl 3-((3-chloropyrazin-2-yl)oxy)azetidine-1-carboxylate; -   tert-butyl     3-((3-((1r,4r)-4-hydroxycyclohexyl)pyridin-2-yl)oxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   benzyl     3-((3-(1-acetyl-4-hydroxypiperidin-4-yl)pyrazin-2-yl)oxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-((3-morpholinopyrazin-2-yl)oxy)azetidin-1-yl)methanone; -   tert-butyl     3-(3-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate; -   tert-butyl     5-(3-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyrazin-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperazin-1-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-((3-((1r,4r)-4-hydroxycyclohexyl)pyridin-2-yl)oxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-((3-((1s,4s)-4-hydroxycyclohexyl)pyridin-2-yl)oxy)azetidin-1-yl)methanone; -   benzyl     3-((3-(3,6-dihydro-2H-pyran-4-yl)quinoxalin-2-yl)oxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(2-methylpyridin-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   1-(4-(3-(1-(1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   benzyl 3-((3-(pyridin-4-yl)pyrazin-2-yl)oxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-(tert-butyldimethylsilyloxy)cyclohex-1-enyl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (S)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one     OR(R)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (S)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one     OR(R)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (1H-benzo[d]imidazol-2-yl)(3-((3-(tetrahydro-2H-pyran-4-yl)quinoxalin-2-yl)oxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(pyridin-3-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   1-(3-(2-((1-(1H-indole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R) and     (S)-1-(3-(2-(1-(6-methylnicotinoyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   benzyl 3-(3′-methoxy-3,4′-bipyridin-2-yloxy)azetidine-1-carboxylate; -   1-(3-(3-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   tert-butyl     3-(3-(1-acetylpiperidin-4-yl)pyridin-2-yloxy)azetidine-1-carboxylate; -   tert-butyl     3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidine-1-carboxylate; -   (R) and     (S)-1-(3-(3-(1-acetylpiperidin-3-yl)pyridin-2-yloxy)azetidin-1-yl)-3,3-dimethylbutan-1-one; -   1-(3-(2-((1-(4-methyl-1H-pyrrole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(4-methyl-1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-((3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)oxy)azetidin-1-yl)methanone; -   1-(4-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)-4-methoxypiperidin-1-yl)ethanone; -   1-(4-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)-3-methoxypiperidin-1-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-((3-(4-hydroxypiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)methanone; -   4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)cyclohexanone; -   tert-butyl     3-(3-(4-hydroxycyclohex-1-enyl)pyridin-2-yloxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxycyclohex-1-enyl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   1-(4-(3-(1-(5-methylpicolinoyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(benzo[d]thiazol-2-yl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   Benzyl     3-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)pyrazin-2-yloxy)azetidine-1-carboxylate; -   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (S)-1-(3-(2-((1-(1H-indole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone     OR(R)-1-(3-(2-((1-(1H-indole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-((1-(1H-indole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone     OR(R)-1-(3-(2-((1-(1H-indole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-(1-(benzo[d]thiazol-2-yl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(2-(1-(quinolin-2-yl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   (S)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone     OR(R)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone     OR(R)-1-(3-(2-((1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (3-((3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)oxy)azetidin-1-yl)(pyrimidin-4-yl)methanone; -   (3-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   1-(4-(3-(1-(1H-benzo[d]imidazol-2-yl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   pyridin-2-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (5-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (6-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   (1H-imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (4-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   benzo[d]thiazol-2-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)pyrrolidin-1-yl)methanone; -   (1H-pyrrol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   isoquinolin-3-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   2-(1-(4-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(5-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(6-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   2-(1-(pyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(pyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   3-methyl-2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)pyridine; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)quinoline; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   2-(1-(3-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(1-(4-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(1-(6-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)quinoline; -   1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)isoquinoline; -   2-(3-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)isoquinoline; -   1-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)isoquinoline; -   (R)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (S)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   3-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)isoquinoline; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)-1H-indole; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (R)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (S)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)isoquinoline; -   3-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)isoquinoline; -   (S)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (R)-2-(3-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)pyrrolidin-1-yl)quinoline; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   (4-chloropyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (5-chloropyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; -   2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)-1H-benzo[d]imidazole; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)-1H-benzo[d]imidazole; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   (S)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)quinoline; -   (R)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   1-(4-(2-(1-(quinolin-2-yl)piperidin-4-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   2-(4-(3-(piperidin-4-yl)pyridin-2-yloxy)piperidin-1-yl)quinoline; -   2-methoxy-1-(4-(3-(1-(quinolin-2-yl)piperidin-4-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(6-chloropyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-2-(3-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   2-(4-((3-(2-methoxypyridin-3-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   1-(4-(2-((1-(pyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(6-methylpyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(6-chloropyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(4-chloropyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   2-(4-((3-(pyridin-3-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   2-(4-((3-(pyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   1-(4-(3-((1-(pyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(4-methylpyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(3-methylpyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(5-chloropyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(2-((1-(3-chloropyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-ol; -   2-(4-((3-(4-methoxypiperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   1-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperazin-2-one; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-3-yl)methanol; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   2-(1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-4-piperidinyl)ethanol; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-4-carbonitrile; -   ((2S)-1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-2-pyrrolidinyl)methanol; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; -   2-(4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-1-piperazinyl)ethanol; -   2-(3-((3-(4-(1-pyrrolidinyl)-1-piperidinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   N,N-dimethyl-1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-4-piperidinamine; -   2-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholine; -   (4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholin-2-yl)methanol; -   2-(3-((3-(4-(trifluoromethyl)piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-3-azetidinol; -   isoquinolin-1-yl(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)methanone; -   quinolin-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)methanone; -   1-(4-(3-((1-(4-methylpyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(5-chloropyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(4-chloropyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(3-chloropyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; -   (R)-1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; -   2-{4-[3-(2-Methyl-pyridin-4-yl)-pyrazin-2-yloxy]-piperidin-1-yl}-quinoline; -   2-(3-((3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(5-benzyl-1-benzofuran-2-yl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   6-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-2-quinazolinamine; -   2-(3-((3-(6-methoxy-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(1,3-benzothiazol-5-yl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(6-chloro-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(3-bromophenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   (3-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)phenyl)methanol; -   (4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)phenyl)methanol; -   2-(3-((3-(5-quinolinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(5-phenyl-2-thiophenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(3-quinolinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   methyl     4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)benzoate; -   2-(3-((3-(3-fluoro-5-(1-methylethoxy)phenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(5-pyrimidinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(2-methyl-4-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(6-(cyclopropylmethoxy)-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-((3-(6-methyl-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; -   2-(3-(3-((3-methyloxetan-3-yl)ethynyl)pyrazin-2-yloxy)azetidin-1-yl)quinoline; -   4-(2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)morpholine; -   2-((1-(5-nitropyridin-2-yl)piperidin-4-yl)oxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)pyridin-3-amine; -   2-((1-(5-chloropyridin-2-yl)piperidin-4-yl)oxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-((1-(5-bromopyridin-2-yl)piperidin-4-yl)oxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   4-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)morpholine; -   2-(4-((3-(azetidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   (6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)pyridin-3-yl)methanol; -   2-((1-(5-fluoropyridin-2-yl)piperidin-4-yl)oxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)nicotinonitrile; -   3-(tetrahydro-2H-pyran-4-yl)-2-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)oxy)pyridine; -   1-(6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)pyridin-3-yl)ethanone; -   4-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   quinolin-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)methanone; -   1-(4-(3-((1-(6-methylpyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(3-methylpyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperazin-1-yl)ethanone; -   2-(4-((3-(piperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   2-(4-((3-(pyrrolidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   2-(4-((3-(3-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   6-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   isoquinolin-1-yl(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)methanone; -   1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)azetidin-3-ol; -   2-(4-((3-(3-chloropyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   6-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)-2-oxa-6-azaspiro[3.3]heptane; -   6-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)quinoline; -   4-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)quinoline; -   1-(4-(3-((1-(5-methylpyridin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   (1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperazin-1-yl)ethanone; -   7-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)quinoline; -   methyl     6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)nicotinate; -   1-(4-(2-((1-(5-methylpyridin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-ol; -   2-(3-((3-(piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholine; -   8-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)quinoline; -   7-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   8-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   (4-((3-morpholinopyrazin-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; -   (4-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; -   isoquinolin-1-yl(4-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)methanone; -   1-(6-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl)ethanone; -   1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-one; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-one; -   1-(4-(5-fluoro-2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (4-((3-morpholinopyridin-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; -   isoquinolin-1-yl(4-((3-morpholinopyridin-2-yl)oxy)piperidin-1-yl)methanone; -   isoquinolin-1-yl(4-((3-morpholinopyrazin-2-yl)oxy)piperidin-1-yl)methanone; -   (4-((2′-methyl-[3,4′-bipyridin]-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; -   isoquinolin-1-yl(4-((2′-methyl-[3,4′-bipyridin]-2-yl)oxy)piperidin-1-yl)methanone; -   2-(3-((3-(p-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-yl)propan-2-ol; -   2-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)propan-2-ol; -   6-(4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidin-1-yl)nicotinaldehyde; -   2-((1-(5-chloropyridin-2-yl)piperidin-4-yl)oxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(3-((3-(4-(methoxymethyl)piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(2-methoxypyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(o-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(2-methoxyphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(4-((3-(4-(methoxymethyl)piperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   2-(3-((3-(pyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(4-fluoro-2-methylphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-phenylpyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(3-chloropyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; -   2-(3-((3-(m-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; -   2-(3-((3-(3-methylpyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(pyridin-2-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(2-fluoropyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; -   N,N-dimethyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; -   1-(4-(2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidine-4-carbonitrile; -   2-(3-((3-(4,4-difluoropiperidin-1-yl)pyridin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(5-fluoro-2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidine-4-carbonitrile; -   2-(3-((3-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(4-methylpiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(5,6-dihydropyridin-1(2H)-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(4-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)piperidin-1-yl)ethanone; -   7-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-2-oxa-7-azaspiro[3.5]nonane; -   2-methoxy-1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   2-(3-((3-(2-azabicyclo[2.2.1]heptan-2-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(3,3-difluoropyrrolidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(azetidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(azepan-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(pyrrolidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   (R)-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-2-yl)methanol; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-1-yl)ethanone; -   (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   2-(3-((3-(3,3-difluoropiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanone; -   (S)-(1-(3-((1-(quinolin-2-yl)pyrrolidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidin-4-yl)methanol; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)methanol; -   (1-(6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)methanol; -   (R)-(1-(3-((1-(quinolin-2-yl)pyrrolidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanone; -   N,N-dimethyl-3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; -   2-(3-((3-(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   3-(3-((3-bromopyridin-2-yl)oxy)azetidin-1-yl)pyridazine; -   methyl     4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate; -   4-(3-((3-bromopyridin-2-yl)oxy)azetidin-1-yl)pyrimidine; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidin-1-yl)ethanone; -   1-(3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanol; -   4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-1,4-oxazepane; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-3-yl)methanol; -   2-(3-((3-(3-(methoxymethyl)phenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   N-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; -   (S)-(1-(3-((1-(quinolin-2-yl)piperidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   (R)-(1-(3-((1-(quinolin-2-yl)piperidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   2-(3-((3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-1,4-diazepan-1-yl)ethanone; -   1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanol; -   (S)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline     OR(R)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   (S)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline     OR(R)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   2-(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline; -   1-(4-(5-methyl-2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)azepan-4-ol; -   (R)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)pyrrolidin-1-yl)quinoline; -   (S)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)pyrrolidin-1-yl)quinoline; -   4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)but-3-yn-2-ol; -   2-(3-((3-(3-methoxyprop-1-yn-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)prop-2-yn-1-ol; -   (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-3-yl)methanol; -   (1-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(5-(piperidin-1-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(5-methyl-2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-4-yl)methanol; -   (1-(6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   (1-(5-(3-methoxyphenyl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)amino)pyrazin-2-yl)piperidin-4-yl)methanol; -   (1-(3-((1-(quinoxalin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   5-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)picolinonitrile; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-4-carboxamide; -   (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-2-yl)methanol; -   (1-(5-bromo-4-((1-(quinoxalin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)ethanol; -   (1-(3-((1-(quinazolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; -   (1-(5-bromo-6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-2-yl)piperidin-4-yl)methanol; -   methyl     1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidine-4-carboxylate; -   (1-(5-fluoro-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(5-fluoro-2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-4-yl)methanol; -   1-(1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)ethanol; -   (1-(5-bromo-4-((1-(quinazolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)ethanol; -   1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-ol; -   (1-(5-chloro-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   2-(3-((5-bromo-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline; -   (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)pyrrolidin-3-yl)methanol; -   (1-(5-(2-methoxypyridin-3-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   2,3-bis((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxaline; -   (1-(2-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidin-4-yl)methanol; -   (1-(5-(2-methylpyridin-4-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(5-(6-methylpyridin-3-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   tert-butyl     4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidine-1-carboxylate; -   benzyl     4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidine-1-carboxylate; -   (1-(5-(3,6-dihydro-2H-pyran-4-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   (1-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidin-4-yl)methanol; -   (1-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)-5-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-yl)piperidin-4-yl)methanol; -   2-(3-((3-(4-methylpiperazin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   tert-butyl     4-(2-(4-(hydroxymethyl)piperidin-1-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate; -   2-(3-((3-(6-fluoropyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((2-(pyridin-3-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((2-(pyridin-4-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline; -   4-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)aniline; -   2-(3-((3-(2-methylpyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(3-methoxyphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(4-methylpyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; -   2-(3-((3-(2-methoxypyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinazoline; -   2-(3-methoxyphenyl)-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxaline; -   2-(3-((3-(3-methoxyphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinazoline; -   2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)-3-(m-tolyl)quinoxaline; -   (1-(5-(2-methoxypyridin-3-yl)-4-((1-(quinazolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol; -   1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidine-4-carbonitrile; -   1-(4-(2-(4-(hydroxymethyl)piperidin-1-yl)-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)piperidin-1-yl)ethanone; -   2-(3-((2-(pyridin-2-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline; -   (4-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)phenyl)methanol;     or -   2-(2-methoxypyridin-3-yl)-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxaline.

Another aspect of the invention relates to a compound, or a pharmaceutically acceptable salt thereof, which is listed below:

-   (3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)(pyrimidin-4-yl)methanone; -   2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)quinoline; -   (1H-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (1H-imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (1H-pyrrol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   pyridin-2-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (6-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (5-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (4-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (3-methylpyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   benzo[d]thiazol-2-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   isoquinolin-3-yl(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)isoquinoline; -   1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)isoquinoline; -   2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)-1H-benzo[d]imidazole; -   2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)quinoline; -   2-(1-(pyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(1-(3-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(1-(4-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   2-(1-(pyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(6-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine; -   3-methyl-2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)pyridine; -   2-(1-(4-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(5-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   2-(1-(6-methylpyridin-2-yl)piperidin-4-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine; -   1-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)isoquinoline; -   3-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)isoquinoline; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)quinoline; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)-1H-indole; -   1-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)isoquinoline; -   3-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)isoquinoline; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)quinoline; -   2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)-1H-benzo[d]imidazole; -   (5-chloropyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (4-chloropyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)piperidin-1-yl)methanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)methanone; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (S)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (S)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (R)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (R)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (S)-3-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (S)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; -   (R)-1-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)isoquinoline; -   (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)-1H-benzo[d]imidazole; -   1-(4-(2-(1-(benzo[d]thiazol-2-yl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(2-(1-(quinolin-2-yl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   tert-butyl     3-(3-(1-acetylpiperidin-4-yl)pyridin-2-yloxy)azetidine-1-carboxylate; -   tert-butyl     3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidine-1-carboxylate; -   1-(4-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxypiperidin-1-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(pyridin-3-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   1-(4-(3-(1-(1H-benzo[d]imidazol-2-yl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(5-methylpicolinoyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(benzo[d]thiazol-2-yl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (R)-1-(3-(2-(1-(6-methylnicotinoyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-(1-(6-methylnicotinoyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R)-1-(3-(3-(1-acetylpiperidin-3-yl)pyridin-2-yloxy)azetidin-1-yl)-3,3-dimethylbutan-1-one; -   (S)-1-(3-(3-(1-acetylpiperidin-3-yl)pyridin-2-yloxy)azetidin-1-yl)-3,3-dimethylbutan-1-one; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   1-(4-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)cyclohexanone; -   tert-butyl     3-(3-((trans)-4-hydroxycyclohexyl)pyridin-2-yloxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-((trans)-4-hydroxycyclohexyl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-((cis)-4-hydroxycyclohexyl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   tert-butyl     3-(3-(4-hydroxycyclohex-1-enyl)pyridin-2-yloxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxycyclohex-1-enyl)pyridin-2-yloxy)azetidin-1-yl)methanone; -   (R)-1-(3-(2-(1-(4-methyl-1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-(1-(4-methyl-1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(4-methyl-1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (R)-1-(3-(2-(1-(1H-indole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-(1-(1H-indole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   benzyl 3-(3-chloropyrazin-2-yloxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-chloropyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-morpholinopyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(2-methylpyridin-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxycyclohex-1-enyl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   benzyl 3-(3-(pyridin-4-yl)pyrazin-2-yloxy)azetidine-1-carboxylate; -   (1H-benzo[d]imidazol-2-yl)(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidin-1-yl)methanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)piperazin-1-yl)ethanone; -   benzyl 3-(3′-methoxy-3,4′-bipyridin-2-yloxy)azetidine-1-carboxylate; -   Benzyl     3-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)pyrazin-2-yloxy)azetidine-1-carboxylate; -   (1H-Benzo[d]imidazol-2-yl)(4-(3-(pyridine-4-yl)pyrazin-2-yloxy)piperidin-1-yl)methanone; -   2-(4-(3-(piperidin-4-yl)pyridin-2-yloxy)piperidin-1-yl)quinoline; -   1-(4-(2-(1-(quinolin-2-yl)piperidin-4-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   2-methoxy-1-(4-(3-(1-(quinolin-2-yl)piperidin-4-yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; -   1-(4-(3-(1-(1H-Benzo[d]imidazol-2-carbonyl)piperidin-4-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   1-(3-(2-(1-picolinoylazetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   1-(4-(3-(1-(1H-pyrrole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; -   (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (R)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)-2-methylpropan-1-one; -   (S)-1-(3-(2-(1-(1H-indole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (R)-1-(3-(2-(1-(1H-indole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone; -   (S)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone;     or -   (R)-1-(3-(2-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyridin-3-yl)piperidin-1-yl)ethanone.

The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.

The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of the present invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.

Examples of isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as ²H and ³H, carbon, such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁸Cl, fluorine, such as ¹⁸F, iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen, such as ¹⁵O, ¹⁷O and ¹⁸O, phosphorus, such as ³²P, and sulphur, such as ³⁵S.

Certain isotopically-labelled compounds of the present invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

Substitution with heavier isotopes such as deuterium, i.e. ²H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and ¹³N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D₂O, d₆-acetone, d_(o)-DMSO.

Specific embodiments of the present invention include the compounds exemplified in the Examples below and their pharmaceutically acceptable salts, complexes, solvates, polymorphs, stereoisomers, metabolites, prodrugs, and other derivatives thereof, Unless otherwise specified, the following definitions apply to terms found in the specification and

The term “C_(α-β)alk” means an alkyl group comprising a minimum of α and a maximum of β carbon atoms in a branched, cyclical or linear relationship or any combination of the three, wherein α and β represent integers. The alkyl groups described in this section may also contain one or two double or triple bonds. A designation of C₀alk indicates a direct bond. Examples of C₁₋₆alkyl include, but are not limited to the following:

The term “benzo group”, alone or in combination, means the divalent radical C₄H₄═, one representation of which is —CH═CH—CH═CH—, that when vicinally attached to another ring forms a benzene-like ring—for example tetrahydronaphthylene, indole and the like.

The terms “oxo” and “thioxo” represent the groups ═O (as in carbonyl) and ═S (as in thiocarbonyl), respectively.

The term “halo” or “halogen” means a halogen atoms selected from F, Cl, Br or I.

The term “C_(α-β)haloalk” means an alk group, as described above, wherein one or more hydrogen atom of the alk group is replaced by F, Cl, Br or I.

The term “carbon-linked” means a substituent is linked to another group through a carbon atom. Examples of “carbon-linked” substituents include, but are not limited to the following:

The term “nitrogen-linked” means a substituent is linked to another group through a nitrogen atom. Examples of “nitrogen-linked” substituents include, but are not limited to the following:

The group N(R^(a))R^(a) and the like include substituents where the two R^(a) groups together form a ring, optionally including a N, O or S atom, and include groups such as:

The group N(C_(α-β)alk) C_(α-β)alk, wherein α and β are as defined above, include substituents where the two C_(α-β)alk groups together form a ring, optionally including a N, O or S atom, and include groups such as:

The term “carbocyclyl” means a ring comprising by itself or in combination with other terms, represents, unless otherwise stated, cyclic version of “C_(α-β)alk”. Thus, the term “carbocyclyl” is meant to be included in the terms “C_(α-β)alk”. Examples of carbocycle include cyclopentyl, cyclohexyl, or partially unsaturated ring such as 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, cyclobutylene, cyclohexylene and the like. Unless otherwise stated, carbocycle can include fully saturated ring such as phenyl or naphthyl.

The term “heteroatom” means N, O and S.

The term “heterocyclyl” means a ring comprising at least one carbon atom and at least one other atom selected from N, O or S. “Heterocyclyl” includes aromatic heterocyclic ring which is commonly known as heteroaryl. Thus, the term “heteroaryl” is meant to be included in the terms “heterocyclyl”. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:

The term “pharmaceutically acceptable salt” means a salt prepared by conventional means, and are well known by those skilled in the art. The “pharmacologically acceptable salts” include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of “pharmacologically acceptable salts,” and Berge et al., J. Pharm. Sci. 66:1 (1977).

The term “saturated, partially-saturated or unsaturated” includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens.

Representative examples of “saturated, partially-saturated or unsaturated” five to eight membered rings, optionally having one to three heteroatoms, are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and phenyl. Further exemplary five membered rings are furyl, thienyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, 2H-imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2-dithiolyl, 1,3-dithiolyl, 3H-1,2-oxathiolyl, 1,2,3-oxadizaolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4oxadiazolyl, 1,2,3-triazolyl, 1,2,4-trizaolyl, 1,3,4-thiadiazolyl, 3H-1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, 1,3,4-dioxazolyl, 5H-1,2,5-oxathiazolyl, and 1,3-oxathiolyl.

Further exemplary six membered rings are 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1,2-dioxinyl, 1,3-dioxinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyndazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-trithianyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 6H-1,3-oxazinyl, 6H-1,2-oxazinyl, 1,4-oxazinyl, 2H-1,2-oxazinyl, 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, 1,4-oxazinyl, o-isoxazinyl, p-isoxazinyl, 1,2,5-oxathiazinyl, 1,2,6-(3 oxathiazinyl, and 1,4,2-oxadiazinyl.

Further exemplary seven membered rings are azepinyl, oxepinyl, thiepinyl and 1,2,4-triazepinyl.

Further exemplary eight membered rings are cyclooctyl, cyclooctenyl and cyclooctadienyl.

The term “monocyclic” means a group having a single saturated, partially-saturated, or unsaturated ring system. Typically a monocyclic ring system can have from 3- to 8 atoms in the ring system. The term includes, but is not limited to, cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, and the like.

The term “bicyclic” means a group having two interconnected saturated, partially-saturated, or unsaturated rings that include stable bridged, fused, or spiro rings. The bicyclic ring may be attached at any carbon or heteroatom which affords a stable group. Typically a bicyclic ring system can have from 6- to 14 atoms in the ring system. The term includes, but is not limited to, benzimidazole, naphthyl, bicyclo[3.1.0]hexane, bicyclo[4.1.0]heptane, spiro[2.4]heptane, spiro[2.5]octane, bicyclo[4.4.0]decane, bicyclo[4.3.0]nonane, bicyclo[3.3.1]nonane, bicyclo[3.2.1]octane, spiro[4.5]decane, spiro[3.5]nonane, norbornane, bicyclo[2.1.0]pentane, bicyclo[3.3.0]octane, bicyclo[2.2.2]octane, bicyclo[3.3.3]undecane, and the like.

The term “tricyclic” means a group having three interconnected saturated, partially-saturated, or unsaturated rings that include stable bridged, fused, or spirorings. Typically a tricyclic ring system can have from 11 to 18 ring atoms in the ring system. The term includes, but is not limited to, adamantyl, tricyclo[5.2.1.0.sup.2,6]decane, and the like.

Exemplary bicyclic rings consisting of two fused partially saturated, fully saturated or fully unsaturated five and/or six membered rings, optionally having one to four heteroatoms, are indolizinyl, indolyl, isoindolyl, indolinyl, cyclopenta(b)pyridinyl, pyrano(3,4-b)pyrrolyl, benzofuryl, isobenzofuryl, benzo[b]thienyl, benzo[c]thienyl, 1H-indazolyl, indoxazinyl, benzoxazolyl, anthranilyl, benzimidazolyl, benzthiazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, indenyl, isoindenyl, naphthyl, tetralinyl, decalinyl, 2H-1-benzopyranyl, pyrido(3,4-b)pyridinyl, pyrido(3,2-b)pyridinyl, pyrido(4,3-b)-pyridinyl, 2H-1,3-benzoxazinyl, 2H-1,4-benzoxazinyl, 1H-2,3-benzoxazinyl, 4H-3,1-benzoxazinyl, 2H-1,2-benzoxazinyl and 4H-1,4-benzoxazinyl.

A cyclic ring group may be bonded to another group in more than one way. If no particular bonding arrangement is specified, then all possible arrangements are intended. For example, the term “pyridyl” includes 2-, 3-, or 4-pyridyl, and the term “thienyl” includes 2-, or 3-thienyl.

The term “substituted” means that a hydrogen atom on a molecule or group is replaced with a group or atom. Typical substitutents include: halogen, C₁₋₈alkyl, hydroxyl, C₁₋₈alkoxy, —NR^(x)R^(x), nitro, cyano, halo or perhaloC₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, —SR^(x), —S(═O)₂R^(x), —C(═O)OR^(x), —C(═O)R^(x), wherein each R^(x) is independently hydrogen or C₁-C₈ alkyl. It is noted that when the substituent is —NR^(x)R^(x), the R^(x) groups may be joined together with the nitrogen atom to form a ring.

A group or atom that replaces a hydrogen atom is also called a substituent.

Any particular molecule or group can have one or more substituent depending on the number of hydrogen atoms that can be replaced.

The symbol “—” represents a covalent bond and can also be used in a radical group to indicate the point of attachment to another group. In chemical structures, the symbol is commonly used to represent a methyl group in a molecule.

The term “leaving group” generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.

The term “protecting group” generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.

The term “silyl protecting groups” means silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-trisilyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

It should be noted that compounds of the invention may contain groups that may exist in tautomeric forms, such as cyclic and acyclic amidine and guanidine groups, heteroatom substituted aromatic heterocyclyl groups (Y′═O, S, NR), and the like, which are illustrated in the following examples:

and though one form is named, described, displayed and/or claimed herein, all the tautomeric forms are intended to be inherently included in such name, description, display and/or claim.

Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

The term “therapeutically effective amount” means an amount of a compound that ameliorates, attenuates or eliminates one or more symptom of a particular disease or condition, or prevents or delays the onset of one of more symptom of a particular disease or condition.

The term “patient” means animals, such as dogs, cats, cows, horses, sheep and humans. Particular patients are mammals. The term patient includes males and females.

The term “pharmaceutically acceptable” means that the referenced substance, such as a compound of Formula I, or a salt of a compound of Formula I, or a formulation containing a compound of Formula I, or a particular excipient, are suitable for administration to a patient.

The terms “treating”, “treat” or “treatment” and the like include preventative (e.g., prophylactic) and palliative treatment.

The term “excipient” means any pharmaceutically acceptable additive, carrier, diluent, adjuvant, or other ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration to a patient.

UTILITY AND METHODS OF USE

Provided herein are methods for treating a disorder or disease by inhibiting PDE10 enzyme. The methods, in general, comprises the step of administering a therapeutically effective amount of a compounds of the present invention, or an individual stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof to treat the disorder or disease.

In certain embodiments, this invention provides a use of a compound as described herein in the manufacture of a medicament for treating a disorder or disease treatable by inhibition of PDE10.

The compounds of the present invention inhibit PDE10 enzyme activity, and hence raise the levels of cAMP or cGMP within cells that express PDE10. Accordingly, inhibition of PDE10 enzyme activity would be useful in the treatment of diseases caused by deficient amounts of cAMP or cGMP in cells. PDE10 inhibitors would also be of benefit in cases wherein raising the amount of cAMP or cGMP above normal levels results in a therapeutic effect. Inhibitors of PDE10 may be used to treat disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, gastro-enterological diseases, endocrinological diseases and urological diseases.

Indications that may be treated with PDE10 inhibitors, either alone or in combination with other drugs, include, but are not limited to, those diseases thought to be mediated in part by the basal ganglia, prefrontal cortex, and hippocampus. These indications include psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.

Psychoses are disorders that affect an individual's perception of reality. Psychoses are characterized by delusions and hallucinations. The compounds of the present invention are suitable for use in treating patients suffering from all forms of psychoses, including, but not limited to, schizophrenia, late-onset schizophrenia, schizoaffective disorders, prodromal schizophrenia, and bipolar disorders. Treatment can be for the positive symptoms of schizophrenia as well as for the cognitive deficits and negative symptoms. Other indications for PDE10 inhibitors include psychoses resulting from drug abuse (including amphetamines and PCP), encephalitis, alcoholism, epilepsy, Lupus, sarcoidosis, brain tumors, multiple sclerosis, dementia with Lewy bodies, or hypoglycemia. Other psychiatric disorders, like posttraumatic stress disorder (PTSD), and schizoid personality can also be treated with PDE10 inhibitors.

Obsessive-compulsive disorder (OCD) has been linked to deficits in the frontal-striatal neuronal pathways (Saxena et al., Br. J. Psychiatry Suppl, 35:26-37, 1998). Neurons in these pathways project to striatal neurons that express PDE10. PDE10 inhibitors cause cAMP to be elevated in these neurons; elevations in cAMP result in an increase in CREB phosphorylation and thereby improve the functional state of these neurons. The compounds of the present invention are therefore suitable for use in the indication of OCD. OCD may result, in some cases, from streptococcal infections that cause autoimmune reactions in the basal ganglia (Giedd et al., Am J Psychiatry. 157:281-283, 2000). Because PDE10 inhibitors may serve a neuroprotective role, administration of PDE10 inhibitors may prevent the damage to the basal ganglia after repeated streptococcal infections and thereby prevent the development of OCD.

In the brain, the level of cAMP or cGMP within neurons is believed to be related to the quality of memory, especially long term memory. Without wishing to be bound to any particular mechanism, it is proposed that, since PDE10 degrades cAMP or cGMP, the level of this enzyme affects memory in animals, for example, in humans. A compound that inhibits cAMP phosphodiesterase (PDE) can thereby increase intracellular levels of cAMP, which in turn activate a protein kinase that phosphorylates a transcription factor (cAMP response binding protein). The phosphorylated transcription factor then binds to a DNA promoter sequence to activate genes that are important in long term memory. The more active such genes are, the better is long-term memory. Thus, by inhibiting a phosphodiesterase, long term memory can be enhanced.

Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. The compounds of the present invention are suitable for use in treating patients suffering from memory impairment in all forms of dementia. Dementias are classified according to their cause and include: neurodegenerative dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular (e.g., infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld-Jacob Disease, multiple sclerosis, traumatic (e.g., subdural hematoma or traumatic brain injury), infectious (e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals, alcohol, some medications), metabolic (e.g., vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g., depression and schizophrenia), and hydrocephalus.

The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. The present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline. The present invention includes methods of treatment for memory impairment as a result of disease. Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline. The compounds of the present invention are suitable for use in the treatment of memory impairment due to, for example, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, spinal cord injury, CNS hypoxia, cerebral senility, diabetes associated cognitive impairment, memory deficits from early exposure of anesthetic agents, multiinfarct dementia and other neurological conditions including acute neuronal diseases, as well as HIV and cardiovascular diseases.

The compounds of the present invention are also suitable for use in the treatment of a class of disorders known as polyglutamine-repeat diseases. These diseases share a common pathogenic mutation. The expansion of a CAG repeat, which encodes the amino acid glutamine, within the genome leads to production of a mutant protein having an expanded polyglutamine region. For example, Huntington's disease has been linked to a mutation of the protein huntingtin. In individuals who do not have Huntington's disease, huntingtin has a polyglutamine region containing about 8 to 31 glutamine residues. For individuals who have Huntington's disease, huntingtin has a polyglutamine region with over 37 glutamine residues. Aside from Huntington's disease (HD), other known polyglutamine-repeat diseases and the associated proteins include dentatorubral-pallidoluysian atrophy, DRPLA (atrophin-1); spinocerebellar ataxia type-1 (ataxin-1); spinocerebellar ataxia type-2 (ataxin-2); spinocerebellar ataxia type-3 (also called Machado-Joseph disease or MJD) (ataxin-3); spinocerebellar ataxia type-6 (alpha 1a-voltage dependent calcium channel); spinocerebellar ataxia type-7 (ataxin-7); and spinal and bulbar muscular atrophy (SBMA, also know as Kennedy disease).

The basal ganglia are important for regulating the function of motor neurons; disorders of the basal ganglia result in movement disorders. Most prominent among the movement disorders related to basal ganglia function is Parkinson's disease (Obeso et al., Neurology. 62(1 Suppl 1):S17-30, 2004). Other movement disorders related to dysfunction of the basal ganglia include tardive dyskinesia, progressive supranuclear palsy and cerebral palsy, corticobasal degeneration, multiple system atrophy, Wilson disease, dystonia, tics, and chorea. The compounds of the invention are also suitable for use to treat movement disorders related to dysfunction of basal ganglia neurons.

PDE10 inhibitors are useful in raising cAMP or cGMP levels and prevent neurons from undergoing apoptosis. PDE10 inhibitors may be anti-inflammatory by raising cAMP in glial cells. The combination of anti-apoptotic and anti-inflammatory properties, as well as positive effects on synaptic plasticity and neurogenesis, make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA).

Autoimmune diseases or infectious diseases that affect the basal ganglia may result in disorders of the basal ganglia including ADHD, OCD, tics, Tourette's disease, Sydenham chorea. In addition, any insult to the brain can potentially damage the basal ganglia including strokes, metabolic abnormalities, liver disease, multiple sclerosis, infections, tumors, drug overdoses or side effects, and head trauma. Accordingly, the compounds of the invention can be used to stop disease progression or restore damaged circuits in the brain by a combination of effects including increased synaptic plasticity, neurogenesis, anti-inflammatory, nerve cell regeneration and decreased apoptosis.

The growth of some cancer cells is inhibited by cAMP and cGMP. Upon transformation, cells may become cancerous by expressing PDE10 and reducing the amount of cAMP or cGMP within cells. In these types of cancer cells, inhibition of PDE10 activity inhibits cell growth by raising cAMP. In some cases, PDE10 may be expressed in the transformed, cancerous cell but not in the parent cell line. In transformed renal carcinoma cells, PDE10 is expressed and PDE10 inhibitors reduce the growth rate of the cells in culture. Similarly, breast cancer cells are inhibited by administration of PDE10 inhibitors. Many other types of cancer cells may also be sensitive to growth arrest by inhibition of PDE10. Therefore, compounds disclosed in this invention can be used to stop the growth of cancer cells that express PDE10.

The compounds of the invention are also suitable for use in the treatment of diabetes and related disorders such as obesity, by focusing on regulation of the cAMP signaling system. By inhibiting PDE-10, especially PDE-10A, intracellular levels of cAMP are increased, thereby increasing the release of insulin-containing secretory granules and, therefore, increasing insulin secretion. See, for example, WO 2005/012485. The compounds of Formula (I) can also be used to treat diseases disclosed in US Patent application publication No. 2006/019975.

Testing

The PDE10 inhibitory activities of the compounds of the present invention can be tested, for example, using the in vitro and in vivo assays described in the Biological Examples below.

Administration and Pharmaceutical Compositions

In general, the compounds of this invention can be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of a compound of this invention, i.e., the active ingredient, depends upon numerous factors, such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.

Therapeutically effective amounts of compounds of formula (I) may range from approximately 0.1-1000 mg per day; preferably 0.5 to 250 mg/day, more preferably 3.5 mg to 70 mg per day.

In general, compounds of this invention can be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

The choice of formulation depends on various factors, such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

The compositions are comprised of, in general, a compounds of the present invention in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compounds of the present invention. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.

Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, Gennaro, A. R. (Mack Publishing Company, 18th ed., 1995).

The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation contains, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compounds of the present invention based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.

The compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of psychoses, especially schizophrenia and bipolar disorder, obsessive-compulsive disorder, Parkinson's disease, Alzheimer's disease, cognitive impairment and/or memory loss, e.g., nicotinic α-7 agonists, PDE4 inhibitors, other PDE10 inhibitors, calcium channel blockers, muscarinic m1 and m2 modulators, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, canabinoid modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and galanthanamine) In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range, and can be administered either simultaneously or sequentially.

Drugs suitable in combination with the compounds of the present invention include, but are not limited to, other suitable schizophrenia drugs such as Clozaril, Zyprexa, Risperidone, and Seroquel; bipolar disorder drugs, including, but not limited to, Lithium, Zyprexa, and Depakote; Parkinson's disease drugs, including, but not limited to, Levodopa, Parlodel, Permax, Mirapex, Tasmar, Contan, Kemadin, Artane, and Cogentin; agents used in the treatment of Alzheimer's disease, including, but not limited to, Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen and Cliquinol; agents used in the treatment of dementia, including, but not limited to, Thioridazine, Haloperidol, Risperidone, Cognex, Aricept, and Exelon; agents used in the treatment of epilepsy, including, but not limited to, Dilantin, Luminol, Tegretol, Depakote, Depakene, Zarontin, Neurontin, Barbita, Solfeton, and Felbatol; agents used in the treatment of multiple sclerosis, including, but not limited to, Detrol, Ditropan XL, OxyContin, Betaseron, Avonex, Azothioprine, Methotrexate, and Copaxone; agents used in the treatment of Huntington's disease, including, but not limited to, Amitriptyline, Imipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine, Setraline, Terabenazine, Haloperidol, Chloropromazine, Thioridazine, Sulpride, Quetiapine, Clozapine, and Risperidone; agents useful in the treatment of diabetes, including, but not limited to, PPAR ligands (e.g. agonists, antagonists, such as Rosiglitazone, Troglitazone and Pioglitazone), insulin secretagogues (e.g., sulfonylurea drugs, such as Glyburide, Glimepiride, Chlorpropamide, Tolbutamide, and Glipizide, and non-sulfonyl secretagogues), α-glucosidase inhibitors (such as Acarbose, Miglitol, and Voglibose), insulin sensitizers (such as the PPAR-γ agonists, e.g., the glitazones; biguanides, PTP-1B inhibitors, DPP-IV inhibitors, and 11beta-HSD inhibitors), hepatic glucose output lowering compounds (such as glucagon antagonists and metaformin, e.g., Glucophage and Glucophage XR), insulin and insulin derivatives (both long and short acting forms and formulations of insulin); and anti-obesity drugs, including, but not limited to, β-3 agonists, CB-1 agonists, neuropeptide Y5 inhibitors, Ciliary Neurotrophic Factor and derivatives (e.g., Axokine), appetite suppressants (e.g., Sibutramine), and lipase inhibitors (e.g., Orlistat).

EXPERIMENTAL

Unless otherwise noted, all materials were purchased from Sinopharm Chemical Reagent Co., Ltd and used without further purification. All microwave assisted reactions were conducted with a Initiator Synthesizer® from Biotage®. All compounds showed NMR spectra consistent with their assigned structures. Melting points were determined on a Buchi apparatus and are uncorrected. Mass spectral data was determined by electrospray ionization technique. All examples were purified to >90% purity as determined by high-performance liquid chromatography. Unless otherwise stated, reactions were run at room temperature.

The following abbreviations are commonly used:

Ac the group CH₃—(CO)— AcOH or HOAc acetic acid Ac₂O acetic anhydride BINAP 2,2′-bis(diphenylphosphino)-1,1′-binaphthalene BnO Benzyloxy Boc₂O di-tert-butyl dicarbonate BTEA-Cl benzyltriethylammonium chloride Bz Benzyl group Cbz carboxylic acid benzyl ester CDI 1,1′-carbonyldiimidazole d Day DCM Dichloromethane DIAD (CH₃)₂CHOOCN═NCOOCH(CH₃)₂ DIEA N,N-diisopropylethylamine Diox Dioxane DIPEA diisopropylethyl amine DMA Dimethylamine DMAP 4-(dimethylamino)pyridine DME Dimethoxyethane DMF N, N-dimethylformamide Dess martin 1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3- Periodinane (1H)-one DMSO dimethyl sulfoxide DPPA diphenyl phosphoryl azide EDCl N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride ESI-MS electrospray ionization mass spectrometry Et₂O diethyl ether EtOAc ethyl acetate EtOH ethyl alcohol Et₃N triethyl amine g Grams h hour or hours HATU O-(7-Azobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate HCl Hydrochloric acid HPLC high pressure liquid chromatography IPA isopropyl alcohol i Pr₂NEt Diisopropylethylamine i PrOH Isopropyl alcohol ISCO in-situ chemical oxidation Lawesson 4-Methoxyphenylthiophosphoric cyclic reagent di(thioanhydride), LR, 2,4-Bis(4-methoxyphenyl)-2,4- dithioxo-1,3,2,4-dithiadiphosphetane, 2,4- Bis-(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane 2,4-disulfide LCMS liquid chromatography mass spectrometry LDA Lithium diisopropyl amide LiHMDS Lithium bis(trimethylsilyl)amide Me Methyl MeCN Acetonitrile MeI Iodomethane MeOH methyl alcohol MeOD deuteurated methyl alcohol mg Milligrams min Min mL Milliliters Mo-(CO)₆ molybdenum hexacarbonyl MTBE methyl tert-butyl ether NBS N-bromosuccinimide NMP 1-methyl-2-pyrrolidinone NMR nuclear magnetic resonance NOESY nuclear Overhauser effect spectroscopy Pd(dppf)Cl₂ [1,1′-Bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane PMBCl 1-(chloromethyl)-4-methoxybenzene PTSA p-toluenesulfonic acid Py Pyridine RT RT sat. Saturated t-bu tert-butyl group TFA trifluoroacetic acid THF Tetrahydrofuran TLC thin layer chromatography TMSCl Trimethylsilyl chloride TBDPS Tert-Butylchlorodiphenyl Tol Toluene TsCl 4-toluenesulfonyl chloride (CH₃C₆H₄SO₂Cl) Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene General Synthetic Methodology:

The compounds of the present invention can be prepared from commercially available starting materials and by using general synthetic techniques known to those of skill in the art. Outlined below are general reaction schemes suitable for preparing the compounds of the invention claimed herein. Further exemplification is found in the specific examples provided. One skilled in the art will understand that similar or related methods can be used for the synthesis of the compounds. One skilled in the art will also appreciate that in several instances it is possible to change the order of the steps used in the preparation of these compounds and obtain similar results

General Scheme 1 above shows a general method for preparing compounds of formula I as defined herein via key intermediate compound (2). More specific examples of General Scheme 1 are depicted below in General Schemes 1A-1B

General Scheme 2 shows a general method for preparing an intermediate compound (3) which is useful in the preparation of compounds of formula (I). More specific examples of General Scheme 2 are depicted below in General Schemes 2A-2B.

It will be appreciated that in the general schemes, other reagents, such as

(a) halo; wherein halo can be iodo; or (b) boronic esters, such as or

(pinacol boronic ester); methyl boronic ester; or ethyl boronic ester; may be used in place of reagent

Alternatively, compound (4) may be prepared as follows:

General Scheme 3 shows a further alternative general method for preparing an intermediate compound (5) which is useful in the preparation of compounds of formula (I). More specific examples of General Scheme 3 are depicted below in General Scheme 3A.

Although the syntheses of certain compounds are depicted above, it will be appreciated that compounds of formula I having other group R¹; for example, a 6-membered heterocyclic ring, can be prepared according to the above General Scheme 3A.

Preparation P1.1: 1-(Quinolin-2-yl)Piperidin-4-ol

Triethylamine (2.9 g, 29.6 mmol), 2-chloro-quinoline (purchased from Alfa Aesar™) (2.4 g, 14.8 mmol) and piperidin-4-ol (1.5 g, 14.8 mmol) were dissolved in DMF (20 mL). The resulting mixture was heated to 100° C. overnight. The mixture was then diluted with water (20 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were combined and washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give 1-(quinolin-2-yl)piperidin-4-ol (2.0 g, 8.7 mmol, 60% yield) as white solid. ESI-MS (M+1): 229 calc. for C₁₄H₁₆N₂O 228.

TABLE P1 EXAMPLES P1.1-P1.7 PREPARED ANALOGOUS TO PREPARATION P1.1 Ex- am- M + ple Structure Chemical Name 1 P1.1

1-(quinolin-2- yl)piperidin- 4-ol 229 P1.2

1-(quinolin-2- yl)azetidin- 3-ol 201 P1.3

(racemic mixture) (racemic mixture) 1-(quinolin-2- yl)piperidin- 3-ol 229 P1.4

(R)-1-(quinolin- 2-yl)pyrrolidin- 3-ol 215 P1.5

(S)-1-(quinolin- 2-yl)pyrrolidin- 3-ol 215 P1.6

1-(quinazolin- 2-yl)azetidin- 3-ol 202 P1.7

1-(quinoxalin- 2-yl)azetidin- 3-ol 202

Preparation P2.1: 2-(4-((3-Chloropyrazin-2-yl)Oxy)Piperidin-1-yl) Quinoline

To a solution of 1-(quinolin-2-yl)piperidin-4-ol (see PREPARATION P1.1; 2.0 g, 8.7 mmol) in DMF (30 mL) at room temperature was added sodium hydride (60% wt in mineral oil) (0.47 g, 17.4 mmol) at 0° C. The mixture was stirred at room temperature for 60 min and then 2,3-dichloro-pyrazine (1.2 g, 8.7 mmol) was added. The reaction mixture was heated to 90° C. overnight and then diluted with water (60 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were washed with water (40 mL) and brine (40 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (10% to 30% EtOAc in petroleum ether) to give the title product (2.0 g, 5.8 mmol, 70% yield) as white solid. ESI-MS (M+1): 341 calc. for C₁₈H₁₂ClN₄O 340.

TABLE P2 EXAMPLES P2.1-P2.15 PREPARED ANALOGOUS TO PREPARATION P2.1 Example Structure Chemical Name M + 1 P2.1 

2-(4-((3-chloropyrazin-2- yl)oxy)piperidin-1-yl)quinoline 341 P2.2 

2-(4-((3-bromopyridin-2- yl)oxy)piperidin-1-yl)quinoline 384 P2.3 

(racemic mixture) (racemix mixture) 2-(3-((3- chloropyrazin-2-yl)oxy)piperidin- 1-yl)quinoline 341 P2.4 

(R)-2-(3-((3-chloropyrazin-2- yl)oxy)pyrrolidin-1-yl)quinoline 327 P2.5 

(S)-2-(3-((3-chloropyrazin-2- yl)oxy)pyrrolidin-1-yl)quinoline 327 P2.6 

2-(3-((3-chloropyrazin-2- yl)oxy)azetidin-1-yl)quinoline 313 P2.7 

2-(3-((3-bromo-5-methylpyridin- 2-yl)oxy)azetidin-1-yl)quinoline 370 P2.8 

2-chloro-3-((1-(quinolin-2- yl)azetidin-3-yl)oxy)quinozaline 363 P2.9 

2-(3-((3-bromopyridin-2- yl)oxy)azetidin-1-yl)quinoline 356 P2.10

2-(3-((3-bromo-5-fluoropyridin-2- yl)oxy)azetidin-1-yl)quinoline 374 P2.11

2-(3-((5-bromo-2- chloropyrimidin-4- yl)oxy)azetidin-1-yl)quinoline 393 P2.12

2-(3-((6-chloropyridazin-3- yl)oxy)azetidin-1-yl)quinoline 313 P2.13

2-(3-((3-chloropyrazin-2- yl)oxy)azetidin-1-yl)quinazoline 314 P2.14

2-(3-((5-bromo-2- chloropyrimidin-4- yl)oxy)azetidin-1-yl)quinoxaline 391, 393 P2.15

2-(3-((6-chloropyrazin-2- yl)oxy)azetidin-1-yl)quinoline 313

Preparation P3.1: 2-(3-((3-Bromopyridin-4-yl)Oxy)Azetidin-1-yl) Quinoline

To a solution of 1-(quinolin-2-yl)azetidin-3-ol (see PREPARATION P1.2, step 1; 320 mg, 1.60 mmol) in DMF (10 mL) was added Cs₂CO₃ (1.04 g, 3.2 mmol) and 3-bromo-4-chloropyridine (307 mg, 1.60 mmol). The mixture was stirred at 90° C. overnight and then diluted with water (20 mL) and extracted with EtOAc (2×30 mL). The combined organic extracts were washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (5% to 30% EtOAc in petroleum ether) to give the title product (350 mg, 0.98 mmol, 61% yield) as white solid. ESI-MS (M+1): 356 calc. for C₁₇H₁₄BrN₃O 355.

TABLE P3 EXAMPLES P3.1-P3.7 PREPARED ANALOGOUS TO PREPARATION P3.1 Example Structure Chemical Name M + 1 P3.1

2-(3-((3-bromopyridin-4- yl)oxy)azetidin-1- yl)quinoline 356 P3.2

2-(3-((2-chloropyrimidin- 4-yl)oxy)azetidin-1- yl)quinoline 313 P3.3

2-(3-((3-bromo-6- chloropyridin-2- yl)oxy)azetidin-1- yl)quinoline 391 P3.4

2-(3-((2,5- dichloropyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 348 P3.5

2-(3-((2-chloro-5- fluoropyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 331 P3.6

2-(3-((5-bromo-2- chloropyrimidin-4- yl)oxy)azetidin-1- yl)quinazoline 393, 395 P3.7

2-(3-((5-bromo-2- chloropyrimidin-4- yl)oxy)azetidin-1- yl)quinoxaline 393

Preparation P4.1: 2-(3-((3-(Piperidin-4-yl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Quinoline Hydrochloride

Step 1: Tert-Butyl 4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate

To a solution of 2-(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.6; 624 mg, 2.0 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (618 mg, 2.0 mmol) and K₃PO₄ (848 mg, 4.0 mmol) in 1,4-dioxane (20 mL) and H₂O (4 mL) was added Pd(dppf)Cl₂ (146 mg, 0.2 mmol) then the reaction mixture was stirred at 110° C. under N₂ atmosphere overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂ (50 mL). The filtrate was concentrated and the crude product was purified by silica gel column to give tert-butyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (600 mg, 1.3 mmol, yield 65%). ESI-MS (M+1): 460 calc. for C₂₆H₂₉N₅O₃ 459.

Step 2: Tert-Butyl 4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidine-1-Carboxylate

A mixture of tert-butyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (459 mg, 1.0 mmol) and wet Pd—C (50%, 300 mg) in MeOH (20 mL) was stirred under H₂ (30 psi) at room temperature overnight then the reaction mixture was filtered through and washed with MeOH. The filtrate was concentrated in vacuo to give tert-butyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate (400 mg, 0.86 mmol, yield 86%). ESI-MS (M+1): 463 calc. for C₂₆H₃₁N₅O₃ 462.

Step 3: 2-(3-((3-(Piperidin-4-yl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Quinoline Hydrochloride

To tert-butyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate (400 mg, 0.86 mmol) was added 4 M HCl in MeOH (20 mL). The reaction mixture was stirred at room temperature for 30 min and concentrated. The residue was dried under high vacuum to give 2-(3-((3-(piperidin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline hydrochloride (310 mg, 0.86 mmol, 100% yield) as a white solid. ESI-MS (M+1): 362 calc. for C₂₁H₂₃N₅O 361.

TABLE P4 EXAMPLES P4.1-P4.9 PREPARED ANALOGOUS TO PREPARATION P4.1 Example Structure Chemical Name M + 1 P4.1

2-(3-((3-(piperidin-4- yl)pyrazin-2-yl)oxy)azetidin-1- yl)quinoline hydrochloride 362 P4.2

2-(3-((5-methyl-3-(piperidin-4- yl)pyridin-2-yl)oxy)azetidin-1- yl)quinoline hydrochloride 375 P4.3

2-(3-((5-fluoro-3-(piperidin-4- yl)pyridin-2-yl)oxy)azetidin-1- yl)quinoline hydrochloride 371 P4.4

2-(3-((3-(piperidin-4- yl)pyridin-2-yl)oxy)azetidin-1- yl)quinoline hydrochloride 361 P4.5

2-(piperidin-4-yl)-3-((1- (quinolin-2-yl)azetidin-3- yl)oxy)quinoxaline hydrochloride 412 P4.6

(1H-benzo[d]imidazol-2-yl)(3- ((3-(piperidin-3-yl)pyrazin-2- yl)oxy)azetidin-1- yl)methanone P4.7

(1-(5-(piperidin-4-yl)-4-((1- (quinolin-2-yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4-yl)methanol hydrochloride 475 P4.8

(1H-benzo[d]imidazol-2-yl)(3- ((3-(piperidin-3-yl)pyridin-2- yl)oxy)azetidin-1- yl)methanone P4.9

(3-((3-(piperidin-3-yl)pyridin- 2-yl)oxy)azetidin-1- yl)(pyridin-2-yl)methanone

Preparation P5.1: (1H-Benzo[D]Imidazol-2-yl)(3-((3-(1,2,5,6-Tetrahydropyridin-3-yl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Methanone

To a solution of tert-butyl 3-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (see EXAMPLE 10.72; 120 mg, 0.252 mmol) in DCM (2 mL) is added 2,2,2-trifluoroacetic acid (116 μL, 1.511 mmol). The reaction was stirred at room temperature 24 hours. The reaction was concentrated, and the residue dissolved in MeOH (2 mL) and applied to a Varian SCX ion exchange column (1 g). The salt was eluted with MeOH (2×5 mL) and the product eluted with 2.0 M NH₃ in MeOH (2×5 mL). The NH₃ containing fractions were concentrated to give the crude amine which was carried on to the next step without further purification.

TABLE P5 EXAMPLES 5.1-5.4 PREPARED ANALOGOUS TO PREPARATION 5 Example Structure Chemical Name P5.1

(1H-benzo[d]imidazol-2-yl)(3-((3- (1,2,5,6-tetrahydropyridin-3- yl)pyrazin-2-yl)oxy)azetidin-1- yl)methanone P5.2

(1H-benzo[d]imidazol-2-yl)(3((3- (1,2,3,6-tetrahydropyridin-4- yl)pyrazin-2-yl)oxy)azetidin-1- yl)methanone P5.3

(1H-benzo[d]imidazol-2-yl)(4((3- (1,2,3,6-tetrahydropyridin-4- yl)pyrazin-2-yl)oxy)piperidin-1- yl)methanone P5.4

(1H-pyrrol-2-yl)(3-((3-(1,2,3,6- tetrahydropyridin-4-yl)pyrazin-2- yl)oxy)azetidin-1-yl)methanone

Preparation P6.1: 2-(3-((6-Chloro-5-Iodopyridazin-3-yl)Oxy)Azetidin-1-yl)Quinoline and 2-(3-((6-Chloro-4-Iodopyridazin-3-yl)Oxy)Azetidin-1-yl)Quinoline

To a solution of 2,2,6,6-tetramethylpiperidin-1-ide (1.12 mg, 7.8 mmol) in THF (20 mL) at −78° C. was added dropwise n-BuLi (3.3 mL, 7.8 mmol). The mixture was stirred at −78° C. for 15 minutes and 2-(3-((6-chloropyridazin-3-yl)oxy)azetidin-1-yl)quinoline (2.02 g, 6.6 mmol) was added. The reaction mixture was stirred at −78° C. for 1 hour. Then I₂ (3.3 g, 13.2 mmol) was added at −78° C. The reaction mixture was stirred at −78° C. for 1 hour, and warmed to room temperature, stirred for 1 hour, and neutralized with saturated NH₄Cl (20 mL), diluted with EtOAc (50 mL) and water (80 mL). The aqueous layer was extracted with EtOAc (3×50 mL) and the combined organic extracts were washed with aqueous Na₂S₂O₃ (3×50 mL) and brine (40 mL), dried over MgSO₄, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give the title product (1.56 g, 3.6 mmol, yield: 55%); without further separation.

TABLE P6 EXAMPLES P6.1-P6.3 PREPARED ANALOGOUS TO PREPARATION P6.1 Example Structure Chemical Name M + 1 P6.1

 

2-(3-((6-chloro-5- iodopyridazin-3- yl)oxy)azetidin-1- yl)quinoline AND 2-(3-((6-chloro-4- iodopyridazin-3- yl)oxy)azetidin-1- yl)quinoline as isomeric mixture 439 P6.2

2-fluoro-3-iodopyrazine P6.3

2-fluoro-3-iodopyridine

Preparation P7.1: (1-(5-Bromo-4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-2-yl)Piperidin-4-yl)Methanol

To a mixture of 2-(3-((5-bromo-2-chloropyrimidin-4-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.11; 0.1 g, 0.25 mmol) and piperidin-4-yl-methanol (0.028 g, 0.25 mmol) was added DMSO (2 mL) and triethylamine (0.05 g, 0.50 mmol). The solution was heated to 150° C. under microwave for 3 hours. The mixture was then extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in hexanes) to give the title product (0.02 g, 0.04 mmol, 17% yield) as white solid. ESI-MS (M+1): 471 calc. for C₂₂H₂₄BrN₅O₂ 470.

TABLE P7 EXAMPLES P7.1-P7.2 PREPARED ANALOGOUS TO PREPARATION P7.1 Example Structure Chemical Name M + 1 P7.1

(1-(5-bromo-4-((1-(quinolin-2- yl)azetidin-3-yl)oxy)pyrimidin- 2-yl)piperidin-4-yl)methanol 470, 472  P7.2

(1-(5-bromo-4-((1-(quinazolin-2- yl)azetidin-3-yl)oxy)pyrimidin- 2-yl)piperidin-4-yl)methanol 472, 474 

Preparation P8.1: 1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-One

1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-ol (see EXAMPLE 1.1; 94 mg, 0.25 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL), treated with Dess-Martin periodinane (DMP) (195 mg, 0.50 mmol, 2.0 equiv) and stirred at room temperature until complete conversion. The organic layer was washed with an aqueous solution of NaHCO₃/Na₂S₂O₃ (3×10 mL)), dried over Na₂SO₄, filtered and evaporated. The resulting residue was purified by flash chromatography (20% to 40% EtOAc in petroleum ether) to 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-one (75 mg, 0.20 mmol, 80% yield) as a white solid. ESI-MS (M+1): 376 calc. for C₂₁H₂₁N₅O₂ 375.

TABLE P8 EXAMPLES P8.1-P8.5 PREPARED ANALOGOUS TO PREPARATION P8.1 Example Structure Chemical Name M + 1 P8.1

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4-one 376 P8.2

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)pyrrolidin-3-one 362 P8.3

1-[3-(1-Quinolin-2-yl- azetidin-3-yloxy)- pyrazin-2-yl]- piperidin-3-one 376 P8.4

1-(5-fluoro-2-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-4-one P8.5

1-(2-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-4-one

Preparation P9.1: 3-Chloro-N-(1-(Quinolin-2-yl)Azetidin-3-yl)Pyrazin-2-Amine

Step 1. Tert-Butyl (1-(Quinolin-2-yl)Azetidin-3-yl)Carbamate

A mixture of Cs₂CO₃ (3.2 g, 10.0 mmol), 2-chloro-quinoline (0.8 g, 5.0 mmol) and tert-butyl azetidin-3-ylcarbamate (0.8 g, 5.0 mmol) was dissolved in DMF (20 mL) and the resulting mixture was heated to 100° C. overnight. Then the mixture was diluted with water (20 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were combined and washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give tert-butyl (1-(quinolin-2-yl)azetidin-3-yl)carbamate (0.8 g, 2.9 mmol, 53% yield) as white solid. ESI-MS (M+1): 300 calc. for C₁₇H₂₁N₃O₂ 299.

Step 2. 1-(Quinolin-2-yl)Azetidin-3-Amine Hydrochloride

To tert-butyl (1-(quinolin-2-yl)azetidin-3-yl)carbamate (0.8 g, 2.9 mmol) was added 4 M HCl in MeOH (20 mL). The reaction mixture was stirred at room temperature for 30 min and concentrated. The remained solid was dried under high vacuum to give 1-(quinolin-2-yl)azetidin-3-amine hydrochloride (557 mg, 2.8 mmol, 96% yield) as a white solid. ESI-MS (M+1): 200 calc. for C₁₂H₁₃N₃ 199.

Step 3. 3-Chloro-N-(1-(Quinolin-2-yl)Azetidin-3-yl)Pyrazin-2-Amine

Triethylamine (560 mg, 5.6 mmol), 1-(quinolin-2-yl)azetidin-3-amine hydrochloride (557 mg, 2.8 mmol) and 2,3-dichloro-pyrazine (414 mg, 2.8 mmol) were dissolved in DMF (20 mL). The resulting mixture was heated to 90° C. overnight. The mixture was then diluted with water (20 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were combined and washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 50% EtOAc in petroleum ether) to give 3-chloro-N-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-amine (479 mg, 1.5 mmol, 55% yield) as white solid. ESI-MS (M+1): 312 calc. for C₁₆H₁₄ClN₅ 311.

Preparation P10.1: 3-Methyl-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)Pyridine

To a solution of 4-bromo-3-methyl-pyridine (170 mg, 1.0 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (254 mg, 1.0 mmol) and KOAc (180 mg, 2.0 mmol) in 1,4-dioxane (10 mL) was added Pd(dppf)Cl₂ (73 mg, 0.1 mmol) then the reaction mixture was stirred at 110° C. under N₂ atmosphere overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂ (30 mL). The filtrate was concentrated and the crude product was purified by silica gel column to give the product (105 mg, 0.50 mmol, yield 60%). ESI-MS (M+1): 220 calc. for C₁₂H₁₈BNO₂ 219.

TABLE P10 EXAMPLES P10.1-P10.2 PREPARED ANALOGOUS TO PREPARATION P8.1 Example Structure Chemical Name M + 1 P10.1

3-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan- 2-yl)pyridine 220 P10.2

3-chloro-4-(4,4,5,5- tetramethyl- 1,3,2-dioxaborolan-2- yl)pyridine 240

Preparation P11.1: Tert-Butyl 3-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate and Tert-Butyl 5-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-3,4-Dihydropyridine-1(2H)—Carboxylate as Isomeric Mixture

Step 1. Tert-Butyl 3-(Trifluoromethylsulfonyloxy)-5,6-Dihydropyridine-1(2H)-Carboxylate and Tert-Butyl 5-(Trifluoromethylsulfonyloxy)-3,4-Dihydropyridine-1(2H)-Carboxylate as Isomeric Mixture

To a solution of tert-butyl 3-oxopiperidine-1-carboxylate (10.00 g, 50.2 mmol) in THF (50 mL) at −78° C. is added dropwise LiHMDS (55.2 mL, 55.2 mmol) (1.0 M in THF). After 20 min, a solution of 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (PhNTf₂) (18.83 g, 52.7 mmol) in THF (50 mL) was added and the reaction warmed to 0° C. and stirred 3 hours. The reaction was quenched with saturated aqueous NaHCO₃ solution (1 mL) and the reaction mixture concentrated. The residue was purified through a plug of neutral Al₂O₃ (10% EtOAc/Hexane eluant) to give a 1:1 mixture of tert-butyl 5-(trifluoromethylsulfonyloxy)-3,4-dihydropyridine-1(2H)-carboxylate (6.28 g, 18.96 mmol, 37.8% yield) and tert-butyl 3-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate (12.56 g, 37.92 mmol, 75.6% yield), an inseparable mixture, as a clear, light yellow oil.

Step 2. Tert-Butyl 3-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate and Tert-Butyl 5-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-3,4-Dihydropyridine-1(2H)-Carboxylate as Isomeric Mixture

A flask with 4,4,4′,4′,5,5,5′-heptamethyl-2,2′-bi(1,3,2-dioxaborolane) (10.48 g, 43.7 mmol), (dppf)PdCl₂ (0.930 g, 1.139 mmol), and potassium acetate (11.18 g, 114 mmol) was flushed with N₂ (3×), then 1,4-dioxane (100 mL) was added followed by a solution of tert-butyl 5-(trifluoromethylsulfonyloxy)-3,4-dihydropyridine-1(2H)-carboxylate and tert-butyl 3-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate (1:1 ratio, 12.58 g, 38.0 mmol) in 1,4-dioxane (100 mL). The solution was heated in an 80° C. oil bath for 20 hours. The reaction was quenched with water (100 mL) and the aqueous layer extracted with EtOAc (3×100 mL). The combined organic layers were washed with saturated aqueous NaCl (100 mL), dried with magnesium sulfate (MgSO₄), and concentrated. The residue was purified by silica gel chromatography using ISCO™ (330 g SiO₂, O-20% EtOAc/hexane) to give tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate and tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate (7.29 g, 23.58 mmol, 62.1% yield) (inseparable 2:1 mixture of olefin regioisomers) as a white solid.

Preparation P12.1: 1-(4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-5,6-Dihydropyridin-1(2H)-yl)Ethanone

Step 1. 4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1,2,3,6-Tetrahydropyridine Hydrochloride

The mixture of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (4.0 g, 12.9 mmol) in HCl/MeOH (20 mL) was stirred at room temperature for 1 hour. Then it was concentrated to give 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine hydrochloride (2.9 g, 11.8 mmol, yield: 91.4%) which was used in the next step without further purification. ESI-MS (M+1): 210 calc. for C₁₁H₂₀BNO₂ 209.

Step 2. 1-(4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-5,6-Dihydropyridin-1(2H)-yl)Ethanone

To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride (2.9 g, 11.8 mmol) in DCM (30 mL) were added Et₃N (3.6 g, 35.4 mmol) and acetyl chloride (AcCl) (932 mg, 11.8 mmol). The reaction mixture was stirred at room temperature for 1 hour, then diluted with DCM (20 mL), washed with H₂O (2.0 mL). The organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered, evaporated to give the crude product (3.2 g, crude). ESI-MS (M+1): 252 calc. for C₁₃H₂₂BNO₃ 251.

Preparation 13.1: 2-Chloro-3-(3,6-Dihydro-2H-Pyran-4-yl)Pyridine

To a solution of 3-bromo-2-chloropyridine (4 g, 10.8 mmol), 4-(3,3,4,4-tetramethyl-borolan-1-yl)-3,6-dihydro-2H-pyran (5.7 g, 13.1 mmol) and Na₂CO₃ (2.28 g, 21.6 mmol) in 1,4-dioxane (60 mL) and H₂O (6 mL) was added Pd(dppf)Cl₂ (410 mg, 0.56 mmol). The reaction mixture was stirred at 110° C. under N₂ for overnight. The reaction mixture was filtered through CELITE® and washed CH₂Cl₂. The organic layers were concentrated to give the crude product which was purified by silica gel column chromatography to give the title compound (3.5 g, 14.2 mmol, 70% yield).

TABLE P13 EXAMPLES P13.1-P13.5 PREPARED ANALOGOUS TO PREPARATION P13.1 Example Structure Chemical Name M + 1 P13.1

2-chloro-3-(3,6-dihydro-2H- pyran-4-yl)pyridine 196 P13.2

3-(3,6-dihydro-2H-pyran-4-yl)- 2-fluoropyridine P13.3

2-chloro-3-(3,6-dihydro-2H- pyran-4-yl)quinoxaline 247 P13.4

tert-butyl 2-fluoro-5′,6′- dihydro-[3,4′-bipyridine]- 1′(2′H)-carboxylate 279 P13.5

1-(4-(3-chloropyrazin-2-yl)- 5,6-dihydropyridin-1(2H)- yl)ethanone

Preparation P14.1: 1-(2-Fluoro-5′,6′-Dihydro-[3,4′-Bipyridin]-1′(2′H)-yl) Ethanone

To a solution of tert-butyl 4-(2-fluoropyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate (see PREPARATION P13.4; 3.72 g, 13.37 mmol) in DCM (50 mL) at 0° C. is added 2,2,2-trifluoroacetic acid (2.059 mL, 26.7 mmol, 2.0 eq.). The reaction was warmed to room temperature and stirred 3 hours. Additional 2,2,2-trifluoroacetic acid (4.059 mL, 53 mmol, 4.0 eq.) was added and the reaction stirred an additional 3 hours. The reaction was concentrated, and the residue dissolved in CH₂Cl₂ (50 mL) and partioned with saturated aqueous NaHCO₃ (25 mL). The aqueous layer was extracted with EtOAc (3×50 mL). The organic layers were combined, dried with magnesium sulfate (MgSO₄), and concentrated to give the crude piperidine (1.20 g, 50%). The aqueous layer also contained product, the aqueous layer was concentrated and the solid diluted with 50 mL 50% MeOH/CH₂Cl₂ and sonicated 10 min. The solid was filtered and the filtrate concentrated to give 2.80 g crude product.

To the two crude products from above were added acetic anhydride (1.364 g, 13.37 mmol). The solutions were stirred at room temperature for 40 hours. The reaction mixtures were combined, and concentrated. The residue was diluted with CH₂Cl₂ and saturated aqueous NaHCO₃ and extracted. The aqueous layer was extracted with CH₂Cl₂ (2×50 mL), and the organic layers combined, dried over magnesium sulfate (MgSO₄), and concentrated. The product was isolated as a brown solid and used in the next step without purification.

TABLE P14 EXAMPLES P14.1-P14.2 PREPARED ANALOGOUS TO PREPARATION 14 Example Structure Chemical Name P14.1

1-(2-fluoro-5',6'-dihydro-[3,4′- bipyridin]-1′(2′H)-yl)ethanone P14.2

1-(3-(2-fluoropyridin-3- yl)piperidin-1-yl)ethanone

Preparation P15.1: 1-(4-(2-Fluoropyridin-3-yl)Piperidin-1-yl)Ethanone

A 2 L Parr shaker bottle was charged with 1-(2-fluoro-5′,6′-dihydro-[3,4′-bipyridin]-1′(2′H)-yl)ethanone (see PREPARATION P14.1; 44.7 g, 0.203 mol), THF (600 mL), and palladium hydroxide on carbon, 20% wet type (22 g, 50 wt %). The bottle was purged three times with H₂ and was shaken at room temperature under 50 psi of H₂. At 1 hour, crude ¹HNMR indicated full conversion (aliquot syringe filtered and concentrated). This reaction was filtered (along with another 44.7 g batch) through a CELITE® pad. The pad was washed with THF (2×250 mL). The filtrate was concentrated under vacuum to afford 88.5 g white solid (98% yield, >99% purity by LCMS, excellent purity by ¹HNMR).

TABLE P15 EXAMPLES P15.1-15.2 PREPARED ANALOGOUS TO PREPARATION 15 Example Structure Chemical Name M + 1 P15.1

1-(4-(2-fluoropyridin-3- yl)piperidin-1-yl)ethanone 223 P15.2

tert-butyl 3-(2-fluoropyridin-3- yl)piperidine-1-carboxylate 281

Preparation P16.1: Tert-Butyl 4-(3-Chloropyrazin-2-yl)Piperidine-1-Carboxylate

Step 1. Tert-Butyl 4-Iodopiperidine-1-Carboxylate

A solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (246 g, 1.224 mol), imidazole (100 g, 1.469 mol, 1.2 eq.) and triphenylphosphine (385 g, 1.469 mol, 1.2 eq.) in THF (750 mL) was cooled using an ice bath. Then a solution of iodine (373 g, 1.469 mol, 1.2 eq.) in THF (750 mL) was added slowly over a period of 1 hour while keeping the internal temperature below 18° C. The resulting mixture was allowed to stir at room temperature for 5 hours and the mixture was diluted with ethyl acetate (2 L), brine (1 L) and water (500 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (1 L×2). The organic layers were combined, washed with 15% aqueous sodium sulfite (1 L), brine (1 L), dried and concentrated. The resulting residue was stirred with hexanes (2 L) and the solid was removed by filtration. The solid was stirred with hexanes (2 L×2) and filtered. The filtrate was concentrated to give 363 g of crude oil which was purified by column chromatography (eluting with hexanes/ethyl acetate=50:1 to 20:1) to afford 319 g of tert-butyl 4-iodopiperidine-1-carboxylate.

Step 2. Tert-Butyl 4-(3-Chloropyrazin-2-yl)Piperidine-1-Carboxylate

To a suspension of activated zinc dust (84.4 g, 1.29 mol, 1.94 eq.) in anhydrous DMA (270 mL) was added 1,2-dibromoethane (9.1 mL, 0.106 mol, 0.16 eq.), followed by the slow addition of chlorotrimethylsilane (13.5 mL, 0.106 mol, 0.16 eq.) over a period of 5 min. The resulting mixture was stirred for 15 min under nitrogen. Then a solution of tert-butyl 4-iodopiperidine-1-carboxylate (329 g, 1.06 mol, 1.59 eq.) in anhydrous DMA (670 mL) was added to the above suspension over a period of 45 min keeping the internal temperature below 65° C. The resulting mixture was stirred for 1 hour while cooling back to room temperature. The prepared zinc reagent was allowed to stand and the upper clear solution was transferred to a degassed and well stirred solution of 2,3-dichloropyrazine (99 g, 0.664 mol, 1 eq.), PdCl₂(dppf) CH₂Cl₂ (16.3 g, 19.9 mmol, 0.03 eq.) and Cul (7.8 g, 41.2 mmol, 0.062 eq.) in anhydrous DMA (670 mL) using a cannula. DMA (400 mL) was used to rinse the remaining zinc dust and added to the above mixture. The resulting mixture was heated to 80° C. under nitrogen and stirred overnight (19 hours). The mixture was cooled to room temperature and diluted with brine (1 L) and ethyl acetate (6 L). The aqueous phase was extracted with ethyl acetate (4 L) and organic extracts were combined, washed with brine (1 L), dried and concentrated. The resulting residue was purified by column chromatography (eluting with hexanes/ethyl acetate=9:1 to 6:1) to give 92 g of tert-butyl 4-(3-chloropyrazin-2-yl)piperidine-1-carboxylate.

Preparation P17.1: 4-(2-Fluoropyridin-3-yl)Morpholine

A microwave reaction vessel was charged with 2-fluoro-3-iodopyridine (purchased from Maybridge™) (0.565 g, 2.53 mmol), morpholine (purchased from Aldrich™) (0.221 ml, 2.53 mmol), Pd₂(dba)₃ (purchased from Strem™) (0.154 g, 0.152 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl (purchased from Strem™) (0.135 g, 0.304 mmol), and sodium t-butoxide (0.8 g, 7.6 mmol). The reaction mixture was stirred and heated in a Discover® model microwave reactor (CEM, Matthews, N.C.) at 150° C. for 20 min (125 watts, Powermax feature on, ramp time 5 min). Solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column, eluting with a gradient of 1% to 5% MeOH in CH₂Cl₂, to provide 4-(2-fluoropyridin-3-yl)morpholine (0.311 g, 67.5% yield).

Preparation P18.1: 4-(3-Fluoropyrazin-2-yl)Cyclohexanone

Step 1. 1,4-Dioxaspiro[4.5]Decan-8-Ol

To a solution of 1,4-dioxaspiro[4.5]decan-8-one (244 g, 1.56 mol, 1.0 eq.) in MeOH (5 L) was slowly added NaBH₄ (59 g, 1.56 mol, 1.0 eq.) keeping the internal temperature <10° C. using an ice bath. The ice bath was removed and the mixture was stirred for 30 min at room temperature. The solvent was then removed under reduced pressure and the resulting solid was dissolved in 50% diethyl ether in EtOAc (5 L), washed with saturated aqueous NH₄Cl (800 mL×3), brine (800 mL), dried over Na₂SO₄, filtered, and evaporated to give 215 g (87% yield) of 1,4-dioxaspiro[4.5]decan-8-ol. GC-MS: 159 (M+1).

Step 2. 8-Iodo-1,4-Dioxaspiro[4.5]Decane

A mixture of imidazole (111 g, 1.63 mol, 1.2 eq.), PPh₃ (428 g, 1.63 mol, 1.2 eq.) and 1,4-dioxaspiro[4.5]decan-8-ol (215 g, 1.36 mol, 1.0 eq.) in THF (1.5 L) was cooled using an ice bath under N₂. To this reaction mixture was added slowly a solution of I₂ (414 g, 1.63 mol, 1.2 eq.) in THF (1 L) keeping the internal temperature <12° C. After the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was partitioned between H₂O (2 L), EtOAc (3 L), and brine (2 L). The aqueous layer was extracted with EtOAc (1 L×2). The combined organic layer was washed with 10% aqueous NaHSO₃ (800 mL, organic layer turned light yellow), brine (1 L), dried over Na₂SO₄, filtered, and evaporated. The crude product was dissolved in diethyl ether (6 L), filtered, and the solid was washed with diethyl ether (300 mL×3). The filtrate was concentrated and purified by column chromatography (100% hexanes to 5% EtOAc in hexanes, R_(f)=0.3 in 5% EtOAc in hexanes) to give 340 g (93.4% yield) of 8-iodo-1,4-dioxaspiro[4.5]decane. GC-MS: 269 (M+1).

Step 3. 2-Fluoro-3-(1,4-Dioxaspiro[4.5]Decan-8-yl)Pyrazine

To a suspension of activated zinc dust (51 g, 0.78 mol, 1.94 eq.) in anhydrous DMA (100 mL) was added 1,2-dibromoethane (5.5 mL, 0.064 mol, 0.16 eq.), followed by the slow addition of chlorotrimethylsilane (8.1 mL, 0.064 mol, 0.16 eq.) over 5 min. The resulting mixture was stirred for 15 min under nitrogen. Then a solution of 8-iodo-1,4-dioxaspiro[4.5]decane (172 g, 0.639 mol, 1.59 eq.) in anhydrous DMA (300 mL) was added to the above suspension over 30 min keeping the internal temperature below 65° C. The resulting mixture was stirred for 1 hour and cooled to room temperature. The prepared zinc reagent was allowed to stand and the upper clear solution was transferred to a degassed and well stirred solution of 2-fluoro-3-iodopyrazine (see PREPARATION P6.2; 90 g, 0.402 mol, 1.0 eq.), PdCl₂(dppf)CH₂Cl₂ (9.8 g, 0.012 mol, 0.03 eq.), and CuI (4.75 g, 0.025 mol, 0.062 eq.) in anhydrous DMA (300 mL) using a cannula. DMA (100 mL) was used to rinse the remaining zinc dust and the solution was added to the above mixture. The resulting mixture was heated to 80° C. under nitrogen and stirred overnight.

Similarly, two other batches were carried out on 10 g (0.045 mol) and 75 g (0.335 mol) scale and the crude from three batches was combined together for work up and purification.

The mixture was diluted with brine (1.5 L) and EtOAc (10 L). The aqueous phase was extracted with EtOAc (6 L) and organic extracts were combined, washed with brine (1 L), dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by column chromatography (hexanes to 40% EtOAc in hexanes, R_(f)=0.4 in 30% EtOAc in hexanes, UV active) to give 92 g of 2-fluoro-3-(1,4-dioxaspiro[4.5]decan-8-yl). GC-MS: 239 (M+1).

Step 4. 4-(3-Fluoropyrazin-2-yl)Cyclohexanone

A solution of 2-fluoro-3-(1,4-dioxaspiro[4.5]decan-8-yl)pyrazine (91 g, 0.382 mol, 1.0 eq.) in 1N aqueous HCl (573 mL) and acetone (4 L) was heated to 37° C. overnight. The reaction mixture was cooled to room temperature and most of acetone was removed under reduced pressure. The crude material was diluted with EtOAc (4 L) and the solution was washed with aqueous saturated NaHCO₃ (500 mL×2), water (500 mL), brine (500 mL), dried over Na₂SO₄, filtered, and evaporated. The crude product was purified by column chromatography (100% hexanes to 50% EtOAc in hexanes, R_(f)=0.3 in 30% EtOAc in hexanes) to give 52 g (70% yield) of 4-(3-fluoropyrazin-2-yl)cyclohexanone. GC-MS: 195 (M+1); calcd for C₁₀H₁₁FN₂O: 194.21

¹H NMR (300 mHz, DMSO-d₆) δ 8.60-8.27 (m, 1H), 8.25-8.24 (m, 1H), 3.57-3.48 (m, 1H), 2.69-2.58 (m, 2H), 2.36-2.31 (m, 2H), 2.21-2.14 (m, 2H), 2.07-1.91 (m, 2H)

TABLE P18.1 EXAMPLES P18.1-P18.2 PREPARED ANALOGOUS TO PREPARATION P18.1 Example Structure Chemical Name M + 1 P18.1

4-(3-fluoropyrazin-2- yl)cyclohexanone 195 P18.2

4-(2-fluoropyridin-3- yl)cyclohexanone

Preparation 19.1: (1S,4S)-4-(2-Fluoropyridin-3-yl)Cyclohexanol and (1R,4R)-4-(2-Fluoropyridin-3-yl)Cyclohexanol as Diastereomeric Mixture

4-(2-fluoropyridin-3-yl)cyclohexanone (see PREPARATION P18.2; 0.420 g, 2.174 mmol) was dissolved in 20 mL MeOH and cooled to 0° C. Sodium boron hydrate (0.123 g, 3.26 mmol) was added slowly portion wise and stirring was continued for 7 hours. The mixture was evaporated and 3 mL of DCM was added to the residue. The mixture was purified and separated via silica gel column chromatography (10-100% EtOAc in hexanes) providing diasteromeric mixture (1s,4s)-4-(2-fluoropyridin-3-yl)cyclohexanol and (1r,4r)-4-(2-fluoropyridin-3-yl)cyclohexanol as white solid.

Preparation P20.1: Benzyl 3-(3-Chloropyrazin-2-yloxy)Azetidine-1-Carboxylate

To a solution of 3-hydroxy-azetidine-1-carboxylic acid benzyl ester (5.19 g, 27.4 mmol, purchased from Ace Synthesis), 2,3-dichloropyrazine (4.116 g, 27.6 mmol, Oakwood) and DMSO (40 mL) was added sodium tert-butoxide (2.64 g, 27.4 mmol) in three portions. The solution was allowed to stir at room temperature. After 2 hours, the reaction was poured into water (200 mL) and the aqueous solution was extracted with ether (3×50 mL). The combined ether layers were washed with water (50 mL), brine (50 mL), and then concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (80 g), eluting with 0% to 20% EtOAc in hexane, to provide benzyl 3-(3-chloropyrazin-2-yloxy)azetidine-1-carboxylate (5.4 g, 61.6% yield), as a yellow oil. MS (ESI) m/z 320.1 (MH+). ICSO (uM): 1.33.

TABLE P20.1 EXAMPLES P20.1-P20.4 PREPARED ANALOGOUS TO PREPARATION P20.1 Example Structure Chemical Name M + 1 P20.1

benzyl 3-(3-chloropyrazin-2- yloxy)azetidine-1-carboxylate 320 P20.2

tert-butyl 3-(3-chloropyrazin-2- yloxy)azetidine-1-carboxylate 308 P20.3

(R)-tert-butyl 3-((3- chloropyrazin-2- yl)oxy)pyaolidine-1- carboxylate 300 P20.4

tert-butyl 4-(3-bromopyridin-2- yloxy)piperidine-1-carboxylate

Preparation P21.1: 2-(Azetidin-3-yloxy)Pyrazine

To a nitrogen-purged round bottomed flask was added benzyl 3-(3-chloropyrazin-2-yloxy)azetidine-1-carboxylate (see PREPARATION P20.1; 0.400 g, 0.688 mmol) and Pd/C (0.10 g, 0.094 mmol) and EtOH (10 mL). Hydrogen gas was bubbled through the solution for 1 minute, then a balloon of hydrogen gas was placed atop the round bottomed flask. After 30 minutes, the balloon was removed and the round bottomed flask sealed with a rubber septum. After 16 hours, the reaction was filtered through CELITE® and the cake was washed liberally with EtOAc. The filtrate was concentrated in vacuo to give crude 2-(azetidin-3-yloxy)pyrazine (0.188 g, 181% yield), as a off-white solid. The product was carried forward in the next step without further purification. MS (ESI) m/z 152.1 (MH+).

Preparation P22.1: 2-(Azetidin-3-yloxy)-3-Chloropyrazine Hydrochloride

To a solution of tert-butyl 3-(3-chloropyrazin-2-yloxy)azetidine-1-carboxylate (see PREPARATION P20.2; 4.3 g, 15.05 mmol) and DCM (50 mL) was added 4M HCl in dioxane (3.76 mL, 15.05 mmol). After 72 hours, a precipitate coated the walls of the flask. The liquid was carefully decanted off and the rinsed with DCM (20 mL) and again carefully decanted off. The precipitate coated round bottomed flask was treated with DCM:saturated NaHCO₃ (1:1, 150 mL). The aqueous layer was extracted with 10% MeOH in DCM (4×25 mL). The combined organic layers were concentrated in vacuo to give crude product. The aqueous layer still contained the majority of the product. The aqueous layer was concentrated in vacuo and the solids stirred with 10% MeOH in DCM (200 mL) for 2 hours, then filtered. The filtrate was concentrated in vacuo to give more crude product. The separate lots of crude product were combined to give crude 2-(azetidin-3-yloxy)-3-chloropyrazine (1.75 g, 62.6% yield), as a tan solid. The product was carried forward in the next step without further purification. MS (ESI) m/z 186.1 (MH+).

TABLE P22.1 EXAMPLES P22.1-P22.2 PREPARED ANALOGOUS TO PREPARATION P22.1 Example Structure Chemical Name M + 1 P22.1

2-(azetidin-3- yloxy)-3- chloropyrazine hydrochloride 186 P22.2

2-(azetidin-3- yloxy)-3- bromopyridine hydrochloride 229, 231 

Preparation P23.1: (1H-benzo[d]imidazol-2-yl)(3-(3-chloropyrazin-2-yloxy)azetidin-1-yl)methanone

To a solution of 2-(azetidin-3-yloxy)-3-chloropyrazine (see PREPARATION P22.1; 0.38 g, 2.047 mmol), 1H-benzo[d]imidazole-2-carboxylic acid (0.37 g, 2.282 mmol), EDCI (0.392 g, 2.047 mmol), butanol (0.121 g, 0.790 mmol) and DCM (25 mL) was added DIPEA (0.62 mL, 3.56 mmol). After 2 hours, the crude reaction was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (12 g), eluting with 0% to 50% EtOAc in hexane, to provide (1H-benzo[d]imidazol-2-yl)(3-(3-chloropyrazin-2-yloxy)azetidin-1-yl)methanone (270 mg, 0.819 mmol, 40.0% yield), as a white solid. MS (ESI) m/z 330.0 (MH⁺). IC₅₀ (uM) 1.375.

TABLE P23 EXAMPLES P23.1-P23.2 PREPARED ANALOGOUS TO PREPARATION P23.1 Example Structure Chemical Name M + 1 P23.1

(1H-benzo[d]imidazol-2- yl)(3-(3-chloropyrazin-2- yloxy)azetidin-1- yl)methanone 330 P23.2

(1H-benzo[d]imidazol-2- yl)(4-((3-chloropyrazin-2- yl)oxy)piperidin-1- yl)methanone

Preparation P24.1: (1H-Benzo[D]Imidazol-2-Yl)(3-Hydroxyazetidin-1-yl)Methanone

1H-benzo[d]imidazole-2-carboxylic acid (1.788 g, 11.03 mmol) was dissolved in 50 ml DMF and HATU (4.19 g, 11.03 mmol) was added. This mixture (A) was stirred for 30 min. 3-hydroxyazetidine hydrochloride (1.2083 g, 11.03 mmol) was added to 50 ml DMF, diisopropylethyl amine (5.76 mL, 33.1 mmol) was added and the mixture (B) was stirred for 5 min. Mixture (B) was added to mixture (A) and the resulting reaction mixture was stirred for 6 hours. The reaction was hydrolyzed with 30 ml water and 30 ml 1M HCl and the resulting mixture was extracted with EtOAc (3×200 ml). The combined organic layers were dried with magnesium sulfate and evaporated. Silica gel chromatography (0-10% MeOH in DCM) provided (1H-benzo[d]imidazol-2-yl)(3-hydroxyazetidin-1-yl)methanone (0.570 g, 2.62 mmol, 23.79% yield) as a yellow oil.

TABLE P24 EXAMPLES P24.1-P24.3 PREPARED ANALOGOUS TO PREPARATION P24.1 Ex- M + ample Structure Chemical Name 1 P24.1

(1H- benzo[d]im- idazol-2-yl)(3- hydroxy- azetidin-1- yl)methanone P24.2

(3-hydroxy- azetidin- 1-yl)(4-methyl- 1H-pyrrol-2- yl)methanone P24.3

(3-hydroxy- azetidin-1- yl)(1H-indol-2- yl)methanone

Preparation P25.1: Tert-Butyl 3-((3-(3,6-Dihydro-2H-Pyran-4-yl)Pyridin-2-yl)Oxy)Azetidine-1-Carboxylate

2-chloro-3-(3,6-dihydro-2H-pyran-4-yl)-pyridine (see PREPARATION P13.1; 3.5 g, 17.9 mmol) and tert-butyl 3-hydroxyazetidine-1-carboxylate (2.8 g, 17.9 mmol) were dissolved in DMSO (20 mL) and sodium tert-butoxide (t-BuONa) (3.4 g, 35.8 mmol) was added to the above solution. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was diluted with water and extracted with ethyl acetate (2×10 mL). The combined organic layers were dried over Na₂SO₄ and concentrated to give the crude product. The crud product was purified by silica gel column chromatography to give the title compound (2.3 g, 7.8 mmol, yield 75%). ¹H NMR (DMSO-D₆, 300 MHz) δ (ppm) 1.38 (s, 9H), 2.41-2.47 (m, 2H), 3.75-3.86 (m, 4H), 4.19-4.30 (m, 4H), 5.26-5.35 (m, 1H), 6.15-6.20 (m, 1H), 7.01 (dd, 1H, J=7.31 Hz, 4.97 Hz), 7.62 (d, 1H, J=7.45 Hz), 8.02 (d, 1H, J=4.82 Hz)

TABLE P25.1 EXAMPLES P25.1-P25.2 PREPARED ANALOGOUS TO PREPARATION P25.1 Example Structure Chemical Name M + 1 P25.1

tert-butyl 3-((3-(3,6-dihydro-2H- pyran-4-yl)pyridin-2- yl)oxy)azetidine-1-carboxylate P25.2

benzyl 3-((3-(3,6-dihydro-2H- pyran-4-yl)quinoxalin-2- yl)oxy)azetidine-1-carboxylate 418

Preparation P26.1. 2-(Azetidin-3-yloxy)-3-(3,6-Dihydro-2H-Pyran-4-yl)Pyridine Hydrochloride

To tert-butyl 3-((3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)oxy)azetidine-1-carboxylate (see PREPARATION P25.1; 2.3 g, 6.9 mmol) was added 4 M HCl in MeOH (100 mL). The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed to give the title compound (1.5 g, 6.5 mmol, yield 95%).

TABLE P26.1 EXAMPLES P26.1-26.8 PREPARED ANALOGOUS TO PREPARATION P26.1 Example Structure Chemical Name M + 1 P26.1

2-(azetidin-3-yloxy)-3-(3,6- dihydro-2H-pyran-4- yl)pyridine hydrochloride 233 P26.2

1-(2-(azetidin-3-yloxy)-5′,6′- dihydro-[3,4′-bipyridin]- 1′(2′H)-yl)ethanone hydrochloride P26.3

2-(azetidin-3-yloxy)-3,3′- bipyridine hydrochloride P26.4

1-(4-(3-(azetidin-3- yloxy)pyrazin-2-yl)-5,6- dihydropyridin-1(2H)- yl)ethanone hydrochloride P26.5

(R)-2-(3,6-dihydro-2H-pyran- 4-yl)-3-(pyrrolidin-3- yloxy)pyrazine hydrochloride 248 P26.6

(S)-2-(3,6-dihydro-2H-pyran- 4-yl)-3-(pyrrolidin-3- yloxy)pyrazine hydrochloride 248 P26.7

(S)-3-(3,6-dihydro-2H-pyran-4- yl)-2-(pyrrolidin-3- yloxy)pyridine hydrochloride 247 P26.8

(R)-3-(3,6-dihydro-2H-pyran-4- yl)-2-(pyrrolidin-3- yloxy)pyridine hydrochloride 247

Preparation P27.1: 2-(Azetidin-3-yloxy)-3-(Tetrahydro-2H-Pyran-4-yl)Pyridine

A mixture of 2-(azetidin-3-yloxy)-3-(3,6-dihydro-2H-pyran-4-yl)pyridine hydrochloride (see PREPARATION P26.1; 3.5 g, 15 mmol) and wet Pd—C (50%, 1.0 g) in MeOH (100 ml) was stirred under H₂ (40 psi) at 30° C. for 3 hours then the reaction mixture was filtered through CELITE® and the filtrate was concentrated in vacuo to give the title compound (3.2 g, 14.6 mmol, yield 91%).

TABLE P27 EXAMPLES P27.1-P27.8 PREPARED ANALOGOUS TO PREPARATION P27.1 Ex- ample Structure Chemical Name M + 1 P27.1

2-(azetidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyridine 235 P27.2

(S)-2-(pyrrolidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyrazine hydrochloride P27.3

(R)-2-(pyrrolidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyrazine hydrochloride P27.4

1-(4-(2-(azetidin-3- yloxy)pyridin- 3-yl)piperidin- 1-yl)ethanone hydrochloride P27.5

1-(4-(3-(azetidin-3- yloxy)pyrazin- 2-yl)piperidin- 1-yl)ethanone hydrochloride P27.6

1-(3-(2-(azetidin-3- yloxy)pyridin- 3-yl)piperidin- 1-yl)ethanone hydrochloride P27.7

(S)-2-(pyrrolidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyridine hydrochloride P27.8

(R)-2-(pyrrolidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyridine hydrochloride

Preparation P28.1: Tert-Butyl 4-((3-(3,6-Dihydro-2H-Pyran-4-yl)Pyridin-2-yl)Oxy)Piperidine-1-Carboxylate

To a solution tert-butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate (see PREPARATION P20.4; 4 g, 11.2 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.58 g, 12.4 mmol) and Na₂CO₃ (2.38 g, 22.4 mmol) in 1,4-dioxane (60 mL) and H₂O (6 mL) was added Pd(dppf)Cl₂ (410 mg, 0.56 mmol) then the reaction mixture was stirred at 110° C. under N₂ for overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂. The organic layer was concentrated and the crude product was purified by silica gel column to give the desired compound (3.5 g, 8.7 mmol, yield 70%).

TABLE P28 EXAMPLES P28.1-P28.4 PREPARED ANALOGOUS TO PREPARATION P28.1 Example Structure Chemical Name M + 1 P28.1

tert-butyl 4-((3-(3,6-dihydro- 2H-pyran-4-yl)pyridin-2- yl)oxy)piperidine-1- carboxylate P28.2

benzyl 3-(3-(3,6-dihydro-2H- pyran-4-yl)pyrazin-2-yloxy) azetidine-1-carboxylate 368 P28.3

tert-butyl 4-(3-((1- ((benzyloxy)carbonyl)azetidin- 3-yl)oxy)pyrazin-2-yl)-5,6- dihydropyridine-1(2H)- carboxylate P28.4

(R)-tert-butyl 3-((3-(3,6- dihydro-2H-pyran-4- yl)pyrazin-2- yl)oxy)pyrrolidine-1- carboxylate 348

Preparation P29.1: 2-(Piperidin-4-yloxy)-3-(Tetrahydro-2H-Pyran-4-yl)Pyridine Hydrochloride

Step 1. Tert-Butyl 4-((3-(Tetrahydro-2H-Pyran-4-yl)Pyridin-2-yl)Oxy)Piperidine-1-Carboxylate

A mixture of tert-butyl 4-((3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidine-1-carboxylate (see PREPARATION P28.1; 3.5 g, 9.6 mmol) and wet Pd—C (50%, 1.0 g) in MeOH (100 mL) was stirred under H₂ (40 psi) at 30° C. overnight then the reaction mixture was filtered through CELITE® and washed with MeOH. The filtrate was concentrated to give of the desired compound (3.2 g, 8.1 mmol, yield 91%).

Step 2. 2-(Piperidin-4-yloxy)-3-(Tetrahydro-2H-Pyran-4-yl)Pyridine Hydrochloride

To tert-butyl 4-((3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)oxy)piperidine-1-carboxylate (3.2 g, 8.8 mmol) was added 4 M HCl in MeOH (100 mL). The solution was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure to give the title compound (2 g, 9.8 mmol, yield 95%). ESI-MS (M+1): 263 calc. for C₁₅H₂₂N₂O₂ 262.

TABLE P29 EXAMPLES P29.1-P29.7 PREPARED ANALOGOUS TO PREPARATION P29.1 Example Structure Chemical Name M + 1 P29.1

2-(piperidin-4-yloxy)-3- (tetrahydro-2H-pyran-4- yl)pyridine hydrochloride 263 P29.2

2-(azetidin-3-yloxy)-3- (tetrahydro-2H-pyran-4- yl)pyrazine hydrochloride 236 P29.3

2-(piperidin-4-yloxy)-3- (tetrahydro-2H-pyran-4- yl)pyrazine hydrochloride 264 P29.4

2′-methyl-2-(piperidin-4-yloxy)- 3,4′-bipyridine hydrochloride 270 P29.5

2-(2-methylpyridin-4-yl)-3- (piperidin-4-yloxy)pyrazine hydrochloride 271 P29.6

1-(4-(3-(piperidin-4- yloxy)pyrazin-2-yl)piperidin-1- yl)ethanone hydrochloride 305 P29.7

1-(4-(2-(piperidin-4- yloxy)pyridin-3-yl)piperidin-1- yl)ethanone hydrochloride 304

Preparation P30.1. 2-(Azetidin-3-yloxy)-3-(Tetrahydro-2H-Pyran-4-yl)Pyrazine

To a N₂ purged round bottom flask was added benzyl 3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)azetidine-1-carboxylate (see PREPARATION P28.2; 490 mg, 1.334 mmol), pearlman's catalyst (37.5 mg, 0.267 mmol) and EtOH (10 mL). A balloon of H₂ was placed atop the round bottom flask. After 20 hours, the reaction was filtered through CELITE® and the cake was washed with EtOAc. The filtrate was concentrated in vacuo to give 2-(azetidin-3-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyrazine (240 mg, 1.020 mmol, 76% yield), as a tan residue. MS (ESI) m/z 236.1 (MH+).

TABLE P30.1 EXAMPLES P30.1-P30.2 PREPARED ANALOGOUS TO PREPARATION P30.1 Ex- ample Structure Chemical Name M + 1 P30.1

2-(azetidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)pyrazine 236 P30.2

2-(azetidin- 3-yloxy)-3- (tetrahydro- 2H-pyran-4- yl)quinoxaline 286

Preparation P31.1: 4-(2-(Piperidin-4-yloxy)Pyridin-3-yl)Morpholine Hydrochloride

Step 1. Tert-Butyl 4-((3-Morpholinopyridin-2-yl)Oxy)Piperidine-1-Carboxylate

To a solution of tert-butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate (see PREPARATION P20.4; 4 g, 11.2 mmol), morpholine (1.46 g, 16.8 mmol), Pd₂(dba)₃ (513 mg, 0.56 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) (349 mg, 0.56 mmol), sodium tert-butoxide (t-BuONa) (2.15 g, 22.4 mmol) then the reaction mixture was stirred at 90° C. for overnight. The mixture was left to reach room temperature, then the reaction mixture was filtered through a pad of CELITE® and the filter cake was washed with CH₂Cl₂ (3×20 mL). The combined filtrates were evaporated in vacuo and the residue was purified by column chromatography to give the product (3.1 g, 8.7 mmol, yield 70%). ESI-MS (M+1): 364 calc. for C₁₉H₂₉N₃O₄ 363.

Step 2. 4-(2-(Piperidin-4-yloxy)Pyridin-3-yl)Morpholine Hydrochloride

To tert-butyl 4-((3-morpholinopyridin-2-yl)oxy)piperidine-1-carboxylate (3.2 g, 8.8 mmol) was added 4 M HCl in MeOH (100 mL). The solution was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure to give the title compound (2.2 g, 8.36 mmol, yield 95%). ESI-MS (M+1): 264 calc. for C₁₄H₂₁N₃O₂ 263

TABLE P31 EXAMPLES P31.1-P31.2 PREPARED ANALOGOUS TO PREPARATION P31.1 Ex- ample Structure Chemical Name M + 1 P31.1

4-(2-(piperidin-4- yloxy)pyridin-3- yl)morpholine hydrochloride 264 P31.2

4-(3-(piperidin-4- yloxy)pyrazin-2- yl)morpholine hydrochloride 265

Example 1.1 1-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperidin-4-Ol

To a mixture of 2-(4-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline (see PREPARATION P1.1; 0.1 g, 0.29 mmol) and piperidin-4-ol (0.029 g, 0.29 mmol) and K₂CO₃ (0.08 g, 0.58 mmol) was added isopropyl alcohol (i-PrOH) (2 mL) and water (0.5 ml). The solution was heated to 160° C. under microwave for 5 hours. Then the mixture was concentrated and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in petroleum ether) to give the title product (0.02 g, 0.04 mmol, 17% yield) as white solid. ESI-MS (M+1): 406 calc. for C₂₃H₂₇N₅O₂ 405.

TABLE 1A EXAMPLES 1.1-1.65 PREPARED ANALOGOUS TO SCHEME 1 ESI-MS Ex. # Structure Chemical Name (M + 1) IC₅₀ (uM) 1.1 

1-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-4-ol 406 0.198 1.2 

4-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)morpholine 392 0.254 1.3 

(R)-1-(3-((1-(quinolin- 2-yl)piperidin-4- yl)oxy)pyrazin-2- yl)pyrrolidin-3-ol 392 0.356 1.4 

(S)-1-(3-((1-(quinolin- 2-yl)piperidin-4- yl)oxy)pyrazin-2- yl)pyrrolidin-3-ol 392 0.198 1.5 

1-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)azetidin-3-ol 378 1.22  1.6 

2-(4-((3-(piperidin-1- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 390 0.403 1.7 

2-(4-((3-(pyrrolidin-1- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 376 0.286 1.8 

2-(4-((3-(azetidin-1- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 362 0.273 1.9 

(1-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 420  0.00435 1.10

6-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2-yl)- 2-oxa-6- azaspiro[3.3]heptane 404 0.345 1.11

7-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2-yl)- 2-oxa-7- azaspiro[3.5]nonane 404  0.0436 1.12

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4-ol 378  0.0261 1.13

2-(3-((3-(piperidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 362  0.0397 1.14

4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)morpholine 364  0.0483 1.15

2-(3-((3-(4- methylpiperidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 376 0.124 1.16

2-(3-((3-(4- (trifluoro- methyl)piperidin- 1-yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 430  0.0614 1.17

2-(3-((3-(2- azabicyclo[2.2.1]heptan- 2-yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 374 0.109 1.18

2-(3-((3-(5,6- dihydropyridin-1(2H)- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 360 0.314 1.19

2-(3-((3-(azetidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 334  0.0861 1.20

2-(3-((3-(pyrrolidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 348 10    1.21

2-(3-((3-(azepan-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 376 0.334 1.22

(R)-(1-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)pyrrolidin-2- yl)methanol 378 0.150 1.23

4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2-yl)- 1,4-oxazepane 378  0.0446 1.24

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)azepan-4-ol 392  0.0295 1.25

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)pyrrolidin-3- yl)methanol 378  0.0434 1.26

2-(3-((3-(4-methyl- 1,4-diazepan-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 391 2.99  1.27

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidine-4- carboxamide 405  0.00968 1.28

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 392  0.0023 1.29

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidine-4- carbonitrile 387  0.00608 1.30

(1-(3-((1-(quinoxalin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 393  0.0378 1.31

(1-(3-((1-(quinazolin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 393 0.014 1.32

2-(3-((3-(4- (methoxy- methyl)piperidin- 1-yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 406  0.0276 1.33

(R)-(1-(3-((1- (quinolin-2- yl)pyrrolidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 406 0.167 1.34

(S)-(1-(3-((1- (quinolin-2- yl)pyrrolidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 406 0.078 1.35

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)quinoxalin-2- yl)piperidin-4- yl)methanol 442  0.00975 1.36

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)amino)pyrazin-2- yl)piperidin-4- yl)methanol 391 0.02  1.37

(1-(5-bromo-6-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyridin-2- yl)piperidin-4- yl)methanol 469, 471   0.000229 1.38

(1-(5-chloro-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 426 0.01  1.39

(1-(5-fluoro-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 410 0.02  1.40

(1-(5-bromo-4-((1- (quinoxalin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 471, 473  0.0242 1.41

(1-(5-bromo-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4-ol 456, 458  0.0737 1.42

methyl 1-(5-bromo-4- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidine-4- carboxylate 498, 500 1.34  1.43

2-(3-((5-bromo-2-(4- methylpiperidin-1- yl)pyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 454, 456 0.358 1.44

(1-(5-bromo-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)pyrrolidin-3- yl)methanol 456, 458  0.0206 1.45

(1-(5-bromo-4-((1- (quinazolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 472  0.0146 1.46

2-(3-((3-(4- methylpiperazin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 377  0.6830 1.47

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)quinoxalin-2- yl)piperidine-4- carbonitrile 437  0.0192 1.48

1-methyl-4-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperazin-2-one 391  0.0339 1.49

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-3- yl)methanol 392  0.0406 1.50

(1-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-4- piperidinyl)methanol 392  0.0233 1.51

2-(1-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-4- piperidinyl)ethanol 406  0.0124 1.52

1-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-4- piperidinecarbonitrile 387  0.0608 1.53

((2S)-1-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-2- pyrrolidinyl)methanol 378  0.0226 1.54

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)pyrrolidin-3-ol 364 0.067  1.55*

2-(4-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-1- piperazinyl)ethanol 407 Not available 1.56

2-(3-((3-(4-(1- pyrrolidinyl)-1- piperidinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 431 0.571 1.57

N,N-dimethyl-1-(3- ((1-(2-quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-4- piperidinamine 405 0.520 1.58

2-methyl-4-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)morpholine 378  0.0628 1.59

(4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)morpholin-2- yl)methanol 394  0.0886 1.60

2-(3-((3-(4- (trifluoromethyl)-1- piperidinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 430  0.0614 1.61

1-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-3-azetidinol 350  0.0947 1.62

(1H-benzo[d]imidazol- 2-yl)(3-((3- morpholinopyrazin-2- yl)oxy)azetidin-1- yl)methanone 381  0.3768 1.63

1-(4-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyrazin-2- yl)piperazin-1- yl)ethanone 422  0.6371 1.64

(1H-benzo[d]imidazol- 2-yl)(3-((3-(4- hydroxypiperidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)methanone 395 0.186 1.65

(1-(6-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4- yl)methanol 392   0.000639 *Note: Example 1.55 can be prepared according to Scheme 1. However, pure product NMR data is not available.

TABLE 1B PREPARATION AND NMR DATA OF EXAMPLES 1.1-1.65 Starting Reaction ¹H NMR (CD₃OD, 400 Ex. # Starting Material (1) Material (2) Condition MHz) δ (ppm) 1.1

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.98 (d, J = 9.2 Hz, 1H); 7.66-7.65 (m, 3H); 7.53-7.52 (m, 2H); 7.23-7.19 (m, 2H); 5.45-5.41 (m, 1H); 4.02-3.98 (m, 4H); 3.81-3.75 (m, 3H); 3.09-3.02 (m, 2H); 2.19-2.12 (m, 2H); 1.95-1.63 (m, 4H); 1.63-1.59 (m, 2H). 1.2 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.03-8.00 (m, 1H); 7.71-7.62 (m, 3H); 7.58-7.57 (m, 2H); 7.23-7.20 (m, 2H); 5.43 (S, 1H); 4.04-4.02 (m, 2H); 3.78-3.76 (m, 6H); 3.49-3.47 (m, 4H); 2.20-2.14 (m, 2H); 1.93-1.89 (m, 2H). 1.3 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.41 (d, J = 10.0 Hz, 1H); 7.94-7.89 (m, 2H); 7.83-7.81 (m, 1H); 7.56-7.53 (m, 2H); 7.41 (m, 2H); 5.58-5.54 (m, 1H); 4.55-4.53 (m, 1H); 4.11-4.06 m, 4H); 4.02-3.87 (m, 4H); 2.36-2.30 (m, 2H); 2.22-2.09 (m, 4H). 1.4 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.18-8.15 (m, 2H); 7.72-7.69 (m, 2H); 7.55 (d, J = 3.2 Hz, 1H); 7.48-7.44 (m, 1H); 7.27-7.26 (m, 2H); 7.17 (d, J = 10.0 Hz, 1H); 5.50-5.48 (m, 1H); 4.51-4.50 (m, 1H);; 4.06-3.83 (m, 8H); 2.16-2.03 (m, 4H); 2.03-2.01 (m, 2H). 1.5 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 7.77 (d, J = 9.2 Hz, 1H); 7.62 (d, J = 8.8 Hz, 1H); 7.50-7.42 (m, 3H); 7.24 (d, J = 3.2 Hz, 1H); 7.14-7.10 (m, 1H); 6.90 (d, J = 9.2 Hz, 1H); 5.23-5.21 (m, 1H); 4.57-4.51 (m, 1H); 4.30-4.26 (m, 2H); 3.91-3.87 (m, 4H); 3.66-3.60 (m, 2H); 2.03-1.98 (m, 2H); 1.83-1.77 (m, 2H). 1.6 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.40 (d, J = 9.6 Hz, 1H); 7.92-7.89 (m, 2H); 7.83-7.81 (m, 1H); 7.67 (d, J = 3.2 Hz, 1H); 7.56-7.53 (m, 3H); 5.54-5.52 (m, 1H); 4.09-4.06 (m, 4H); 3.49-3.47 (m, 4H); 2.35-2.27 (m, 2H); 2.18-2.12 (m, 2H); 1.90-1.68 (m, 6H). 1.7 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.90 (d, J = 8.8 Hz, 1H); 7.61-7.60 (m, 2H); 7.49-7.47 (m, 2H); 7.24-7.13 (m, 3H); 5.33-5.31 (m, 1H); 4.03-3.98 (m, 2H); 3.80-3.65 (m, 6H); 2.14-2.09 (m, 2H); 2.00-1.88 (m, 6H). 1.8 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.96 (d, J = 9.2 Hz, 1H); 7.63-7.61 (m, 2H); 7.49-7.47 (m, 2H); 7.29 (d, J = 3.2 Hz, 1H); 7.21-7.161 (m, 2H); 5.32-5.30 (m, 1H); 4.22-4.18 (m, 4H); 4.05-3.99 (m, 2H); 3.73-3.69 (m, 2H); 2.33-2.29 (m, 2H); 2.14-2.09 (m, 2H); 1.89-1.84 (m, 2H). 1.9 compound A

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.40 (d, J = 9.6 Hz, 1H); 7.91 (s, 2H); 7.67-7.66 (m, 1H); 7.57-7.53 (m, 4H); 5.56-5.54 (m, 1H); 4.23-4.20 (m, 2H); 4.09-4.06 (m, 5H); 3.47-3.40 (m, 2H); 2.94-2.87 (m, 2H); 2.35-2.69 (m, 2H); 2.17-2.12 (m, 2H); 2.00 (s, 2H); 1.85-1.81 (m, 1H); 1.37-1.35 (m, 2H). 1.10 compound A

TEA, DMSO, 100° C. 7.98 (d, J - 9.2 Hz, 1H); 7.64-7.62 (m, 2H); 7.52-7.51 (m, 2H); 7.34-7.33 (m, 1H); 7.22-7.18 (m, 2H); 5.33-5.31 (m, 1H); 5.01-4.79 (m, 4H); 4.33 (s, 4H); 4.11-4.05 (m, 2H); 3.72-3.67 (m, 2H); 2.17-2.12 (m, 2H); 1.94-1.89 (m, 2H). 1.11

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 7.83 (d, J = 8.8 Hz, 1H); 7.69-7.68 (m, 2H); 7.56-7.45 (m, 3H); 7.19-7.18 (m, 1H); 6.54 (d, J = 8.8 Hz, 1H); 5.48 (s, 1H); 4.62-4.60 (m, 2H); 4.40 (s, 4H); 4.19-4.18 (m, 2H); 3.36-3.33 (m, 4H); 1.92-1.89 (m, 4H). 1.12 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.86-7.72 (m, 3H); 7.58-7.47 (m, 3H); 7.30-7.20 (m, 1H); 6.56 (d, J = 8.8 Hz, 1H); 5.51 (s, 1H); 4.63-4.59 (m, 2H); 4.23-4.19 (m, 1H); 3.97-3.94 (m, 2H); 3.86-3.84 (m, 1H); 3.12-3.09 (m, 2H); 2.20-1.93 (m, 3H); 1.66-1.60 (m, 2H). 1.13 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 7.88 (d, J = 8.8 Hz, 1H); 7.76-7.75 (m, 2H); 7.61 (d, J = 8.4 Hz, 1H); 7.60-7.55 (m, 1H); 7.48 (d, J = 2.8 Hz, 1H); 7.25-7.21 (m, 1H); 6.61 (d, J = 8.8 Hz, 1H); 5.56-5.52 (m, 1H); 4.66-4.62 (m, 2H); 4.26-4.23 (m, 2H); 3.48-3.45 (m, 4H); 1.68-1.658 (m, 6H). 1.14 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 8.35 (d, J - 9.2 Hz, 1H); 7.90 (d, J = 8.0 Hz, 1H); 7.81-7.78 (m, 3H); 7.59 (d, J = 3.2 Hz, 1H); 7.54-7.52 (m, 1H); 6.98 (d, J = 9.2 Hz, 1H); 5.67-5.64 (m 1H); 4.98-4.93 (m, 2H); 4.61-4.55 (m, 2H); 3.81-3.79 (m, 4H); 3.56-3.53 (m, 4H). 1.15 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.32 (d, J = 9.6 Hz, 1H); 7.87 (d, J = 8.0 Hz, 1H); 7.78-7.76 (m, 3H); 7.52-7.50 (m, 2H); 6.96 (d, J = 9.6 Hz, 1H); 5.66-5.61 (m, 1H); 4.97 (s, 2H); 4.55-4.59 (m, 2H); 4.22-4.19 (m, 2H); 2.94-2.87 (m, 2H); 1.98-1.72 (m, 2H); 1.65-1.60 (m, 1H); 1.35-1.26 (m, 2H); 1.27-1.26 (s, 3H). 1.16 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.33 (d, J = 9.6 Hz, 1H); 7.88 (d, J = 7.6 Hz, 1H); 7.79-7.76 (m, 3H); 7.56-7.50 (m, 2H); 6.97 (d, J = 9.6 Hz, 1H); 5.66-5.62 (m, 1H); 4.97-4.92 (m, 2H); 4.59-4.55 (m, 2H); 4.34-4.30 (m, 2H); 2.90-2.83 (m, 2H); 2.46-2.38 (m, 1H); 1.94-1.91 (m, 2H); 1.71-1.60 (m, 2H). 1.17 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.92 (d, J = 9.2 Hz, 1H); 7.59-7.57 (m, 2H); 7.48-7.43 (m, 2H); 7.18-7.13 (m, 2H); 6.64 (d, J = 9.2 Hz, 1H); 5.42-5.40 (m, 1H); 4.55-4.50 (m, 2H); 4.16-4.08 (m, 2H); 3.63-3.61 (m, 1H); 3.24-3.20 (m, 2H); 2.48-2.46 (m, 1H); 1.42-1.39 (m, 4H); 1.29-1.28 (m, 2H). 1.18 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.40-8.31 (m, 1H); 7.87-7.78 (m, 1H); 7.78-7.72 (m, 3H); 7.52-7.48 (m, 2H); 6.96 (d, J = 2.4 Hz, 1H); 5.88-5.85 (m, 1H); 5.79-5.75 (m, 1H); 5.66-5.63 (m, 1H); 4.97-4.94 (m, 2H); 4.60-4.55 (m, 2H); 4.02-4.01 (m, 2H); 3.73-3.70 (m, 2H); 2.31-2.29 (m, 2H). 1.19 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 7.77-7.69 (m, 1H); 7.67-7.66 (m, 1H); 7.66-7.64 (m, 1H); 7.55-7.43 (m, 2H); 7.22-7.12 (m, 2H); 6.50-6.40 (m, 1H); 5.49-5.42 (m, 1H); 4.539-4.49 (m, 2H); 4.15-4.11 (m, 6H); 2.35-2.26 (m, 2H). 1.20 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 7.79 (s, 1H); 7.47-7.45 (m, 1H); 7.41-7.39 (m, 1H); 7.33-7.31 (m, 2H); 6.99 (s, 1H); 6.56-6.55 (m, 1H); 6.51-6.48 (m, 1H); 5.15-5.11 (m, 1H); 4.46-4.41 (m, 1H); 3.88-3.79 (m, 2H); 3.61-3.56 (m, 5H); 1.81-1.78 (m, 4H). 1.21 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.01-7.99 (m, 1H); 7.68-7.66 (m, 3H); 7.57-7.55 (m, 1H); 7.31-7.25 (m, 2H); 6.73-6.71 (m, 1H); 5.54-5.51 (m, 1H); 4.64-4.60 (m, 2H); 4.22-4.18 (m, 2H); 3.72-3.69 (m, 4H); 1.83-1.81 (m, 4H); 1.56-1.54 (m, 4H). 1.22 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.34 (s, 1H); 7.91-7.78 (m, 3H); 7.57-7.50 (m, 2H); 7.40-7.39 (m, 1H); 6.69-6.97 (m, 1H); 5.67-5.66 (m, 1H); 4.95 (s, 2H); 4.72-4.62 (m, 3H); 3.92-3.88 (m, 1H); 3.78-3.63 (m, 2H); 3.61-3.58 (m, 1H); 2.08-2.05 (m, 4H). 1.23 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.94-7.96 (m, 1H); 7.62-7.67 (m, 3H); 7.52-7.54 (m, 1H); 7.38-7.52 (m, 1H); 7.20-7.24 (m, 1H); 6.67-6.69 (m, 1H); 5.52 (s, 1H); 4.59-4.60 (m, 2H); 4.14-4.17 (m, 2H); 3.82-3.85 (m, 6H); 3.69-3.81 (m, 2H); 1.95-1.98 (m, 2H). 1.24 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.37-8.35 (m, 1H); 7.91-7.89 (m, 1H); 7.80-7.79 (m, 2H); 7.63 (s, 1H); 7.54-7.50 (m, 1H); 7.43-7.42 (m, 1H); 7.00-6.98 (m, 1H); 5.66 (s, 1H); 4.99-4.96 (m, 2H); 4.62-4.59 (m, 2H); 3.91-3.88 (m, 2H); 3.74-3.70 (m, 3H); 2.16-1.83 (m, 5H); 1.74 (s, 1H). 1.25 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.35 (d, J = 9.6 Hz, 1H); 7.95 (d, J = 8.0 Hz, 1H); 7.80-7.78 (m, 2H); 7.53-7.51 (m, 2H); 6.99-6.98 (m, 1H); 6.97 (d, J = 9.2 Hz, 1H); 5.69 (s, 1H); 4.97-4.95 (m, 2H); 4.70-4.66 (m, 2H); 4.12-4.04 (m, 2H); 3.95-3.92 (m, 1H); 3.78-3.73 (m, 2H); 3.66-3.57 (m, 1H); 2.61-2.57 (m, 2H); 2.17-1.93 (m, 1H); 1.91-1.88 (m, 1H). 1.26 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.33 (d, J = 9.2 Hz, 1H); 7.88 (d, J = 7.6 Hz, 1H); 7.76-7.78 (m, 3H); 7.52-7.50 (m, 2H); 6.97 (d, J = 9.2 Hz, 1H); 5.64-5.62 (m, 1H); 4.96 (s, 2H); 4.61 (s, 2H); 4.14 (s, 1H); 3.87-3.75 (m, 4H); 3.54-3.50 (m, 2H); 3.41-3.39 (m, 1H); 2.96 (s, 3H); 2.31-2.30 (m, 2H). 1.27 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.97-7.96 (m, 1H); 7.89 (d, J = 9.2 Hz, 1H); 7.70-7.69 (m, 2H); 7.57-7.52 (m, 1H); 7.44-7.43 (m, 1H); 6.53 (d, J = 9.2 Hz, 1H); 5.54-5.47 (m, 2H); 5.39 (s, 1H); 4.73 (s, 1H); 4.32 (s, 1H); 4.19-4.18 (m, 2H); 2.84-2.77 (m, 2H); 2.54-2.51 (m, 1H); 2.37-2.29 (m, 1H); 1.96-1.73 (m, 4H). 1.28 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.96 (d, J = 9.2 Hz, 1H); 7.70-7.31 (m, 3H); 7.54-7.49 (m, 2H); 7.25-7.23 (m, 1H); 6.66 (d, J = 9.2 Hz, 1H); 5.52 (s, 2H); 4.62-4.58 (s, 2H); 4.22-4.17 (m 4H); 3.41-3.39 (m, 2H); 2.79-2.78 (m, 2H); 1.79-1.75 (m, 3H); 1.34-1.30 (m, 2H). 1.29 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.94-7.92 (m, 1H); 7.73 (d, J = 2.8 Hz, 1H); 7.65-7.64 (m, 2H); 7.55-7.51 (m, 2H); 7.20-7.18 (m, 1H); 6.65 (d, J = 9.2 Hz, 1H); 5.51 (s, 1H); 4.60-4.55 (m, 2H); 4.18-4.14 (s, 2H); 3.79-3.73 (m, 2H); 3.35-3.29 (m, 2H); 2.95-2.93 (m, 1H); 2.01-1.96 (m, 2H); 1.94-1.89 (m, 2H). 1.30

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.23 (s, 1H); 7.82-7.79 (m, 1H); 7.69 (d, J = 2.8 Hz, 1H); 7.64-7.62 (m, 2H); 7.59 (d, J = 1.2 Hz, 1H); 7.40-7.36 (m, 1H); 5.56-5.55 (m, 1H); 4.72-4.68 (m, 2H); 4.31-4.20 (m, 4H); 3.40-3.39 (m, 2H); 2.84-2.77 (m, 2H); 1.79-1.76 (m, 3H); 1.34-1.30 (m, 2H). 1.31

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 9.02 (s, 1H); 7.74-7.67 (m, 3H); 7.53 (d, J = 8.4 Hz, 1H); 7.47 (d, J = 2.8 Hz, 1H); 7.27-7.23 (m, 1H); 5.51-5.54 (m, 1H); 4.64-4.59 (m, 2H); 4.22-4.18 (m, 4H); 3.49-3.40 (m, 2H); 2.81-2.75 (m, 2H); 1.78-1.75 (m, 2H); 1.66-1.64 (m, 2H); 1.37-1.27 (m, 2H). 1.32 compound B

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 7.87-7.73 (m, 3H); 7.59-7.47 (m, 3H); 7.22-7.21 (m, 1H); 6.58-6.56 (m, 1H); 5.51 (s, 1H); 4.62-4.61 (m, 2H); 4.20-4.16 (m, 4H); 3.31-3.22 (m, 5H); 2.81-2.75 (m, 2H); 1.80-1.77 (m, 3H); 1.36-1.27 (m, 2H). 1.33

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h (CDCl₃) 8.16 (s, 1H); 8.03-7.98 (m, 1H); 7.72-7.67 (m, 2H); 7.54-7.52 (m, 1H); 7.46-7.41 (m, 2H); 6.88-6.86 (m, 1H); 5.83 (s, 1H); 4.27-3.98 (m, 7H); 3.59-3.40 (m, 1H); 2.99-2.83 (m, 2H); 2.54-2.53 (m, 2H); 2.01-1.72 (m, 3H); 1.41-1.32 (m, 2H). 1.34

K₂CO₃, i-PrOH, H₂O, MW 160° C., 5 h 8.37 (s, 1H); 7.91-7.88 (m, 2H); 7.68-7.67 (m, 1H); 7.60-7.59 (m, 1H); 7.54-7.50 (m, 1H); 7.30-7.20 (m, 2H); 5.90-5.89 (m, 1H); 4.23-4.09 (m, 7H); 4.01-3.99 (m, 1H); 2.93-2.86 (m, 2H); 2.61-2.59 (m, 2H); 1.78-1.75 (m, 3H); 1.33-1.27 (m, 2H). 1.35

K₂CO₃, i-PrOH, water MW 160° C. 8.35 (d, J = 9.2 Hz, 1H); 7.90 (d, J = 8.0 Hz, 1H); 7.82-7.78 (m, 2H); 7.71-7.66 (m, 2H); 7.54-7.40 (m, 3H); 7.00 (d, J = 9.2 Hz, 1H); 5.79-5.83 (m, 1H); 5.07-5.03 (m, 2H); 4.68-4.65 (m, 2H); 4.52-4.49 (m, 2H); 3.47-3.45 (m, 2H); 3.07-3.01 (m, 2H); 1.92-1.76 (m, 3H); 1.49-1.39 (m, 2H). 1.36

K₂CO₃, i-PrOH, water MW 160° C. 8.05 (d, J = 9.2 Hz, 1H); 7.67-7.64 (m, 3H); 7.55 (m, 1H); 7.54-7.50 (m, 1H); 7.25-7.246 (m, 1H); 6.72 (d, J = 9.2 Hz, 1H); 4.81-4.79 (m, 1H); 4.60-4.56 (m, 2H); 4.14-4.11 (m, 2H); 3.53-3.43 (m, 4H); 2.73-2.66 (m, 2H); 1.83-1.79 (m, 2H); 1.62-1.56 (m, 2H); 1.51-1.44 (m, 3H). 1.37

TEA, DMSO, 150° C. 7.93 (d, J = 9.2 Hz, 1H); 7.86-7.61 (m, 2H); 7.53-7.49 (m, 2H); 7.22-7.18 (m, 1H); 6.65 (d, J = 8.8 Hz, 1H); 6.24 (d, J = 8.8 Hz, 1H); 5.44-5.41 (m, 1H); 4.58-4.54 (m, 2H); 4.27-4.24 (m, 2H); 4.16-4.12 (m, 2H); 3.41-3.40 (m, 2H); 2.84-2.77 (m, 2H); 1.79-1.76 (m, 2H); 1.71-1.67 (m, 1H); 1.26-1.15 (m, 2H). 1.38

TEA, DMSO, 150° C. 8.32 (d, J = 9.6 Hz, 1H); 8.14 (d, J = 2.4 Hz, 1H); 7.88 (d, J = 8.0 Hz, 1H); 7.76-7.81 (m, 2H); 7.53-7.49 (m, 1H); 6.95 (d, J = 9.6 Hz, 1H); 5.70-5.66 (m, 1H); 5.06-4.97 (m, 2H); 4.66-4.60 (m, 4H); 4.30-4.28 (m, 1H); 3.45-3.44 (m, 1H); 3.02-2.96 (m, 2H); 2.14-1.76 (m, 3H); 1.36-1.18 (m, 2H). 1.39

TEA, DMSO, 150° C. 7.90 (d, J = 2.8 Hz, 1H); 7.80 (d, J = 8.8 Hz, 1H); 7.67 (d, J = 8.4 Hz, 1H); 7.53-7.45 (m, 2H); 7.18-7.14 (m, 1H); 6.51 (d, J = 9.2 Hz, 1H); 5.49-5.44 (m, 1H); 4.54-4.50 (m, 4H); 4.22-4.19 (m, 2H); 3.44-3.43 (m, 2H); 2.80-2.74 (m, 2H); 1.74-1.67 (m, 2H); 1.17-1.09 (m, 3H). 1.40

TEA, DMSO, 150° C. 8.52 (s, 1H); 8.21-20 (m, 1H); 7.97-7.95 (m, 1H); 7.70-7.67 (m, 2H); 7.57-7.53 (m, 1H); 5.68-5.66 (m, 1H); 5.00-4.90 (m, 2H); 4.70-4.59 (m, 4H); 4.29-4.28 (m, 1H); 3.44-3.42 (m, 1H); 2.97-2.94 (m, 2H); 1.91-1.80 (m, 3H); 1.32-1.15 (m, 2H). 1.41

TEA, DMSO, 150° C. 8.34 (d, J = 9.2 Hz, 1H); 8.24-8.22 (m, 1H); 7.89 (d, J = 8.0 Hz, 1H); 7.80-7.78 (m, 2H); 7.54-7.50 (m, 1H); 6.97 (d, J = 9.2 Hz, 1H); 5.70-5.66 (m, 1H); 4.97-4.90 (m, 2H); 4.63-4.59 (m, 2H); 4.29-4.25 (m, 2H); 3.91-3.90 (m, 1H); 3.40-3.31 (m, 2H); 1.95-1.91 (m, 2H); 1.54-1.49 (m, 2H). 1.42 compound C

Et₃N, DMSO, MW 150° C. 8.38-8.40 (m, 1H); 8.22-8.21 (m, 1H); 7.90 (d, J = 8.0 Hz, 1H); 7.82-7.76 (m, 2H); 7.54-7.50 (m, 1H); 6.99 (d, J = 9.6 Hz, 1H); 5.69-5.65 (m, 1H); 4.99-4.95 (m, 2H); 4.63-4.50 (m, 4H); 3.69 (s, 3H); 3.16-3.09 (m, 2H); 2.72-2.66 (m, 1H); 2.00-1.96 (m, 2H); 1.70-1.60 (m, 2H). 1.43 compound C

Et₃N, DMSO, MW 150° C. (CD₃Cl₃) 8.13 (s, 1H); 7.85 (d, J = 8.8 Hz, 1H); 7.73 (d, J = 8.4 Hz, 1H); 7.60-7.51 (m, 2H); 7.25-7.19 (m, 1H); 6.57 (d, J = 8.8 Hz, 1H); 5.53-5.49 (m, 1H); 4.60-4.55 (m, 4H); 4.28-4.24 (m, 2H); 2.88-2.81 (m, 2H); 1.71-1.60 (m, 3H); 1.25-1.10 (m, 2H); 0.97-0.95 (m, 3H). 1.44 compound C

Et₃N, DMSO, MW 150° C. (CD₃Cl₃) 8.13 (s, 1H); 7.85 (d, J = 8.8 Hz, 1H); 7.72 (d, J = 8.4 Hz, 1H); 7.59-7.57 (m, 1H); 7.54-7.50 (m, 1H); 7.25-7.19 (m, 1H); 6.56 (d, J = 8.8 Hz, 1H); 5.51-5.47 (m, 1H); 4.59-4.55 (m, 2H); 4.27-4.24 (m, 2H); 3.70-3.61 (m, 4H); 3.51-3.46 (m, 1H); 3.32-3.27 (m, 1H); 2.54-2.50 (m, 1H); 2.09-2.08 (m, 1H); 1.81-1.76 (m, 1H). 1.45

TEA, DMSO, 150° C. (CDCl₃) 9.04 (s, 1H); 8.15 (s, 1H); 7.71-7.71 (m, 3H); 7.28-7.27 (m, 1H); 5.53 (s, 1H); 4.72-4.67 (m, 4H); 4.40-4.37 (m, 2H); 3.55-3.54 (m, 2H); 2.92-2.85 (m, 2H); 1.85-1.82 (m, 2H); 1.26-1.22 (m, 3H). 1.46 compound B

NEAT, MW 150° C. (CDCl₃) 7.84 (d, J = 9.2 Hz, 1H); 7.76-7.72 (m, 2H); 7.59-7.51 (m, 3H); 7.21 (d, s, 1H); 6.56 (d, J = 9.2 Hz, 1H); 5.52-5.51 (m, 1H); 4.63-4.59 (m, 2H); 4.23-4.20 (m, 2H); 3.57 (s, 4H); 2.55-2.51 (m, 4H); 2.31 (s, 3H). 1.47

TEA, DMSO, 150° C. (CDCl₃) 7.91 (d, J = 9.2 Hz, 1H); 7.77-7.69 (m, 3H); 7.64-7.62 (m, 1H); 7.58-7.55 (m, 1H); 7.50-7.45 (m, 2H); 7.27-7.23 (m, 1H); 6.64 (d, J = 8.8 Hz, 1H); 5.76-5.73 (m, 1H); 4.76-4.72 (m, 2H); 4.31-4.28 (m, 2H); 4.02-3.96 (m, 2H); 3.59-3.54 (m, 2H); 2.90-2.89 (m, 1H); 2.10-2.01 (m, 4H) 1.48 compound B

DMSO 120° C. (DMSO-d₆) 2.86 (s, 4H) 3.82 (t, J = 5.50 Hz, 2H) 4.08 (s, 3H) 4.31 (d, J = 13.20 Hz, 2H) 4.61-4.76 (m, 2H) 5.48-5.61 (m, 1H) 6.91 (d, J = 9.68 Hz, 1H) 7.35 (t, J = 7.92 Hz, 1H) 7.60-7.72 (m, 3H) 7.78-7.89 (m, 2H) 8.21 (d, J = 10.12 Hz, 1H). 1.49 compound B

DMSO 120° C. (DMSO-d₆) 1.16 (d, J = 10.12 Hz, 1H) 1.46-1.61 (m, 1H) 1.64-1.81 (m, 3H) 2.61 (dd, J = 12.76, 10.56 Hz, 1H) 2.74-2.90 (m, 1H) 3.17-3.34 (m, 2H) 4.03 (d, J = 13.64 Hz, 1H) 4.11-4.26 (m, 3H) 4.58 (dd, J = 10.34, 7.26 Hz, 2H) 5.44-5.61 (m, 1H) 6.81 (d, J = 9.68 Hz, 1H) 7.20-7.33 (m, 1H) 7.49-7.67 (m, 3H) 7.70-7.82 (m, 2H) 8.08 (d, J = 9.68 Hz, 1H). 1.50 compound B

DMSO 120° C. (DMSO-d₆) 1.10-1.32 (m, 2H) 1.71 (d, J = 14.08 Hz, 3H) 2.68-2.85 (m, 2H) 3.27 (d, J = 6.16 Hz, 1H) 4.08-4.25 (m, 5H) 4.64 (dd, J = 10.78, 7.26 Hz, 2H) 5.43-5.58 (m, 1H) 6.86 (d, J = 9.24 Hz, 1H) 7.30 (t, J = 8.14 Hz, 1H) 7.51-7.69 (m, 3H) 7.72-7.84 (m, 2H) 8.14 (d, J = 9.68 Hz, 1H). 1.51 compound B

DMSO 120° C. (DMSO-d₆) 1.09-1.44 (m, 4H) 1.71 (d, J = 14.96 Hz, 3H) 2.76 (t, J = 13.86 Hz, 2H) 4.05-4.25 (m, 6H) 4.62 (dd, J = 10.56, 7.04 Hz, 2H) 5.43-5.57 (m, 1H) 6.85 (d, J = 9.24 Hz, 1H) 7.29 (t, J = 8.36 Hz, 1H) 7.50-7.68 (m, 3H) 7.71-7.84 (m, 2H) 8.12 (d, J = 9.68 Hz, 1H). 1.52 compound B

DMSO 120° C. (DMSO-d₆) 1.82 (td, J = 8.80, 3.52 Hz, 2H) 1.96 (br. s., 3H) 3.08-3.31 (m, 4H) 4.27 (d, J = 14.96 Hz, 2H) 4.59-4.74 (m, 2H) 5.47-5.58 (m, 1H) 6.89 (d, J = 9.68 Hz, 1H) 7.34 (d, J = 7.92 Hz, 1H) 7.58-7.70 (m, 3H) 7.76-7.86 (m, 2H) 8.18 (d, J = 10.12 Hz, 1H). 1.53 compound B

DMSO 120° C. (DMSO-d₆) 1.74-2.02 (m, 8H) 4.13-4.28 (m, 2H) 4.37-4.48 (m, 1H) 4.52-4.65 (m, 2H) 5.41-5.56 (m, 1H) 6.83 (d, J = 9.24 Hz, 1H) 7.21-7.37 (m, 2H) 7.52-7.70 (m, 3H) 7.76 (d, J = 8.80 Hz, 1H) 8.11 (d, J = 9.68 Hz, 1H) 1.54 compound B

DMSO 120° C. 1.76-1.99 (m, 4H) 4.14-4.27 (m, 4H) 4.32 (br. s., 2H) 4.55-4.68 (m, 2H) 5.41-5.56 (m, 1H) 6.86 (d, J = 9.68 Hz, 1H) 7.23-7.36 (m, 2H) 7.54-7.70 (m, 3H) 7.77 (d, J = 8.80 Hz, 1H) 8.14 (d, J = 9.68 Hz, 1H) 1.55* compound B

DMSO 120° C. Not Available 1.56 compound B

DMSO 120° C. (DMSO-d₆) 1.37-1.54 (m, 2H) 1.65 (br. s., 4H) 1.89 (d, J = 16.28 Hz, 2H) 2.18 (t, J = 10.78 Hz, 1H) 2.48 (br. s., 3H) 2.87 (t, J = 13.86 Hz, 3H) 4.03-4.16 (m, 4H) 4.55 (dd, J = 10.56, 6.60 Hz, 2H) 5.45-5.57 (m, 1H) 6.79 (d, J = 8.80 Hz, 1H) 7.16-7.29 (m, 1H) 7.52-7.62 (m, 3H) 7.68-7.82 (m, 2H) 8.04 (d, J = 9.24 Hz, 1H). 1.57 compound B

DMSO 120° C. (DMSO-d₆) 1.33-1.51 (m, 2H) 1.74-1.88 (m, 2H) 2.15 (s, 6H) 2.78 (t, J = 14.08 Hz, 2H) 4.04-4.24 (m, 5H) 4.55 (dd, J = 10.12, 7.04 Hz, 2H) 5.45-5.57 (m, 1H) 6.79 (d, J = 8.80 Hz, 1H) 7.18-7.29 (m, 1H) 7.48-7.62 (m, 3H) 7.67-7.83 (m, 2H) 8.04 (d, J = 9.68 Hz, 1H). 1.58 compound B

DMSO 120° C. (DMSO-d₆) 1.11 (d, J = 6.16 Hz, 3H) 2.58 (dd, J = 12.98, 10.34 Hz, 2H) 2.80-2.95 (m, 3H) 3.94- 4.19 (m, 4H) 4.55 (dd, J = 10.12, 7.04 Hz, 2H) 5.45-5.59 (m, 1H) 6.79 (d, J = 9.24 Hz, 1H) 7.19-7.28 (m, 1H) 7.49-7.66 (m, 3H) 7.71 (d, J = 9.24 Hz, 1H) 7.82 (d, J = 3.08 Hz, 1H) 8.04 (d, J = 9.68 Hz, 1H). 1.59 compound B

DMSO 120° C. (DMSO-d₆) 2.60-2.72 (m, 1H) 2.84-2.96 (m, 1H) 3.97-4.21 (m, 7H) 4.55 (dd, J = 10.12, 7.04 Hz, 2H) 4.82 (t, J = 5.94 Hz, 2H) 5.47-5.60 (m, 1H) 6.79 (d, J = 9.24 Hz, 1H) 7.18-7.29 (m, 1H) 7.49-7.65 (m, 3H) 7.71 (d, J = 9.24 Hz, 1H) 7.82 (d, J = 3.08 Hz, 1H) 8.04 (d, J = 9.24 Hz, 1H). 1.60 compound B

DMSO 120° C. (DMSO-d₆) 1.48-1.62 (m, 2H) 1.80-1.92 (m, 2H) 2.85 (t, J = 14.52 Hz, 2H) 4.07-4.18 (m, 2H) 4.26 (d, J = 14.08 Hz, 2H) 4.55 (dd, J = 10.56, 7.04 Hz, 2H) 5.52 (t, J = 3.96 Hz, 1H) 6.79 (d, J = 9.24 Hz, 2H) 7.18-7.28 (m, 1H) 7.49-7.64 (m, 3H) 7.72 (d, J = 9.24 Hz, 1H) 7.81 (d, J = 3.08 Hz, 1H) 8.05 (d, J = 9.24 Hz, 1H). 1.61 compound B

DMSO 120° C. (DMSO-d₆) 3.84-3.88 (m, 1H) 4.02-4.14 (m, 2H) 4.27-4.38 (m, 2H) 4.52 (dd, J = 10.56, 6.60 Hz, 3H) 5.44-5.53 (m, 1H) 5.66 (d, J = 6.16 Hz, 1H) 6.79 (d, J = 9.24 Hz, 1H) 7.19-7.28 (m, 1H) 7.38 (d, J - 3.08 Hz, 1H) 7.49-7.75 (m, 4H) 8.04 (d, J = 9.24 Hz, 1H). 1.62

Cs₂CO₃, DMSO, 90° C. 3.57 (t, 4H, J = 4.68 Hz), 3.84 (t, 4H, J = 4.38 Hz), 4.24-4.32 (m, 1H), 4.53-4.61 (m, 1H), 4.68 (dd, 1H, J = 11.25 Hz, 5.41 Hz), 5.23 (dd, 1H, J = 11.84 Hz, 6.28 Hz), 5.53-5.60 (m, 1H), 7.31-7.38 (m, 2H), 7.61 (d, 1H, J = 2.78 Hz), 7.64-7.74 (m, 2H), 7.80 (d, 1H, J = 2.92 Hz) 1.63

Cs₂CO₃, DMSO (DMSO-D₆) 2.02 (s, 3H), 3.44-3.49 (m, 2H), 3.52-3.60 (m, 6H), 4.19 (dd, 1H, J = 11.54 Hz, 3.52 Hz), 4.57 (dd, 1H, J = 11.15 Hz, 6.65 Hz), 4.71 (dd, 1H, J = 11.54 Hz, 3.52 Hz), 5.15 (dd, 1H, J = 11.54 Hz, 6.65 Hz), 5.44-5.50 (m, 1H), 7.26 (t, 1H, J = 7.43 Hz), 7.32 (t, 1H, J = 7.24 Hz), 7.52 (d, 1H, J = 8.02 Hz), 7.64 (d, 1H, J = 2.93 Hz), 7.73 (d, 1H, J = 8.02 Hz), 7.84 (d, 1H, J = 2.93 Hz), 13.25 (s, 1H) 1.64

Cs₂CO₃, DMSO (CDCl₃) 1.67-1.75 (m, 1H), 1.96-2.08 (m, 4H), 3.11-3.22 (m, 2H), 3.86-4.07 (m, 3H), 4.34 (dd, 1H, J - 11.84 Hz, 3.80 Hz), 4.74 (dd, 1H, J = 11.55 Hz, 6.43 Hz), 4.90 (dd, 1H, J = 12.13 Hz, 2.78 Hz), 5.27-5.39 (m, 1H), 5.49-5.58 (m, 1H), 7.28-7.41 (m, 2H), 7.52 (d, 1H, J = 2.92 Hz), 7.54 (d, 1H, J = 7.60 Hz), 7.78 (d, 1H, J = 2.78 Hz), 7.81 (d, 1H, J = 7.89 Hz), 11.07 (s, 1H) 1.65

K₂CO₃, i-PrOH, H₂O, MW 160° C. 8.35 (d, J = 9.6 Hz, 1H); 7.89 (d, J = 7.6 Hz, 1H); 7.82-7.78 (m, 3H); 7.53-7.49 (m, 2H); 6.98 (d, J = 9.6 Hz, 1H); 5.62 (s, 1H); 5.01-5.00 (m, 2H); 4.60-4.55 (m, 2H); 4.40-4.37 (m, 2H); 3.46-3.45 (m, 2H); 3.31-3.30 (m, 2H); 1.89-1.86 (m, 3H); 1.29-1.28 (m, 2H). *Note: Example 1.55 can be prepared according to Scheme 1. However, pure product NMR data is not available.

Examples 2.1 and 2.2 (S)-(1-(3-((1-(Quinolin-2-yl)Piperidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Methanol and (R)-(1-(3-((1-(Quinolin-2-yl)Piperidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Methanol as Separated Isomers Step 1: (1-(3-((1-(Quinolin-2-yl)Piperidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Methanol

To a mixture of 2-(3-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline (racemix mixture) (see PREPARATION P2.3; 0.1 g, 0.29 mmol) and piperidin-4-ylmethanol (0.033 g, 0.29 mmol) and K₂CO₃ (0.08, 0.58 mmol) was added i-PrOH (2 mL) and water (0.5 ml). The solution was heated to 160° C. under microwave for 5 hours. Then the mixture was concentrated and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in petroleum ether) to give the title product (0.020 g, 0.04 mmol, 17% yield) as white solid. ESI-MS (M+1): 420 calc. for C₂₄H₂₉N₅O₂ 419.

Step 2. (S)-(1-(3-((1-(Quinolin-2-yl)Piperidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Methanol and (R)-(1-(3-((1-(Quinolin-2-yl)Piperidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Methanol

(1-(3-((1-(quinolin-2-yl)piperidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol (0.020 g, 0.04 mmol) was separated by chiral prep. HPLC (Column: Chiralcel OD-H 250*30 mm, 5u; Mobile phase: 85% hexane in EtOH (0.05% diethyl amine); Flow rate: 30 mL/minute) to give examples 2.1 and 2.2. as separated enantiomers, and the absolute configuration of each compound was not further determined

¹H NMR (CD₃OD, 400 MHz): δ (ppm) of the two separated isomers:

7.95 (d, J=9.2 Hz, 1H); 7.60-7.50 (m, 1H); 7.40-7.37 (m, 2H); 7.29-7.27 (m, 1H); 7.14-7.12 (m, 1H); 6.99 (d, J=9.2 Hz, 1H); 5.26-5.25 (m, 1H); 4.71-4.68 (m, 1H); 4.39-4.34 (m, 1H); 3.93-3.90 (m, 1H); 3.57-3.48 (m, 2H); 3.46-3.30 (m, 1H); 3.11 (m, 2H); 2.437-2.37 (m, 1H); 2.22-2.16 (m, 1H); 2.06-2.04 (m, 3H); 1.44-1.404 (m, 1H); 1.35-1.32 (m, 3H); 0.93-0.70 (m, 2H).

7.77 (d, J=9.2 Hz, 1H); 7.60 (d, J=2.8 Hz, 1H); 7.52 (s, 2H); 7.41-7.39 (m, 1H); 7.30-7.28 (m, 1H); 7.16-7.14 (m, 1H); 6.91 (d, J=9.2 Hz, 1H); 5.27 (s, 1H); 4.72-4.37 (m, 1H); 4.35-4.32 (m, 1H); 3.93-3.90 (m, 1H); 3.55-3.50 (m, 2H); 3.40-3.37 (m, 1H); 3.12-3.00 (m, 2H); 2.42-2.36 (m, 1H); 2.22-2.16 (m, 1H); 2.05 (s, 2H); 1.68-1.66 (m, 1H); 1.29-1.25 (m, 1H); 1.16-1.15 (m, 5H); 0.82-0.79 (m, 2H).

Example 3.1 1-(2-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridin-3-yl)Piperidine-4-Carbonitrile

A mixture of 2-(3-((3-bromopyridin-2-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.9; 177 mg, 0.50 mmol), piperidine-4-carbonitrile (55 mg, 0.50 mmol), Pd₂(dba)₃ (22 mg, 0.025 mmol), 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) (16 mg, 0.025 mmol) and t-BuONa (106 mg, 1.0 mmol) in toluene (10 mL) was stirred at 100° C. for 10 hours. The mixture was left to reach RT and filtered through a pad of CELITE® and the filter cake was washed with CH₂Cl₂ (30 mL). The combined filtrate was evaporated in vacuo and the residue was purified by flash column chromatography (30% to 50% EtOAc in petroleum ether) and followed by purification by reverse phase HPLC (10% to 80% water/MeCN) to afford 1-(2-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridin-3-yl)piperidine-4-carbonitrile (80 mg, 0.20 mmol, yield 40%). ESI-MS (M+1): 386 calc. for C₂₃H₂₃N₅O 385.

TABLE 2A EXAMPLES 3.1-3.9 PREPARED ANALOGOUS TO SCHEME 3 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 3.1

1-(5-fluoro-2-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyrridin-3- yl)piperidine-4- carbonitrile 404 0.0151  3.2

1-(2-((1-(quinolin-2- yl)azetidin-3- yl)oxy)puridin-3- yl)piperidine-4- carbonitrile 386 0.0689  3.3

(1-(5-methyl-2-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyridin-3- yl)piperidin-4- yl)methanol 405 0.00152 3.4

(1-(5-fluoro-2-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyridin-3- yl)piperidin-4- yl)methanol 409 0.00168 3.5

(1-(4-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-4- yl)methanol 391 0.00708 3.6

(1-(5-bromo-4-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 471 0.007  3.7

  (racemic mixture) (1-(5-bromo-4-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyrimidin-2- yl)piperidin-3- yl)methanol 470, 472 0.06   3.8

  (racemic mixture) (1-(5-bromo-4-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)pyrimidin-2- yl)piperidin-2- yl)methanol 470, 472 0.26   3.9

(1-(5-(piperidin-1-yl)-4- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 475 0.0184 

TABLE 2B PREPARATION AND NMR DATA OF EXAMPLES 3.1-3.9 Starting Materials Reaction ¹H NMR (CD₃OD, Ex. # (1) and (2) condition 400 MHz) δ (ppm) 3.1

  (see Preparation P2.9)  

Pd₂(dba)₃, BINAP, t-BuONa, toluene 8.31 (d, J = 9.2 Hz, 1H); 7.87 (d, J = 7.6 Hz, 1H); 7.77 (d, J = 1.2 Hz, 1H); 7.77-7.76 (m, 1H); 7.61-7.47 (m, 2H); 7.16-7.13 (m, 1H); 6.95 (d, J = 21.6 Hz, 1H); 5.59-5.48 (m, 1H); 4.95-4.89 (m, 2H); 4.54-4.50 (m, 2H) 3.34-3.27 (m, 2H); 3.03-2.93 (m, 3H); 2.10- 2.05 (m, 2H); 1.96-1.93 (m, 2H). 3.2

  (see Preparation P2.10)  

Pd₂(dba)₃, BINAP, t-BuONa, toluene 8.32 (d, J = 9.6 Hz, 1H); 7.87 (d, J = 7.6 Hz, 1H); 7.84-7.76 (m, 3H); 7.51-7.42 (m, 1H); 7.34- 7.31 (m, 1H); 6.99-6.95 (m, 2H); 5.65-5.62 (m, 1H); 4.96-4.92 (m, 2H); 4.56-4.52 (m, 2H) 3.33-3.30 (m, 2H); 3.02-2.94 (m, 3H); 2.11- 2.07 (m, 2H); 1.99-1.94 (m, 2H). 3.3

  (see Preparation P2.7)  

Pd₂(dba)₃, t- Butylxphos K₃PO₄, toluene 8.30 (s, 1H); 7.71-7.67 (m, 2H); 7.60-7.55 (m, 2H); 7.30-7.26 (m, 1H); 7.12 (d, J = 2.8 Hz, 1H); 6.77 (d, J = 9.2 Hz, 1H); 5.55- 5.54 (m, 1H); 4.71-4.60 (m, 2H); 4.26-4.22 (m, 2H); 3.44-3.43 (m, 2H); 3.31-3.29 (m, 2H); 2.59- 2.58 (m, 2H); 2.20 (s, 3H); 1.84- 1.80 (m, 2H); 1.61-1.30 (m, 3H). 3.4

  (see Preparation P2.10)  

Pd₂(dba)₃, t- Butylxphos K₃PO₄, toluene 8.01-7.99 (m, 1H); 7.68-7.47 (m, 4H); 7.21-7.12 (m, 2H); 6.75 (d, J = 9.2 Hz, 1H); 5.43-5.40 (m, 1H); 4.52-4.45 (m, 3H); 4.03- 4.00 (m, 2H); 3.25-3.23 (m, 2H); 3.50-3.11 (m, 3H); 2.51 (s, 2H); 1.70-1.67 (m, 2H); 1.29-1.19 (m, 1H). 3.5

  (see Preparation P3.1)  

Pd₂(dba)₃, BINAP, NaOtBu, toluene 8.16-8.14 (m, 2H); 7.89 (d, J = 8.8 Hz, 1H); 7.73 (d, J = 8.2 Hz, 1H); 7.61-7.59 (m, 2H); 7.25- 7.23 (m, 1H); 6.59 (d, J = 9.2 Hz, 1H); 6.46 (d, J = 4.2 Hz, 1H); 5.14-5.12 (m, 1H); 4.62- 4.58 (m, 2H); 4.26-4.23 (m, 2H) 3.52-3.50 (m, 4H); 2.83-2.62 (m, 3H); 1.83-1.80 (m, 2H); 1.63- 1.62 (m, 1H); 1.48-1.41 (m, 2H). 3.6

  (see Preparation P2.11)  

Pd₂(dba)₃, BINAP, NaOtBu, dioxane (CDCl₃) 8.07(s, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.50-7.45 (m, 1H), 7.19-7.14 (m, 1H), 6.53 (d, J = 8.8 Hz, 1H), 5.49-5.43 (m, 1H), 4.61-4.51 (m, 4H), 4.23-4.19 (m, 2H), 3.46- 3.39 (m, 2H), 2.83-2.76 (m, 2H), 1.76-1.68 (m, 3H), 1.20-1.10 (m, 2H). 3.7

  (see Preparation P2.11)  

  (racemic mixture) Pd₂(dba)₃, BINAP, NaOtBu, dioxane 8.35 (d, J = 9.2 Hz, 1H); 8.21- 8.19 (m, 1H); 7.99 (d, J = 8.0 Hz, 1H); 7.80-7.55 (m, 2H); 7.54-7.50 (m, 1H); 6.98 (d, J = 9.2 Hz, 1H); 5.67-5.646 (m, 1H); 5.01-4.94 (m, 2H); 4.64-4.58 (m, 4H); 3.56- 3.52 (m, 1H); 3.46-3.41 (m, 1H); 3.30-3.03 (m, 2H); 1.86-1.74 (m, 3H); 1.54-1.32 (m, 2H). 3.8

  (see Preparation P2.11)  

  (racemic mixture) Pd₂(dba)₃, BINAP, NaOtBu, dioxane 8.14 (s, 1H); 8.04 (d, J = 8.8 Hz, 1H); 7.70-7.68 (m, 2H); 7.66- 7.55 (m, 1H); 7.29-7.25 (m, 1H); 6.77 (d, J = 8.8 Hz, 1H); 5.59- 5.56 (m, 1H); 4.71-4.65 (m, 2H); 4.29-4.25 (m, 1H); 3.77-3.66 (m, 2H); 3.29-3.27 (m, 2H); 2.97- 2.99 (m, 1H); 2.95-2.94 (m, 1H); 1.91-1.97 (m, 1H); 1.71-1.64 (m, 5H). 3.9

  (see Preparation P6.1)  

Pd2(dba)3, BINAP, t-BuONa, toluene 8.39 (d, J = 9.6 Hz, 1H); 7.93- 7.90 (m, 2H); 7.82-7.80 (m, 2H); 7.56-7.52 (m, 1H); 7.01 (d, J = 9.2 Hz, 1H); 5.79 (s, 1H); 5.01- 4.99 (m, 2H); 4.71-4.67 (m, 4H); 3.47-3.46 (m, 1H); 3.35-3.25 (m, 4H); 3.16-3.11 (m, 2H); 1.93- 1.83 (m, 8H); 1.67-1.66 (m, 2H); 1.29 (s, 2H).

Example 4.1 (1-(2-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyridin-3-yl)Piperidin-4-yl)Methanol Step 1: 1-(2-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyridin-3-yl)Piperidine-4-Carbonitrile

To a solution of 2-(4-((3-bromopyridin-2-yl)oxy)piperidin-1-yl)quinoline (see PREPARATION P2.2; 383 mg, 1.0 mmol) in toluene (10 mL) were added piperidine-4-carbonitrile (110 mg, 1.0 mmol), Pd₂(dba)₃ (92 mg, 0.1 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) (62 mg, 0.1 mmol) and sodium tert-butoxide (t-BuONa) (180 mg, 2.0 mmol). The mixture was stirred and heated at reflux overnight under N₂ atmosphere. Then the reaction mixture was filtered, diluted with water (50 mL), and extracted with EtOAc (3×20 mL). The combined organic extracts were washed with water (60 mL) and brine (60 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 50% EtOAc in hexanes) to give the title product (290 mg, 0.7 mmol, 70% yield) as white solid. ESI-MS (M+1): 414 calc. for C₂₅H₂₇BrN₅O 413.

Step 2: 1-(2-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyridin-3-yl)Piperidine-4-Carbaldehyde

To a solution of 1-(2-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidine-4-carbonitrile (290 mg, 0.70 mol) in 20 mL of THF was added DIBAL-H (1.4 mol, 1 M in toluene) dropwise at −65° C. The mixture was stirred for 1 hour at RT and then quenched with saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc (2×20 mL) and the combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated to give the product (0.232 g, 0.56 mmol, 80% yield). ESI-MS (M+1): 417 calc. for C₂₅H₂₈N₄O₂ 416.

Step 3: (1-(2-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyridin-3-yl)Piperidin-4-yl)Methanol

To a solution of 1-(2-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyridin-3-yl)piperidine-4-carbaldehyde (232 mg, 0.56 mol) in 20 mL of THF was added DIBAL-H (1.4 mol, 1 M in toluene) dropwise at RT. The mixture was stirred for 1 hour at RT and then quenched with saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc (2×20 mL) and the combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated to give the product (0.150 g, 0.36 mmol, 60% yield). ESI-MS (M+1): 419 calc. for C₂₅H₃₀N₄O₂ 418. ¹H NMR (CD₃OD, 400 MHz) δ (ppm): 7.96 (d, J=9.2 Hz, 1H); 7.72-7.70 (m, 1H); 7.64-7.60 (m, 2H); 7.52-7.48 (m, 1H); 7.23-7.16 (m, 3H); 6.87-6.84 (m, 1H); 5.38 (s, 1H); 4.81-4.79 (m, 2H); 4.01-3.98 (m, 2H); 3.79-3.74 (m, 2H); 3.40-3.39 (m, 2H); 2.58-2.51 (m, 2H); 2.11-2.08 (m, 2H); 1.93-1.77 (m, 4H); 1.40-1.36 (m, 3H). PDE10 IC₅₀ (uM): 0.01.

Example 5.1 (Racemic Mixture) 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Ethanol Step 1. 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Ethanone

To a mixture of 2-(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.6; 312 mg, 1.0 mmol) and 1-(piperidin-4-yl)ethanone (127 mg, 1.0 mmol) and K₂CO₃ (276 mg, 2.0 mmol) was added i-PrOH (3 mL) and water (1.0 ml). The solution was heated to 160° C. under microwave for 5 hours. Then the mixture was concentrated and extracted with EtOAc (2×30 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in petroleum ether) to give the title product (72 mg, 0.18 mmol, 18% yield) as white solid. ESI-MS (M+1): 404 calc. for C₂₃H₂₅N₅O₂ 403.

Step 2: (Racemic Mixture) 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Ethanol

1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)ethanone (100 mg, 0.25 mmol) was dissolved in 10 ml of methanol. This solution was cooled down to 0° C. using an ice bath and sodium tetraborohydride (19 mg, 0.50 mmol) was added in portions. The reaction mixture was stirred for 4 hours at ambient temperature, and then saturated aqueous solution of ammonium chloride (5 mL) was added. The methanol was evaporated off under reduced pressure then the reaction mixture was taken up in ethyl acetate. The organic layer was separated from the aqueous layer. This extraction was repeated one more time and then the organic layers were combined and dried over magnesium sulphate, followed by concentrating under reduced pressure. The residue was purified by column chromatography on silica gel to give (racemic mixture) 1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)ethanol (75 mg, 0.19 mmol, 75% yield). ESI-MS (M+1): 406 calc. for C₂₃H₂₇N₅O₂ 405.

TABLE 3A EXAMPLES 5.1-5.2 PREPARED ANALOGOUS TO SCHEME 5 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 5.1

  (as racemic mixture) 1-(1-(3-((1-quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4-yl)ethanol 406 0.0469 5.2

  (as racemic mixture) 1-(1-(5-bromo-4-((1- (quinolin-2-yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4-yl)ethanol 484, 486 0.242 

TABLE 3B PREPARATION AND NMR DATA OF EXAMPLES 5.1-5.2 ¹H NMR (CDCl₃, Ex. # Starting material (1) Reaction condition 400 MHz) δ (ppm) 5.1

NaBH₄, MeOH 8.35 (d, J = 9.2 Hz, 1H); 7.90 (d, J = 7.6 Hz, 1H); 7.82-7.13 (m, 4H); 6.94 (d, J = 5.6 Hz, 1H); 5.68-5.63 (m, 1H); 4.61-4.57 (m, 2H); 4.64-4.60 (m, 2H); 4.20- 4.15 (m, 2H); 3.54-3.51 (m, 1H); 2.94-2.6 (m, 2H); 1.98- 1.95 (m, 1H); 1.93-1.76 (m, 1H); 1.76-1.73 (m, 4H); 1.17-1.16 (d, 3H). 5.2

NaBH₄, MeOH 8.09 (s, 1H); 7.90 (d, J = 9.2 Hz, 1H); 7.64-7.59 (m, 2H); 7.52-7.50 (m, 1H); 7.20- 7.19 (m, 1H); 6.61(d, J = 9.2 Hz, 1H); 5.45 (s, 1H); 4.67-4.63 (m, 2H); 4.55- 4.51 (m, 2H); 4.16-4.12 (m, 2H); 3.50-47 (m, 1H); 3.32- 3.27 (m, 2H); 1.98-1.88 (m, 1H); 1.68-1.65 (m, 1H); 1.52-1.51 (m, 1H); 1.50- 1.48 (m, 2H); 1.15-1.13 (m, 3H).

Example 6.1 1-(4-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperazin-1-yl)Ethanone Step 1. 2-(4-((3-(Piperazin-1-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline

To a mixture of 2-(4-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline (see PREPARATION P2.1; 0.34 g, 1.0 mmol) and piperazine (0.83 g, 1.0 mmol) and K₂CO₃ (0.27 g, 2.0 mmol) was added i-PrOH (2 mL) and water (0.5 ml). The solution was heated to 160° C. under microwave for 5 hours. Then the mixture was concentrated and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in petroleum ether) to give the title product (0.11 g, 0.30 mmol, 30% yield) as white solid. ESI-MS (M+1): 391 calc. for C₂₂H₂₆N₆O 390.

Step 2. 1-(4-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperazin-1-yl)Ethanone

To a solution of 2-(4-((3-(piperazin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline (130 mg, 0.33 mmol) in dry DCM (10 mL) was added Et₃N (1 mL). The reaction mixture was cooled to 0° C. with an ice bath, and acetyl chloride (80 mg, 0.66 mmol) was added dropped to the reaction mixture. 1 hour later, the reaction mixture was warmed to RT, and stirred overnight. Then the reaction mixture was washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum to give the crude product. The crude product was purified via flash chromatography on silica gel (20% to 45% EtOAc in petroleum ether) to give 1-(4-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperazin-1-yl)ethanone (108 mg, 0.25 mmol, 78% yield) as a white solid. ESI-MS (M+1): 433 calc. for C₂₄H₂₈N₆O₂ 432.

TABLE 4A EXAMPLES 6.1-6.4 PREPARED ANALOGOUS TO SCHEME 6 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 6.1

1-(4-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperazin-1- yl)ethanone 433 0.0306 6.2

1-(6-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2-yl)-2,6- diazaspiro[3.3]heptan- 2-yl)ethanone 445 1.27  6.3

(1-(4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperazin-1- yl)ethanone 405 0.0775 6.4

1-(4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2-yl)- 1,4-diazepan-1- yl)ethanone 419 0.0903

TABLE 4B PREPARATION AND NMR DATA OF EXAMPLES 6.1-6.4 Starting Reaction ¹H NMR (CD₃OD, 400 Ex. # Starting Material (1) Material (2) Condition MHz) δ (ppm) 6.1

  Prepared from compound of preparation P2.1 and piperazine according to Scheme 3

Et₃N, DCM 7.95-7.88 (m, 1H); 7.70- 7.57 (m, 4H); 7.50-7.46 (m, 1H); 7.21-7.12 (m, 2H); 5.41-5.39 (m, 1H); 4.05-3.99 (m, 2H); 3.71- 3.63 (m, 4H); 3.59-3.57 (m, 2H); 3.51-3.43 (m, 4H); 2.14-2.10 (m, 2H); 2.14 (s, 3H); 1.92-1.84 (m, 2H). 6.2

  Prepared from compound of preparation P2.1 and 2,6- diazaspiro[3.3]heptane according to Scheme 3

Et₃N, DCM 7.88 (d, J = 9.2 Hz, 1H); 7.71 (d, J = 8.0 Hz, 1H); 7.59-7.53 (m, 2H); 7.52- 7.49 (m, 1H); 7.37-7.36 (m, 1H); 7.24-7.19 (m, 1H); 7.01 (d, J = 9.2 Hz, 1H); 5.35-5.31 (m, 1H); 4.29-4.23 (m, 6H); 4.09- 4.02 (m, 4H); 3.71-3.65 (m, 2H); 2.129-2.09 (m, 2H); 1.92-1.89 (m, 2H); 1.82 (s, 3H). 6.3

  Prepared from compound of preparation P2.6 and piperazine according to Scheme 3

TEA, DCM 7.97 (d, J = 8.8 Hz, 1H); 7.70 (d, J = 7.6 Hz, 1H); 7.67-7.63 (m, 2H); 7.59 (d, J = 3.2 Hz, 1H); 7.55- 7.51 (m, 1H); 7.24-7.20 (m, 1H); 6.70 (d, J = 8.8 Hz, 1H); 5.59-5.56 (m, 1H); 4.64-4.60 (m, 2H); 4.22-4.13 (m, 2H); 3.69- 3.50 (m, 8H); 2.10 (s, 3H). 6.4

  Prepared from compound of preparation P2.6 and 1,4- diazepane according to Scheme 3

TEA, DCM 8.31 (d, J = 9.6 Hz, 1H); 7.87 (d, J = 8.0 Hz, 1H); 7.76-7.78 (m, 3H); 7.51- 7.49 (m, 1H); 7.43-7.42 (m, 1H); 6.95 (d, J = 9.6 Hz, 1H); 5.63 (s, 1H); 4.94-4.93 (m, 2H); 4.61- 4.58 (m, 2H); 3.95-3.84 (m, 4H); 3.79-3.76 (m, 2H); 3.60-3.53 (m, 2H); 2.06-1.95 (m, 5H).

Example 7.1 2-(4-((3-(4-Methoxypiperidin-1-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline

To a solution of 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-ol (see EXAMPLE 1.1; 100 mg, 0.25 mmol) in dry acetonitrile (CH₃CN) (10 mL) was added Cs₂CO₃ (162 mg, 0.5 mmol). The reaction mixture was cooled to 0° C. with an ice bath, and iodomethane (70 mg, 0.50 mmol) was added dropwise to the reaction mixture. 1 hour later, the reaction mixture was warmed to RT, and stirred overnight. Then the reaction mixture was washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum to give the crude product. The crude product was purified via flash chromatography on silica gel (20% to 45% EtOAc in petroleum ether) to give 2-(4-((3-(4-methoxypiperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline (81 mg, 0.19 mmol, 78% yield) as a white solid. ESI-MS (M+1): 420 calc. for C₂₄H₂₉N₅O₂ 419.

TABLE 5A EXAMPLES 7.1-7.2 PREPARED ANALOGOUS TO SCHEME 7 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 7.1

2-(4-((3-(4- methoxypiperidin-1- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 420 0.0596 7.2

2-(4-((3-(4- (methoxy- methyl)piperidin- 1-yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 434 1.12 

TABLE 5B PREPARATION AND NMR DATA OF EXAMPLES 7.1-7.2 ¹H NMR Ex. Starting Reaction (CD₃OD, 400 MHz) # Starting Material (1) Material (2) Condition δ (ppm) 7.1

CH₃I Cs₂CO₃, CH₃CN 7.95 (d, J = 9.2 Hz, 1H); 7.65-7.51 (m, 5H); 7.22-7.15 (m, 2H); 5.42-5.39 (m, 1H); 4.41-4.01 (m, 1H); 3.99-3.41 (m, 6H); 3.15 (s, 3H); 3.12-3.08 (m, 2H); 2.15-2.10 (m, 2H); 1.99-1.87 (m, 4H); 1.60-1.56 (m, 2H). 7.2

CH₃I Cs₂CO₃, CH₃CN 7.95 (d, J = 9.2 Hz, 1H); 7.63-7.60 (m, 3H); 7.50-7.49 (m, 2H); 7.19-7.15 (m, 2H); 5.46-5.38 (m, 1H); 4.17-4.14 (m, 2H); 3.99-3.94 (m, 2H); 3.78-3.72 (m, 2H); 3.32-3.20 (m, 7H); 2.79-2.72 (m, 2H); 2.13-2.09 (m, 2H); 1.77-1.72 (m, 3H); 1.33-1.30 (m, 2H).

Example 8.1 1-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperidin-4-One

1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-ol (see Example 1.1; 0.10 g, 0.25 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL), treated with Dess-Martin periodinane (DMP) (200 mg, 0.50 mmol, 2.0 equiv) and stirred at RT until complete conversion. The organic layer was washed with an aqueous solution of NaHCO₃/Na₂S₂O₃ (3×10 mL)), dried over Na₂SO₄, filtered and evaporated. The resulting residue was purified by flash chromatography on silica gel (20% to 40% EtOAc in petroleum ether) to give 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-one (0.084 g, 0.20 mmol, 83% yield) as a white solid. ESI-MS (M+1): 404 calc. for C₂₃H₂₅N₅O₂ 403.

TABLE 6A EXAMPLES 8.1-8.2 PREPARED ANALOGOUS TO SCHEME 8 Ex. IC₅₀ # Structure Chemical Name M + 1 (uM) 8.1

1-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-4-one 404 0.195 8.2

1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-4-one 376 0.11 

TABLE 6B PREPARATION AND NMR DATA OF EXAMPLES 8.1-8.2 ¹H NMR Ex. Reaction (CDCl₃, 400 MHz) # Starting Material (1) Condition δ (ppm) 8.1

DMP, DCM 7.86 (d, J = 9.6 Hz, 1H); 7.72- 7.68 (m, 2H); 7.58-7.49 (m, 3H); 7.21-7.191 (m, 1H); 7.10 (d, J = 9.2 Hz, 1H); 5.42-5.40 (m, 1H); 4.13-4.07 (m, 2H); 3.86-3.83 (m, 4H); 3.67-3.61 (m, 2H); 2.53- 2.50 (m, 4H); 2.20-2.15 (m, 2H); 1.94-1.89 (m, 2H). 8.2

DMP, DCM 7.83 (d, J = 8.8 Hz, 1H); 7.74- 7.73 (m, 2H); 7.56-7.48 (m, 3H); 7.19-7.17 (m, 1H); 6.54 (d, J = 9.2 Hz, 1H); 5.52 (s, 1H); 4.62- 4.58 (m, 2H); 4.20-4.17 (m, 2H); 3.84-3.81 (m, 4H); 2.50-2.47 (m, 4H).

Example 9.1 2-(1-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Propan-2-Ol Step 1. Methyl 1-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperidine-4-Carboxylate

To a mixture of 2-[4-(3-chloro-pyrazin-2-yloxy)-piperidin-1-yl]-quinoline (see PREPARATION P2.1; 0.34 g, 1.0 mmol) and methyl piperidine-4-carboxylate (0.14 g, 1.0 mmol) and K₂CO₃ (0.27 g, 2.0 mmol) was added i-PrOH (2 mL) and water (0.5 ml). The solution was heated to 160° C. under microwave for 5 hours. Then the mixture was concentrated and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 60% EtOAc in petroleum ether) to give the title product (0.12 g, 0.27 mmol, 27% yield) as white solid. ESI-MS (M+1): 448 calc. for C₂₅H₂₉N₅O₃ 447.

Step 2. 2-(1-(3-((1-(Quinolin-2-yl)Piperidin-4-yl)Oxy)Pyrazin-2-yl)Piperidin-4-yl)Propan-2-ol

To a methyl 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidine-4-carboxylater (130 mg, 0.30 mol) in 20 mL of THF was added CH₃MgBr (0.50 mol, 3 M in ether) dropwise at RT. The mixture was stirred for 1 hour at RT and then quenched with saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc (2×20 mL) and the combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated to give crude product which was purified by silica gel chromatography (EtOAc:Petrol ether=1:1) to give 2-(1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-yl)propan-2-ol (0.125 g, 0.28 mmol, 66% yield) as a white solid. ESI-MS (M+1): 448 calc. for C₂₆H₃₃N₅O₂ 447.

TABLE 7A EXAMPLES 9.1-9.2 PREPARED ANALOGOUS TO SCHEME 9 Ex. IC₅₀ # Structure Chemical Name M + 1 (uM) 9.1

2-(1-(3-((1-(quinolin-2- yl)piperidin-4- yl)oxy)pyrazin- 2-yl)piperidin- 4-yl)propan-2-ol 448 0.0858 9.2

2-(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin- 2-yl)piperidin- 4-yl)propan-2-ol 420 0.0836

TABLE 7B PREPARATION AND NMR DATA OF EXAMPLES 9.1-9.2 ¹H NMR Ex. Starting Reaction (CDCl₃, 400 MHz) # Starting Material (1) Material (2) Condition δ (ppm) 9.1

CH₃MgBr THF 7.89-7.86 (m, 1H); 7.69- 7.67 (m, 2H); 7.57 (d, J = 8.0 Hz, 1H); 7.53-7.48 (m, 2H); 7.24-7.18 (m, 1H); 7.01 (d, J = 9.2 Hz, 1H); 5.36-5.41 (m, 1H); 4.30-4.27 (m, 2H); 4.07- 4.01 (m, 2H); 3.89-3.73 (m, 2H); 2.73-2.67 (m, 2H); 2.17-2.12 (m, 2H); 1.97-1.90 (m, 2H); 1.81- 1.78 (m, 2H); 1.48-1.40 (m, 3H); 1.16 (s, 6H). 9.2

CH₃MgBr THF (CDCl₃) 7.85 (d, J = 8.8 Hz, 1H); 7.75-7.73 (m, 2H); 7.58 (d, J = 8.0 Hz, 1H); 7.57-7.52 (m, 2H); 7.24-7.20 (m, 1H); 6.57 (d, J = 8.8 Hz, 1H); 5.54- 5.50 (m, 1H); 4.64-4.60 (m, 2H); 4.28-4.21 (m, 4H); 2.74-2.39 (m, 2H); 1.82-1.79 (m, 3H); 1.29- 1.20 (m, 2H); 1.16 (s, 6H).

Example 10.1 2-(4-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline

To a solution of 2-(4-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline (see PREPARATION P2.1; 340 mg, 1.0 mmol), 3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (see PREPARATION P12.1; 219 mg, 1.0 mmol) and K₃PO₄ (424 mg, 2.0 mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) was added Pd(dppf)Cl₂ (73 mg, 0.1 mmol) then the reaction mixture was stirred at 110° C. under N₂ atmosphere overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂ (30 mL). The filtrate was concentrated and the crude product was purified by silica gel column to give 2-(4-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline (200 mg, 0.50 mmol, yield 60%). ESI-MS (M+1): 398 calc. for C₂₄H₂₃N₅O 397.

TABLE 8A EXAMPLES 10.1-10.78 PREPARED ANALOGOUS TO SCHEME 10 Ex. ESI-MS IC₅₀ # Structure Chemical Name (M + 1) (uM) 10.1 

2-(4-((3-(3- methylpyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 398 0.0347 10.2 

2-(4-((3-(pyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 384 0.0357 10.3*

2-(4-((3-(pyridin-3- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 384 Not available 10.4 

2-(4-((3-(2- methoxypyridin-3- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 414 0.118  10.5 

2-{4-[3-(2-Methyl- pyridin-4-yl)-pyrazin- 2-yloxy]-piperidin-1- yl}-quinoline 398 0.0816 10.6 

2-(4-((3-(3- chloropyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 418 0.0839 10.7 

2-(3-((3-(3- methylpyridin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 370 0.298  10.8 

2-(3-((3-(3- chloropyridin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 390 0.155  10.9 

2-(3-((3-(2- methoxypyridin-3- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 386 0.0837 10.10

2-(3-((3-(o- tolyl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 369 0.128  10.11

2-(3-((3-(2-methoxy- phenyl)pyrazin-2- yl)oxy)azetidin- 1-yl)quinoline 385 0.15  10.12

2-(3-((3-(pyridin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 356 0.0245 10.13

2-(3-((3-(pyridin-2- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 356 1.22  10.14

2-(3-((3-(2- fluoropyridin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 374 0.0395 10.15

2-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzonitrile 380 0.377   10.16*

2-(3-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 369 Not available 10.17

3-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzonitrile 380 0.0413 10.18

4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzonitrile 380 0.0394 10.19

2-(3-((3-(p- tolyl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 369 0.0987 10.20

2-(3-((3-(4-fluoro-2- methylphenyl)pyrazin- 2-yl)oxy)azetidin-1- yl)quinoline 387 0.918  10.21

2-(3-((3- phenylpyrazin-2- yl)oxy)azetidin-1- yl)quinoline 355 0.0961 10.22

N,N-dimethyl-4-(3- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzamide 426 0.015  10.23

1-(3-(3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)phenyl)ethanone 397 0.0112 10.24

2-(3-((3-(3- (methoxy- methyl)phen- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 399 0.0452 10.25

N,N-dimethyl-3-(3- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzamide 426 0.0228 10.26

1-(4-(3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)phenyl)ethanone 397 0.0244 10.27

N-methyl-4-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)benzamide 412 0.015  10.28

5-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)picolinonitrile 381 0.0506 10.29

(R)-2-(3-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)pyrrolidin-1- yl)quinoline 398 0.255  10.30

(S)-2-(3-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)pyrrolidin-1- yl)quinoline 398 0.639  10.31

2-(3-((2-(pyridin-3- yl)pyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 356 0.0356 10.32

2-(3-((2-(pyridin-4- yl)pyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 356 0.0323 10.33

4-(4-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)aniline 370 0.110  10.34

2-(3-((3-(6- fluoropyridin-3- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 374 0.0457 10.35

2-(3-((3-(4- methylpyridin-3- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 370 0.251  10.36

2-(3-((3-(2- methylpyridin-3- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 370 0.135  10.37

2-(3-((3-(3- methoxy- phenyl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 385 0.019  10.38

2-(3-((3-(3- methoxy- phenyl)pyrazin-2- yl)oxy)azetidin-1- yl)quinazoline 386 0.148  10.39

2-(3-((3-(2- methoxypyridin-3- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinazoline 387 0.1780 10.40

2-((1-(quinolin-2- yl)azetidin-3-yl)oxy)- 3-(m-tolyl)quinoxaline 419 0.0535 10.41

2-(3-((3-(3,6-dihydro- 2H-pyran-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 361 0.0149 10.42

2-(3-((3-(5-benzyl-1- benzofuran-2-yl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 485 0.363  10.43

6-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)-2- quinazolinamine 422 0.0033 10.44

2-(3-((3-(6-methoxy- 3-pyridinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 386 0.0254 10.45

2-(3-((3-(1,3- benzothiazol-5-yl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 412 0.0307 10.46

2-(3-((3-(6-chloro-3- pyridinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 390 0.0097 10.47

2-(3-((3-(3- bromophenyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 433 0.0459 10.48

(3-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)phen- yl)methanol 385 0.0233 10.49

(4-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl(phen- yl)methanol 385 0.0105 10.50

2-(3-((3-(5- quinolinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 406 0.087  10.51

2-(3-((3-(5-phenyl-2- thiophenyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 437 0.254  10.52

2-(3-((3-(3-pyridinyl)- 2-pyrazinyl)oxy)-1- azetidinyl)quinoline 356 0.0137 10.53

2-(3-((3-(3- quinolinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 406 0.0193 10.54

methyl 4-(3-((1-(2- quinolinyl)-3- azetidinyl)oxy)-2- pyrazinyl)benzoate 413 0.0432 10.55

2-(3-((3-(3-fluoro- 5-(1-methyl- ethoxy)phenyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 431 0.174  10.56

2-(3-((3-(5- pyrimidinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 357 0.0821 10.57

2-(3-((3-(2-methyl-4- pyridinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 370 0.0127 10.58

2-(3-((3-(2-methoxy- 5-pyrimidinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 387 0.0428 10.59

2-(3-((3-(6- (cyclopropylmethoxy)- 3-pyridinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 426 0.0502 10.60

2-(3-((3-(6-methyl-3- pyridinyl)-2- pyrazinyl)oxy)-1- azetidinyl)quinoline 370 0.0078 10.61

(1-(5-(3-methoxy- phenyl)-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 498 0.0033 10.62

(l-(5-(2- methylpyridin-4-yl)-4- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 483 0.0003 10.63

(1-(5-(2- methoxypyridin-3-yl)- 4-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 499 0.0006 10.64

(1-(5-(6- methylpyridin-3-yl)-4- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 483 0.0002 10.65

(1-(5-(3,6-dihydro-2H- pyran-4-yl)-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl(methanol 474 0.0011 10.66

tert-butyl 4-(2-(4- (hydroxy- methyl)piperidin- 1-yl)-4- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-5- yl)-5,6-dihydro- pyridine-1(2H)- carboxylate 573 0.0003 10.67

(1-(5-(2-methoxy- pyridin-3-yl)- 4-((1-(quinazolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 500 0.0031 10.68

(1H-benzo[d]imidazol- 2-yl)(3-(3-(2- methylpyridin-4- yl)pyrazin-2- yloxy)azetidin-1- yl)methanone 387 0.156  10.69

benzyl 3-(3′-methoxy- 3,4′-bipyridin-2- yloxy)azetidine-1- carboxylate   393.2 7.641  10.70

(1H- Benzo[d]imidazol- 2-yl)(4-(3- (pyridine-4- yl)pyrazin-2- yloxy)piperidin-1- yl)methanone. 401 0.2295 10.71

(1H-benzo[d]imidazol- 2-yl)(3-((3-(3,6- dihydro-2H-pyran-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)methanone 378 0.222  10.72

tert-butyl 3-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyrazin-2-yl)- 3,4-dihydropyridine- 1(2H)-carboxylate   477.2 0.227  10.73

tert-butyl 5-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyrazin-2-yl)- 3,4-dihydropyridine- 1(2H)-carboxylate   477.2 0.0365 10.74

2-(3-((3-(m- tolyl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 369 0.0573 10.75

2-(3-methoxyphenyl)- 3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)quinoxaline 435  0.00668 10.76

2-(2-methoxypyridin- 3-yl)-3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)quinoxaline 436 0.0055 10.77

2-(3-((2-(pyridin-2- yl)pyrimidin-4- yl)oxy)azetidin-1- yl)quinoline 355 0.109  10.78

(4-(4-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)phenyl)methanol 384  0.00845 *Note: Examples 10.3 and 10.15 can be prepared according to Scheme 10. However, NMR data of pure products are not available.

TABLE 8B PREPARATION AND NMR DATA OF EXAMPLES 10.1-10.78 ¹H NMR Ex. Starting Reaction (CD₃OD, 400 MHz) # Starting Material (1) Material (2) Condition δ (ppm) 10.1 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.83-8.74 (m, 2H); 8.42- 8.40 (m, 3H); 8.20-8.10 (m, 1H); 7.90-7.88 (m, 3H); 7.54-7.48 (m, 2H); 5.65-5.61 (m, 1H); 4.01- 3.93 (m, 4H); 2.45 (s, 3H); 2.35-2.30 (m, 2H); 2.07-2.02 (m, 2H). 10.2 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.59 (dd, J = 1.6, 0.4 Hz, 2H); 8.30 (d, J =2.4 Hz, 1H); 8.23 (d, J = 2.8 Hz, 1H); 8.09 (dd, J = 1.6, 2.0 Hz, 2H); 7.94 (d, J = 4.8 Hz, 1H); 7.95-7.93 (m, 2H); 7.62-7.51 (m, 1H); 7.47-7.14 (m, 2H); 5.54-5.52 (m, 1H); 4.08- 4.03 (m, 2H); 3.64-3.62 (m, 2H); 2.17-2.15 (m, 2H); 1.94-1.90 (m, 2H) 10.3*

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water See * note. 10.4 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.20-8.17 (m, 3H); 7.94 (d, J = 9.2 Hz, 1H); 7.74 (d, J = 5.2 Hz, 1H); 7.62-7.59 (m, 2H); 7.51- 7.47 (m, 1H); 7.20-7.07 (m, 2H); 7.06-7.04 (m, 1H); 5.43-5.39 (m, 1H); 3.86 (s, 5H); 3.70-3.63 (m, 2H); 2.10-2.04 (m, 2H); 1.85-1.77 (m, 2H). 10.5 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.29 (d, J = 2.8 Hz, 1H); 8.23-8.10 (m, 2H); 7.96- 7.89 (m, 3H); 7.63-7.61 (m, 3H); 7.22-7.15 (m, 2H); 5.56-5.53 (m, 1H); 4.06-4.00 (m, 2H); 3.74- 3.68 (m, 2H); 2.56 (s, 3H); 2.21-2.16 (m, 2H); 1.97-1.91 (m, 2H). 10.6 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.69-8.60 (m, 2H); 8.35- 8.34 (m, 3H); 7.95-7.90 (m, 3H); 7.53-7.46 (m, 3H); 5.61-5.58 (m, 1H); 3.97-3.93 (m, 4H); 2.67- 2.32 (m, 2H); 2.09-2.02 (m, 2H). 10.7 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.70-8.60 (m, 2H); 8.41 (d, J = 2.0 Hz, 1H); 8.07 (d, J = 8.8 Hz, 1H); 7.94 (s, 1H); 7.85- 7.83 (m, 1H); 7.64-7.58 (m, 2H); 7.37-7.34 (m, 2H); 6.63 (d, J = 8.8 Hz, 1H); 5.65 (s, 1H); 4.94- 4.50 (m, 4H); 2.4 (s, 3H). 10.8 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.75-8.60 (m, 2H); 8.45-8.31 (m, 3H); 7.78-7.72 (m, 3H); 7.32 (d, J = 5.2 Hz, 1H); 7.52-7.48 (m, 1H); 6.95- 6.93 (m, 1H); 5.76-5.73 (m, 1H); 4.96-4.91 (m, 2H); 4.52-4.48 (m, 2H). 10.9 

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.28-8.27 (m, 2H); 8.26-8.07 (m, 2H); 7.91 (d, J = 8.0 Hz, 1H); 7.75-7.73 (m, 1H); 7.70- 7.66 (m, 2H); 7.44-7.40 (m, 1H); 7.03-7.00 (m, 1H); 6.56 (d, J = 9.6 Hz, 1H); 5.64-5.62 (m, 1H); 5.10-4.46 (m, 4H); 3.89 (s, 3H). 10.10

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.29 (d, J = 2.4 Hz, 1H); 8.08 (d, J = 5.6 Hz, 1H); 7.83 (d, J = 8.8 Hz, 1H); 7.72 (d, J = 8.4 Hz, 1H); 7.59-7.52 (m, 2H); 7.36-7.21 (m, 5H); 6.53 (d, J = 8.8 Hz, 1H); 5.55 (s, 1H); 4.60-4.56 (m, 2H); 4.16-4.13 (m, 2H); 2.22 (s, 3H). 10.11

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.30-8.25 (m, 1H); 8.09-8.03 (m, 1H); 7.83-7.81 (m, 1H); 7.74- 7.72 (m, 1H); 7.57-7.50 (m, 3H); 7.40-7.35 (m, 2H); 7.24-7.19 (m, 1H); 7.05-7.01 (m, 1H); 6.56 (d, J = 8.8 Hz, 1H); 5.58-5.55 (m, 1H); 4.60- 4.58 (m, 2H); 4.56-4.12 (m, 2H); 2.22 (s, 3H). 10.12

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.71-8.60 (m, 2H); 8.30-8.29 (s, 1H); 8.07 (d, J = 2.8 Hz, 1H); 7.95-7.97 (m, 2H); 7.81 (d, J = 8.4 Hz, 1H); 7.54-7.52 (m, 1H); 7.49- 7.45 (m, 2H); 7.18-7.15 (m, 1H); 6.53 (d, J = 8.8 Hz, 1H); 5.60-5.57 (m, 1H); 4.62-4.58 (m, 2H); 4.23-4.20 (m, 2H). 10.13

Pd(PPh₃)₄, toluene 9.09-8.97 (m, 2H); 8.74- 8.70 (m, 2H); 8.70-8.60 (m, 1H); 8.51 (d, J = 2.4 Hz, 1H); 8.33 (d, J = 9.6 Hz, 1H); 8.12-8.09 (m, 1H); 7.86 (d, J = 8.4 Hz, 1H); 7.78-7.76 (m, 2H); 7.47-7.50 (m, 1H); 6.98 (d, J = 9.2 Hz, 1H); 5.91-5.88 (m, 1H); 5.153-5.03 (m, 4H). 10.14

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.39-8.34 (m, 2H); 8.29- 8.16 (m, 1H); 8.11-8.09 (m, 2H); 7.96-7.89 (m, 4H); 7.52-7.24 (m, 1H); 6.64-6.62 (m, 1H); 5.69 (s, 1H); 5.25-5.01 (m, 2H); 4.91-4.63 (m, 2H).  10.15*

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water See * note. 10.16

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 7.74 (s, 1H); 7.65 (d, J = 8.4 Hz, 1H); 7.50-7.42 (m, 6H); 7.26- 7.22 (m, 1H); 7.14-7.10 (m, 2H); 6.47 (d, J = 8.8 Hz, 1H); 5.52-5.49 (m, 1H); 4.56-4.52 (m, 2H); 4.51-4.15 (m, 2H); 2.31 (s, 3H). 10.17

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.35 (s, 1H); 8.34-8.30 (m, 1H); 8.1 (d, J = 0.28 Hz, 1H); 7.75 (d, J = 3.6 Hz, 1H); 7.65 (d, J = 7.6 Hz, 2H); 7.59-7.459 (m, 3H); 7.24-7.19 (m, 1H); 5.61- 5.57 (m, 1H); 6.58 (d, J = 8.8 Hz, 1H); 5.64-5.61 (m, 1H); 4.66-4.62 (m, 2H); 4.26-4.23 (m, 2H). 10.18

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.25 (d, J = 1.6 Hz, 1H); 8.21 (d, J = 2.8 Hz, 1H); 7.87-7.82 (m, 3H); 7.80-7.55 (m, 5H); 7.50-7.46 (m, 1H); 6.95 (d, J = 9.6 Hz, 1H); 5.77-5.73 (m, 1H); 5.00- 4.91 (m, 2H); 4.64-4.60 (m, 2H). 10.19

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.27 (d, J = 2.8 Hz, 1H); 8.00-7.97 (m, 3H); 7.86 (d, J = 9.2 Hz, 1H); 7.74 (d, J = 8.4 Hz, 1H); 7.60-7.51 (m, 2H); 7.26-7.20 (m, 3H); 6.58 (d, J = 9.2 Hz, 1H); 5.63-5.59 (m, 1H); 4.06- 4.62 (m, 2H); 4.29-4.25 (m, 2H); 2.38 (s, 3H). 10.20

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.33-8.22 (m, 3H); 7.84 (d, J = 8.0 Hz, 1H); 7.74-7.73 (m, 2H); 7.47 (s, 1H); 7.36-7.34 (m, 1H); 7.03-6.97 (m, 2H); 6.89-6.87 (m, 1H); 5.70- 5.67 (m, 1H); 4.939-4.89 (m, 2H); 4.47-4.43 (m, 2H); 2.18 (s, 3H). 10.21

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.28-8.25 (m, 1H); 8.10- 8.08 (m, 1H); 7.98-7.95 (m, 2H); 7.84 (d, J = 8.8 Hz, 1H); 7.61-7.55 (m, 2H); 7.47-7.30 (m, 4H); 7.19-7.16 (m, 1H); 6.55 (d, J = 8.8 Hz, 1H); 5.52-5.49 (m, 1H); 4.54- 4.49 (m, 2H); 4.13-4.09 (m, 2H). 10.22

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.23 (s, 1H); 8.10-8.06 (m, 1H); 7.85 (s, 3H); 7.61-7.54 (m, 2H); 7.45- 7.43 (m, 3H); 7.16-7.15 (m, 1H); 6.55 (d, J = 8.8 Hz, 1H); 5.52 (s, 1H); 4.54-4.50 (m, 2H); 4.151-4.11 (m, 2H); 3.03 (s, 3H); 2.91 (s, 3H). 10.23

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.63 (s, 1H); 8.35 (d, J = 1.6 Hz, 1H); 8.25 (d, J = 7.6 Hz, 1H); 8.08-8.06 (m, 2H); 7.99- 7.97 (m, 2H); 7.65-7.63 (m, 2H); 7.39-7.35 (m, 1H); 7.25 (s, 1H); 6.61- 6.59 (m, 1H); 5.64 (s, 1H); 5.01-4.58 (m, 4H); 2.62 (s, 3H). 10.24

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.33 (d, J = 2.4 Hz, 1H); 8.90-7.09 (m, 5H); 7.66- 7.62 (m, 2H); 7.47-7.36 (m, 3H); 6.57 (d, J = 9.2 Hz, 1H); 5.60 (s, 1H); 5.07-4.70 (m, 5H); 4.43- 4.33 (m, 1H); 3.39 (s, 3H). 10.25

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.30 (s, 1H); 8.08-8.03 (m, 4H); 7.83- 7.82 (m, 1H); 7.64-7.59 (m, 2H); 7.49-7.34 (m, 2H); 7.32-7.25 (m, 1H); 6.61 (d, J = 7.6 Hz, 1H); 5.59 (s, 1H); 5.03-4.44 (m, 4H); 3.09 (s, 3H); 3.00 (s, 3H). 10.26

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.36 (d, J = 2.4 Hz, 1H); 8.17-7.98 (m, 7H); 7.68-7.64 (m, 2H); 7.40-7.37 (m, 1H); 6.59 (d, J = 9.2 Hz, 1H); 5.65 (s, 1H); 5.02-4.62 (m, 4H); 3.61 (s, 3H). 10.27

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.31-8.25 (m, 2H); 8.09- 8.08 (m, 2H); 8.07-7.79 (m, 3H); 7.70-7.69 (m, 2H); 7.43-7.39 (m, 1H); 6.90-6.87 (m, 1H); 5.69- 5.65 (m, 1H); 4.92-4.88 (m, 4H); 4.55-4.51 (m, 2H); 2.84 (s, 3H). 10.28

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 9.42 (s, 1H); 8.52 (d, J = 6.0 Hz, 1H); 8.31 (d, J = 5.2 Hz, 1H); 8.11 (d, J = 5.6 Hz, 1H); 7.83 (d, J = 9.2 Hz, 1H); 7.69 (d, J = 8.4 Hz, 1H); 7.79-7.15 (m, 1H); 7.55- 7.46 (m, 2H); 7.29-7.15 (m, 1H); 6.54 (d, J = 8.8 Hz, 1H); 5.63-5.61 (m, 1H); 4.65-4.61 (m, 2H); 4.24-4.21 (m, 2H). 10.29

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.51 (d, J = 4.4 Hz, 1H); 8.59-8.50 (m, 2H); 8.45-8.46 (m, 2H); 8.37- 8.40 (m, 1H); 7.89-7.96 (m, 2H); 7.77-7.81 (m, 1H); 7.50-7.54 (m, 1H); 7.23-7.28 (m, 1H); 6.08- 6.11 (m, 1H); 4.24-4.33 (m, 2H); 4.05-4.18 (m, 2H); 2.80 (s, 3H); 2.65- 2.70 (m, 2H). 10.30

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water 8.71 (d, 7 = 4.4 Hz, 1H); 8.57-8.51 (m, 3H); 8.46- 8.45 (m, 1H); 8.44-8.40 (m, 1H); 7.96-7.92 (m, 2H); 7.91-7.80 (m, 1H); 7.78-7.54 (m, 1H); 7.53- 7.25 (m, 1H); 6.11-6.08 (m, 1H); 4.33-4.04 (m, 4H); 2.80 (s, 3H); 2.70- 2.65 (m, 2H). 10.31

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 10.00 (s, 1H); 9.29 (d, J = 8 Hz, 1H); 8.86 (d, J = 4.8 Hz, 1H); 8.70 (d, J = 1.6 Hz, 1H); 8.13 (d, J = 9.2 Hz, 1H); 8.00-7.93 (m, 2H); 7.75- 7.71 (m, 2H); 7.48-7.44 (m, 1H); 6.97-6.94 (m, 2H); 5.69 (s, 1H); 5.27- 5.23 (m, 2H); 4.85-4.65 (m, 2H). 10.32

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.95 (s, 2H); 8.76-8.75 (m, 3H); 8.15 (d, J = 9.2 Hz, 1H); 7.96-7.94 (m, 1H); 7.73- 7.71 (m, 2H); 7.47-7.45 (m, 1H); 7.00 (d, J = 5.6 Hz, 1H); 6.70 (d, J = 9.2 Hz, 1H); 5.80 (s, 1H); 5.32-5.04 (m, 2H); 4.70- 4.69 (m, 2H). 10.33

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.50 (d, J = 1.6 Hz, 1H); 8.27 (d, J = 8 Hz, 2H); 7.92 (d, J = 8.8 Hz, 1H); 7.78-7.76 (m, 1H); 7.66-7.64 (m, 1H); 7.60-7.55 (m, 1H); 7.27- 7.25 (m, 1H); 6.77 (d, J = 8 Hz, 2H); 6.68-6.66 (m, 1H); 6.60 (d, J = 5.6 Hz, 1H); 5.77-5.75 (m, 1H); 4.77-4.73 (m, 2H); 4.34-4.30 (m, 2H); 3.99 (s, 2H). 10.34

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 9.06-9.01 (m, 1H); 858-8.50 (m, 1H); 8.31-8.29 (m, 1H); 8.19- 8.16 (m, 1H); 7.82-7.70 (m, 1H); 7.58-7.49 (m, 3H); 7.21-7.17 (m, 1H); 6.99-6.96 (m, 1H); 6.56 (d, J = 8.8 Hz, 1H); 5.62-5.59 (m, 1H); 4.64- 4.60 (m, 2H); 4.25-4.22 (m, 2H). 10.35

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.60 (s, 1H); 8.51-8.50 (m, 1H); 8.35-8.34 (m, 1H); 8.17-8.15 (m, 1H); 7.88-7.86 (m, 1H); 7.72-7.70 (m, 1H); 7.61-7.52 (m, 2H); 7.26-7.21 (m, 2H); 6.59-6.56 (m, 1H); 5.62-5.57 (m, 1H); 4.62-4.59 (m, 2H); 4.16-4.13 (m, 2H); 2.27 (s, 3H). 10.36

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.78 (s, 1H); 851-8.38 (m, 2H); 8.27 (s, 1H); 8.13-8.10 (m, 1H); 7.86-7.84 (m, 2H); 7.69-7.62 (m, 2H); 7.42- 7.38 (m, 1H); 6.68 (d, J = 8.4 Hz, 1H); 5.68 (s, 1H); 5.01-4.90 (m, 2H); 4.57-4.52 (m, 2H); 2.75 (s, 3H). 10.37

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 833-8.32 (m, 1H); 8.07-8.06 (m, 1H); 8.13-8.10 (m, 1H); 7.89 (d, J = 9.2 Hz, 1H); 7.79-7.70 (m, 3H); 7.64- 7.56 (m, 2H); 7.42-7.38 (m, 1H); 7.02-7.00 (m, 1H); 6.68 (d, J = 8.8 Hz, 1H); 5.65-5.63 (m, 1H); 4.70-4.66 (m, 2H); 4.32- 4.29 (m, 2H); 3.87 (s, 3H). 10.38

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 9.02 (s, 1H); 8.30-8.29 (m, 1H); 8.13-8.12 (m, 1H); 7.72-7.63 (m, 5H); 7.39-7.35 (m, 1H); 7.27-7.23 (m, 1H); 7.00-6.97 (m, 1H); 5.64-5.61 (m, 1H); 4.76-4.71 (m, 2H); 4.38-4.35 (m, 2H); 3.85 (s, 3H). 10.39

Pd(dppf) Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 9.01 (s, 1H); 8.26-8.23 (m, 2H); 8.11-8.09 (m, 1H); 7.76-7.74 (m, 1H); 7.68-7.66 (m, 2H); 7.62-7.61 (m, 1H); 7.26-7.22 (m, 1H); 7.01-6.98 (m, 1H); 5.62-5.59 (m, 1H); 4.69-4.65 (m, 2H); 4.25-4.22 (m, 2H); 3.83 (s, 3H). 10.40

Pd(dppf)Cl₂, K₃PO₄, Dioxane/ water (CDCl₃) 8.15-8.13 (m, 1H); 7.73-7.71 (m, 2H); 7.70-7.63 (m, 2H); 7.60- 7.56 (m, 5H); 7.44-7.40 (m, 1H); 7.34-7.32 (m, 1H); 7.28-7.25 (m, 1H); 6.65 (d, J = 8.8 Hz, 1H); 5.85-5.79 (m, 1H); 4.79- 4.76 (m, 2H); 4.38-4.35 (m, 2H); 2.48 (s, 3H). 10.41

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 2.57 (br. s., 2H) 4.11-4.22 (m, 4H) 4.29 (d, J = 2.20 Hz, 2H) 4.51-4.63 (m, 2H) 5.58 (d, J = 6.60 Hz, 1H) 6.79 (d, J = 9.68 Hz, 1H) 7.09 (s, 1H), 7.19-7.29 (m, 1H) 7.46-7.63 (m, 2H) 7.72 (d, J = 8.80 Hz, 1H) 8.00-8.12 (m, 2H) 8.27 (d, J = 2.64 Hz, 1H). 10.42

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.03 (s, 2H) 4.28-4.40 (m, 2H) 4.57- 4.69 (m, 2H) 5.67- 5.78 (m, 1H) 6.82 (d, J = 9.24 Hz, 1H) 7.12- 7.32 (m, 7H) 7.49-7.64 (m, 4H) 7.72 (d, J = 9.24 Hz, 1H) 7.83 (s, 1H) 8.06 (d, J = 9.24 Hz, 1H) 8.24 (d, J = 2.64 Hz, 1H) 8.41 (d, J = 2.64 Hz, 1H). 10.43

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.35 (d, J = 5.67 Hz, 2H) 4.73 (t, J = 7.82 Hz, 2H) 5.35 (br s, 2H) 5.64-5.75 (m, 1H) 6.64 (d, J = 8.80 Hz, 1H) 7.52-7.70 (m, 4H) 7.77 (d, J = 7.63 Hz, 1H) 7.92 (d, J = 9.00 Hz, 1H) 8.09 (d, J = 2.54 Hz, 1H) 8.35 (d, J = 2.54 Hz, 1H) 8.49-8.60 (m, 2H) 9.11 (s, 1H). 10.44

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 3.90 (s, 3H) 4.13-4.26 (m, 2H) 4.60 (dd, J = 10.34, 7.26 Hz, 2H) 5.57-5.72 (m, 1H) 6.81 (d, J = 9.24 Hz, 1H) 6.95 (d, J = 9.68 Hz, 1H) 7.24 (t, J = 8.14 Hz, 1H) 7.48-7.64 (m, 2H) 7.72 (d, J = 9.24 Hz, 1H) 8.06 (d, J = 9.24 Hz, 1H) 8.21 (d, J = 2.64 Hz, 1H) 8.34- 8.43 (m, 2H) 8.91 (d, J = 2.64 Hz, 1H). 10.45

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.24 (d, J = 14.96 Hz, 2H) 4.59- 4.68 (m, 2H) 5.68 (s, 1H) 6.83 (d, J = 9.24 Hz, 1H) 7.21-7.31 (m, 1H) 7.51-7.66 (m, 3H) 7.73 (d, J = 8.36 Hz, 1H) 8.08 (d, J = 9.68 Hz, 1H) 8.17- 8.32 (m, 3H) 8.45 (d, J = 2.64 Hz, 1H) 8.80 (s, 1H). 10.46

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.18-4.27 (m, 2H) 4.54-4.66 (m, 2H) 5.59-5.69 (m, 1H) 6.81 (d, J = 9.24 Hz, 1H) 7.20-7.29 (m, 1H) 7.49- 7.76 (m, 4H) 8.07 (d, J = 9.68 Hz, 1H) 8.31 (d, J = 2.20 Hz, 1H) 8.41- 8.56 (m, 2H) 9.07 (d, J = 2.64 Hz, 1H). 10.47

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.19 (d, J = 9.68 Hz, 2H) 4.56- 4.65 (m, 2H) 5.64 (d, J = 6.60 Hz, 1H) 6.82 (d, J = 9.24 Hz, 1H) 7.18- 7.29 (m, 1H) 7.41-7.77 (m, 6H) 8.02-8.17 (m, 2H) 8.21-8.29 (m, 1H) 8.42 (d, J = 2.64 Hz, 1H) 10.48

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.16 (dd, J = 10.56, 4.40 Hz, 2H) 4.51-4.63 (m, 4H) 5.34 (d, J = 5.72 Hz, 1H) 5.58- 5.68 (m, 1H) 6.79 (d, J = 9.24 Hz, 1H) 7.23 (t, J = 8.14 Hz, 1H) 7.35- 7.63 (m, 4H) 7.71 (d, J = 8.80 Hz, 1H) 7.91- 8.08 (m, 3H) 8.22 (d, J = 2.64 Hz, 1H) 8.39 (d, J = 2.64 Hz, 1H). 10.49

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 3.92-4.01 (m, 2H) 4.29-4.43 (m, 4H) 5.36-5.46 (m, 1H) 6.59 (d, J = 9.24 Hz, 1H) 7.03 (t, J = 7.70 Hz, 1H) 7.22 (d, J = 8.36 Hz, 2H) 7.28-7.43 (m, 2H) 7.51 (d, J = 8.80 Hz, 1H) 7.82 (d, J = 8.36 Hz, 3H) 7.99 (d, J = 2.64 Hz, 1H) 8.16 (d, J = 2.64 Hz, 1H). 10.50

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 3.92 (dd, J = 10.56, 4.40 Hz, 2H) 4.49 (dd, J = 9.90, 7.26 Hz, 2H) 5.51-5.65 (m, 1H) 6.71 (d, J = 9.24 Hz, 1H) 7.17-7.27 (m, 1H) 7.36-7.75 (m, 4H) 7.77- 7.92 (m, 2H) 8.01 (d, J = 9.68 Hz, 1H) 8.13 (d, J = 8.80 Hz, 2H) 8.38 (d, J = 2.64 Hz, 1H) 8.49 (d, J = 3.08 Hz, 1H) 8.88 (dd, J = 4.18, 1.54 Hz, 1H) 10.51

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.31 (dd, J = 9.68, 3.96 Hz, 2H) 4.57-4.70 (m, 2H) 5.72 (br. s., 1H) 6.83 (d, J = 9.24 Hz, 1H) 7.24 (t, J = 7.70 Hz, 1H) 7.33- 7.65 (m, 6H) 7.73 (d, J = 7.92 Hz, 3H) 8.03- 8.11 (m, 2H) 8.15 (d, J = 2.64 Hz, 1H) 8.30 (d, J = 2.64 Hz, 1H) 10.52

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.19 (dd, J = 10.56, 3.96 Hz, 2H) 4.59 (dd, J = 10.56, 7.04 Hz, 2H) 5.57-5.73 (m, 1H) 6.80 (d, J = 9.24 Hz, 1H) 7.19-7.30 (m, 1H) 7.48-7.64 (m, 3H) 7.72 (d, J = 9.24 Hz, 1H) 8.05 (d, J = 9.24 Hz, 1H) 8.29 (d, J = 2.64 Hz, 1H) 8.39- 8.49 (m, 2H) 8.63 (d, J = 5.28 Hz, 1H) 9.22 (s, 1H) 10.53

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.23-4.36 (m, 2H) 4.60-4.70 (m, 2H) 5.64-5.75 (m, 1H) 6.84 (d, J = 9.24 Hz, 1H) 7.27 (d, J = 7.92 Hz, 1H) 7.50-7.90 (m, 5H) 8.03- 8.20 (m, 3H) 8.33 (d, J = 2.64 Hz, 1H) 8.51 (d, J = 2.64 Hz, 1H) 9.07 (s, 1H) 9.55 (d, J = 2.20 Hz, 1H). 10.54

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 3.87 (s, 3H) 4.20 (dd, J = 10.34, 4.18 Hz, 2H) 4.59 (dd, J = 10.34, 6.82 Hz, 2H) 5.59-5.70 (m, 1H) 6.80 (d, J = 9.24 Hz, 1H) 7.18-7.29 (m, 1H) 7.49-7.64 (m, 2H) 7.72 (d, J = 9.24 Hz, 1H) 8.00-8.11 (m, 3H) 8.17-8.31 (m, 3H) 8.44 (d, J = 2.64 Hz, 1H) 10.55

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 1.24 (d, J = 6.16 Hz, 6H) 4.09- 4.24 (m, 2H) 4.54- 4.67 (m, 3H) 5.57- 5.71 (m, 1H) 6.75- 6.93 (m, 2H) 7.18- 7.29 (m, 1H) 7.36- 7.63 (m, 4H) 7.72 (d, J = 9.24 Hz, 1H) 8.05 (d, J = 9.24 Hz, 1H) 8.26 (d, J = 2.64 Hz, 1H) 8.40 (d, J = 2.64 Hz, 1H). 10.56

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 4.22 (dd, J = 10.34, 4.18 Hz, 2H) 4.59 (dd, J = 10.34, 7.26 Hz, 2H) 5.62-5.71 (m, 1H) 6.81 (d, J = 9.24 Hz, 1H) 7.18-7.29 (m, 1H) 7.49-7.76 (m, 5H) 8.05 (d, J = 9.68 Hz, 1H) 8.35 (d, J = 2.64 Hz, 1H) 8.48 (d, J = 2.64 Hz, 1H) 9.42 (s, 1H) 10.57

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 2.54 (s, 3H) 4.21 (dd, J = 10.56, 4.40 Hz, 2H) 4.60 (dd, J = 10.34, 7.26 Hz, 2H) 5.60-5.69 (m, 1H) 6.80 (d, J = 9.24 Hz, 1H) 7.19- 7.29 (m, 1H) 7.49- 7.63 (m, 2H) 7.72 (d, J = 9.24 Hz, 1H) 7.83- 7.92 (m, 2H) 8.05 (d, J = 9.24 Hz, 1H) 8.33 (d, J = 2.64 Hz, 1H) 8.45 (d, J = 2.64 Hz, 1H) 8.56 (d, J = 5.28 Hz, 1H) 10.58

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 3.98 (s, 3H) 4.17-4.26 (m, 2H) 4.59 (dd, J = 10.56, 7.04 Hz, 2H) 5.60-5.72 (m, 1H) 6.81 (d, J = 9.68 Hz, 1H) 7.24 (t, J = 8.14 Hz, 1H) 7.49-7.64 (m, 3H) 7.72 (d, J = 8.36 Hz, 1H) 8.05 (d, J = 9.24 Hz, 1H) 8.27 (d, J = 2.64 Hz, 1H) 8.41 (s, 1H) 9.25 (s, 1H). 10.59

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 0.31 (d, J = 5.28 Hz, 2H) 0.54 (d, J = 8.36 Hz, 2H) 4.08- 4.27 (m, 5H) 4.51-4.67 (m, 2H) 5.64 (br. s., 1H) 6.73-7.01 (m, 2H) 7.24 (d, J = 8.36 Hz, 1H) 7.46-7.79 (m, 4H) 8.04 (d, J = 9.68 Hz, 1H) 8.20 (br. s., 1H) 8.32-8.46 (m, 1H) 8.87 (br. S., 1H) 10.60

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (d₆-DMSO) 2.52 (s, 3H) 4.19 (dd, J = 10.12, 3.96 Hz, 2H) 4.60 (dd, J = 10.34, 7.26 Hz, 2H) 5.65 (d, J = 6.60 Hz, 1H) 6.80 (d, J = 9.24 Hz, 1H) 7.19-7.30 (m, 1H) 7.39 (d, J = 9.24 Hz, 1H) 7.49- 7.64 (m, 2H) 7.72 (d, J = 8.36 Hz, 1H) 8.06 (d, J = 9.24 Hz, 1H) 8.22- 8.46 (m, 3H) 9.10 (s, 1H) 10.61

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water 8.35 (d, J = 9.6 Hz, 1H); 8.19 (s, 1H); 7.89 (d, J = 8.0 Hz, 1H); 7.80-7.76 (m, 2H); 7.54-7.50 (m, 1H); 7.34-7.30 (m, 1H); 7.11-7.10 (m, 2H); 6.98- 6.96 (m, 2H); 5.83-5.81 (m, 1H); 5.02 (s, 2H); 4.65-4.61 (m, 4H); 3.81 (s, 3H); 3.49 (d, J = 6 Hz; 2H); 3.31-3.29 (m, 2H); 1.92-1.89 (m, 3H); 1.42-1.38 (m, 2H). 10.62

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.56-8.51 (m, 2H); 8.16 (d, J = 9.6 Hz, 1H); 7.90 (d, J = 6.4 Hz, 1H); 7.89-7.80 (m, 1H); 7.78-7.72 (m, 3H); 7.47 (m, 1H); 6.72-6.69 (m, 1H); 5.75-5.72 (m, 1H); 4.80-4.68 (m, 3H); 4.30- 4.29 (m, 2H); 3.61 (s, 2H); 3.08-3.02 (m, 2H); 2.78 (s, 3H); 1.93-1.85 (m, 3H); 1.40-1.25 (m, 3H). 10.63

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water 8.37-8.35 (m, 1H); 8.33- 8.19 (m, 2H); 7.89-7.87 (m, 1H); 7.80-7.77 (m, 3H); 7.52-7.49 (m, 1H); 7.07-7.04 (m, 1H); 6.98 (d, J = 9.2 Hz, 1H); 5.83-5.80 (m, 1H); 4.97 (br, 3H); 4.57-4.53 (m, 4H); 4.35-4.34 (m, 1H); 3.91 (s, 3H); 3.50-3.49 (m, 1H); 3.30-3.29 (m, 2H); 2.02-1.95 (m, 2H); 1.41-1.37 (m, 2H). 10.64

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.59 (s, 1H); 8.18 (s, 1H); 7.86 (d, J = 8.4 Hz, 1H); 7.75-7.69 (m, 2H); 7.59-7.51 (m, 2H); 7.26-7.13 (m, 2H); 6.57 (d, J = 8.8 Hz, 1H); 5.59 (s, 1H); 4.78-4.75 (m, 2H); 4.61-4.58 (m, 2H); 4.23-4.21 (m, 2H); 3.73-3.68 (m, 3H); 2.94- 2.88 (m, 2H); 2.54 (s, 3H); 1.86-1.83 (m, 2H); 1.26-1.24 (m, 2H). 10.65

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 8.40 (d, J = 9.2, 1H); 8.06 (d, J = 10.8 Hz, 1H); 7.95 (d, J = 8.0 Hz, 1H); 7.84-7.80 (m, 2H); 7.58-7.55 (m, 1H); 7.03 (d, J = 9.6 Hz, 1H); 6.24-6.22 (m, 1H); 5.82- 5.81 (m, 1H); 5.03-5.01 (m, 2H); 4.72-7.69 (m, 2H); 4.62-4.55 (m, 2H); 4.37-4.35 (m, 1H); 4.29 (s, 2H); 3.91-3.89 (m, 2H); 3.51 (d, J =6.0 Hz, 1H); 3.25 (t, J = 12.8 Hz, 2H); 2.50 (s, 2H); 2.26-1.89 (m, 3H); 1.52- 1.34 (m, 2H). 10.66

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 7.95 (s, 1H); 7.83 (d, J = 9.2 Hz, 1H); 7.76-7.74 (m, 1H); 7.54 (d, J = 8.0 Hz, 1H); 7.51-7.47 (m, 1H); 7.17 (d, J = 11.2 Hz, 1H); 6.55-6.53 (m, 1H); 5.77 (s, 1H); 5.52-5.46 (m, 1H); 4.65 (d, J = 13.4 Hz, 2H); 4.57 (t, J = 9.2 Hz, 2H); 4.20-4.17 (m, 2H); 3.94 (s, 2H); 3.50- 3.46 (m, 4H); 2.85-2.79 (m, 2H); 2.36 (s, 2H); 1.76-1.73 (m, 3H); 1.42 (s, 9H); 1.22-1.13 (m, 2H). 10.67

Pd(dppf)Cl₂, K₃PO₄, dioxane/ water (CDCl₃) 9.24 (s, 1H); 8.27-8.26 (m, 2H); 7.99- 7.87 (m, 3H); 7.64-7.52 (m, 2H); 7.03-6.99 (m, 1H); 5.71-5.70 (m, 1H); 5.06-5.05 (m, 2H); 4.71- 4.58 (m, 4H); 3.94 (s, 3H); 3.60-3.58 (m, 2H); 3.21-3.20 (m, 2H); 2.07- 1.93 (m, 3H); 1.47- 1.41 (m, 2H). 10.68

Pd(PPh₃)₄, Na₂CO₃, dioxane/ water (CDCl₃, 300 MHz) 2.65 (s, 3H), 4.34-4.43 (m, 1H), 4.74 (dd, 1H, J = 11.11 Hz, 6.58 Hz), 4.90-4.99 (m, 1H), 5.35 (dd, 1H, J = 11.69 Hz, 6.58 Hz), 5.59-5.68 (m, 1H), 7.29-7.42 (m, 2H), 7.52 (d, 1H, J = 7.75 Hz), 7.78-7.89 (m, 3H), 8.16 (br s, 1H), 8.39 (br s, 1H), 8.62 (d, 1H, J = 4.97 Hz), 10.37 (br s, 1H) 10.69

Pd(PPh₃)₄, Na₂CO₃, dioxane, water (CDCl₃:CD₃OD) 3.86 (s, 3H), 3.96 (dd, 2H, J = 10.17 Hz, 3.91 Hz), 4.40 (dd, 2H, J = 9.98 Hz, 6.65 Hz), 5.10 (s, 2H), 5.40-5.45 (m, 1H), 7.30- 7.37 (m, 5H), 7.39-7.40 (m, 1H), 8.15 (d, 1H, J = 2.74 Hz), 8.30 (d, 1H, J = 2.74 Hz), 8.33 (d, 1H, J = 4.69 Hz), 8.36 (s, 1H) 10.70

Pd(t-Bu₃P)₂ K₂CO₃ dioxane/ H₂O (CDCl₃) 10.54 (1H, br. s.), 8.73 (2H, d, J = 5.1 Hz), 8.27-8.37 (1H, m), 8.11-8.20 (1H, m), 8.01 (2H, d, J = 5.6 Hz), 7.82 (1H, d, J = 7.9 Hz), 7.53 (1H, d, J = 8.0 Hz), 7.28-7.44 (2H, m), 5.59 (1H, d, J = 3.4 Hz), 5.00 (1H, d, J = 8.0 Hz), 4.63-4.84 (1H, m), 4.07 (1H, d, J = 7.9 Hz), 3.75-3.96 (1H, m), 2.24 (2H, m), 2.06 (2H, m). 10.71

Pd(PPh₃)₄, Na₂CO₃, dioxane, water (DMSO-D₆) 2.55-2.62 (m, 2H), 3.82 (t, 1H, J = 5.26 Hz), 4.20-4.34 (m, 3H), 4.58 (dd, 1H, J = 11.11 Hz, 6.58 Hz), 4.73 (dd, 1H, J = 11.40 Hz, 2.92 Hz), 5.16 (dd, 1H, J = 11.55 Hz, 6.14 Hz), 5.48-5.58 (m, 1H), 7.12 (br s, 1H), 7.22-7.35 (m, 2H), 7.52 (d, 1H, J = 7.45 Hz), 7.73 (d, 1H, J = 7.45 Hz), 8.10 (d, 1H, J = 2.19 Hz), 8.28 (d, 1H, J = 2.48 Hz), 13.25 (s, 1H). 10.72

 

(dppf)PdCl₂, KOAc, dioxane, 80° C. 8.27 (1H, d, J = 2.5 Hz), 8.05 (1H, d, J = 2.0 Hz), 7.60-7.72 (2H, m), 7.33-7.40 (2H, m), 7.20 (1H, br. s.), 5.63 (1H, br. s.), 5.23-5.40 (1H, m), 4.63-4.80 (2H, m), 4.46 (2H, br. s.), 4.35 (1H, d, J = 12.0 Hz), 3.56-3.70 (4H, m), 2.45 (2H, br. s.), 1.47 (10 H, s) 10.73

(dppf)PdCl₂, KOAc, dioxane, 80° C. 8.21 (1H, d, J = 2.5 Hz), 8.03 (1H, d, J = 2.0 Hz), 7.59-7.77 (2H, m), 7.29-7.47 (2H, m), 7.19 (1H, br. s.), 5.61 (1H, br. s.), 5.15-5.35 (1H, m), 4.62-4.78 (2H, m), 4.44 (2H, br. s.), 4.31 (1H, d, J = 12.4 Hz), 3.47-3.69 (4H, m), 2.42 (2H, br. s.), 1.47 (10H, s) 10.74

Pd(PPh₃)₄, Na₂CO₃, Dioxane/ water (CDCl₃) 7.74 (s, 1H); 7.65 (d, J= 8.4 Hz, 1H); 7.50-7.42 (m, 6H); 7.26- 7.22 (m, 1H); 7.14-7.10 (m, 2H); 6.47 (d, J= 8.8 Hz, 1H); 5.52-5.49 (m, 1H); 4.56-4.52 (m, 2H); 4.51-4.15 (m, 2H); 2.31 (s, 3H). 10.75

Pd(dppf) Cl₂, K₃PO₄, Dioxane/ water (CDCl₃) 8.07-8.02 (m, 3H); 7.83-7.81 (m, 1H); 7.72-7.60 (m, 6H); 7.45- 7.35 (m, 2H); 7.05-7.02 (m, 1H); 6.59-6.56 (m, 1H); 5.74-5.72 (m, 1H); 5.17-4.55 (m, 4H); 3.88 (s, 3H). 10.76

Pd(dppf) Cl₂, K₃PO₄, Dioxane/ water (CDCl₃) 8.33-8.32 (m, 1H); 8.14-8.10 (m, 2H); 7.91-7.85 (m, 3H); 7.77- 7.65 (m, 4H); 7.46-7.44 (m, 1H); 7.10-7.08 (m, 1H); 6.63-6.60 (m, 1H); 5.86-5.81 (m, 1H); 5.20- 4.40 (m, 4H); 3.92 (s, 3H). 10.77

Pd(dppf) Cl₂, K₃PO₄, Dioxane/ water (CDCl₃) 8.79-8.77 (m, 1H); 8.71-8.70 (m, 1H); 8.50-8.49 (m, 1H); 8.11- 8.10 (m, 1H); 7.94-7.88 (m, 2H); 7.79-7.76 (m, 1H); 7.66-7.56 (m, 2H); 7.47-7.44 (m, 1H); 7.27- 7.24 (m, 1H); 6.68-6.66 (m, 1H); 5.73-7.50 (m, 1H); 4.77-7.73 (m, 2H); 4.42-4.39 (m, 2H). 10.78

Pd(dppf) Cl₂, K₃PO₄, Dioxane/ water (CDCl₃) 8.60-8.59 (m, 1H); 8.45-8.43 (m, 2H); 7.96-7.94 (m, 1H); 7.86- 7.84 (m, 1H); 7.67-7.51 (m, 4H); 7.30-7.29 (m, 1H); 6.74-6.72 (m, 1H); 6.68-6.66 (m, 1H); 5.82- 5.76 (m, 1H); 4.83 (s, 2H); 4.82-4.80 (m, 2H); 4.39-4.36 (m, 2H). *Note: Examples 10.3 and 10.15 can be prepared according to Scheme 10. However, NMR data of pure products are not available.

Example 11.1 (S)-2-(3-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline or (R)-2-(3-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline as Racemic Mixture Step 1: (Racemic Mixture) 2-(3-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline

To a solution of (racemic mixture) 2-(3-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline (see PREPARATION P2.3; 340 mg, 1.0 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (219 mg, 1.0 mmol) and K₃PO₄ (424 mg, 2.0 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was added Pd(dppf)Cl₂ (73 mg, 0.1 mmol) then the reaction mixture was stirred at 110° C. under N₂ atmosphere overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂ (30 mL). The filtrate was concentrated and the crude product was purified by silica gel column to give (racemic mixture) 2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline (200 mg, 0.50 mmol, yield 60%). ESI-MS (M+1): 384 calc. for C₂₃H₂₁N₅O 383.

Step 2. (S)-2-(3-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline and (R)-2-(3-((3-(2-Methylpyridin-4-yl)Pyrazin-2-yl)Oxy)Piperidin-1-yl)Quinoline as Separated Single Isomer

2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline (0.020 g, 0.04 mmol) was separated by chiral prep. HPLC (Column: Chiralcel OD-H 250*30 mm, 5u; Mobile phase: 85% hexane in EtOH (0.05% diethyl amine); Flow rate: 30 mL/minute) to give Examples 11.1 and 11.2; wherein each of the absolute configuration was not further determined.

TABLE 9A EXAMPLES 11.1-11.8 PREPARATION ANALOGOUS TO SCHEME 11 ESI-MS IC₅₀ Ex. # Structure Chemical Name (M + 1) (uM) 11.1 and 11.2*

 

(S)-2-(3-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline and (R)-2-(3-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 398 5.1 and 3.95 11.3 and 11.4*

 

(S)-1-(3-(2-((1-(1H- indole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone (R)-1-(3-(2-((1-(1H- indole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 419 0.2992 and 1.983 11.5 and 11.6*

 

(S)-1-(3-(2-((1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone and (R)-1-(3-(2-((1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 420 0.04487 and 0.002515 11.7 and 11.8*

 

(S)-1-(3-(2-((1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1-yl)-2- methylpropan-1-one and (R)-1-(3-(2-((1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1-yl)-2- methylpropan-1-one 448 1.337 and 0.0271 *The examples are separated enantiomers, wherein each absolute configuration was not further determined. Their M + 1 mass is the same. Therefore the reported NMR and PDE10 data herein can be for either isomer.

TABLE 9B PREPARATION AND NMR DATA OF EXAMPLES 11.1-11.8 Reaction Ex. # Starting Material (1) and (2) Condition ¹H NMR (CD₃OD, 400 MHz): δ (ppm) 11.1 and 11.2*

 

Pd(dppf)Cl₂, K₃PO₄ dioxane/ water 8.25-8.24 (m, 2H); 7.98-7.96 (m, 1H); 7.61 (d, J = 9.2 Hz, 1H); 7.45-7.43 (m, 1H); 7.38-7.34 (m, 2H); 7.30-7.21 (m, 2H); 7.21-7.09 (m, 1H); 7.13-6.85 (m, 1H); 5.46-5.45 (m, 1H); 4.90-4.85 (m, 1H); 3.44-3.43 (m, 1H); 3.43-3.29 (m, 2H); 2.26 (s, 3H); 2.12-2.08 (m, 3H); 1.60-1.55 (m, 1H). and 8.25-8.235 (m, 2 H); 7.97-7.96 (m, 1H); 7.61 (d, J = 8.8 Hz, 1H); 7.45-7.42 (m, 1H); 7.38-7.34 (m, 2H); 7.30-6.82 (m, 3H); 5.46-5.44 (m, 1H); 4.88-4.87 (m, 1H); 3.44-3.43 (m, 1H); 3.40-3.29 (m, 2H); 3.26 (s, 3H); 2.11-2.08 (m, 3H); 1.70-1.61 (m, 1H). 11.3 and 11.4*

(see Example 18.10) 7.96-8.12 (1H, m), 7.55-7.75 (2H, m), 7.45 (1H, d, J = 8.3 Hz), 7.23 (1H, t, J = 7.6 Hz), 6.95-7.15 (2H, m), 6.90 (1H, d, J = 4.4 Hz), 5.59 (1H, m), 5.02 (1H, m.), 4.56-4.77 (3H, m), 4.15-4.22 (1H, m), 3.95-4.07 (1H, dd, J = 9.6 Hz, J = 13.2 Hz), 2.88-3.24 (2H, m), 2.65 (1H, t, J = 12.9 Hz), 2.13 (3H, s), 1.95- 2.06 (1H, m), 1.77-1.95 (2H, m), 1.48-1.77 (1H, m) and 7.96-8.12 (1H, m), 7.55-7.75 (2H, m), 7.45 (1H, d, J = 8.3 Hz), 7.23 (1H, t, J = 7.6 Hz), 6.95-7.15 (2H, m), 6.90 (1H, d, J = 4.4 Hz), 5.59 (1H, m), 5.02 (1H, m.), 4.56-4.77 (3H, m), 4.15-4.22 (1H, m), 3.95-4.07 (1H, dd, J = 9.6 Hz, J = 13.2 Hz), 2.88-3.24 (2H, m), 2.65 (1H, t, J = 12.9 Hz), 2.13 (3H, s), 1.95- 2.06 (1H, m), 1.77-1.95 (2H, m), 1.48-1.77 (1H, m) 11.5 and 11.6*

(see Example 15.14) 8.04 (1H, t, J = 5.1 Hz), 7.59-7.72 (3H, m), 7.33 (2H, d, J = 2.8 Hz), 6.95-7.07 (1H, m), 5.46-5.66 (1H, m), 5.17-5.34 (1H, m), 4.63- 4.75 (2H, m), 4.58 (1H, d, J = 12.0 Hz), 4.26 (1H, d, J = 12.0 Hz), 3.95-4.08 (1H, dd, J = 9.4 Hz, J = 13.7 Hz), 2.92-3.26 (3H, m), 2.50-2.76 (1H, m), 2.07-2.19 (3H, m), 1.97- 2.07 (1H, m), 1.76-1.96 (2H, m), 1.45-1.76 (1H, m) and 8.04 (1H, t, J = 5.1 Hz), 7.59-7.72 (3H, m), 7.33 (2H, d, J = 2.8 Hz), 6.95-7.07 (1H, m), 5.46-5.66 (1H, m), 5.17-5.34 (1H, m), 4.63- 4.75 (2H, m), 4.58 (1H, d, J = 12.0 Hz), 4.26 (1H, d, J = 12.0 Hz), 3.95-4.08 (1H, dd, J = 9.4 Hz, J = 13.7 Hz), 2.92-3.26 (3H, m), 2.50-2.76 (1H, m), 2.07-2.19 (3H, m), 1.97- 2.07 (1H, m), 1.76-1.96 (2H, m), 1.45-1.76 (1H, m) 11.7 and 11.8*

(see Example 15.15) (CDCl₃) 10.57 (1H, br. s.), 8.04 (1H, d, J = 13.3 Hz), 7.82 (1H, d, J = 8.0 Hz), 7.49-7.62 (2H, m), 7.28-7.41 (2H, m), 6.82-7.02 (1H, m), 5.45-5.65 (1H, m), 5.25-5.35 (1H, m), 4.80-4.98 (1H, m), 4.72 (2H, m), 4.30-4.38 (1H, m), 3.85-4.15 (1H, dd, J = 9.5 Hz, J = 14.9 Hz), 2.97-3.20 (2H, m), 2.68-2.97 (2H, m), 1.95-2.16 (1H, m), 1.72-1.85 (2H, m), 1.51-1.67 (1H, m), 1.15 (6H, m) and (CDCl₃) 10.57 (1H, br. s.), 8.04 (1H, d, J = 13.3 Hz), 7.82 (1H, d, J = 8.0 Hz), 7.49-7.62 (2H, m), 7.28-7.41 (2H, m), 6.82-7.02 (1H, m), 5.45-5.65 (1H, m), 5.25-5.35 (1H, m), 4.80-4.98 (1H, m), 4.72 (2H, m), 4.30-4.38 (1H, m), 3.85-4.15 (1H, dd, J = 9.5 Hz, J = 14.9 Hz), 2.97-3.20 (2H, m), 2.68-2.97 (2H, m), 1.95-2.16 (1H, m), 1.72-1.85 (2H, m), 1.51-1.67 (1H, m), 1.15 (6H, m). *The starting materials and reaction condition used in Preparation and NMR data of examples 11.1-11.8 are the same for each pair of examples.

Example 12.1 -(4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Phenyl)Ethanol as Racemic Mixture

1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanone (see EXAMPLE 10.26; 99 mg, 0.25 mmol) was dissolved in 10 ml of methanol. This solution was cooled down to 0° C. using an ice bath and sodium tetraborohydride (19 mg, 0.50 mmol) was added in portions. The reaction mixture was stirred for 4 hours at ambient temperature, and then saturated aqueous solution of ammonium chloride (5 mL) was added. The methanol was evaporated off under reduced pressure then the reaction mixture was taken up in ethyl acetate. The organic layer was separated from the aqueous layer. This extraction was repeated one more time and then the organic layers were combined and dried over magnesium sulphate, followed by concentrating under reduced pressure. The residue was purified by column chromatography on silica gel to give (racemic mixture) 1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanol (75 mg, 0.19 mmol, 75% yield). ESI-MS (M+1): 399 calc. for C₂₄H₂₂N₄O₂ 398.

TABLE 10A EXAMPLES 12.1-12.2 PREPARED ANALOGOUS TO SCHEME 12 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 12.1

1-(4-(3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)phenyl)ethanol 399 0.0553 12.2

1-(3-(3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyrazin-2- yl)phenyl)ethanol 399 0.045

TABLE 10B PREPARATION AND NMR DATA OF EXAMPLES 12.1-12.2 Reaction ¹H NMR (CD₃OD, 400 MHz) Ex. # Starting material (1) Condition δ (ppm) 12.1

NaBH₄, MeOH 8.14-8.05 (m, 2H); 8.04-8.02 (m, 3H); 7.90-7.88 (m, 1H); 7.79-7.75 (m, 2H); 7.53-7.47 (m, 3H); 6.98-6.95 (m, 1H); 5.76-5.73 (m, 1H); 5.00-4.96 (m, 2H); 4.91-4.89 (m, 1H) ; 4.63-4.59 (m, 2H);1.46-1.45 (d, 3H). 12.2

NaBH₄, MeOH 8.14-8.05 (m, 2H); 8.04-8.02 (m, 3H); 7.90-7.88 (m, 1H); 7.79-7.75 (m, 2H); 7.53-7.47 (m, 3H); 6.98-6.95 (m, 1H); 5.76-5.73 (m, 1H); 5.00-4.96 (m, 2H); 4.91-4.89 (m, 1H); 4.63-4.59 (m, 2H);1.46-1.45 (d, 3H).

Example 13.1 2-(3-((3-(4,4-Difluoropiperidin-1-yl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Quinoline

In a 50 mL flask, 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-one (see PREPARATION P8.1 and Example 8.2; 0.187 g, 0.50 mmol) was dissolved in anhydrous CH₂Cl₂ (15 mL). The solution was cooled to −10° C. under nitrogen atmosphere and diethylaminosulfur trifluoride (DAST) (0.26 g, 0.10 mmol) was added dropwise. The reaction mixture was allowed to warm to RT and stirred for 2 hours. The mixture was poured into cold water (10 mL). The separated aqueous layer was back extracted twice with CH₂Cl₂ (20 mL). The combined organic layers were dried over magnesium sulfate (MgSO₄). After filtration, the solvent was evaporated in vacuo, and the concentrate was purified via flash chromatography on silica gel (20% to 45% EtOAc in petroleum ether) to give 2-(3-((3-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline (0.148 g, 0.37 mmol, 75% yield) as a white solid. ESI-MS (M+1): 398 calc. for C₂₁H₂₁F₂N₅O 397.

TABLE 13A EXAMPLES 13.1-13.5 PREPARATION ANALOGOUS TO SCHEME 13 ESI-MS IC₅₀ Ex. # Structure Chemical Name (M + 1) (uM) 13.1

2-(3-((3-(4,4- difluoropiperidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 398 0.00423 13.2

2-(3-((3-(3,3- difluoropyrrolidin-1- yl)pyrazin-2- yl)oxy)azetidin-l- yl)quinoline 384 0.0953 13.3

2-(3-((3-(3,3- difluoropiperidin-1- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 398 0.0921 13.4

2-(3-((3-(4,4- difluoropiperidin-1- yl)-5-fluoropyridin-2- yl)oxy)azetidin-1- yl)quinoline 415 0.144 13.5

2-(3-((3-(4,4- difluoropiperidin-1- yl)pyridin-2- yl)oxy)azetidin-1- yl)quinoline 397 0.0359

TABLE 13B PREPARATION AND NMR DATA OF EXAMPLES 13.1-13.5 Reaction ¹H NMR (CDCl₃, 400 MHz) Ex. # Starting Material (1) Condition δ (ppm) 13.1

DAST, DCM (CD₃OD) 7.91 (s, 1H); 7.68-7.59 (m, 1H); 7.59- 7.50 (m, 2H); 7.49-7.44 (m, 2H); 7.18-7.14 (m, 1H); 6.66 (d, J = 9.2 Hz, 1H); 5.52-5.48 (m, 1H); 4.59- 4.54 (m, 2H); 4.18-4.12 (m, 2H); 3.60-3.58 (m, 4H); 2.02-1.92 (m, 4H). 13.2

DAST, DCM 8.08 (d, J = 2.8 Hz, 1H); 7.94 (d, J = 8.4 Hz, 1H); 7.73-7.67 (m, 3H); 7.43- 7.34 (m, 2H); 6.61-6.58 (m, 1H); 5.54-5.53 (m, 1H); 5.11-4.40 (m, 6H); 3.98- 3.90 (m, 2H); 2.41-2.37 (m, 2H). 13.3

DAST, DCM 8.40-8.37 (m, 1H); 7.83- 7.76 (m, 4H); 7.55 (d, J = 2.8 Hz, 1H); 7.54-7.50 (m, 1H); 6.95 (d, J = 9.6 Hz, 1H); 5.69-5.65 (m, 1H); 4.99-4.94 (m, 2H); 4.61-4.54 (m, 2H); 3.86- 3.80 (m, 2H); 3.59-3.57 (m, 2H); ; 2.11-2.02 (m, 2H); 1.94-1.90 (m, 2H). 13.4

DAST, DCM 8.09-8.01 (m, 1H); 7.68- 7.66 (m, 2H); 7.61-7.55 (m, 2H); 7.29-7.25 (m, 1H); 7.15 (dd, J - 1.6, 4.8 Hz, 1H); 6.76 (d, J = 8.8 Hz, 1H); 5.56-5.53 (m, 1H); 4.70-4.65 (m, 2H); 4.26- 4.22 (m, 2H); 3.29-3.21 (m, 4H); 2.14-2.07 (m, 4H). 13.5

DAST, DCM 7.66 (d, J = 3.6 Hz, 1H); 7.66-7.55 (m, 3H); 7.47- 7.43 (m, 1H); 7.20-7.13 (m, 2H); 6.86-6.83 (m, 1H); 6.63 (d, J = 8.8 Hz, 1H); 5.50-5.46 (m, 1H); 4.57- 4.53 (m, 2H); 4.139-4.09 (m, 2H); 3.09 (s, 4H); 2.05- 1.98 (m, 4H).

Example 14.1 2-(4-(3-(Piperidin-4-yl)Pyridin-2-yloxy)Piperidin-1-yl)Quinoline Step 1. Tert-Butyl 4-(2-(1-(Quinolin-2-yl)Piperidin-4-yloxy)Pyridin-3-yl)Piperidine-1-Carboxylate

Sodium hydride (60% dispersion in mineral oil, 254 mg, 10.58 mmol) was added to a solution of 1-(quinolin-2-yl)piperidin-4-ol (see PREPARATION P1.1; 805 mg, 3.53 mmol) in DMF (16.8 ml) under an atmosphere of nitrogen and the mixture was stirred for 15 mins at RT. Tert-butyl 4-(3-chloropyrazin-2-yl)piperidine-1-carboxylate (see PREPARATION P16.1; 1050 mg, 3.53 mmol) was next added, and the mixture was heated at 100° C. After the reaction was complete, the mixture was cooled to RT and diluted with EtOAc and water. The layers were separated and the aqueous was extracted with EtOAc (2×). The combined organic layers were dried over sodium sulfate, filtered and concentrated and used in the next step without further purification.

Step 3. 2-(4-(3-(Piperidin-4-yl)Pyridin-2-yloxy)Piperidin-1-yl)Quinoline

Trifluoroacetic acid (0.272 mL, 3.53 mmol) was added to a solution of tert-butyl 4-(3-(1-(quinolin-2-yl)piperidin-4-yloxy)pyrazin-2-yl)piperidine-1-carboxylate (1726 mg, 3.53 mmol) in DCM (2 mL) and stirred at RT until the starting material was completely consumed. The mixture was then diluted with ethyl acetate and neutralized with saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organics were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered and concentrated. The brown solid was triturated with acetone and dried to give the title compound as a white solid (370 mg, 27% yield). [M+1] 390.2. IC₅₀ (uM) 0.05444. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 1.53-1.69 (m, 1H) 1.86-2.00 (m, 2H) 2.12-2.34 (m, 6H) 3.03-3.14 (m, 2H) 3.23-3.32 (m, 1H) 3.53-3.71 (m, 4H) 4.13-4.22 (m, 2H) 5.35-5.43 (m, 1H) 7.06 (d, J=9.19 Hz, 1H) 7.20-7.26 (m, 1H) 7.52-7.59 (m, 1H) 7.62 (d, J=7.82 Hz, 1H) 7.67-7.82 (m, 1H) 7.89-7.95 (m, 1H) 7.97 (d, J=2.74 Hz, 1H) 8.06 (d, J=2.74 Hz, 1H)

Example 15.1 Methyl 4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Piperidine-1-Carboxylate

To a solution of 2-(3-((3-(piperidin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline hydrochloride (see PREPARATION P4.1; 100 mg, 0.29 mmol) in dry DCM (10 mL) was added Et₃N (1 mL). The reaction mixture was cooled to 0° C. with an ice bath, and methyl carbonochloridate (54 mg, 0.58 mmol) was added dropped to the reaction mixture. After 1 hour, the reaction mixture was warmed to RT, and stirred overnight. Then the reaction mixture was washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum to give the crude product. The crude product was purified via flash chromatography on silica gel (20% to 45% EtOAc in petroleum ether) to give methyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate (93 mg, 0.23 mmol, 79% yield) as a white solid. ESI-MS (M+1): 404 calc. for C₂₃H₂₅N₅O₂ 403.

TABLE 12A EXAMPLES 15.1-15.18 PREPARED ANALOGOUS TO SCHEME 15 ESI-MS IC₅₀ Ex. # Structure Chemical Name (M + 1) (uM) 15.1

methyl 4-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidine-1- carboxylate 420 0.158 15.2

2-(3-((3-(1- (methylsulfo- nyl)piperidin-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 440 0.208 15.3

2-methoxy-1-(4-(3- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 434 0.165 15.4

1-(4-(5-methyl-2- ((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 417 0.0678 15.5

1-(4-(5-fluoro-2-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 421 0.0648 15.6

1-(4-(2-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 403 0.0688 15.7

1-(4-(3-((1- (quinolin-2- yl)azetidin-3- yl)oxy)quinoxalin-2- yl)piperidin-1- yl)ethanone 454 0.0029 15.8

Benzyl 3-(3-(1- acetyl-1,2,3,6- tetrahydropyridin-4- yl)pyrazin-2- yloxy)azetidine-1- carboxylate 409 0.5825 15.9

1-(4-(2-(1-(quinolin- 2-yl)piperidin-4- yloxy)pyridin-3- yl)piperidin-1- yl)ethanone 432 1.64 15.10

2-methoxy-1-(4-(3- (1-(quinolin-2- yl)piperidin-4- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 462.2 0.04166 15.11

1-(4-(3-(1-(1H- Benzo[d]imidazol-2- carbonyl)piperidin- 4-yloxy)pyrazin-2- yl)-5,6- dihydropyridin- 1(2H)-yl)ethanone 447 0.07184 15.12

1-(4-(3-(1-(1H- benzo[d]imidazole- 2-carbonyl)azetidin- 3-yloxy)pyrazin-2- yl)-5,6- dihydropyridin- 1(2H)-yl)ethanone 419 0.010379 15.13

1-(3-(2-(1- picolinoylazetidin-3- yloxy)pyridin-3- yl)piperidin-1- yl)ethanone 381 0.04099 15.14

(R) and (S)-1-(3-(2- (1-(1H- benzo[d]imidazole- 2-carbonyl)azetidin- 3-yloxy)pyridin-3- yl)piperidin-1- yl)ethanone 420 0.006468 15.15

(R) and (S)-1-(3-(2- (1-(1H- benzo[d]imidazole- 2-carbonyl)azetidin- 3-yloxy)pyridin-3- yl)piperidin-1-yl)-2- methylpropan-1-one 448 0.0414 15.16

1-(4-(3-(1-(1H- pyrrole-2- carbonyl)azetidin-3- yloxy)pyrazin-2-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 368 0.2099 15.17

1-(3-(3-(1-(1H- benzo[d]imidazole- 2-carbonyl)azetidin- 3-yloxy)pyrazin-2- y1)-5,6- dihydropyridin- 1(2H)-yl)ethanone 419.1 0.121 15.18

1-(4-(2-(4- (hydroxy- methyl)piperidin- 1-yl)-4-((1- (quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-5- yl)piperidin-1- yl)ethanone 517 0.00039

TABLE 12B PREPARATION AND NMR DATA OF EXAMPLES 15.1-15.18 Reaction ¹H NMR (CD₃OD, 400 MHz) Ex. # Starting Material (1) and (2) Condition δ (ppm) 15.1

 

TEA, DCM 8.38-8.35 (m, 1H); 8.18-8.17 (m, 1H); 8.17-8.02 (m, 1H); 7.92-7.90 (m, 1H); 7.83-7.76 (m, 2H); 7.55- 7.51 (m, 1H); 7.01-6.99 (m, 1H); 5.70-5.67 (m, 1H); 5.00-4.95 (m, 1H); 4.63-4.59 (m, 2H); 4.58-4.24 (m, 2H); 4.21-3.69 (m, 2H); 3.35 (s, 3H); 3.35-3.34 (m, 2H); 3.02- 3.01 (m, 2H); 1.81-1.75 (m, 2H). 15.2

 

TEA, DCM (CDCl₃) 8.19 (d, J = 2.8 Hz, 1H); 8.13 (d, J = 9.2 Hz, 1H); 7.99-7.93 (m, 2H); 7.76-7.70 (m, 2H); 7.48- 7.44 (m, 1H); 6.62 (d, J = 9.2 Hz, 1H); 5.58 (s, 1H); 5.14-4.39 (m, 4H); 3.23-3.10 (m, 1H); 3.92-3.93 (m, 2H); 2.90-2.81 (m, 2H); 2.81 (s, 3H); 1.97-1.96 (m, 4H). 15.3

 

TEA, DCM 8.11 (d, J = 2.8 Hz, 1H); 8.03-8.01 (m, 2H); 7.66-7.55 (m, 3H); 7.30- 7.25 (m, 1H); 6.75 (d, J = 8.8 Hz, 1H); 5.63-5.59 (m, 1H); 4.69-4.64 (m, 2H); 4.58-4.55 (m, 1H); 4.12- 3.92 (m, 2H); 3.43-3.36 (m, 4H); 3.23-3.14 (m, 1H); 2.07 (s, 3H); 2.82-2.79 (m, 1H); 1.98-1.71 (m, 4H). 15.4

 

TEA, DCM 8.33 (d, J = 9.6 Hz, 1H); 7.89-7.87 (m, 1H); 7.89-7.77 (m, 3H); 7.51- 7.45 (m, 2H); 6.98-6.96 (m, 1H); 5.61-5.60 (m, 1H); 4.68-4.65 (m, 2H); 4.67-4.52 (m, 3H); 4.02-4.05 (m, 1H); 3.27-3.11 (m, 2H); 2.72- 2.71 (m, 1H); 2.25 (s, 3H); 2.12 (s, 3H); 1.73-1.68 (m, 2H); 1.61-1.58 (m, 2H). 15.5

 

TEA, DCM (CDCl₃) 7.83 (d, J = 8.2 Hz, 1H); 7.77-7.69 (m, 2H); 7.56-7.47 (m, 2H); 7.19-7.10 (m, 2H); 6.54 (d, J = 8.8 Hz, 1H); 5.49-5.46 (m, 1H); 4.74-4.70 (m, 1H); 4.60-4.56 (m, 2H); 4.15-4.13 (m, 2H); 3.86-3.82 (m, 1H); 3.13-2.96 (m, 2H); 2.58- 2.51 (m, 1H); 2.04 (s, 3H); 1.90- 1.79 (m, 2H); 1.49-1.40 (m, 2H). 15.6

 

TEA, DCM 7.99-7.96 (m, 2H); 7.64-7.52 (m, 4H); 7.22 (s, 1H); 6.96-6.93 (m, 1H); 6.70 (d, J = 8.8 Hz, 1H); 5.56 (s, 1H); 4.63-4.59 (m, 3H); 4.19- 4.15 (m, 2H); 3.99-3.94 (m, 1H); 3.22-3.12 (m, 2H); 2.68-2.67 (m, 1H); 2.07 (s, 3H); 1.88-1.83 (m, 2H); 1.64-1.53 (m, 2H). 15.7

 

TEA, DCM (CDCl₃) 8.12 (d, J = 9.2 Hz, 1H); 8.03-7.95 (m, 2H); 7.79-7.58 (m, 5H); 7.56-7.41 (m, 1H); 6.64 (d, J = 9.6 Hz, 1H); 5.76-5.75 (m, 1H); 5.20-4.71 (m, 4H); 3.99-3.96 (m, 1H); 3.48-3.43 (m, 2H); 2.82-2.71 (m, 1H); 2.145 (s, 3H); 2.03-2.00 (m, 3H); 1.97-1.84 (m, 1H). 15.8

 

TFA; DIEA, DCM 8.11-8.20 (1H, m), 7.97 (1H, s), 7.24-7.42 (5H, m), 6.92 (1H, br. s.), 5.35-5.52 (1H, m), 5.09 (2H, s), 4.36-4.56 (2H, m), 4.19-4.36 (2H, m), 4.07 (2H, d, J = 6.6 Hz), 3.74 (2H, dt, J = 15.3, 5.7 Hz), 2.77 (1H, br. s.), 2.57-2.73 (1H, m), 2.16 (3H, s) 15.9

 

DIPEA, DMF (CDCl₃) 1.65-1.79 (m, 1H) 1.85- 1.96 (m, 5H) 2.10 (s, 3H) 2.13- 2.21 (m, 2H) 2.65-2.75 (m, 1H) 3.13-3.28 (m, 2H) 3.68 (td, J = 8.71, 4.30 Hz, 2H) 3.92 (d, J = 12.52 Hz, 1H) 4.08-4.18 (m, 2H) 4.70 (d, J = 13.50 Hz, 1H) 5.40 (dt, J = 7.78, 4.03 Hz, 1H) 7.05 (d, J = 9.19 Hz, 1H) 7.20-7.26 (m, 1H) 7.50-7.57 (m, 1H) 7.61 (d, J = 7.63 Hz, 1H) 7.71 (d, J = 8.41 Hz, 1H) 7.91 (d, J = 9.19 Hz, 1H) 7.94 (d, J = 2.74 Hz, 1H) 8.05 (d, J = 2.74 Hz, 1H) 15.10

 

DIPEA, DMF (CDCl3) 1.69-1.81 (m, 1H) 1.84- 1.98 (m, 5H) 2.16 (dd, J = 7.63, 2.93 Hz, 2H) 2.75 (t, J = 11.64 Hz, 1H) 3.09-3.19 (m, 1H) 3.20-3.29 (m, 1H) 3.42 (s, 3H) 3.68 (t, J = 9.10 Hz, 2H) 3.99 (d, J = 12.72 Hz, 1H) 4.09-4.18 (m, 4H) 4.67 (d, J = 12.52 Hz, 1H) 5.40 (dt, J = 7.53, 3.86 Hz, 1H) 7.05 (d, J = 9.00 Hz, 1H) 7.21-7.24 (m, 1H) 7.55 (t, J = 7.53 Hz, 1H) 7.61 (d, J = 7.63 Hz, 1H) 7.71 (d, J = 8.61 Hz, 1H) 7.91 (d, J = 9.19 Hz, 1H) 7.94 (d, J = 2.74 Hz, 1H) 8.05 (d, J = 2.74 Hz, 1H) 15.11

 

THF (CDCl₃) 10.47 (1H, br. s.), 8.13 (1H, d, J = 2.6 Hz), 7.96 (1H, br. s.), 7.83 (1H, d, J = 7.7 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.29-7.45 (2H, m), 6.91 (1H, br. s.), 5.52 (1H, d, J = 3.7 Hz), 5.06 (1H, d, J = 5.4 Hz), 4.58- 4.74 (1H, m), 4.31 (1H, br. s.), 4.20 (1H, br. s.), 4.11 (1H, d, J = 5.7 Hz), 3.80 (2H, t, J = 5.6 Hz), 3.64 (1H, t, J = 5.6 Hz), 2.74 (2H, d, J = 15.5 Hz), 2.19-2.32 (2H, m), 2.15 (3H, d, J = 7.3 Hz), 1.90-2.10 (2H, m) 15.12

 

THF (CDCl₃) 10.79 (1H, br. s.), 8.22 (1H, dd, J = 6.8, 2.5 Hz), 7.93-8.04 (1H, m), 7.69 (2H, br. s.), 7.31-7.44 (2H, m), 6.95 (1H, br. s.), 5.48- 5.67 (1H, m), 5.36 (1H, dd, J = 12.0, 6.4 Hz), 4.85-5.05 (1H, m), 4.75 (1H, dd, J = 11.7, 6.5 Hz), 4.30- 4.43 (2H, m), 4.23 (1H, d, J = 2.7 Hz), 3.82 (1H, t, J = 5.7 Hz), 3.66 (1H, t, J = 5.8 Hz), 2.76 (2H, d, J = 19.0 Hz), 2.16 (3H, d, J = 8.8 Hz) 15.13

 

DCM (CDCl₃) 8.58 (1H, t, J = 5.6 Hz), 8.13 (1H, d, J = 7.8 Hz), 8.03 (1H, br. s.), 7.82 (1H, t, J = 7.5 Hz), 7.42- 7.55 (1H, m), 7.37 (1H, br. s.), 6.92 (1H, br. s.), 5.51 (1H, br. s.), 5.15 (1H, dd, J = 11.2, 6.4 Hz), 4.53- 4.82 (3H, m), 4.25 (1H, br. s.), 3.81-4.05 (1H, m), 2.83-3.04 (2H, m), 2.51-2.75 (1H, m), 2.13 (3H, s), 1.95-2.12 (1H, m), 1.74-1.94 (3H, m) 15.14

 

DCM ppm 8.04 (1H, ddd, J = 9.1, 5.0, 1.8 Hz), 7.52-7.81 (3H, m), 7.33 (2H, br. s.), 7.01 (1H, ddd, J = 10.4, 7.4, 4.9 Hz), 5.48-5.66 (1H, m), 5.25 (1H, dd, J = 11.6, 6.4 Hz), 4.76- 4.85 (1H, m), 4.58-4.76 (2H, m), 4.22-4.33 (1H, m), 3.95-4.15 (1H, m), 2.95-3.21 (2H, m), 2.56- 2.70 (1H, m), 2.21 (3H, s), 1.98- 2.07 (1H, m), 1.78-1.99 (2H, m), 1.51-1.76 (1H, m) 15.15

 

[(CH₃)₂CH]₂NC₂H₅ DCM (CDCl₃) 10.57 (1H, br. s.), 8.04 (1H, d, J = 13.3 Hz), 7.82 (1H, d, J = 8.0 Hz), 7.49-7.62 (2H, m), 7.28- 7.41 (2H, m), 6.82-7.02 (1H, m), 5.45-5.65 (1H, m), 5.25-5.35 (1H, m), 4.80-4.98 (1H, m), 4.72 (2H, m), 4.30-4.38 (1H, m), 3.85-4.15 (1H, dd, J = 9.5 Hz, J = 14.9 Hz), 2.97- 3.20 (2H, m), 2.68-2.97 (2H, m), 1.95-2.16 (1H, m), 1.72-1.85 (2H, m), 1.51-1.67 (1H, m), 1.15 (6H, m). 15.16

 

DCM (CDCl₃) 9.36 (1H, br. s.), 8.10- 8.29 (1H, d, J = 2.5 Hz), 7.94 (1H, d, J = 2.5 Hz), 6.95 (1H, br. s.), 6.47 (1H, br. s.), 6.27 (1H, d, J = 2.8 Hz), 5.52 (1H, m), 4.52-4.79 (2H, m), 4.22-4.32 (4H, m), 3.81 (1H, t, J = 5.6 Hz), 3.66 (1H, t, J = 5.6 Hz), 2.65-2.74 (2H, m), 2.17 (3H, s) 15.17

 

EDI, DIPEA, DMF (DMSO-d₆) δ ppm 8.30 (1H, br. s.), 8.12 (1H, br. s.), 7.63 (2H, br. s.), 7.15-7.38 (3H, m), 5.53 (1H, br. s.), 5.19 (1H, dd, J = 11.3, 6.0 Hz), 4.75 (1H, d, J = 11.1 Hz), 4.52-4.67 (1H, m), 4.45 (2H, br. s.), 4.24 (1H, d, J = 10.8 Hz), 3.57 (peak obscured by solvent), 3.17 (2H, s), 2.48 (peak obscured by solvent), 2.35 (1H, br. s.), 2.06 (3H, s). 15.18

 

TEA, DCM; 4M NaOH, MeOH 8.06-8.04 (m, 1H); 7.96 (s, 1H); 7.72-7.70 (m, 2H); 7.59-7.56 (m, 1H); 7.28-7.26 (m, 1H); 6.80-6.78 (m, 1H); 5.63-5.60 (m, 1H); 4.72- 4.64 (m, 4H); 4.25-4.23 (m, 2H); 4.04-4.01 (m, 1H); 3.47-3.45 (m, 2H). 3.25-3.20 (m, 2H); 2.96- 2.90 (m, 2H); 2.73-2.67 (m, 1H); 2.13 (s, 3H); 1.93-1.61 (m, 7H); 1.33-1.17 (m, 3H).

Example 16.1 3-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrazin-2-yl)Prop-2-yn-1-ol

A microwave tube was charged with 2-(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.6; 150 mg, 0.5 mmol), triethylamine (100 mg, 1.0 mmol), CuI (10 mg, 0.05 mmol), Pd (PPh₃)₂Cl₂ (35 mg, 0.05 mmol), prop-2-yn-1-ol (28 mg, 0.05 mmol). After several cycles of vacuum/purge with argon, 2 mL of DMF are added. The reaction mixture is then stirred at 110° C. under microwave for 2 hours. The reaction mixture is poured onto a solution of NaHCO₃ and diluted with EtOAc and the layers are separated. The organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (5% to 30% EtOAc in petroleum ether) to give the title product (99 mg, 0.3 mmol, 61% yield) as white solid. ESI-MS (M+1): 333 calc. for C₁₉H₁₆N₄O₂ 332.

TABLE 13A EXAMPLES 16.1-16.3 PREPARATION ANALOGOUS TO SCHEME 16 ESI-MS IC₅₀ Ex. # Structure Chemical Name (M + 1) (uM) 16.1

3-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)prop-2-yn-1-ol 333 0.342 16.2

4-(3-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrazin-2- yl)but-3-yn-2-ol 347 0.212 16.3

2-(3-((3-(3- methoxyprop-1-yn- 1-yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 347 0.282

TABLE 13B PREPARATION AND NMR DATA OF EXAMPLES 16.1-16.3 Reaction ¹H NMR(CD₃OD, 400 MHz): δ Ex. # Strarting Material (1) and (2) Condition (ppm) 16.1

TEA, CuI, Pd(PPh₃)₂Cl₂, DMF, MW 8.15-8.11 (m, 2H); 7.98 (d, J = 8.8 Hz, 1H); 7.65 (d, J = 8.2 Hz, 1H); 7.55-7.54 (m, 2H); 7.24 (s, 1H); 6.66 (d, J = 9.6 Hz, 1H); 5.58 (s, 1H); 4.64-4.60 (m, 2H); 4.49 (s, 2H); 4.40-4.24 (m, 2H). 16.2

TEA, CuI, Pd(PPh₃)₂Cl₂, DMF, MW 7.90 (d, J = 8.0 Hz, 1H); 7.82- 7.76 (m, 3H); 7.54-7.50 (m, 2H); 6.99-6.97 (m, 1H); 5.71-5.67 (m, 1H); 5.00-4.75 (m, 2H); 4.77-4.72 (m, 1H); 4.64-4.60 (m, 2H); 1.53- 1.51 (d, 3H). 16.3

TEA, CuI, Pd(PPh₃)₂Cl₂, DMF, MW 7.98 (d, J = 9.6 Hz, 1H); 7.92- 7.90 (m, 1H); 7.81-7.78 (m, 3H); 7.55-7.51 (m, 1H); 6.98 (d, J = 9.6 Hz, 1H); 5.73-5.69 (m, 1H); 5.00- 4.96 (m, 3H); 4.96-4.60 (m, 2H); 4.40 (s, 2H); 3.46 (s, 3H).

Example 17.1 2-(3-((3-((3-Methyloxetan-3-yl)Ethynyl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Quinoline Step. 1. Trimethyl((3-Methyloxetan-3-yl)Ethynyl)Silane

A 250-mL round-bottom flask was charged with 3-(2,2-dibromovinyl)-3-methyloxetane (2.177 g, 8.51 mmol) in THF (85 mL) to give a clear solution. The flask was cooled in a dry ice/acetone bath for 15 min, then n-butyllithium (7.83 mL, 19.56 mmol) (as a 2.5 M solution in hexane) was added dropwise over five min. After stirring at −78° C. for 45 min, trimethylchlorosilane (3.81 mL, 29.8 mmol) was added over 2 min. The cooling bath was removed after 30 min and the reaction was allowed to warm to RT for 30 min. The mixture was diluted with water (50 mL) and ether (50 mL). The layers were separated, and the aqueous layer was extracted with ether (25 mL). The combined organic extracts were dried over magnesium sulfate, filtered, and evaporated. The residue was dissolved in a small amount of ether and filtered through a small pad of silica gel. The filtrate was evaporated to give trimethyl((3-methyloxetan-3-yl)ethynyl)silane (1.344 g, 7.99 mmol, 94% yield) as a pale-yellow oil.

Step. 2. 2-(3-((3-((3-Methyloxetan-3-yl)Ethynyl)Pyrazin-2-yl)Oxy)Azetidin-1-yl)Quinoline

Tetrakis(triphenylphosphine)palladium (288 mg, 0.249 mmol), copper(i) iodide (190 mg, 0.998 mmol) and 2-(3-(3-chloropyrazin-2-yloxy)azetidin-1-yl)quinoline (see PREPARATION P2.6; 312 mg, 0.998 mmol) were combined in a microwave vial which was degassed and backfilled with nitrogen (procedure was repeated three times). DMF (1663 μL) was added followed by diisopropylamine (2097 μL, 14.96 mmol) and trimethyl((3-methyloxetan-3-yl)ethynyl)silane (840 mg, 4.99 mmol). The tube was sealed and heated to 85° C. for 16 hours. The solvent was removed under reduced pressure. The residue was dissolved in EtOAc and washed with brine and water. The aqueous layer was back extracted with EtOAc (3×) and the combined organic phase was dried over Na₂SO₄. The solvent was removed under reduced pressure. The crude material was purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0% to 50% EtOAc in hexane, to provide 2-(3-(3-((3-methyloxetan-3-yl)ethynyl)pyrazin-2-yloxy)azetidin-1-yl)quinoline (45 mg, 0.121 mmol, 12.11% yield) as orange powder. ¹H NMR (400 MHz, chloroform-d) δ ppm 1.76 (s, 3H) 4.28 (dd, J=9.88, 4.21 Hz, 2H) 4.47 (d, J=5.48 Hz, 2H) 4.67 (dd, J=9.59, 6.65 Hz, 2H) 4.97 (d, J=5.48 Hz, 2H) 5.52-5.62 (m, 1H) 6.63 (d, J=8.80 Hz, 1H) 7.21-7.41 (m, 2H) 7.45-7.65 (m, 1H) 7.76 (d, J=8.22 Hz, 1H) 7.90 (d, J=8.80 Hz, 1H) 8.03 (d, J=2.74 Hz, 1H) 8.17 (d, J=2.54 Hz, 1H). ESI (M+1) 373.1; calc for C₂₂H₂₀N₄O₂ 372. (PDE10 IC₅₀=0.0446 nM).

Example 18.1 4-(2-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridin-3-yl)Morpholine

To a solution of 1-(quinolin-2-yl)azetidin-3-ol (see PREPARATION P1.2; 237 mg, 1.186 mmol) in DMF (1.6 mL) was added sodium hydride, 60% in oil (49.4 mg, 1.235 mmol). The reaction mixture was stirred at RT for 15 min and 4-(2-fluoropyridin-3-yl)morpholine (see PREPARATION P17.1; 150 mg, 0.823 mmol) was added. The reaction mixture was heated at 60° C. for 3 hours. The reaction mixture was partitioned between EtOAc and brine. The aqueous layer was back extracted with EtOAc (3×) and the combined organic layers were dried (Na₂SO₄) and concentrated. The crude material was purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0% to 80% EtOAc in hexane, to provide 4-(2-(1-(quinolin-2-yl)azetidin-3-yloxy)pyridin-3-yl)morpholine (273 mg, 0.753 mmol, 91% yield) as off-white solid.

TABLE 14A EXAMPLES 18.1-18.10 PREPARED ANALOGOUS TO SCHEME 18 IC₅₀ Ex. # Structure Chemical Name M + 1 (uM) 18.1

4-(2-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyridin-3- yl)morpholine 363 0.012 18.2

tert-butyl 3-(3-(1- acetylpiperidin-4- yl)pyridin-2- yloxy)azetidine-1- carboxylate 376.3 10.2 18.3

(1H-benzo[d]imidazol- 2-yl)(3-((3-(3,6- dihydro-2H-pyran-4- yl)pyridin-2- yl)oxy)azetidin-1- yl)methanone 377 0.000864 18.4

1-(4-(2-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyridin-3-yl)- 5,6-dihydropyridin- 1(2H-yl)ethanone 418.0 0.07689 18.5

4-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyrazin-2- yl)cyclohexanone 392.1 0.1142 18.6

tert-butyl 3-((3- ((1r,4r)-4- hydroxycyclo- hexyl)pyridin-2- yl)oxy)azetidine-1- carboxylate 349.1 0.01575 18.7

(1H-benzo[d]imidazol- 2-yl)(3-((3-((1s,4s)-4- hydroxycyclo- hexyl)pyridin-2- yl)oxy)azetidin-1- yl)methanone 393.2 0.02111 18.8

1-(3-(2-((1-(4-methyl- 1H-pyrrole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 383 7.942 18.9

1-(4-(3-(1-(4-methyl- 1H-pyrrole-2- carbonyl)azetidin-3- yloxy)pyrazin-2-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 382 0.2495  18.10

1-(3-(2-((1-(1H- indole-2- carbonyl)azetidin-3- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 419 0.8864

TABLE 14B PREPARATION AND NMR DATA OF EXAMPLES 18.1-18.10 Starting Material Reaction ¹H NMR (CD₃OD, Ex. # (1) and (2) Condition 400 MHz) δ (ppm) 18.1

NaH, DMF, 60° C. (CDCl₃) 3.07-3.15 (m, 4H) 3.82-3.92 (m, 4H) 4.24 (dd, J = 9.39, 4.30 Hz, 2H) 4.65 (dd, J = 9.39, 6.65 Hz, 2H) 5.55-5.64 (m, 1H) 6.61 (d, J = 8.80 Hz, 1H) 6.90 (dd, J = 7.73, 4.99 Hz, 1H) 7.12 (d, J = 7.63 Hz, 1H) 7.23 (t, J = 7.43 Hz, 1H) 7.50-7.64 (m, 2H) 7.71-7.91 (m, 3H). 18.2

NaOtBu, DMSO (DMSO-D₆) 1.39 (s, 9H), 1.41- 1.48 (m, 1H), 1.53-1.63 (m, 1H), 1.73-1.83 (m, 2H), 2.02 (s, 3H), 2.61 (t, 1H, J = 10.76 Hz), 2.98- 3.07 (m, 1H), 3.15 (t, 1H, J = 10.95 Hz), 3.78-3.86 (m, 2H), 3.90 (d, 1H, J = 11.93 Hz), 4.21- 4.31 (m, 2H), 4.51 (d, 1H, J = 11.54 Hz), 5.27-5.33 (m, 1H), 6.97 (dd, 1H, J = 7.24 Hz, 4.89 Hz), 7.59 (dd, 1H, J = 7.24 Hz, 1.56 Hz), 7.97 (dd, 1H, J = 4.89 Hz, 1.76 Hz) 18.3

KOtBu, DMSO (CDCl₃) 8.11-7.95 (m, 1H); 7.70-7.21 (m, 5H); 6.91-6.85 (m, 1H); 6.00 (s, 1H); 5.52-5.45 (m, 1H); 5.30-5.28 (m, 1H); 4.85- 4.60 (m, 2H); 4.30-4.20 (m, 3H); 3.85-3.78 (m, 2H); 2.51-2.40 (m, 2H). 18.4

KOtBu, DMSO (DMSO-d₆) ppm 13.23 (1H, br. s.), 8.07 (1H, d, J = 4.8 Hz), 7.44-7.80 (3H, m), 7.28 (2H, br. s.), 6.91-7.09 (2H, m), 5.75 (2H, s), 5.51 (1H, br. s.), 5.16 (1H, br. s.), 4.93 (1H, br. s.), 4.51-4.77 (2H, m), 4.14 (1H, d, J = 13.3 Hz), 3.80 (1H, br. s.), 3.61 (1H, d, J = 4.4 Hz), 3.46 (1H, br. s.), 2.01-2.20 (4H, m), 1.78 (1H, br. s.) 18.5

NaOtBu, DMSO (CDCl₃) 2.06-2.30 (m, 4H), 2.43-2.63 (m, 4H), 3.47-3.60 (m, 1H), 4.37 (dd, 1H, J = 11.84 Hz, 3.80 Hz), 4.74 (dd, 1H, J = 11.11 Hz, 6.43 Hz), 4.91 (dd, 1H, J = 11.98 Hz, 3.07 Hz), 5.28-5.39 (m, 1H), 5.52-5.62 (m, 1H), 7.29-7.42 (m, 2H), 7.53 (d, 1H, J = 7.75 Hz), 7.81 (d, 1H, J = 8.04 Hz), 7.97 (d, 1H, J = 2.78 Hz), 8.15 (d, 1H, J = 2.63 Hz), 10.35 (s, 1H) 18.6

KOtBu DMSO (CDCl₃) 7.95 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 6.96 (dd, J = 5.3, 6.9 Hz, 1H), 5.47-5.27 (m, 1H), 4.50-4.27 (m, 2H), 3.94 (dd, J = 3.7, 9.8 Hz, 2H), 3.75-3.53 (m, 1H), 2.86 (t, J = 11.5 Hz, 1H), 2.10 (d, J = 11.5 Hz, 2H), 1.94 (d, J = 12.6 Hz, 2H), 1.77-1.16 (m, 13H) 18.7

KOtBu DMSO (CDCl₃) 8.02-7.91 (m, 1H), 7.69 (br. s., 2H), 7.56-7.46 (m, 2H), 7.34 (dd, J = 2.9, 6.1 Hz, 2H), 7.02-6.87 (m, 1H), 5.54 (br. s., 1H), 5.29 (dd, J = 6.4, 11.6 Hz, 1H), 4.99-4.79 (m, 1H), 4.71 (dd, J = 6.8, 11.5 Hz, 1H), 4.35-4.21 (m, 1H), 3.72- 3.55 (m, 1H), 2.85 (t, J = 10.2 Hz, 1H), 2.09 (d, J = 10.6 Hz, 2H), 1.95 (d, J = 11.9 Hz, 2H), 1.60-1.38 (m, 4H) 18.8

NaOtBu DMSO 8.02 (1H, ddd, J = 6.9, 5.1, 1.7 Hz), 7.65 (1H, td, J = 9.2, 1.4 Hz), 7.00 (1H, td, J = 7.5, 5.1 Hz), 6.73 (1H, s), 6.41 (1H, d, J = 3.2 Hz), 5.40-5.62 (1H, m), 4.47-4.75 (3H, m), 4.43 (3H, m), 4.01-4.27 (1H, m), 2.90- 3.24 (2H, m), 2.13 (3H, s), 2.09 (3H, s), 1.95-2.06 (1H, m), 1.80-1.95 (2H, m), 1.53-1.80 (1H, m) 18.9

NaOtBu DMSO (CDCl₃) 9.09 (1H, br. s.), 8.16 (1H, d, J = 2.6 Hz), 7.96 (1H, d, J = 2.6 Hz), 6.83 (1H, d, J = 8.2 Hz), 6.72 (1H, br. s.), 6.29 (1H, s), 5.51 (1H, m), 5.08 (1H, m), 4.75 (2H, m), 4.32 (2H, m), 4.01 (2H, m), 3.57-3.74 (1H, m), 2.28 (3H, s), 2.15 (1H, m), 2.11 (3H, s), 2.01 (1H, m)  18.10

NaOtBu DMSO 8.04 (1H, t, J = 5.3 Hz), 7.58- 7.72 (2H, m), 7.45 (1H, d, J = 8.2 Hz), 7.23 (1H, t, J = 7.7 Hz), 6.95-7.12 (2H, m), 6.90 (1H, d, J = 4.5 Hz), 5.61 (1H, m), 5.02 (1H, m), 4.55-4.68 (2H, m), 4.22 (1H, m), 4.08-3.96 (1H, dd, J = 9.5 Hz, J = 14.9 Hz), 3.00-3.26 (3H, m), 2.49-2.80 (1H, m), 2.13 (3H, s), 2.03 (1H, m), 1.86 (2H, m), 1.45-1.77 (1H, m)

Example 19.1 (1H-Benzo[D]Imidazol-2-yl)(3-(3-(4-Hydroxycyclohex-1-Enyl)Pyrazin-2-yloxy)Azetidin-1-yl)Methanone Step 1. (1H-Benzo[D]Imidazol-2-yl)(3-(3-(4-(Tert-Butyldimethylsilyloxy)Cyclohex-1-Enyl)Pyrazin-2-yloxy)Azetidin-1-yl)Methanone

A glass microwave vessel was charged with (1H-benzo[d]imidazol-2-yl)(3-(3-chloropyrazin-2-yloxy)azetidin-1-yl)methanone (see PREPARATION P23.1; 219 mg, 0.664 mmol), tert-butyldimethyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enyloxy)silane (366 mg, 1.082 mmol, purchased from Small Molecules Inc.), sodium carbonate (211 mg, 1.992 mmol), and dioxane:water (10:1, 15 mL). The solution was purged with N₂ for 5 minutes, then palladium tetrakis (153 mg, 0.133 mmol) was added. The reaction mixture was stirred and heated in a Biotage Initiator at 120° C. for 60 minutes. The reaction was poured into water (30 mL) and extracted with EtOAc (2×20 mL). The combined EtOAc layers were eluted through a plug of silica gel. The filtrate was concentrated in vacuo to give crude (1H-benzo[d]imidazol-2-yl)(3-(3-(4-(tert-butyldimethylsilyloxy)cyclohex-1-enyl)pyrazin-2-yloxy)azetidin-1-yl)methanone (550 mg, 164% yield), as a yellow solid. The product was carried forward in the next step without further purification. MS (ESI) m/z 506.3 (MH⁺).

Step 2. (1H-Benzo[D]Imidazol-2-yl)(3-(3-(4-(Tert-Butyldimethylsilyloxy)Cyclohex-1-Enyl)Pyrazin-2-yloxy)Azetidin-1-yl)Methanone

To a solution of (1H-benzo[d]imidazol-2-yl)(3-(3-(4-(tert-butyldimethylsilyloxy)cyclohex-1-enyl)pyrazin-2-yloxy)azetidin-1-yl)methanone (336 mg, 0.664 mmol) and THF (6 mL) was added 1M TBAF in THF (1.6 mL, 1.600 mmol). After 24 hours, the reaction solution was eluted through a short plug of silica gel. The filtrate was concentrated in vacuo and adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (12 g), eluting with 0% to 4% MeOH in DCM, to provide (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxycyclohex-1-enyl)pyrazin-2-yloxy)azetidin-1-yl)methanone (75 mg, 28.8% yield), as a light yellow solid. MS (ESI) m/z 392.1 (MH⁺). IC₅₀ (uM) 0.07168. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 1.63-1.67 (m, 1H), 1.77-1.87 (m, 1H), 2.00-2.07 (m, 1H), 2.26-2.35 (m, 1H), 2.60-2.71 (m, 2H), 2.74-2.84 (m, 1H), 4.07-4.13 (m, 1H), 4.33 (dd, 1H, J=11.74 Hz, 4.11 Hz), 4.71 (dd, 1H, J=11.74 Hz, 6.65 Hz), 4.90 (dd, 1H, J=11.93 Hz, 4.11 Hz), 5.31 (dd, 1H, J=11.93 Hz, 6.65 Hz), 5.52-5.58 (m, 1H), 6.76 (br s, 1H), 7.29-7.41 (m, 2H), 7.54 (d, 1H, J=7.82 Hz), 7.82 (d, 1H, J=8.02 Hz), 7.93 (d, 1H, J=2.54 Hz), 8.19 (d, 1H, J=2.54 Hz), 10.59 (s, 1H).

Example 20.1 (Racemic Mixture) 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Ethanol Step 1: 1-(1-(3,6-Dichloropyridazin-4-yl)Piperidin-4-yl)Ethanone

Triethylamine (2.2 g, 20.0 mmol), 3,4,6-trichloro-pyridazine (1.8 g, 10.0 mmol) and 1-(piperidin-4-yl)ethanone (1.3 g, 10.0 mmol) was dissolved in DMF (20 mL) and the resulting mixture was stirred at room temperature overnight. The mixture was then diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were combined and washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (20% to 50% EtOAc in hexanes) to give 1-(1-(3,6-dichloropyridazin-4-yl)piperidin-4-yl)ethanone (1.0 g, 3.8 mmol, 39% yield) as white solid. ESI-MS (M+1): 274 calc. for C₁₁H₁₃ClN₃O 273.

Step 2: 1-(1-(6-Chloro-3-(1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Ethanone

To a solution of 1-(quinolin-2-yl)azetidin-3-ol (see PREPARATION P1.2, step 1; 0.78 g, 3.8 mmol) in DMF (20 mL) at room temperature was added sodium hydride (60% wt in mineral oil) (0.18 g, 7.6 mmol). The mixture was stirred at room temperature for 10 min and then 1-(1-(3,6-dichloropyridazin-4-yl)piperidin-4-yl)ethanone (1.0 g, 3.8 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour and then diluted with water (20 mL) and extracted with EtOAc (2×30 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, and filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (5% to 30% EtOAc in hexanes) to give the title product (1.1 g, 2.6 mmol, 70% yield) as white solid. ESI-MS (M+1): 438 calc. for C₂₄H₂₅ClN₄O₂ 437.

Step 3: 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Ethanone

A mixture of 1-(1-(6-chloro-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)ethanone (1.1 g, 2.6 mmol) and wet Pd—C (50%, 1.0 g) in MeOH (30 mL) was stirred under H₂ (40 psi) at room temperature for 1.5 hours then the reaction mixture was filtered through CELITE® and washed with MeOH. The filtrate was concentrated in vacuo to give 1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)ethanone (0.98 g, 2.5 mmol, yield 96%). ESI-MS (M+1): 404 calc. for C₂₄H₂₆N₄O₂ 403.

Step 4: (Racemic Mixture) 1-(1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Ethanol

1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)ethanone (100 mg, 0.25 mmol) was dissolved in 10 ml of methanol. This solution was cooled down to 0° C. using an ice bath and sodium tetraborohydride (19 mg, 0.50 mmol) was added by portions. The reaction mixture was stirred for 4 hours at ambient temperature, and then saturated aqueous solution of ammonium chloride (5 mL) was added. The methanol was evaporated off under reduced pressure then the reaction mixture was taken up in ethyl acetate. The organic layer was separated from the aqueous layer. The aqueous layer was back extracted one more time with ethyl acetate. The organic layers were combined and dried over magnesium sulfate, followed by concentration under reduced pressure. The residue was purified by column chromatography on silica gel to give (racemic mixture) 1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)ethanol (76 mg, 0.19 mmol, 75% yield). ESI-MS (M+1): 406 calc. for C₂₃H₂₂N₅O₂ 405. PDE10 IC₅₀ (uM): 0.0767. ¹HNMR (CD₃OD, 400 MHz) δ (ppm): δ (ppm) 8.40 (m, 1H); 8.14-8.10 (d, J=8.8 Hz, 1H); 7.97 (d, J=8.8 Hz, 1H); 7.64-7.58 (m, 2H); 7.51-7.46 (m, 1H); 7.20-7.16 (m, 1H); 6.80-6.79 (m, 1H); 6.62 (d, J=9.2 Hz, 1H); 5.62-5.59 (m, 1H); 4.61-4.57 (m, 2H); 4.18-4.15 (m, 2H); 3.96-3.93 (m, 2H); 3.48-3.43 (m, 1H); 2.73-2.67 (m, 2H); 1.91-1.88 (m, 1H); 1.66-1.64 (m, 1H); 1.42-1.34 (m, 3H); 1.11-1.10 (d, 3H).

TABLE 15A EXAMPLE 20.1 PREPARED ANALOGOUS TO SCHEME 20 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 20.1

1-(1-(3-((1-(quinolin- 2-yl)azetidin-3- yl)oxy)pyridazin-4- yl)piperidin-4- yl)ethanol 406 0.0767

Example 21.1 1-(4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-1-yl)Ethanone Step 1. Tert-Butyl 4-(3-Chloro-6-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate and Tert-Butyl 4-(6-Chloro-3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate, as Isomeric Mixture

To a solution of 2-(3-((6-chloro-5-iodopyridazin-3-yl)oxy)azetidin-1-yl)quinoline and 2-(3-((6-chloro-4-iodopyridazin-3-yl)oxy)azetidin-1-yl)quinoline as isomeric mixture, (see PREPARATION P6.1; 521 mg, 1.2 mmol) in 1,4-dioxane (15 mL) was treated with Na₂CO₃ (255 mg, 2.4 mmol) in 2 mL of water as a solution, followed by additional of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (557 mg, 1.8 mmol) and Pd(dppf)Cl₂ (88 mg, 0.12 mmol). The resulting mixture was heated at refluxing overnight under N₂ atmosphere. The solution was filtered, and the filtrate was concentrated. The residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give the title product (509 mg, 1.0 mmol, yield: 83%). ESI-MS (M+1): 494 calc. for C₂₆H₂₈ClN₅O₃ 493.

Step 2. Tert-Butyl 4-(3-Chloro-6-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidine-1-Carboxylate and Tert-Butyl 4-(6-Chloro-3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidine-1-Carboxylate as Isomeric Mixture

To a solution of tert-butyl 4-(3-chloro-6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate and tert-butyl 4-(6-chloro-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate (509 mg, 1.0 mmol) as isomeric mixture obtained in Step 1 in MeOH (10 mL) was added Pd/C (50%, 300 mg). The reaction solution was stirred at room temperature overnight under H₂ atmosphere. The mixture was filtered through CELITE® and concentrated to give the product (334 mg, 0.73 mmol, yield: 73%). ESI-MS (M+1): 462 calc. for C₂₆H₃₁N₅O₃ 461.

Step 3. 1-(4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl) Piperidin-1-yl)Ethanone

A mixture of product obtained in Step 2 (334 mg, 0.73 mmol) in HCl/MeOH (10 mL, saturated with HCl gas) was stirred at room temperature for 1 hour. Then it was concentrated to give 2-(3-((6-chloro-5-(piperidin-4-yl)pyridazin-3-yl)oxy)azetidin-1-yl)quinoline hydrochloride and 2-(3-((6-chloro-4-(piperidin-4-yl)pyridazin-3-yl)oxy)azetidin-1-yl)quinoline hydrochloride as isomeric mixture, which was used in the next step without further purification.

Step 4. 1-(4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-1-yl)Ethanone

To a solution of mixture of product obtained in Step 3 in CH₂Cl₂ (10 mL) was added Et₃N (148 mg, 1.46 mmol) and acetyl chloride (69 mg, 0.88 mmol). The reaction mixture was stirred at room temperature for 1 hour, then diluted with CH₂Cl₂ (20 mL), washed with water (20 mL). The organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered, evaporated to give the crude product. Purified by column chromatography, and followed by prep. HPLC (10% to 80% water/MeCN) to give the title compound as the major product, whereas the other isomer was not generated in sufficient quantity to be characterized (30 mg, 0.07 mmol, yield: 10%). PDE10 IC₅₀ (uM): 0.851. ¹HNMR (CD₃OD, 400 MHz) 6 (ppm): 8.83-8.81 (m, 1H), 8.36 (d, J=9.2 Hz, 1H), 7.90 (d, J=8.0 Hz, 1H), 7.80-7.77 (m, 2H), 7.57-7.49 (m, 2H), 7.00 (d, J=9.2 Hz, 1H), 5.81-5.79 (m, 1H), 5.03-4.98 (m, 2H), 4.73-4.68 (m, 3H), 4.04 (d, J=10 Hz, 1H), 3.30-3.14 (m, 2H), 2.74-2.69 (m, 1H), 2.12 (s, 3H), 2.00-1.95 (m, 2H), 1.72-1.55 (m, 2H).

Example 22.1 and 22.2 (1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol and (1-(6-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol as Isomeric Mixture Step 1. (1-(3-Chloro-6-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol and (1-(6-Chloro-3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol as Isomeric Mixture

To a solution of 2-(3-((6-chloro-5-iodopyridazin-3-yl)oxy)azetidin-1-yl)quinoline and 2-(3-((6-chloro-4-iodopyridazin-3-yl)oxy)azetidin-1-yl)quinoline as isomeric mixture, (see PREPARATION P6.1; 655 mg, 1.5 mmol) in 1,4-dioxane (15 mL) was added Pd₂(dba)₃ (83 mg, 0.09 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) (56 mg, 0.09 mmol), sodium tertbutoxide (t-BuONa) (177 mg, 1.84 mmol) and piperidin-4-ylmethanol (212 mg, 1.84 mmol). The resulting mixture was heated at refluxing overnight under N₂ atmosphere. The solution was filtered through CELITE®, and the filter was concentrated. The residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give the title product (423 mg, 0.99 mmol, yield: 60%). ESI-MS (M+1): 426 calc. for C₂₂H₂₄ClN₅O₂ 425.

Step 2. (1-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol and (1-(6-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyridazin-4-yl)Piperidin-4-yl)Methanol as Isomeric Mixture

To a solution of (mixture) (1-(3-chloro-6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)methanol and (1-(6-chloro-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyridazin-4-yl)piperidin-4-yl)methanol (423 mg, 0.99 mmol) in MeOH (15 mL) was added Pd/C (50%, 200 mg). The reaction solution was stirred at room temperature overnight under H₂ atmosphere. The mixture was filtered through CELITE® and the filtrate was concentrated, the residue was purified by reverse phase prep. HPLC (10% to 80% water/MeCN) to give the products examples 22.1 and 22.2 as isomeric mixture without further separation. ESI-MS (M+1): 392 calc. for C₂₂H₂₅N₅O₂ 391. M+1:392 PDE10 IC₅₀ (uM): 0.001 and 0.04 NMR; ¹H NMR (CD₃OD, 400 MHz) δ (ppm) 8.58 (d, J=6.8 Hz, 1H), 8.38 (d, J=9.6 Hz, 1H), 7.93-7.90 (m, 1H), 7.82-7.80 (m, 2H), 7.56-7.51 (m, 1H), 7.28 (d, J=6.8 Hz, 1H), 7.01 (d, J=9.2 Hz, 1H), 5.72-5.68 (m, 1H), 5.02-4.97 (m, 2H), 4.74-4.69 (m, 2H), 4.58-4.55 (m, 2H), 3.46 (d, J=6.0 Hz, 2H), 3.41-3.34 (m, 2H), 1.98-1.93 (m, 3H), 1.49-1.45 (m, 2H). and 8.80 (d, J=2.4 Hz, 1H), 8.39 (dd, J=9.6 Hz, 1.6 Hz, 1H), 7.92 (d, J=7.6 Hz, 1H), 7.93-7.80 (m, 2H), 7.56-7.52 (m, 1H), 7.00 (d, J=9.2 Hz, 1H), 6.88-6.67 (m, 1H), 5.72-5.70 (m, 1H), 5.04-4.98 (m, 2H), 4.67-4.63 (m, 2H), 4.33-4.23 (m, 2H), 3.47-3.45 (m, 2H), 3.30-3.18 (m, 2H), 1.96-1.92 (m, 3H), 1.50-1.38 (m, 2H).

Example 23.1 1-(4-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-5-yl)Piperidin-1-yl)Ethanone Step 1. Tert-Butyl 4-(2-Chloro-4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-5-yl)-5,6-Dihydropyridine-1(2H)-Carboxylate

To a solution of 2-(3-((5-bromo-2-chloropyrimidin-4-yl)oxy)azetidin-1-yl)quinoline (see PREPARATION P2.11; 600 mg, 1.5 mmol) in 1,4-dioxane (15 mL) was treated with Na₂CO₃ (318 mg, 3 mmol) in 3 mL of water as a solution, followed by additional of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (556 mg 1.8 mmol) and Pd(dppf)Cl₂ (110 mg, 0.15 mmol). The resulting mixture was heated at refluxing overnight under N₂ atmosphere. The solution was filtered through CELITE®, and the filter was concentrated. The residue was purified by flash column chromatography on silica gel (20% to 70% EtOAc in petroleum ether) to give the title product (472 mg, 0.95 mmol, yield: 63%). ESI-MS (M+1): 494 calc. for C₂₆H₂₈ClN₅O₃ 493.

Step 2. Tert-Butyl 4-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-5-yl)Piperidine-1-Carboxylate

To a solution of tert-butyl 4-(2-chloro-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (472 mg, 0.95 mmol) in MeOH (10 mL) was added Pd/C (10%, 200 mg). The reaction solution was stirred at room temperature overnight under H₂ atmosphere. The mixture was filtered through CELITE® and concentrated to give the product (307 mg, 0.66 mmol, yield: 78%). ESI-MS (M+1): 462 calc. for C₂₆H₃₁N₅O₃ 461.

Step 3. 1-(4-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-5-yl)Piperidin-1-yl)Ethanone

The mixture of tert-butyl 4-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)piperidine-1-carboxylate (307 mg, 0.66 mmol) in HCl/MeOH (10 mL, saturated with HCl gas) was stirred at room temperature for 1 hour. Then it was concentrated to give 2-(3-((5-(piperidin-4-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline hydrochloride which was used in the next step below without further purification.

To a solution of 2-(3-((5-(piperidin-4-yl)pyrimidin-4-yl)oxy)azetidin-1-yl)quinoline hydrochloride in CH₂Cl₂ (10 mL) were added Et₃N (100 mg, 0.99 mmol) and acetyl chloride (62 mg, 0.79 mmol). The reaction mixture was stirred at room temperature for 1 hour, then diluted with CH₂Cl₂ (20 mL), washed with water (20 mL). The organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered, evaporated to give the crude product. Purified by column chromatography, and followed by prep. HPLC (10% to 80% water/MeCN) to give 1-(4-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-5-yl)piperidin-1-yl)ethanone (34 mg, 0.08 mmol, yield 13%). M+1 IC₅₀ (uM) 404 0.765 ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 8.73 (s, 1H), 8.44 (s, 1H), 8.14 (d, J=9.2 Hz, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.75-7.65 (m, 2H), 7.47-7.40 (m, 1H), 6.64 (d, J=9.2 Hz, 1H), 5.71 (s, 1H), 5.04-4.98 (m, 2H), 4.79-4.71 (m, 2H), 4.68-4.63 (m, 1H), 3.97-3.93 (m, 1H), 3.26-3.19 (m, 1H), 3.11-3.04 (m, 1H), 2.71-2.64 (m, 1H), 2.14 (s, 3H), 2.03-1.89 (m, 2H), 1.69-1.63 (m, 2H).

Example 24.1 (1-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-2-yl)Piperidin-4-yl)Methanol

A mixture of (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol (see PREPARATION P7.1; 115 mg, 0.25 mmol) and wet Pd—C (50%, 50 mg) in MeOH (10 mL) was stirred under H₂ (15 psi) at room temperature for 1.5 hours then the reaction mixture was filtered through CELITE® and washed with MeOH. The filtrate was concentrated in vacuo to give (1-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol (93 mg, 0.24 mmol, yield 96%). ESI-MS (M+1): 392 calc. for C₂₂H₂₅N₅O₂ 391.

TABLE 16A EXAMPLES 24.1-24.3 PREPARED ANALOGOUS TO SCHEME 24 IC₅₀ Ex. # Structure Chemical Name M + 1 (uM) 24.1

(1-(4-((1-(quinolin-2- yl)azetidin-3- yl)oxy)pyrimidin-2- yl)piperidin-4- yl)methanol 392 0.0142 24.2

(R)-(1H- benzo[d]imidazol-2- yl)(3-(3-(tetrahydro-2H- pyran-4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)methanone 394 2.782 24.3

1-(4-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)piperidin-4- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 449 0.2591

TABLE 16B PREPARATION AND NMR DATA OF EXAMPLES 24.1-24.3 Reaction ¹H NMR (CD₃OD, Ex. # Starting material (1) Condition 400 MHz) δ (ppm) 24.1

H₂, Pd/C, MeOH 8.35 (d, J = 9.2 Hz, 1H); 8.14- 8.10 (m, 1H); 7.89 (d, J = 8.0 Hz, 1H); 7.79-7.78 (m, 2H); 7.53- 7.49 (m, 1H); 6.97 (d, J = 9.2 Hz, 1H); 6.55 (d, J = 6.8 Hz, 1H); 5.78-5.74 (m, 1H); 5.00-4.96 (m, 1H); 4.67-4.63 (m, 3H); 4.33- 4.31 (m, 2H); 3.47-3.46 (m, 2H); 3.29-3.21 (m, 2H); 1.97-1.86 (m, 3H); 1.41-1.34 (m, 2H). 24.2

Pd/C,H₂, MeOH (CDCl₃) 8.12-8.09 (m, 1H); 7.95- 7.94 (m, 1H); 7.72-7.70 (m, 2H); 7.36-7.35 (m, 2H); 5.79-5.71 (m, 1H); 4.78-4.37 (m, 2H); 4.10-3.95 (m, 4H); 3.53-3.49 (m, 2H); 3.21- 3.16 (m, 1H); 2.44-2.34 (m, 2H); 1.95-1.92 (m, 2H); 1.73-1.69 (m, 2H). 24.3

Pd/C,H₂, MeOH (CDCl₃) 10.47 (1H, br. s.), 8.07 (1H, d, J = 2.5 Hz), 7.94 (1H, d, J = 2.6 Hz), 7.83 (1H, d, J = 7.6 Hz), 7.54 (1H, d, J = 7.6 Hz), 7.29-7.43 (2H, m), 5.38-5.53 (1H, m), 5.06 (1H, br. s.), 4.56-4.81 (2H, m), 4.12 (1H, d, J = 4.7 Hz), 3.95 (1H, d, J = 13.2 Hz), 3.82 (1H, br. s.), 3.09-3.33 (2H, m), 2.71 (1H, t, J = 12.0 Hz), 2.19 (2H, br. s.), 2.12 (3H, s), 2.01 (2H, br. s.), 1.84-1.97 (3H, m), 1.63-1.84 (1H, m)

Example 25.1 (1-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)-5-(Tetrahydro-2H-Pyran-4-yl)Pyrimidin-2-yl)Piperidin-4-yl)Methanol Step 1. (1-(5-(3,6-Dihydro-2H-Pyran-4-yl)-4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Pyrimidin-2-yl)Piperidin-4-yl)Methanol

To a solution of (1-(5-bromo-4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol (see PREPARATION P7.1; 115 mg, 0.25 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (52.5 mg, 0.25 mmol) and K₃PO₄ (100 mg, 0.5 mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) was added Pd(dppf)Cl₂ (15 mg, 0.02 mmol) then the reaction mixture was stirred at 110° C. under N₂ atmosphere overnight. The reaction mixture was filtered through CELITE® and washed with CH₂Cl₂ (30 mL). The filtrate was concentrated and the crude product was purified by silica gel column to give (1-(5-(3,6-dihydro-2H-pyran-4-yl)-4-(1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol (100 mg, 0.21 mmol, yield 84%). ESI-MS (M+1): 474 calc. for C₂₇H₃₁N₅O₃ 473.

Step 2. (1-(4-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)-5-(Tetrahydro-2H-Pyran-4-yl)Pyrimidin-2-yl)Piperidin-4-yl)Methanol

A mixture of (1-(5-(3,6-dihydro-2H-pyran-4-yl)-4-(1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)methanol (100 mg, 0.21 mmol) and wet Pd—C (50%, 50 mg) in MeOH (10 mL) was stirred under H₂ (30 psi) at room temperature for 6 hours then the reaction mixture was filtered through CELITE® and washed with MeOH. The filtrate was concentrated in vacuo to give (1-(4-((1-(quinolin-2-yl)azetidin-3-yl)oxy)-5-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-yl)piperidin-4-yl)methanol (90 mg, 0.19 mmol, yield 90%). ESI-MS (M+1): 476 calc. for C₂₇H₃₃N₅O₃ 475. PDE10 IC₅₀ (uM): 0.0029 ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 8.23 (d, J=9.2 Hz, 1H); 8.08-8.06 (m, 1H); 7.95-7.93 (m, 1H); 7.80-7.78 (m, 2H); 7.55-7.51 (m, 1H); 6.74-6.70 (m, 1H); 5.73-5.72 (m, 1H); 5.19-5.10 (m, 2H); 4.70-4.51 (m, 4H); 4.27 (d, J=6.4 Hz, 1H); 4.08-4.06 (m, 2H); 3.57-3.48 (m, 3H); 3.20-3.14 (m, 2H); 2.89-2.88 (m, 1H); 2.02-1.93 (m, 3H); 1.78-1.76 (m, 4H); 1.42-4.37 (m, 2H).

Example 26.1 (3-((3-(3,6-Dihydro-2H-Pyran-4-yl)Pyridin-2-yl)Oxy)Azetidin-1-yl)(Pyrimidin-4-yl)Methanone

To a solution of 2-(azetidin-3-yloxy)-3-(3,6-dihydro-2H-pyran-4-yl)pyridine hydrochloride (see PREPARATION P26.1; 100 mg, 0.45 mmol), pyrimidine-4-carboxylic acid (55 mg, 0.45 mmol) and triethylamine (96.13 mg, 0.95 mmol) in CH₂Cl₂ (10 mL) was added 4-Dimethylaminopyridine (DMAP) (55 mg, 0.47 mmol) and propyl phosphonic anhydride (500 mg, 0.9 mmol). The reaction mixture was stirred at room temperature for overnight. Then the reaction mixture was concentrated and the crude product was purified by silica gel column chromatography to give the desired compound (48 mg, 0.16 mmol, yield 66%). [M+1]: 339. IC₅₀ (uM): 0.99.

TABLE 17A EXAMPLES 26.1-26.42 PREPARED ANALOGOUS TO SCHEME 26 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 26.1 

(3-((3-(3,6-dihydro-2H- pyran-4-yl)pyridin-2- yl)oxy)azetidin-1- yl)(pyrimidin-4- yl)methanone 339 0.99 26.2 

(1H-imidazol-2-yl)(4- (3-(tetrahydro-2H- pyran-4-yl)pyridin-2- yloxy)piperidin-1- yl)methanone 357 3.673 26.3 

(1H-pyrrol-2-yl)(4-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)piperidin-1- yl)methanone 356 4.261 26.4 

pyridin-2-yl(4-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)piperidin-1- yl)methanone 368 1.26 26.5 

(6-methylpyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 382 1.177 26.6 

(5-methylpyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 382 1.648 26.7 

(4-methylpyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 382 0.118 26.8 

(3-methylpyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 382 1.002 26.9 

benzo[d]thiazol-2-yl(4- (3-(tetrahydro-2H- pyran-4-yl)pyridin-2- yloxy)piperidin-1- yl)methanone 424 0.324 26.10

isoquinolin-3-yl(4-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)piperidin-1- yl)methanone 418 0.126 26.11

(5-chloropyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 402 >10 26.12

(4-chloropyridin-2- yl)(4-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)piperidin-1- yl)methanone 402 8.89 26.13

(S)-(1H- benzo[d]imidazol-2- yl)(3-(3-(3,6-dihydro- 2H-pyran-4-yl)pyridin- 2-yloxy)pyrrolidin-1- yl)methanone 391 0.715 26.14

(S)-(1H- benzo[d]imidazol-2- yl)(3-(3-(3,6-dihydro- 2H-pyran-4-yl)pyrazin- 2-yloxy)pyrrolidin-1- yl)methanone 392 0.201 26.15

(R)-(1H- benzo[d]imidazol-2- yl)(3-(3-(3,6-dihydro- 2H-pyran-4-yl)pyridin- 2-yloxy)pyrrolidin-1- yl)methanone 391 0.767 26.16

(R)-(1H- benzo[d]imidazol-2- yl)(3-(3-(3,6-dihydro- 2H-pyran-4-yl)pyrazin- 2-yloxy)pyrrolidin-1- yl)methanone 392 1.464 26.17

(1H-benzo[d]imidazol- 2-yl)(3-(3-(tetrahydro- 2H-pyran-4-yl)pyrazin- 2-yloxy)azetidin-1- yl)methanone 380 0.8837 26.18

(1H-benzo[d]imidazol- 2-yl)(4-((3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yl)oxy)piperidin-1- yl)methanone 407 0.116 26.19

1-(4-(2-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyridin-3- yl)piperidin-1- yl)ethanone 420.2 0.1016 26.20

(1H-benzo[d]imidazol- 2-yl)(3-(3-(pyridin-3- yl)pyrazin-2- yloxy)azetidin-1- yl)methanone 373.1 0.1786 26.21

1-(4-(3-(1-(5- methylpicolinyl)azetidin- 3-yloxy)pyrazin-2- yl)-5,6-dihydropyridin- 1(2H)-yl)ethanone 394 1.03 26.22

(R) and (S)-1-(3-(2-(1-(6- methylnicotinoyl)azetidin- 3-yloxy)pyridin-3- yl)piperidin-1- yl)ethanone 395 8.34 26.23

(R) and (S)-1-(3-(3-(1- acetylpiperidin-3- yl)pyridin-2- yloxy)azetidin-1-yl)- 3,3-dimethylbutan-1- one 374 41.85 26.24

1-(4-(3-(1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 421 0.1614 26.25

1-(4-(3-(1-(1H-pyrrole- 2-carbonyl)azetidin-3- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 370 0.1386 26.26

(1H-benzo[d]imidazol- 2-yl)(3-(pyrazin-2- yloxy)azetidin-1- yl)methanone 296 12.31 26.27

(1H-Benzo[d]imidazol- 2-yl)(3-(3-(tetrahydro- 2H-pyran-4- yl)quinoxalin-2- yloxy)azetidin-1- yl)methanone 430.1 0.786 26.28

(1H-benzo[d]imidazol- 2-yl)(3-((3-(3,6- dihydro-2H-pyran-4- yl)pyridin-2- yl)oxy)azetidin-1- yl)methanone 377 0.000864 26.29

isoquinolin-1-yl(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)methanone 418 0.640 26.30

quinolin-2-yl(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)methanone 418 0.809 26.31

quinolin-2-yl(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)methanone 419 0.994 26.32

isoquinolin-1-yl(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)methanone 419 7.32 26.33

(4-((3-(2- methylpyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)(quinolin-2- yl)methanone 426 2.66 26.34

isoquinolin-1-yl(4-((3- (2-methylpyridin-4- yl)pyrazin-2- yl)oxy)piperidin-1- yl)methanone 426 3.59 26.35

(4-((2′-methyl-[3,4′- bipyridin]-2- yl)oxy)piperidin-1- yl)(quinolin-2- yl)methanone 425 1.23 26.36

isoquinolin-1-yl(4-((2′- methyl-[3,4′-bipyridin]- 2-yl)oxy)piperidin-1- yl)methanone 425 2.13 26.37

isoquinolin-1-yl(4-((3- morpholinopyridin-2- yl)oxy)piperidin-1- yl)methanone 419 11.1 26.38

(4-((3- morpholinopyridin-2- yl)oxy)piperidin-1- yl)(quinolin-2- yl)methanone 420 1.08 26.39

isoquinolin-1-yl(4-((3- morpholinopyrazin-2- yl)oxy)piperidin-1- yl)methanone 420 5.4 26.40

(4-((3- morpholinopyridin-2- yl)oxy)piperidin-1- yl)(quinolin-2- yl)methanone 419 16.1 26.41

(R)-(1H- benzo[d]imidazol-2- yl)(3-((3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yl)oxy)pyrrolidin-1- yl)methanone 3933 1.82 26.42

(S)-(1H- benzo[d]imidazol-2- yl)(3-(3-(tetrahydro- 2H-pyran-4-yl)pyridin- 2-yloxy)pyrrolidin-1- yl)methanone 393 0.409

TABLE 17B PREPARATION AND NMR DATA OF EXAMPLES 26.1-26.42 Starting Material ¹H NMR (CD₃OD, Ex. # (1) and (2) Reaction Condition 400 MHz) δ (ppm) 26.1 

TEA, DCM, DMAP, PPA 9.24-9.23 (m, 1H); 9.02-9.00 (m, 1H); 8.40-8.27 (m, 1H); 8.06-8.04 (m, 1H); 7.50-7.46 (m, 1H); 6.67-6.66 (m, 1H); 5.71-5.60 (m, 1H); 5.20-5.05 (m, 1H); 4.91-4.85 (m, 1H); 4.31-4.28 (m, 2H); 4.05-4.00 (m, 2H); 3.90-3.87 (m, 2H); 2.51-2.45 (m, 1H); 1.31-1.27 (m, 2H). 26.2 

HATU, Et₃N, THF, reflux 7.88-7.86 (m, 1H); 7.47-7.44 (m, 1H); 7.08 (s, 2H); 6.83- 6.80 (m, 1H); 5.33-5.30 (m, 1H); 4.37-3.92 (m, 4H); 3.86-3.64 (m, 2H); 3.51-3.42 (m, 2H); 3.02-2.98 (m, 1H); 2.03-1.98 (m, 2H); 1.81-1.67 (m, 6H). 26.3 

HATU, Et₃N, THF, reflux 7.96-7.94 (m, 1H); 7.56-7.54 (m, 1H); 6.92-6.89 (m, 2H); 6.58-6.57 (m, 1H); 6.18-6.16 (m, 1H); 5.40-5.37 (m, 1H); 4.04-3.99 (m, 4H); 3.78-3.76 (m, 2H); 3.58-3.51 (m, 2H); 3.07-3.01 (m, 1H); 2.10-2.05 (m, 2H); 1.88-1.75 (m, 6H). 26.4 

HATU, Et₃N, THF, reflux 8.61-8.58 (m, 1H); 8.01-7.90 (m, 2H); 7.64-7.60 (m, 1H); 7.55-7.50 (m, 2H); 6.92-6.88 (m, 1H); 5.41-5.37 (m, 1H); 4.06-3.78 (m, 4H); 3.62-3.40 (m, 4H); 3.12-3.06 (m, 1H); 2.18-1.72 (m, 8H). 26.5 

HATU, Et₃N, THF, reflux 7.86-7.85 (m, 1H); 7.75-7.71 (m, 1H); 7.46-7.44 (m, 1H); 7.295-7.26 (m, 2H); 6.83- 6.80 (m, 1H); 5.33-5.30 (m, 1H); 3.97-3.73 (m, 4H); 3.52-3.45 (m, 3H); 3.34-3.29 (m, 1H); 3.00-3.98 (m, 1H); 2.47 (s, 3H); 2.08-1.65 (m, 8H). 26.6 

HATU, Et₃N, THF, reflux 8.34-8.33 (m, 1H); 7.88-7.82 (m, 1H); 7.71-7.68 (m, 1H); 7.45-7.40 (m, 2H); 6.82-6.78 (m, 1H); 5.35-5.25 (m, 1H); 3.95-3.32 (m, 8H); 3.05-2.95 (m, 1H); 2.99 (s, 3H); 2.08- 1.44 (m, 8H). 26.7 

HATU, Et₃N, THF, reflux 8.50-8.47 (m, 1H); 7.95-7.93 (m, 1H); 7.59-7.43 (m, 3H); 6.91-6.88 (m, 1H); 5.46-5.38 (m, 1H); 4.05-3.35 (m, 8H); 3.10-3.02 (m, 1H); 2.48 (s, 3H); 2.21-1.76 (m, 8H). 26.8 

HATU, Et₃N, THF, reflux 8.42-8.41 (m, 1H); 7.94-7.92 (m, 1H); 7.85-7.83 (m, 1H); 7.54-7.42 (m, 2H); 6.91-6.88 (m, 1H); 5.39-5.37 (m, 1H); 4.04-3.84 (m, 4H); 3.58-3.67 (m, 5H); 2.35 (s, 3H); 2.18- 1.70 (m, 8H). 26.9 

HATU, Et₃N, THF, reflux 8.18-7.97 (m, 3H); 7.58-7.53 (m, 3H); 6.93-6.90 (m, 1H); 5.45-5.38 (m, 1H); 4.42-4.22 (m, 2H); 3.92-3.70 (m, 4H); 3.44-3.35 (m, 2H); 3.05-2.95 (m, 1H); 2.11-2.04 (m, 2H); 1.85-1.61 (m, 6H). 26.10

HATU, Et₃N, THF, reflux 9.29 (s, 1H); 8.16-7.71 (m, 6H); 7.54-7.48 (m, 1H); 6.90-6.87 (m, 1H); 5.42-5.38 (m, 1H); 4.10-3.45 (m, 8H); 3.11-3.05 (m, 1H); 2.21-1.70 (m, 8H). 26.11

HATU, Et₃N, THF, reflux (CDCl₃) 8.48-8.47 (m, 1H); 7.93-7.91 (m, 1H); 7.71-7.70 (m, 1H); 7.60-7.58 (m, 1H); 7.38-7.36 (m, 1H); 6.81-6.78 (m, 1H); 5.39-5.36 (m, 1H); 4.23-3.90 (m ,3H); 3.78-3.69 (m, 2H); 3.54-3.45 (m, 3H); 2.97-2.96 (m, 1H); 2.06-1.82 (m, 4H); 1.71-1.69 (m, 4H). 26.12

HATU, Et₃N, THF, reflux (CDCl₃) 8.50-8.48 (m, 1H); 8.00-7.98 (m, 1H); 7.67-7.66 (m, 1H); 7.46-7.44 (m, 1H); 7.37-7.35 (m, 1H); 6.88-6.85 (m, 1H); 5.44-5.40 (m, 1H); 4.09-3.96 (m, 3H); 3.82-3.71 (m, 2H); 3.57-3.50 (m, 3H); 3.04-3.00 (m, 1H); 2.13-1.96 (m, 4H); 1.76-1.74 (m, 4H). 26.13

HATU, Et₃N, THF, reflux (CDCl₃) 8.05-8.04 (m, 1H); 7.66 (s, 2H); 7.44-7.43 (m, 1H); 7.37-7.29 (m, 2H); 6.88-6.84 (m, 1H); 5.92- 5.77 (m, 2H); 4.83-4.32 (m, 2H); 4.21-4.02 (m, 3H); 3.90-3.75 (m, 3H); 2.38-2.26 (m, 4H). 26.14

HATU, Et₃N, THF, reflux 8.11-8.07 (m, 1H); 8.00-7.96 (m, 1H); 7.67-7.62 (m, 2H); 7.35-7.29 (m, 2H); 6.76 (s, 1H); 5.38-5.26 (m, 1H); 4.62-4.31 (m, 3H); 4.26-4.22 (m, 2H); 3.99-3.98 (m, 1H); 3.83-3.78 (m, 3H); 2.58-2.32 (m, 4H). 26.15

HATU, Et₃N, THF, reflux (CDCl₃) 8.08-8.07 (m, 1H); 7.93-7.92 (m, 1H); 7.69-7.68 (m, 2H); 7.37-7.35 (m, 2H); 5.71-5.67 (m, 1H); 4.64-4.62 (m, 1H); 4.43-4.40 (m, 1H); 4.06-3.95 (m, 4H); 3.50-3.48 (m, 2H); 3.13-3.11 (m, 1H); 2.37-2.29 (m, 2H); 1.95-1.88 (m, 2H); 1.68-1.64 (m, 2H). 26.16

HATU, Et₃N, THF, reflux (CDCl₃) 8.06-8.05 (m, 1H); 7.68 (br, 2H); 7.44-7.42 (m, 1H); 7.34-7.30 (m, 2H); 6.89-6.87 (m, 1H); 5.95-5.90 (m, 1H); 5.85-5.75 (m, 1H); 4.72-4.68 (m, 1H); 4.58-4.57 (m, 1H); 4.39-4.38 (m, 1H); 4.23-4.13 (m, 3H); 3.79-3.77 (m, 2H); 2.43-2.41 (m, 4H). 26.17

EDCI, HOBt, DIPEA, DCM (DMSO-D₆) 1.73-1.83 (m, 4H), 3.28 (peak obscured by residual water), 3.43-3.55 (m, 2H), 3.90 (d, 2H, J = 10.67 Hz), 4.16 (dd, 1H, J = 12.13 Hz, 3.22 Hz), 4.57 (dd, 1H, J = 11.55 Hz, 6.43 Hz), 4.69 (dd, 1H, J = 10.82 Hz, 3.51 Hz), 5.14 (dd, 1H, J = 12.28 Hz, 7.45 Hz), 5.46- 5.55 (m, 1H), 7.22-7.36 (m, 2H), 7.52 (d, 1H, J = 7.75 Hz), 7.72 (d, 1H, J = 7.60 Hz), 8.09 7.52 (d, 1H, J = 2.34 Hz), 8.22 7.52 (d, 1H, J = 2.48 Hz), 13.24 (s, 1H) 26.18

HATU, TEA, THF 7.95-7.90 (m, 1H); 7.71-7.22 (m, 5H); 6.92-6.88 (m, 1H); 5.43-5.41 (m, 1H); 4.28-3.80 (m, 6H); 3.60-3.51 (m, 2H); 3.10-3.01 (m, 1H); 2.20-1.70 (m, 8H). 26.19

EDCI, HOBt, DIPEA, DCM (DMSO-D₆) 1.34-1.68 (m, 2H), 1.75-1.88 (m, 1H), 1.99 (d, 3H, J = 6.72 Hz), 2.55- 2.67 (m, 1H), 3.02-3.22 (m, 2H), 3.89 (d, 1H, J = 12.86 Hz), 4.11 (d, 1H, J = 9.94 Hz), 4.47-4.70 (m, 3H), 5.11- 5.20 (m, 1H), 5.43-5.52 (m, 1H), 7.01 (dd, 1H, J = 7.02 Hz, 4.97 Hz), 7.21-7.35 (m, 2H), 7.51 (d, 1H, J = 8.48 Hz), 7.62 (d, 1H, J = 8.48 Hz), 7.72 (d, 1H, J = 8.18 Hz), 8.03 (d, 1H, J = 4.97 Hz), 13.23 (s, 1H) 26.20

EDCI, HOBt, DIPEA, DCM (DMSO-D) 4.23 (dd, 1H, J = 10.96 Hz, 3.23 Hz), 4.59 (dd, 1H, J = 11.11 Hz, 7.02 Hz), 4.77 (dd, 1H, J = 11.40 Hz, 3.36 Hz), 5.17 (dd, 1H, J = 11.55 Hz, 6.43 Hz), 5.54- 5.64 (m, 1H), 7.21-7.36 (m, 2H), 7.49-7.59 (m, 2H), 7.73 (d, 1H, J = 7.89 Hz), 8.30 (d, 1H, J = 2.48 Hz), 8.43-8.51 (m, 2H), 8.65 (d, 1H, J = 4.68 Hz), 9.25 (d, 1H, J = 1.90 Hz), 13.24 (s, 1H) 26.21

EDC HOBT DIEA DCM 8.46 (1H, s), 8.15-8.24 (1H, m), 7.97-8.06 (1H, m), 7.92 (1H, d, J = 8.0 Hz), 7.74 (1H, d, J = 7.9 Hz), 6.88- 7.01 (1H, m), 5.50-5.59 (1H, m), 5.14 (1H, dd, J = 11.3, 6.9 Hz), 4.70-5.80 (1H, m), 4.64 (1H, dd, J = 11.5, 6.9 Hz), 4.16-4.35 (3H, m), 3.75 (2H, dt, J = 14.0, 5.8 Hz), 2.80 (1H, br. s.), 2.70 (1H, br. s.), 2.40 (3H, s), 2.22 (3H, s) 26.22

EDC HOBT DIEA DCM 8.73 (1H, br. s.), 7.94-8.09 (2H, m), 7.57-7.71 (1H, m), 7.40 (1H, d, J = 7.9 Hz), 6.99 (1H, td, J = 7.1, 5.0 Hz), 5.50 (1H, br. s.), 4.74 (4H, m), 4.23 (1H, m), 3.87- 4.13 (1H, m), 2.87-3.24 (2H, m), 2.63-2.74 (1H, m), 2.58 (3H, s), 2.09-2.21 (3H, m), 1.96-2.09 (1H, m), 1.76-1.96 (2H, m), 1.47- 1.76 (1H, m) 26.23

DIEA DCM 7.94-8.06 (1H, m), 7.64 (1H, dd, J = 10.9, 7.4 Hz), 6.99 (1H, td, J = 7.6, 5.0 Hz), 5.30- 5.53 (1H, m), 4.50-4.76 (2H, m), 4.33-4.48 (1H, m), 4.16-4.33 (1H, m), 3.88-4.12 (2H, m), 2.86- 3.25 (2H, m), 2.53-2.77 (1H, m), 2.10-2.20 (3H, m), 2.07 (2H, s), 1.95-2.03 (1H, m), 1.74-1.94 (2H, m), 1.46-1.74 (1H, m), 1.04 (9H, s) 26.24

HATU DIEA DMF (CDCl₃) 10.67 (1H, br. s.), 8.15 (1H, d, J = 2.3 Hz), 7.96 (1H, d, J = 2.3 Hz), 7.82 (1H, d, J = 7.7 Hz), 7.55 (1H, d, J = 7.7 Hz), 7.28-7.44 (2H, m), 5.45-5.64 (1H, m), 5.34 (1H, dd, J = 12.0, 6.6 Hz), 4.92 (1H, t, J = 8.3 Hz), 4.74 (2H, dd, J = 11.9, 5.0 Hz), 4.34 (1H, t, J = 8.7 Hz), 3.95 (1H, d, J = 13.9 Hz), 3.08-3.40 (2H, m), 2.73 (1H, t, J = 11.7 Hz), 2.12 (3H, s), 1.85-2.04 (3H, m), 1.76 (1H, m) 26.25

HATU DIEA DMF (CDCl₃) 9.42 (1H, br. s.), 8.14 (1H, d, J = 2.5 Hz), 7.93 (1H, d, J = 2.5 Hz), 6.96 (1H, br. s.), 6.48 (1H, br. s.), 6.28 (1H, d, J = 2.6 Hz), 5.36- 5.63 (1H, m), 4.68-5.02 (2H, m), 4.64 (1H, br. s.), 4.36 (2H, br. s.), 3.96 (1H, d, J = 13.3 Hz), 3.06-3.41 (2H, m), 2.72 (1H, t, J = 12.0 Hz), 2.13 (3H, s), 1.90 (3H, d, J = 3.7 Hz), 1.68-1.81 (1H, m) 26.26

HATU DIEA DMF (DMSO-D₆) 4.16 (dd, 1H, J = 11.40, 2.92 Hz), 4.54-4.71 (m, 2H), 5.15 (dd, 1H, J = 11.40, 6.28 Hz), 5.45-5.53 (m, 1H), 7.21-7.37 (m, 2H), 7.52 (d, 1H, J = 7.75 Hz), 7.73 (d, 1H, J = 7.89 Hz), 8.26 (dd, 2H, J = 11.98, 2.48 Hz), 8.43 (s, 1H), 13.25 (s, 1H). 26.27

EDC, HOBt, DIEA (CDCl₃) 11.22 (br. s., 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.52- 7.80 (m, 4H), 7.36 (dd, J = 5.8, 2.9 Hz, 2H), 5.71- 5.84 (m, 1H), 5.46 (dd, J = 11.7, 6.4 Hz, 1H), 5.01 (dd, J = 11.8, 2.9 Hz, 1H), 4.87 (dd, J = 11.3, 6.9 Hz, 1H), 4.45 (dd, J = 11.5, 2.3 Hz, 1H), 4.15 (d, J = 10.1 Hz, 2H), 3.64 (t, J = 11.3 Hz, 2H), 3.39-3.56 (m, 1H), 2.04- 2.24 (m, 2H), 1.92 (d, J = 12.6 Hz, 2H) 26.28

Et₃N, DMAP, DCM, propyl phosphonic anhydride (CDCl₃) 8.11-7.95 (m, 1H); 7.70-7.21 (m, 5H); 6.91-6.85 (m, 1H); 6.00 (s, 1H); 5.52- 5.45 (m, 1H); 5.30-5.28 (m, 1H); 4.85-4.60 (m, 2H); 4.30-4.20 (m, 3H); 3.85-3.78 (m, 2H); 2.51-2.40 (m, 2H). 26.29

HATU, Et₃N, THF, reflux (CDCl₃) 8.57-5.56 (m, 1H); 8.11-8.09 (m, 1H); 78.00- 7.96 (m, 2H); 7.92-7.86 (m, 2H); 7.78-7.75 (m, 1H); 7.51-7.49 (m, 1H); 6.92-6.89 (m, 1H); 5.41-5.39 (m, 1H); 4.20-4.18 (m, 1H); 4.09-4.04 (m, 2H); 3.92-3.90 (m, 1H); 3.59-3.52 (m, 2H); 3.37-3.35 (m, 1H); 3.19-3.17 (m, 1H); 3.05-3.03 (m, 1H); 2.22-2.20 (m, 1H); 2.08-2.07 (m, 1H); 1.94-1.93 (m, 1H); 1.84-1.77 (m, 1H); 1.76-1.69 (m, 4H). 26.30

HATU, Et₃N, THF, reflux 8.50-8.47 (m, 1H); 8.09-8.06 (m, 1H); 8.01-7.99 (m, 1H); 7.96-7.95 (m, 1H); 7.86-7.81 (m, 1H); 7.70-7.66 (m, 2H); 7.57-7.54 (m, 1H); 6.93-6.90 (m, 1H); 5.45-5.44 (m, 1H); 4.07-4.03 (m, 3H); 3.92-3.85 (m, 1H); 3.61-3.52 (m, 4H); 3.17-3.12 (m, 1H); 2.25-1.77 (m, 8H). 26.31

HATU, Et₃N, THF, reflux (CDCl₃) 11.2 (s, 1H); 8.36 (d, J = 8.4 Hz, 1H); 8.18 (d, J = 8.4 Hz, 1H); 8.05 (d, J = 2.8 Hz, 1H); 7.91 (d, J = 2.8 Hz, 1H); 7.88 (d, J = 8 Hz, 1H); 7.80 (d, J = 7.2 Hz, 1H); 7.74 (d, J = 24.4 Hz, 1H); 7.65 (dd, J = 16.4 Hz, J = 24 Hz, 1H); 5.40 (t, J = 3.6 Hz, 1H); 4.10-4.05 (m, 3H); 3.88-3.76 (m, 1H); 3.60-3.58 (m, 1H); 3.57-3.53 (m, 3H); 3.24 (t, J = 3.6 Hz, 1H); 2.17-2.03 (m, 1H); 2.01-1.91 (m, 5H); 1.77 (t, J = 10.4 Hz, 1H). 26.32

HATU, TEA, THF (CDCl₃) 8.61 (s, 1H); 8.19- 7.90 (m, 7H); 5.41 (s, 1H); 4.14-3.98 (m, 4H); 3.63-3.55 (m, 2H); 3.40-3.20 (m, 3H); 2.25-2.24 (m, 1H); 2.11-1.86 (m, 4H); 1.81-1.73 (m, 3H). 26.33

HATU, TEA, THF (CDCl₃) 8.48-8.47 (m, 1H); 8.44-8.40 (m, 3H); 8.33-8.30 (m, 2H); 8.14-8.11 (m, 1H); 7.89-7.87 (m, 1H); 7.81-7.74 (m, 2H); 7.65-7.61 (m, 1H); 5.63-5.59 (m, 1H); 4.30-4.28 (m, 1H); 3.99-3.96 (m, 1H); 3.73-3.66 (m, 1H); 3.63-3.57 (m, 1H); 2.91 (s, 3H); 2.33- 2.32 (m, 1H); 2.23-2.21 9m, 1H); 2.10-1.98 (m, 2H). 26.34

HATU, TEA, THF (CDCl₃) 8.81-8.79 (m, 1H); 8.55-8.51 (m, 2H); 8.43-8.38 (m, 2H); 8.28-8.27 (m, 1H); 8.15-8.13 (m, 1H); 7.98-7.92 (m, 2H); 7.90-7.88 (m, 1H); 7.82-7.78 (m, 1H); 5.56-5.55 (m, 1H); 4.24-4.22 (m, 1H); 3.89-3.87 (m, 1H); 3.44-3.40 (m, 1H); 3.24-3.20 (m, 1H); 2.88 (s, 3H); 2.34-3.21 (m, 1H); 2.16-2.03 (m, 2H); 1.94-1.91 (m, 1H). 26.35

HATU, TEA, THF (CDCl₃) 8.76-8.75 (m, 1H); 8.36-8.29 (m, 2H); 8.14-8.13 (m, 1H); 7.94-7.71 (m, 5H); 6.69-6.65 (m, 1H); 7.63-7.61 (m, 1H); 7.11-7.08 (m, 1H); 5.55-5.51 (m, 1H); 4.12-4.09 (m, 1H); 3.78-3.69 (m, 2H); 3.52-3.48 (m, 1H); 2.86 (s, 3H); 2.25-2.22 (m, 1H); 2.15-2.09 (m, 1H); 1.97-1.86 (m, 2H). 26.36

HATU, TEA, THF (CDCl₃) 8.70-8.69 (m, 1H); 8.55 (br, 1H); 8.29-8.28 (m, 1H); 8.12-8.09 (m, 1H); 8.04-7.94 (m, 4H); 7.84-7.80 (m, 3H); 7.11-7.08 (m, 1H); 5.51-5.50 (m, 1H); 4.13-4.11 (m, 1H); 3.89-3.85 (m, 1H); 3.30-3.27 (m, 1H); 3.18-3.13 (m, 1H); 2.85 (s, 3H); 2.27- 2.24 (m, 1H); 2.06-1.98 (m, 2H); 1.81-1.79 (m, 1H). 26.37

HATU, TEA, THF (CDCl₃) 8.55 (d, J = 6.0 Hz, 1H); 8.10 (d, J = 8.4 Hz, 1H); 8.01-7.81 (m, 4H); 7.79-7.74 (m, 1H); 7.35-7.33 (m, 1H); 6.94-6.91 (m, 1H); 5.43-5.42 (m, 1H); 4.22-4.16 (m, 1H); 3.91-3.89 (m, 5H); 3.41-3.37 (m, 1H); 3.22-3.14 (m, 5H); 2.26-2.07 (m, 2H); 2.00-1.96 (m, 1H); 1.87-1.83 (m, 1H). 26.38

HATU, TEA, THF (CDCl₃) 8.40 (d, J = 8.4 Hz, 1H); 8.18 (d, J = 8.8 Hz, 1H); 7.90-7.79 (m, 1H); 7.71-7.69 (m, 1H); 7.67-7.63 (m, 3H); 7.53-7.52 (m, 1H); 5.44-5.40 (m, 1H); 4.08-4.04 (m, 1H); 3.82-3.69 (m, 6H); 3.59-3.48 (m, 5H); 2.22-2.18 (m, 1H); 2.12-2.09 (m, 1H); 1.98-1.97 (m, 1H); 1.93-1.91 (m, 1H). 26.39

HATU, TEA, THF (CDCl₃) 8.57-8.56 (m, 1H); 8.12-7.94 (m, 4H); 7.84-7.80 (m, 1H); 7.65-7.64 (m, 1H); 7.52-7.51 (m, 1H); 5.39-5.38 (m, 1H); 4.16-4.15 (m, 1H); 3.88-3.80 (m, 5H); 3.60-3.59 (m, 4H); 3.32-3.31 (m, 1H); 3.17-3.16 (m, 1H); 2.25-2.24 (m, 1H); 2.07-1.97 (m, 2H); 1.84-1.83 (m, 1H). 26.40

HATU, TEA, THF (CDCl₃) 8.35 (d, J = 8.4 Hz, 1H); 8.15 (d, J = 8.4 Hz, 1H); 7.88-7.80 (m, 2H); 7.78-7.60 (m, 3H); 7.31-7.29 (m, 1H); 6.92-6.89 (m, 1H); 5.46-5.45 (m, 1H); 4.13-4.11 (m, 1H); 3.90-3.89 (m, 4H); 3.79-3.77 (m, 2H); 3.52-3.51 (m, 1H); 3.21-3.20 (m, 4H); 2.21-2.20 (m, 1H); 2.11-2.10 (m, 1H); 2.03-2.02 (m, 1H); 1.96-1.95 (m, 1H).. 26.41

HATU, Et₃N, THF, (CDCl₃) 8.05-7.99 (m, 1H); 7.73-7.71 (m, 2H); 7.51-7.41 (m, 3H); 6.97-6.89 (m, 1H); 5.73-5.72 (m, 1H); 4.47-4.40 (m, 1H); 4.26-4.23 (m, 1H); 4.05-3.92 (m, 4H); 3.54-3.51 (m, 2H); 3.04-2.93 (m, 1H); 2.39-2.33 (m, 2H); 1.76-1.73 (m, 4H). 26.42

HATU, Et₃N, THF, (CDCl₃) 7.98-7.96 (m, 1H); 7.65-7.64 (m, 2H); 7.37-7.29 (m, 3H); 6.86-6.81 (m, 1H); 5.77-5.69 (m, 1H); 4.75-4.73 (m, 1H); 4.56-4.50 (m, 1H); 4.35-4.29 (m, 1H); 3.97-3.80 (m, 3H); 3.44-3.39 (m, 2H); 2.96-2.86 (m, 1H); 2.37-2.26 (m, 2H); 1.68-1.62 (m, 4H).

Example 27.1 2-(3-((3-(Tetrahydro-2H-Pyran-4-yl)Pyridin-2-yl)Oxy)Azetidin-1-yl)Quinoline

A mixture of 2-(azetidin-3-yloxy)-3-(tetrahydro-2H-pyran-4-yl)pyridine (see PREPARATION P27.1; 100 mg, 0.45 mmol), 2-chloroquinoline (73 mg, 0.45 mmol), Pd₂(dba)₃ (56 mg, 0.062 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) (40 mg, 0.06 mmol), KI (40 mg, 0.13 mmol) and sodium tert-butoxide (t-BuONa) (110 mg, 1.2 mmol) was dissolved in toluene (5 mL). The reaction mixture was heated in a microwave at 130° C. for 4 hours. The solvent was evaporated and the crude product was purified by silica gel column chromatography to give the product (6.7 mg, 0.018 mmol, yield 10%). [M+1] 363. IC50 (uM) 0.331.

TABLE 18A EXAMPLES 27.1-27.84 PREPARED ANALOGOUS TO SCHEME 27 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 27.1

2-(3-(3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yloxy)azetidin-1- yl)quinoline 362 1.8 27.2

3-(3-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)azetidin-1- yl)isoquinoline 363 4.965 27.3

1-(3-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)azetidin-1- yl)isoquinoline 363 4.413 27.4

2-(3-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)azetidin-1-yl)-1H- benzo[d]imidazole 352 1.009 27.5

2-(3-((3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yl)oxy)azetidin-1- yl)quinoline 363 0.331 27.6

2-(1-(pyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyrazine 341 2.389 27.7

2-(1-(3- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyrazine 355 1.723 27.8

2-(1-(4- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyrazine 355 1.334 27.9

2-(1-(pyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyridine 340 1.015 27.10

2-(1-(6- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyrazin-4-yl)pyrazine 355 1.441 27.11

3-methyl-2-(4-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)piperidin-1- yl)pyridine 354 0.568 27.12

2-(1-(4- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyridine 354 0.236 27.13

2-(1-(5- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyridine 354 0.262 27.14

2-(1-(6- methylpyridin-2- yl)piperidin-4-yloxy)- 3-(tetrahydro-2H- pyran-4-yl)pyridine 354 1.668 27.15

1-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)piperidin-1- yl)isoquinoline 391 2.808 27.16

3-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)piperidin-1- yl)isoquinoline 391 0.235 27.17

2-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)piperidin-1- yl)quinoline 391 0.0693 27.18

2-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyrazin-2- yloxy)piperidin-1-yl)- 1H-indole 380 0.229 27.19

1-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yloxy)piperidin-1- yl)isoquinoline 390 1.813 27.20

3-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yloxy)piperidin-1- yl)isoquinoline 390 0.353 27.21

2-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yloxy)piperidin-1- yl)quinoline 390 0.0098 27.22

2-(4-(3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yloxy)piperidin-1-yl)-1H- benzo[d]imidazole 379 0.199 27.23

(S)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)quinoline 376 0.340 27.24

(S)-3-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)isoquinoline 376 2.971 27.25

(S)-1-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)isoquinoline 376 0.730 27.26

(S)-2-(2-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)-1H- benzo[d]imidazole 418 2.472 27.27

(R)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)quinoline 376 0.384 27.28

(R)-3-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)isoquinoline 376 1.829 27.29

(R)-1-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)isoquinoline 376 0.981 27.30

(R)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yloxy)pyrrolidin-1- yl)-1H- benzo[d]imidazole 365 3.587 27.31

(S)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)quinoline 377 0.447 27.32

(S)-3-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)isoquinoline 377 1.362 27.33

(S)-1-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)isoquinoline 377 0.819 27.34

(R)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)quinoline 377 0.109 27.35

(R)-1-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)isoquinoline 377 4.43 27.36

(R)-2-(3-(3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yloxy)pyrrolidin-1- yl)-1H- benzo[d]imidazole 366 0.306 27.37

1-(4-(2-(1- (benzo[d]thiazol-2- yl)azetidin-3- yloxy)pyridin-3-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 407.0 0.3457 27.38

1-(4-(2-(1-(quinolin- 2-yl)azetidin-3- yloxy)pyridin-3-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 401.0 0.04343 27.39

1-(4-(3-(1-(1H- benzo[d]imidazol-2- yl)azetidin-3- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 393 0.6896 27.40

1-(4-(3-(1-(quinolin- 2-yl)azetidin-3- yloxy)pyrazin-2- yl)piperidin-1- yl)ethanone 404 0.00839 27.41

1-(4-(3-(1-(quinolin- 2-yl)azetidin-3- yloxy)pyrazin-2-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 402 0.004109 27.42

1-(4-(3-(1- (benzo[d]thiazol-2- yl)azetidin-3- yloxy)pyrazin-2-yl)- 5,6-dihydropyridin- 1(2H)-yl)ethanone 408 0.06307 27.43

2-((1-(5-nitropyridin- 2-yl)piperidin-4- yl)oxy)-3-(tetrahydro- 2H-pyran-4- yl)pyridine 385 1.4 27.44

6-(4-((3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yl)oxy)piperidin-1- yl)pyridin-3-amine 355 1.7 27.45

2-((1-(5- chloropyridin-2- yl)piperidin-4- yl)oxy)-3-(tetrahydro- 2H-pyran-4- yl)pyridine 374 1.41 27.46

2-((1-(5- chloropyridin-2- yl)piperidin-4- yl)oxy)-3-(tetrahydro- 2H-pyran-4- yl)pyridine 418 0.138 27.47

(6-(4-((3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yl)oxy)piperidin-1- yl)pyridin-3- yl)methanol 370 1.17 27.48

6-(4-((3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yl)oxy)piperidin-1- yl)nicotinaldehyde 368 1.48 27.49

2-((1-(5- fluoropyridin-2- yl)piperidin-4- yl)oxy)-3-(tetrahydro- 2H-pyran-4- yl)pyridine 358 2.96 27.50

2-((1-(5- chloropyridin-2- yl)piperidin-4- yl)oxy)-3-(tetrahydro- 2H-pyran-4- yl)pyridine 356 1.1 27.51

6-(4-((3-(tetrahydro- 2H-pyran-4- yl)pyridin-2- yl)oxy)piperidin-1- yl)nicotinonitrile 365 0.828 27.52

3-(tetrahydro-2H- pyran-4-yl)-2-((1-(5- (trifluoromethyl)pyridin- 2-yl)piperidin-4- yl)oxy)pyridine 408 2.20 27.53

1-(6-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)pyridin-3- yl)ethanone 382 0.384 27.54

7-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)quinoline 404 0.266 27.55

8-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)quinoline 404 >10 27.56

methyl 6-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)nicotinate 398 0.1980 27.57

7-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 405 0.5150 27.58

8-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 405 7.84 27.59

4-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 405 0.125 27.60

6-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)piperidin-1- yl)quinoline 405 0.276 27.61

(R)-2-(3-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)pyrrolidin-1- yl)quinoline 377 1.43 27.62

(S)-2-(3-((3- (tetrahydro-2H-pyran- 4-yl)pyrazin-2- yl)oxy)pyrrolidin-1- yl)-1H- benzo[d]imidazole 366 3.93 27.63

6-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)quinoline 404 0.472 27.64

4-methyl-2-(4-((3- (tetrahydro-2H-pyran- 4-yl)pyridin-2- yl)oxy)piperidin-1- yl)quinoline 404 0.101 27.65

4-(3-((3- bromopyridin-2- yl)oxy)azetidin-1- yl)pyrimidine 307 57.7 27.66

3-(3-((3- bromopyridin-2- yl)oxy)azetidin-1- yl)pyridazine 307 0.0253 27.67

1-(4-(3-((1-(pyridin- 2-yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 381 2.85 27.68

1-(4-(3-((1-(6- methylpyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 395 1.05 27.69

1-(4-(3-((1-(5- methylpyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 395 1.62 27.70

1-(4-(3-((1-(4- methylpyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 395 0.997 27.71

1-(4-(3-((1-(3- methylpyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 395 3.01 27.72

1-(4-(3-((1-(6- chloropyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 415 0.235 27.73

1-(4-(3-((1-(5- chloropyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 415 0.821 27.74

1-(4-(3-((1-(4- chloropyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 415 0.096 27.75

1-(4-(3-((1-(3- chloropyridin-2- yl)piperidin-4- yl)oxy)pyrazin-2- yl)piperidin-1- yl)ethanone 415 1.44 27.76

1-(4-(2-((1-(pyridin- 2-yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 380 1.08 27.77

1-(4-(2-((1-(5- methylpyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 394 1.18 27.78

1-(4-(2-((1-(6- methylpyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 394 1.17 27.79

1-(4-(2-((1-(4- methylpyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 394 1.77 27.80

1-(4-(2-((1-(3- methylpyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 394 1.49 27.81

1-(4-(2-((1-(6- chloropyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 414 0.558 27.82

1-(4-(2-((1-(5- chloropyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 414 1.2 27.83

1-(4-(2-((1-(4- chloropyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 414 >10 27.84

1-(4-(2-((1-(3- chloropyridin-2- yl)piperidin-4- yl)oxy)pyridin-3- yl)piperidin-1- yl)ethanone 414 3.58

TABLE 18B PREPARATION AND NMR DATA OF EXAMPLES 27.1-27.84 Starting material Reaction ¹H NMR (CD₃OD, 400 Ex. # (1) and (2) condition MHz) δ (ppm) 27.1

Pd₂(dba)₃, BINAP, KI, t- BuONa, toluene 8.41-8.39 (m, 1H); 7.95- 7.91 (m, 2H); 7.80-7.78 (m, 1H); 7.53-7.44 (m, 2H); 7.33-7.28 (m, 1H); 7.14-7.12 (m, 1H); 6.32- 6.27 (m, 1H); 5.92-5.84 (m, 1H); 4.82-4.77 (m, 1H); 4.24-4.12 (m, 3H); 4.02-3.94 (m, 2H); 3.56- 3.48 (m, 2H); 2.92-2.84 (m, 1H); 1.73-1.48 (m, 4H). 27.2

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.92 (s, 1H); 8.13- 8.12 (m, 1H); 7.94-7.93 (m, 1H); 7.28-7.26 (m, 1H); 7.55-7.48 (m, 2H); 7.27-7.21 (m, 1H); 6.51- 6.45 (m, 1H); 5.61-5.59 (m, 1H); 4.60-4.56 (m, 2H); 4.14-4.05 (m, 2H); 3.58-3.52 (m, 2H); 3.34- 3.25 (m, 1H); 1.99-1.95 (m, 2H); 1.80-1.76 (m, 2H). 27.3

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (d₆-DMSO) 8.18-8.17 (m, 1H); 8.05-8.04 (m, 1H); 7.95-7.93 (m, 2H); 7.28- 7.25 (m, 1H); 7.17-7.09 (m, 1H); 7.48-7.42 (m, 1H); 7.09-7.08 (m, 1H); 5.55-5.51 (m, 1H); 4.80- 7.76 (m, 2H); 4.36-4.33 (m, 2H); 3.91-3.89 (m, 2H); 3.44-3.43 (m, 2H); 3.33-3.32 (m, 1H); 1.76- 1.71 (m, 4H). 27.4

Pyridine, MW 8.18-8.17 (m, 1H); 8.01- 8.00 (m, 1H); 7.40-7.29 (m, 4H); 5.70-5.67 (m, 1H); 4.52-4.48 (m, 2H); 4.07-4.03 (m, 2H); 3.62- 3.56 (m, 2H); 3.40-3.30 (m, 1H); 2.00-1.94 (m, 2H); 1.83-1.78 (m, 2H); 1.48-1.20 (m, 3H). 27.5

i-PrOH, K₂CO₃, MW 8.10-8.09 (m, 1H); 7.97- 7.90 (m, 2H); 7.67-7.48 (m, 3H); 7.21-7.29 (m, 1H); 6.70-6.65 (m, 1H); 5.59-5.51 (m, 1H); 4.62- 4.58 (m, 2H); 4.19-4.15 (m, 2H); 4.00-3.97 (m, 2H); 3.56-3.53 (m, 2H); 3.43-3.41 (m, 1H); 1.92- 1.72 (m, 4H). 27.6

K₂CO₃, i-PrOH, MW, 160° C. 8.08-7.96 (m, 3H); 7.55- 7.50 (m, 1H); 6.86-6.82 (m, 1H); 6.64-6.60 (m, 1H); 5.40-5.32 (m, 1H); 4.04-3.81 (m, 4H); 3.58- 3.42 (m, 4H); 3.32-3.21 (m, 1H); 2.15-2.05 (m, 2H); 1.92-1.71 (m, 6H). 27.7

K₂CO₃, i-PrOH, MW, 160° C. 8.19-7.96 (m, 3H); 7.52- 7.50 (m, 1H); 6.94-6.91 (m, 1H); 5.36-5.29 (m, 1H); 4.08-4.01 (m, 2H); 3.62-3.54 (m, 2H); 3.36- 3.31 (m, 3H); 3.11-3.08 (m, 2H); 2.30 (s, 3H); 2.17-2.15 (m, 2H); 1.99- 1.77 (m, 6H). 27.8

K₂CO₃, i-PrOH, MW, 160° C. 8.02-7.91 (m, 3H); 6.69 (s, 1H); 6.52-6.50 (m, 1H); 5.35-5.33 (m, 1H); 4.02- 3.98 (m, 2H); 3.86-3.82 (m, 2H); 3.57-3.40 (m, 4H); 3.28-3.27 (m, 1H); 2.26 (s, 3H); 2.08-2.06 (m, 2H); 1.92-1.73 (m, 6H) 27.9

K₂CO₃, i-PrOH, MW, 160° C. 8.07-8.05 (m, 1H); 7.95- 7.94 (m, 1H); 7.53-7.51 (m, 2H); 6.90-6.84 (m, 2H); 6.64-6.61 (m, 1H); 5.33-5.32 (m, 1H); 4.02- 3.98 (m, 2H); 3.87-3.82 (m, 2H); 3.55-3.44 (m, 4H); 3.12-3.08 (m, 1H); 2.08-2.04 (m, 2H); 1.84- 1.72 (m, 6H) 27.10

K₂CO₃, i-PrOH, MW, 160° C. 8.02-7.95 (m, 2H); 7.47- 7.38 (m, 1H); 6.61-6.49 (m, 2H); 5.35-5.33 (m, 1H); 4.03-3.99 (m, 2H); 3.89-3.84 (m, 2H); 3.58- 3.51 (m, 2H); 3.46-3.40 (m, 2H); 3.28-3.27 (m, 1H); 2.33 (s, 3H); 2.11- 2.06 (m, 2H); 1.92-1.74 (m, 6H) 27.11

K₂CO₃, i-PrOH, MW, 160° C. 8.05 (m, 1H); 8.03-7.94 (m, 1H); 7.54-7.51 (m, 2H); 6.93-6.87 (m, 2H); 5.30-5.29 (m, 1H); 4.04- 4.01 (m, 2H); 3.60-3.54 (m, 2H); 3.36-3.32 (m, 2H); 3.11-3.05 (m, 3H); 2.30 (s, 3H); 2.18-2.13 (m, 2H); 1.97-1.93 (m, 2H); 1.80-1.77 (m, 4H) 27.12

K₂CO₃, i-PrOH, MW, 160° C. 7.95-7.90 (m, 2H); 7.50- 7.48 (m, 1H); 6.89-6.85 (m, 1H); 6.67 (s, 1H); 6.49-6.47 (m, 1H); 5.30- 5.29 (m, 1H); 4.00-3.96 (m, 2H); 3.85-3.79 (m, 2H); 3.53-3.29 (m, 4H), 3.12-3.03 (m, 1H); 2.24 (s, 3H); 2.07-2.02 (m, 2H); 1.81-1.70 (m, 6H) 27.13

K₂CO₃, i-PrOH, MW, 160° C. 7.98-7.96 (m, 1H); 7.92- 7.91 (m, 1H); 7.53-7.51 (m, 1H); 7.35-7.32 (m, 1H); 6.92-6.89 (m, 1H); 6.77 (d, J = 8.8 Hz, 1H); 5.30-5.26 (m, 1H); 3.91- 3.88 (m, 2H); 3.79-3.73 (m, 2H); 3.41-3.36 (m, 4H); 2.95-2.91 (m, 1H); 2.11 (s, 3H); 1.97-1.92 (m, 2H); 1.66-1.63 (m, 6H) 27.14

K₂CO₃, i-PrOH, MW, 160° C. 7.95-7.94 (m, 1H); 7.53- 7.51 (m, 1H); 7.42-7.38 (m, 1H); 6.90-6.87 (m, 1H); 6.60 (d, J = 8.8 Hz, 1H); 6.50 (d, J = 7.2 Hz, 1H); 5.31-5.29 (m, 1H); 4.02-3.98 (m, 2H); 3.87- 3.82 (m, 2H); 3.56-3.41 (m, 4H); 3.12-3.08 (m, 1H); 2.33 (s, 3H); 2.07- 2.03 (m, 2H); 1.83-1.72 (m, 6H) 27.15

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.11 (d, J = 8.4 Hz, 1H); 8.06-8.05 (m, 1H); 7.95-7.94 (m, 1H); 7.89-7.85 (m, 3H); 7.70- 7.66 (m, 1H); 7.32-7.31 (m, 1H); 5.47-5.45 (m, 1H); 4.08-4.03 (m, 4H); 3.88-3.87 (m, 2H); 3.56- 3.50 (m, 2H); 3.25-3.19 (m, 1H); 2.37-2.33 (m, 2H); 2.17-2.16 (m, 2H); 1.99-1.89 (m, 2H); 1.75- 1.72 (m, 2H) 27.16

K₂CO₃, i-PrOH, MW, 160° C. 8.91 (s, 1H); 8.05-8.04 (m, 1H); 7.99-7.98 (m, 1H); 7.83 (d, J = 8.4 Hz, 1H); 7.67-7.64 (m, 1H); 7.55- 7.51 (m, 1H); 7.31-7.27 (m, 1H); 7.01 (s, 1H); 5.39-5.38 (m, 1H); 4.03- 3.94 (m, 2H); 3.93-3.90 (m, 2H); 3.58-3.49 (m, 4H); 3.42-3.37 (m, 1H); 2.18-2.16 (m, 2H); 1.97- 1.90 (m, 4H); 1.80-1.76 (m, 2H) 27.17

K₂CO₃, i-PrOH, MW, 160° C. 8.03-7.95 (m, 3H); 7.63- 7.61 (m, 2H); 7.52-7.48 (m, 1H); 7.22-7.17 (m, 2H); 5.41-5.40 (m, 1H); 4.08-3.98 (m, 4H); 3.71- 3.65 (m, 2H); 3.57-3.51 (m, 2H); 3.28-3.27 (m, 1H); 2.14-2.13 (m, 2H); 1.93-1.87 (m, 4H); 1.79- 1.75 (m, 2H) 27.18

K₂CO₃, i-PrOH, MW, 160° C. 8.09-8.00 (m, 2H); 7.42- 7.31 (m, 4H); 5.50-5.48 (m, 1H); 4.06-4.02 (m, 2H); 3.94-3.88 (m, 2H) 3.80-3.74 (m, 2H); 3.61-3.54 (m, 2H); 3.36- 3.35 (m, 1H); 2.31-2.26 (m, 2H); 2.15-2.09 (m, 2H) 1.97-1.93 (m, 2H); 1.81-1.77 (m, 2H) 27.19

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.09-8.04 (m, 2H); 7.96-7.94 (m, 1H); 7.71-7.69 (m, 1H); 7.59- 7.55 (m, 1H); 7.49-7.45 (m, 1H); 7.38-7.36 (m, 1H); 7.20-7.18 (m, 1H); 6.81-6.78 (m, 1H); 5.38- 5.37 (m, 1H); 4.03-4.01 (m, 2H); 3.67-3.66 (m, 2H); 3.54-3.49 (m, 2H); 3.42-3.39 (m, 2H); 3.07- 3.01 (m, 1H); 2.25-2.04 (m, 4H); 1.77-1.68 (m, 4H) 27.20

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.96 (s, 1H); 8.03- 8.01 (m, 1H); 7.79-7.77 (m, 1H); 7.57-7.42 (m, 3H); 7.26-7.25 (m, 1H); 6.87-6.84 (m, 2H); 5.43- 5.41 (m, 1H); 4.08-3.92 (m, 4H); 3.62-3.50 (m, 4H); 3.13-3.06 (m, 1H); 2.17- 2.16 (m, 2H); 1.98-1.95 (m, 2H); 1.79-1.73 (m, 4H) 27.21

K₂CO₃, i-PrOH, MW, 160° C. 7.98-7.95 (m, 2H); 7.63- 7.61 (m, 2H); 7.54-7.50 (m, 2H); 7.22-7.17 (m, 2H); 6.92-6.88 (m, 1H); 5.38-5.37 (m, 1H); 4.09- 3.98 (m, 4H); 3.73-3.67 (m, 2H); 3.56-3.50 (m, 2H); 3.12-3.07 (m, 1H); 2.13-2.10 (m, 2H); 1.89- 1.85 (m, 2H); 1.78-1.75 (m, 4H) 27.22

K₂CO₃, i-PrOH, MW, 160° C. 7.97-7.95 (m, 1H); 7.55- 7.53 (m, 1H); 7.24-7.21 (m, 2H); 7.00-6.97 (m, 2H); 6.92-6.89 (m, 1H); 5.37- 5.35 (m, 1H); 4.02-3.98 (m, 2H); 3.84-3.78 (m, 2H); 3.58-3.52 (m, 4H); 2.14-2.12 (m, 3H); 1.94- 1.89 (m, 2H); 1.78-1.74 (m, 4H) 27.23

HATU, Et₃N, THF, reflux (CDCl₃) 8.03-8.02 (m, 1H); 7.86-7.83 (m, 1H); 7.73-7.71 (m, 1H); 7.57- 7.51 (m, 2H); 7.42-7.40 (m, 1H); 7.19-7.15 (m, 1H); 6.88-6.85 (m, 1H); 6.74-6.71 (m, 1H); 5.80- 5.79 (m, 1H); 4.02-3.82 (m, 6H); 3.46-3.41 (m, 2H); 2.98-2.95 (m, 1H); 2.38-2.34 (m, 2H); 1.72- 1.61 (m, 4H). 27.24

HATU, Et₃N, THF, reflux (CDCl₃) 8.90 (s, 1H); 8.05- 8.03 (m, 1H); 7.75-7.73 (m, 1H); 7.54-7.52 (m, 1H); 7.47-7.40 (m, 2H); 7.18-7.15 (m, 1H); 6.89- 6.86 (m, 1H); 6.50-6.49 (m, 1H); 5.81-5.79 (m, 1H); 3.99-3.91 (m, 3H); 3.78-3.70 (m, 3H); 3.49- 3.43 (m, 2H); 2.98-2.96 (m, 1H); 2.41-2.39 (m, 2H); 1.74-1.62 (m, 4H). 27.25

HATU, Et₃N, THF, reflux (CDCl₃) 8.21-8.19 (m, 1H); 8.03-7.98 (m, 2H); 7.70-7.59 (m, 1H); 7.58- 7.46 (m, 1H); 7.40-7.38 (m, 2H); 7.03-7.01 (m, 1H); 6.86-6.83 (m, 1H); 5.78-5.77 (m, 1H); 4.25- 4.05 (m, 2H); 4.02-3.94 (m, 4H); 3.53-3.43 (m, 2H); 3.12-2.96 (m, 1H); 2.39-2.36 (m, 2H); 1.74- 1.57 (m, 4H). 27.26

Pyridine, MW (CDCl₃) 7.99-7.98 (m, 1H); 7.42-7.39 (m, 3H); 7.27-7.25 (m, 2H); 6.92- 6.88 (m, 1H); 5.38-5.37 (m, 1H); 3.97-3.90 (m, 2H); 3.53-3.21 (m, 6H); 2.80-2.78 (m, 1H); 2.07- 2.03 (m, 1H); 1.68-1.50 (m, 5H). 27.27

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.44-8.42 (m, 1H); 8.00-7.99 (m, 1H); 7.98-7.78 (m, 3H); 7.68- 7.64 (m, 1H); 7.45-7.43 (m, 1H); 7.08-7.06 (m, 1H); 6.92-6.90 (m, 1H); 5.85-5.83 (m, 1H); 4.64- 4.60 (m, 1H); 4.39-4.30 (m, 1H); 4.28-4.27 (m, 2H); 4.02-3.96 (m, 2H); 3.54-3.46 (m, 2H); 3.00- 2.95 (m, 1H); 2.66-2.52 (m, 1H); 2.50-2.42 (m, 1H); 1.72-1.62 (m, 4H). 27.28

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 9.22 (s, 1H); 8.03- 8.02 (m, 1H); 8.02-7.85 (m, 1H); 7.67-7.58 (m, 2H); 7.45-7.43 (m, 1H); 7.34-7.30 (m, 1H); 6.93- 6.89 (m, 1H); 6.85-6.80 (m, 1H); 5.84-5.83 (m, 1H); 4.07-3.81 (m, 6H); 3.52-3.44 (m, 2H); 3.00- 2.93 (m, 1H); 2.50-2.44 (m, 2H); 1.73-1.67 (m, 4H). 27.29

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.19-8.10 (m, 2H); 8.01-7.99 (m, 1H); 7.71-7.67 (m, 2H); 7.45- 7.25 (m, 2H); 6.93-6.90 (m, 2H); 5.83-5.80 (m, 1H); 4.37-4.09 (m 2H); 4.01-3.91 (m, 4H); 3.60- 3.38 (m, 2H); 3.00-2.87 (m, 1H); 2.51-2.42 (m, 2H); 1.74-1.62 (m, 4H). 27.30

Pyridine, MW (CDCl₃) 8.00-7.99 (m, 1H); 7.43-7.21 (m, 5H); 6.92-6.89 (m, 1H); 5.44 (s, 1H); 3.98-3.92 (m, 2H); 3.59-3.32 (m, 6H); 2.83- 2.78 (m, 1H); 2.137-2.11 (m, 1H); 2.00-1.99 (m, 1H); 1.77-1.45 (m, 5H). 27.31

i-PrOH, H₂O, K₂CO₃, MW 8.41-8.38 (m, 1H); 8.14- 8.06 (m, 2H); 8.05-7.81 (m, 3H); 7.51-7.45 (m, 1H); 7.35-7.25 (m, 1H); 5.91-5.92 (m, 1H); 4.26- 3.94 (m, 7H); 3.56-3.48 (m, 2H); 2.68-2.48 (m, 2H); 1.96-1.85 (m, 2H); 1.78-1.66 (m, 2H). 27.32

i-PrOH, H₂O, K₂CO₃, MW 8.95 (s, 1H); 8.12-8.10 (m, 1H); 8.05-8.04 (m, 1H); 7.96-7.93 (m, 1H); 7.77- 7.71 (m, 1H); 7.69-7.67 (m, 1H); 7.38-7.36 (m, 1H); 7.18-7.17 (m, 1H); 5.95-5.77 (m, 1H); 4.05- 3.80 (m, 7H); 3.53-3.43 (m, 2H); 2.60-2.51 (m, 2H); 1.94-1.82 (m, 2H); 1.76-1.71 (m, 1H); 1.66- 1.65 (m, 1H). 27.33

Pd₂(dba)₃, BINAP, NaOtBu, Toluene 8.15-8.13 (m, 1H); 7.93- 7.87 (m, 2H); 7.78-7.76 (m, 1H); 7.63-7.61 (m, 1H); 7.53-7.48 (m, 1H); 7.40-7.35 (m, 1H); 6398- 6.97 (m, 1H); 5.66-5.65 (m, 1H); 4.24-4.12 (m, 2H); 3.95-3.87 (m, 1H); 3.78-3.71 (m, 3H); 3.41- 3.33 (m, 2H); 3.12-3.00 (m, 1H); 2.30-2.25 (m, 2H); 1.77-1.69 (m, 1H); 1.67-1.59 (m, 2H); 1.48- 1.41 (m, 1H). 27.34

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.25-8.15 (m, 3H); 7.96-7.95 (m, 1H); 7.75-7.70 (m, 2H); 7.48- 7.45 (m, 1H); 6.91-6.90 (m, 1H); 5.81-5.80 (m, 1H); 4.47-4.25 (m, 2H); 4.05- 4.01 (m, 4H); 3.54-3.50 (m, 2H); 3.27-3.07 (m, 1H); 2.65-2.45 (m, 2H); 1.97-1.90 (m, 2H); 1.74- 1.65 (m, 2H). 27.35

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.06-8.05 (m, 1H); 8.03-8.01 (m, 2H); 7.91-7.90 (m, 1H); 7.70- 7.68 (m, 1H); 7.56-7.55 (m, 1H); 7.43-7.42 (m, 1H); 7.05-7.03 (m, 1H); 5.73-5.72 (m, 1H); 4.33- 4.29 (m, 1H); 4.23-4.21 (m, 1H); 4.07-3.97 (m, 2H); 3.91-3.88 (m, 2H); 3.55-3.49 (m, 2H); 3.16- 3.14 (m, 1H); 2.37-2.34 (m, 2H); 1.96-1.78 (m, 3H); 1.65-1.64 (m, 1H). 27.36

i-PrOH H₂O K₂CO₃ MW 8.14-8.13 (m, 1H0; 8.05- 8.04 (m, 1H); 7.40-7.38 (m, 2H); 7.31-7.28 (m, 2H); 5.85-5.84 (m, 1H); 4.13-4.10 (m, 1H); 3.98- 3.87 (m, 6H); 3.53-3.50 (m, 2H); 3.28-3.24 (m, 1H); 2.57-2.54 (m, 2H); 1.92-1.86 (m, 2H); 1.77- 1.66 (m, 2H). 27.37

Pd₂dba₃, DavePhos 8.04 (1H, dd, J = 5.0, 1.8 Hz), 7.69 (1H, d, J = 7.9 Hz), 7.54-7.63 (1H, m), 7.51 (1H, d, J = 8.0 Hz), 7.25-7.45 (2H, m), 7.06- 7.21 (1H, m), 7.01 (2H, td, J = 4.3, 2.4 Hz), 5.58- 5.74 (1H, m), 4.98-5.22 (1H, m), 4.56-4.74 (2H, m), 4.15-4.33 (2H, m), 3.90 (1H, br. s.), 3.51- 3.80 (2H, m), 2.10-2.29 (4H, m), 1.71-2.00 (1H, m) 27.38

Pd₂dba₃, DavePhos 7.93-8.13 (2H, m), 7.69 (2H, d, J = 8.0 Hz), 7.49- 7.63 (2H, m), 7.19-7.32 (1H, m), 6.94-7.07 (2H, m), 6.77 (1H, d, J = 8.9 Hz), 5.64 (1H, br. s.), 5.01- 5.22 (1H, m), 4.60-4.72 (2H, m), 4.09-4.29 (2H, m), 3.90 (1H, br. s.), 3.49- 3.82 (2H, m), 2.08-2.29 (4H, m), 1.87 (1H, br. s.) 27.39

1,10- phenanthroline CuI Cs₂CO₃ DMF/H₂O 8.13 (1H, d, J = 2.6 Hz), 8.00 (1H, d, J = 2.8 Hz), 7.17-7.32 (2H, m), 6.95- 7.07 (2H, m), 5.50-5.74 (1H, m), 4.62 (3H, dd, J = 8.8, 6.7 Hz), 4.13-4.32 (2H, m), 4.02 (1H, d, J = 13.7 Hz), 3.34-3.55 (2H, m), 2.69-2.91 (1H, m), 2.11 (3H, s), 1.63- 2.03 (4H, m) 27.40

1,10- phenanthroline CuI Cs₂CO₃ DMF/H₂O 8.13 (1H, d, J = 2.8 Hz), 7.96-8.07 (2H, m), 7.68 (2H, d, J = 8.3 Hz), 7.55 (1H, td, J = 7.7, 1.3 Hz), 7.25 (1H, t, J = 7.5 Hz), 6.76 (1H, d, J = 8.9 Hz), 5.55- 5.70 (1H, m), 4.53-4.74 (3H, m), 4.16-4.33 (2H, m), 4.03 (1H, d, J = 13.9 Hz), 3.36-3.45 (2H, m), 2.70-2.89 (1H, m), 2.11 (3H, s), 1.65-2.04 (4H, m) 27.41

1,10- phenanthroline CuI Cs₂CO₃ DMF/H₂O 8.15-8.23 (1H, m), 7.96- 8.07 (2H, m), 7.68 (2H, d, J = 8.3 Hz), 7.55 (1H, t, J = 7.7 Hz), 7.25 (1H, t, J = 7.3 Hz), 6.96 (1H, d, J = 3.8 Hz), 6.75 (1H, d, J = 8.9 Hz), 5.65 (1H, dt, J = 6.4, 3.2 Hz), 4.59-4.75 (2H, m), 4.16-4.36 (4H, m), 3.74 (2H, dt, J = 14.9, 5.8 Hz), 2.80 (1H, br. s.), 2.70 (1H, br. s.), 2.09- 2.22 (3H, s) 27.42

1,10- phenanthroline CuI Cs₂CO₃ DMF/H₂O 8.22 (1H, t, J = 2.2 Hz), 7.99-8.06 (1H, m), 7.69 (1H, d, J = 8.0 Hz), 7.51 (1H, d, J = 8.0 Hz), 7.33 (1H, t, J = 7.7 Hz), 7.09-7.17 (1H, m), 6.97 (1H, d, J = 3.7 Hz), 5.70 (1H, td, J = 6.7, 3.0 Hz), 4.63-4.73 (2H, m), 4.31 (4H, dd, J = 10.2, 3.1 Hz), 3.77 (2H, dt, J = 19.8, 5.8 Hz), 2.81 (1H, m), 2.72 (1H, m), 2.13- 2.22 (3H, m) 27.43

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 9.04 (d, J = 2.8 Hz, 1H); 8.20 (d, J = 2.8 Hz, 1H); 8.19-8.00 (m, 1H); 7.45 (d, J = 7.2 Hz, 1H); 6.90-6.86 (m, 1H); 5.47-5.45 (m, 1H); 6.62 (dd, J = 2 Hz, J = 9.2 Hz, 1H); 4.08-4.00 (m, 4H); 3.83-3.78 (m, 2H); 3.56- 3.50 (m, 2H); 3.06-2.99 (m, 1H); 2.14-2.09 (m, 2H); 1.96-1.81 (m, 2H); 1.78-1.75 (m, 4H). 27.44

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 10.72 (s, 2H); 8.03-7.50 (m, 3H); 7.12- 7.93 (m, 3H); 5.43-5.42 (m, 1H); 4.07-4.04 (m, 2H); 3.83-3.50 (m, 6H); 3.05-3.01 (m, 1H); 2.19- 2.14 (m, 2H); 2.05-1.99 (m, 2H); 1.77-1.72 (m, 4H). 27.45

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.05-8.04 (m, 1H); 7.95-7.92 (m, 1H); 7.37-7.33 (m, 2H); 6.81- 6.77 (m, 1H); 6.57 (d, J = 9.2 Hz, 1H); 5.32 (s, 1H); 4.00 (dd, J = 2 Hz, J = 3.2 Hz, 2H); 3.80-3.75 (m, 2H); 3.49-3.43 (m, 4H); 3.05-2.94 (m, 1H); 2.04- 2.00 (m, 2H); 1.82-1.79 (m, 2H); 1.72-1.51 (m, 4H). 27.46

K₂CO₃, i-PrOH, MW, 160° C. 8.10 (d, J = 2.4 Hz, 1H); 7.97 (dd, J = 1.6 Hz, J = 4.8 Hz, 1H); 7.75 (dd, J = 2.4 Hz, J = 9.2 Hz, 1H); 7.56-7.54 (m, 1H); 6.99 (d, J = 9.2 Hz, 1H); 6.92 (dd, J = 4.8 Hz, J = 7.2 Hz, 1H); 5.39-5.37 (m, 1H); 4.04-4.03 (m, 2H); 4.01- 3.85 (m, 2H); 3.62-3.51 (m, 4H); 3.15-3.02 (m, 1H); 2.15-2.09 (m, 2H); 1.92-1.80 (m, 2H); 1.78- 1.75 (m, 4H). 27.47

K₂CO₃, i-PrOH, MW, 160° C. 8.03-7.98 (m, 2H); 7.88- 7.87 (m, 1H); 7.58-7.56 (m, 1H); 7.45 (d, J = 9.6 Hz, 1H); 6.94 (dd, J = 5.2 Hz, J = 7.6 Hz, 1H); 5.46 (m, 1H); 4.57 (s, 5H); 4.05-4.00 (m, 2H); 3.95- 3.90 (m, 2H); 3.82-3.77 (m, 2H); 3.58-3.52 (m, 2H); 3.14-3.03 (m, 1H); 2.25-2.20 (m, 2H); 2.05- 2.02 (m, 2H); 1.82-1.76 (m, 4H). 27.48

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 9.77 (s, 1H); 8.63 (s, 1H); 8.02 (dd, J = 9.2 Hz, J = 15.2 Hz, 2H); 7.47 (d, J = 7.2 Hz, 1H); 6.91- 6.85 (m, 2H); 5.45 (s, 1H); 4.06-4.00 (m, 4H); 3.99- 3.80 (m, 2H); 3.53-3.47 (m, 2H); 3.02-2.99 (m, 1H); 2.17-2.12 (m, 2H); 2.00-1.97 (m, 2H); 1.77- 1.72 (m, 4H). 27.49

K₂CO₃, i-PrOH, MW, 160° C. 8.01-7.96 (m, 2H); 7.66- 7.63 (m, 1H); 7.57-7.54 (m, 1H); 7.16-7.12 (m, 1H); 6.94-6.91 (m, 1H); 5.39-5.37 (m, 1H); 4.04- 4.00 (m, 2H); 3.88-3.83 (m, 2H); 3.62-3.51 (m, 4H); 3.13-3.04 (m, 1H); 2.15-2.12 (m, 2H); 1.94- 1.80 (m, 2H); 1.78-1.75 (m, 4H). 27.50

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.02-8.01 (m, 1H); 7.72 (s, 1H); 7.62 (d, J = 9.2 Hz, 1H); 7.51 (d, J = 7.2 Hz, 1H); 6.96-6.91 (m, 2H); 5.41 (d, J = 3.2 Hz, 1H); 4.06 (d, J = 11.2 Hz, 2H); 3.80-3.76 (m, 2H); 3.62-3.50 (m, 4H); 3.04-3.00 (m, 1H); 2.19- 2.18 (m, 2H); 2.16-2.15 (m, 2H); 1.75-1.72 (m, 4H). 27.51

K₂CO₃, i-PrOH, MW, 160° C. 8.39 (dd, J = 0.8 Hz, J = 2.4 Hz, 1H); 7.97 (dd, J = 2 Hz, J = 5.2 Hz, 1H); 7.74 (dd, J = 2.4 Hz, J = 9.2 Hz, 1H); 7.58-7.56 (m, 1H); 6.95-6.92 (m, 2H); 5.40- 5.38 (m, 1H); 4.04-3.97 (m, 4H); 3.75-3.69 (m, 2H); 3.57-3.50 (m, 2H); 3.13-3.04 (m, 1H); 2.12- 2.07 (m, 2H); 1.88-1.86 (m, 2H); 1.80-1.74 (m, 4H). 27.52

K₂CO₃, i-PrOH, MW, 160° C. 8.32 (s, 1H); 7.98 (dd, J = 1.6 Hz, J = 4.8 Hz, 1H); 7.85 (dd, J = 2.4 Hz, J = 9.6 Hz, 1H); 7.57-7.55 (m, 1H); 7.13 (d, J = 9.6 Hz, 1H); 6.93 (dd, J = 5.2 Hz, J = 7.2 Hz, 1H); 5.42-5.00 (m, 1H); 4.01-3.96 (m, 4H); 3.77-3.70 (m, 2H); 3.57-3.51 (m, 2H); 3.13- 2.98 (m, 1H); 2.17-2.12 (m, 2H); 1.94-1.89 (m, 2H); 1.80-1.75 (m, 4H). 27.53

K₂CO₃, i-PrOH, MW, 160° C. 8.74 (d, J = 2 Hz, 1H); 8.05 (dd, J = 2.8 Hz, J = 6.8 Hz, 1H); 7.97 (dd, J = 1.6 Hz, J = 4.8 Hz, 1H); 7.56-7.54 (m, 1H); 6.96- 6.86 (m, 2H); 5.41-5.39 (m, 1H); 4.07-4.00 (m, 4H); 3.76-3.70 (m, 2H); 3.58-3.51 (m, 2H); 3.16- 3.05 (m, 1H); 2.50 (s, 3H); 2.09-2.07 (m, 2H); 1.87- 1.75 (m, 6H). 27.54

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.33-8.07 (m, 1H); 7.97-7.93 (m, 2H); 7.54 (d, J = 5.6 Hz, 1H); 7.24 (d, J = 6.8 Hz, 1H); 7.13 (d, J = 9.2 Hz, 1H); 7.14-7.02 (m, 1H); 6.87- 6.85 (m, 1H); 5.47 (s, 1H); 4.04-4.04 (m, 6H); 3.51- 3.49 (m, 2H); 3.00-2.98 (m, 1H); 2.58-2.46 (m, 3H); 2.19-2.10 (m, 4H); 1.72 (s, 4H). 27.55

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.08-7.99 (m, 2H); 7.52-7.43 (m, 3H); 7.31-7.10 (m, 2H); 6.89- 6.86 (m, 1H); 5.47 (s, 1H); 4.05-3.94 (m, 6H); 3.54- 3.48 (m, 2H); 3.06-2.98 (m, 1H); 2.68 (s, 3H); 2.19-1.74 (m, 8H). 27.56

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.74 (d, J = 2.4 Hz, 1H); 7.96-7.93 (m, 2H); 7.38-7.35 (m, 1H); 6.81-6.78 (m, 1H); 6.59- 6.56 (m, 1H); 5.37-5.35 (m, 1H); 4.02-3.94 (m, 4H); 3.80 (s, 3H); 3.65- 3.59 (m, 2H); 3.49-3.43 (m, 2H); 2.97-2.95 (m, 1H); 2.06-2.00 (m, 2H); 1.85-1.79 (m, 2H); 1.72- 1.66 (m, 4H). 27.57

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.31-8.04 (m, 1H); 8.07-8.03 (m, 1H); 7.97-7.91 (m, 1H); 7.86 (d, J = 2.4 Hz, 1H); 7.55-7.51 (m, 1H); 7.22-7.20 (m, 1H); 7.09-6.97 (m, 1H); 5.41 (s, 1H); 4.02-3.99 (m, 6H); 3.48 (t, J = 10.8 Hz, 2H); 3.19-3.13 (m, 1H); 2.56-2.44 (m, 3H); 2.19- 1.95 (m, 4H); 1.93-1.68 (m, 4H). 27.58

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.08-8.04 (m, 2H); 7.92 (d, J = 2.4 Hz, 1H); 7.53-7.51 (m, 2H); 7.31-7.24 (m, 1H); 7.10 (d, J = 8.8 Hz, 1H); 5.43 (s, 1H); 4.07-4.05 (m, 4H); 3.91 (s, 2H); 3.53 (t, J = 11.6 Hz, 2H); 3.25-3.19 (m, 1H); 2.70 (s, 3H); 2.21-1.90 (m, 6H); 1.74- 1.72 (m, 2H). 27.59

K₂CO₃, i-PrOH, MW, 160° C. (CDCl₃) 8.00 (d, J = 2.8 Hz, 1H); 7.86 (d, J = 2.8 Hz, 1H); 7.71 (d, J = 8.4 Hz, 1H); 7.65 (d, J = 8 Hz, 1H); 7.47 (t, J = 7.6 Hz, 1H); 7.20-7.17 (m, 2H); 6.83 (s, 1H); 5.34-5.31 (m, 1H); 4.07-3.98 (m, 4H); 3.64-3.59 (m, 2H); 3.50- 3.44 (m, 2H); 3.19-3.14 (m, 1H); 2.54 (s, 3H); 2.10-2.05 (m, 2H); 1.97- 1.82 (m, 3H); 1.74-1.70 (m, 2H). 27.60

K₂CO₃, i-PrOH, MW, 160° C. 8.35 (d, J = 9.6 Hz, 1H); 8.09 (d, J = 2.8 Hz, 1H); 8.01 (d, J = 2.8 Hz, 1H); 7.83-7.65 (m, 3H); 7.52 (d, J = 9.6 Hz, 1H); 5.54-5.53 (m, 1H); 4.14-3.99 (m, 6H); 3.56-3.53 (m, 2H); 3.36-3.32 (m, 1H); 2.50 (s, 3H); 2.35-2.29 (m, 2H); 2.15-2.10 (m, 2H); 1.96- 1.92 (m, 2H); 1.81-1.77 (m, 2H). 27.61

Pd₂(dba)₃, BINAP, NaOtBu, Toluene (CDCl₃) 8.93 (s, 1H); 8.10- 8.09 (m, 1H); 7.96-7.95 (m, 1H); 7.77-7.74 (m, 1H); 7.56-7.53 (m, 1H); 7.49-7.45 (m, 1H); 7.20- 7.17 (m, 1H); 6.53 (s, 1H); 5.78-5.77 (m, 1H); 4.05- 3.96 (m, 3H); 3.83-3.71 (m, 3H); 3.52-3.46 (m, 2H); 3.17-3.14 (m, 1H); 2.47-2.42 (m, 2H); 1.95- 1.82 (m, 2H); 1.76-1.63 (m, 2H). 27.62

i-PrOH, H₂O, K₂CO₃, MW 8.13-8.12 (m, 1H); 8.04- 8.03 (m, 1H); 7.41-7.39 (m, 2H); 7.38-7.28 (m, 2H); 5.86-5.84 (m, 1H); 4.15-4.10 (m, 1H); 4.00- 3.88 (m, 5H); 3.56-3.50 (m, 2H); 3.27-3.21 (m, 1H); 2.60-2.50 (m, 2H); 1.93-1.87 (m, 2H); 1.77- 1.68 (m, 2H). 27.63

i-PrOH, H₂O, K₂CO₃, MW (CDCl₃) 8.10-7.99 (m, 3H); 7.56-7.54 (m, 1H); 7.47-7.45 (m, 2H); 7.10- 7.08 (m, 1H); 6.91-6.88 (m, 1H); 5.50 (s, 1H); 4.07-4.04 (m, 6H); 3.56- 3.50 (m, 2H); 3.06-2.99 (m, 1H); 2.46 (s, 3H); 2.26-2.21 (m, 4H); 1.76- 1.75 (m, 4H). 27.64

i-PrOH, H₂O, K₂CO₃, MW (CDCl₃) 8.17-8.15 (m, 1H); 7.99-7.98 (m, 1H); 7.81-7.79 (m, 1H); 7.68- 7.64 (m, 1H); 7.46-7.42 (m, 2H); 7.00 (s, 1H); 6.90-6.87 (m, 1H); 5.49 (s, 1H); 4.05-4.02 (m, 6H); 3.54-3.48 (m, 2H); 3.05- 2.97 (m, 1H); 2.69 (s, 3H); 2.21-2.10 (m, 4H); 1.75- 1.73 (m, 4H). 27.65

K₂CO₃, i-PrOH, water MW, 160° C. (CDCl₃) 8.50-8.49 (m, 1H); 8.04-8.02 (m, 1H); 7.84-7.82 (m, 1H); 7.69- 7.66 (m, 1H); 7.15-7.13 (m, 1H); 6.87-6.84 (m, 1H); 5.59-5.56 (m, 1H); 4.84- 4.80 (m, 2H); 4.46-4.42 (m, 2H). 27.66

K₂CO₃, i-PrOH, water MW, 160° C. (CDCl₃) 8.52 (s, 1H); 8.12- 8.11 (m, 1H); 7.99-7.98 (m, 1H); 7.78-7.76 (m, 1H); 6.79-6.75 (m, 1H); 6.16-6.14 (m, 1H); 5.48 (s, 1H); 4.49-4.45 (m, 2H); 4.13-4.11 (m, 2H). 27.67

Cs₂CO₃, MeCN, MW, 120° C. 8.07 (d, J = 2.8 Hz, 1H); 8.02-7.94 (m, 3H); 7.42- 7.39 (m, 1H); 6.98-6.94 (m, 1H); 5.54-5.48 (m, 1H); 4.62-4.58 (m, 1H); 4.11-.3.98 (m, 1H); 3.93- 3.90 (m, 2H); 3.80-.3.77 (m, 2H); 3.34-3.31 (m, 1H); 3.20-3.26 (m, 1H); 2.82-2.78 (m, 1H); 2.25- 2.22 (m, 2H), 2.13 (s, 3H); 2.06-2.02 (m, 2H); 1.92- 1.90 (m, 3H); 1.90-1.68 (m, 1H). 27.68

Cs₂CO₃, MeCN, MW, 120° C. 8.07 (d, J = 2.8 Hz, 1H); 8.00 (d, J = 2.8 Hz, 1H); 7.92 (dd, J = 7.2 Hz, 9.2 Hz, 1H); 7.23 (d, J = 9.2 Hz, 1H); 6.81 (d, J = 8.8 Hz, 1H), 5.54-5.48 (m, 1H); 4.62-4.58 (m, 1H); 4.11-.3.98 (m, 1H); 3.93- 3.90 (m, 2H); 3.80-.3.77 (m, 2H); 3.40-3.25 (m, 2H) 2.82-2.78 (m, 1H); 2.57 (s, 3H), 2.28-2.22 (m, 2H), 2.13 (s, 3H); 2.08-2.02 (m, 2H); 1.92-1.90 (m, 3H); 1.90-1.70 (m, 1H). 27.69

Cs₂CO₃, MeCN, MW, 120° C. 8.06 (d, J = 2.8 Hz, 1H); 8.00 (d, J = 2.8 Hz, 1H); 7.94-7.91 (m, 1H); 7.75 (s, 1H); 7.38 (d, J = 9.2 Hz, 1H), 5.54-5.48 (m, 1H); 4.62-4.58 (m, 1H); 4.11- .3.98 (m, 1H); 3.92-.390 (m, 2H); 3.80-3.72 (m, 2H); 3.40-3.31 (m, 2H) 2.82-2.78 (m, 1H); 2.30 (s, 3H), 2.29-2.21 (m, 2H), 2.11 (s, 3H); 2.06-2.02 (m, 2H), 1.92-1.89 (m, 3H); 1.89-1.71 (m, 1H). 27.70

Cs₂CO₃, MeCN, MW, 120° C. 8.07 (d, J = 2.8 Hz, 1H); 8.00 (d, J = 2.8 Hz, 1H); 7.81 (d, J = 6.4 Hz, 1H); 7.29 (s, 1H); 6.87 (dd, J = 1.2 Hz, 6.4 Hz, 1H), 5.54- 5.48 (m, 1H); 4.62-4.58 (m, 1H); 4.11-.3.98 (m, 1H); 3.93-3.90 (m, 2H); 3.80-3.77 (m, 2H); 3.34- 3.26 (m, 2H) 2.82-2.78 (m, 1H); 2.50 (s, 3H), 2.25- 2.22 (m, 2H), 2.13 (s, 3H); 2.06-2.02 (m, 2H), 1.92- 1.90 (m, 3H); 1.89-1.68 (m, 1H). 27.71

Cs₂CO₃, MeCN, MW, 120° C. 8.11-8.04 (m, 3H); 8.00 (d, J = 2.8 Hz, 1H); 7.28 (dd, J = 6.0 Hz, 7.6 Hz, 1H); 5.54-5.48 (m, 1H); 4.62- 4.58 (m, 1H); 4.10-4.01 (m, 1H); 3.73-.3.67 (m, 2H); 3.55-3.50 (m, 2H); 3.40-3.29 (m, 2H) 2.82- 2.78 (m, 1H); 2.48 (s, 3H), 2.32-2.26 (m, 2H), 2.12- 2.08 (m, 5H), 1.95-1.89 (m, 3H); 1.89-1.68 (m, 1H). 27.72

Cs₂CO₃, MeCN, MW, 120° C. 8.03 (d, J = 2.8 Hz, 1H); 7.98 (d, J = 2.8 Hz, 1H); 7.47 (dd, J = 7.2 Hz, 8.4 Hz, 1H); 6.72 (d, J = 8.4 Hz, 1H); 6.58 (d, J = 7.2 Hz, 1H), 5.40-5.37 (m, 1H); 4.62-4.58 (m, 1H); 4.04-4.00 (m, 1H); 3.93- .3.87 (m, 2H); 3.56-3.49 (m, 2H); 3.34-3.26 (m, 2H) 2.78-2.77 (m, 1H); 2.12- 2.07 (m, 5H), 1.93-1.72 (m, 6H). 27.73

Cs₂CO₃, MeCN, MW, 120° C. 8.05-8.03 (m, 2H); 7.99 (d, J = 2.8 Hz, 1H); 7.75 (dd, J = 2.4 Hz, 9.6 Hz, 1H); 7.14 (dd, J = 0.8 Hz, 9.6 Hz, 1H); 5.44-5.42 (m, 1H); 4.62-4.58 (m, 1H); 4.04-4.00 (m, 1H); 3.93- .3.87 (m, 2H); 3.67-3.61 (m, 2H); 3.34-3.26 (m, 2H) 2.78-2.77 (m, 1H); 2.02- 2.15 (m, 2H), 2.11 (s, 3H), 1.97-1.68 (m, 6H). 27.74

Cs₂CO₃, MeCN, MW, 120° C. 8.04 (d, J = 2.8 Hz, 1H); 7.98 (d, J = 2.8 Hz, 1H); 7.90 (d, J = 6.0 Hz, 1H); 6.88 (d, J = 2.4 Hz, 1H); 6.85-6.82 (m, 1H), 5.42- 5.40 (m, 1H); 4.62-4.58 (m, 1H); 4.04-4.00 (m, 1H); 3.76-.3.71 (m, 2H); 3.50-3.44 (m, 2H); 3.33- 3.22 (m, 2H) 2.78-2.77 (m, 1H); 2.16-2.11 (m, 5H), 1.93-1.68 (m, 6H). 27.75

Cs₂CO₃, MeCN, MW, 120° C. 8.24-8.22 (m, 1H); 8.04 (d, J = 2.8 Hz, 1H); 7.94 (d, J = 2.8 Hz, 1H), 7.00 (d, J = 1.6 Hz, 1H); 6.93-6.89 (m, 1H), 5.39-5.35 (m, 1H); 4.72-4.58 (m, 1H); 3.97- 3.94 (m, 1H); 3.69-.3.63 (m, 2H); 3.41-3.31 (m, 2H); 3.29-3.24 (m, 2H) 2.78-2.77 (m, 1H); 2.22- 2.15 (m, 5H), 2.05-1.73 (m, 6H). 27.76

Pd₂(dba)₃, BINAP, Cs₂CO₃, 1.4- dioxane, 120° C. 8.06-7.98 (m, 2H); 7.94- 7.91 (m, 1H); 7.57-7.55 (m, 1H); 7.46-7.43 (m, 1H); 7.00-6.92 (m, 2H), 5.54-5.48 (m, 1H); 4.68- 4.62 (m, 1H); 4.08-.4.02 (m, 1H); 3.91-.3.88 (m, 2H); 3.83-3.79 (m, 2H); 3.30-3.06 (m, 2H) 2.72- 2.68 (m, 1H); 2.30-2.20 (m, 2H), 2.11 (s, 3H), 2.10- 2.00 (m, 2H); 2.00-1.60 (m, 4H). 27.77

Pd₂(dba)₃, BINAP, Cs₂CO₃, 1.4- dioxane, 120° C. 8.00-7.98 (m, 1H); 7.92 (dd, J = 7.2 Hz, 9.2 Hz, 1H); 7.58-7.55 (m, 1H); 7.23(d, J = 9.2 Hz, 1H); 6.95-6.92 (m, 1H), 6.81- 6.80 (m, 1H), 5.54-5.48 (m, 1H); 4.68-4.62 (m, 1H); 4.08-4.02 (m, 1H); 3.95-.3.89 (m, 2H); 3.83- 3.77 (m, 2H); 3.30-3.06 (m, 2H) 2.72-2.68 (m, 1H); 2.57 (s, 3H), 2.25-2.19 (m, 2H), 2.12 (s, 3H), 2.04- 2.00 (m, 2H), 1.89-1.60 (m, 4H). 27.78

Cs₂CO₃, MeCN, MW, 120° C. 7.98 (dd, J = 4.0 Hz, 4.8 Hz, 1H); 7.84 (d, J = 1.2 Hz, 1H); 7.63 (dd, J = 4.0 Hz, 8.8 Hz, 1H); 7.54 (dd, J = 1.6 Hz, 7.6 Hz, 1H); 7.05 (d, J = 5.2 Hz, 1H), 6.93-6.89 (m, 1H), 5.40- 5.37 (m, 1H); 4.68-4.62 (m, 1H); 4.08-4.02 (m, 1H); 3.85-.3.79 (m, 2H); 3.60-3.52 (m, 2H); 3.31- 3.08 (m, 2H), 2.72-2.68 (m, 1H); 2.23 (s, 3H), 2.17-2.10 (m, 5H), 1.94- 1.88 (m, 4H), 1.72-1.61 (m, 2H). 27.79

Cs₂CO₃, MeCN, MW, 120° C. 8.00-7.98 (m, 1H); 7.80 (d, J = 6.8 Hz, 1H); 7.57-7.55 (m, 1H); 7.28 (s, 1H); 6.95-6.91 (m, 1H), 6.87- 6.84 (m, 1H), 5.47-5.45 (m, 1H); 4.66-4.62 (m, 1H); 4.08-4.02 (m, 1H); 3.92-.3.86 (m, 2H); 3.80- 3.73 (m, 2H); 3.31-3.09 (m, 2H), 2.72-2.68 (m, 1H); 2.47 (s, 3H), 2.25- 2.19 (m, 2H), 2.12 (s, 3H), 2.04-1.99 (m, 2H), 1.89- 1.85 (m, 2H), 1.80-1.55 (m, 2H). 27.80

Cs₂CO₃, MeCN, MW, 120° C. 8.07-8.05 (m, 1H); 7.97 (dd, J = 2.0 Hz, 4.8 Hz, 1H); 7.55-7.51 (m, 2H); 6.95-6.88 (m, 2H); 5.38- 5.32 (m, 1H); 4.68-4.62 (m, 1H); 4.08-4.02 (m, 1H); 3.40-.3.30 (m, 2H); 3.30-3.10 (m, 4H); 2.76- 2.70 (m, 1H); 2.32 (s, 3H), 2.22-2.12 (m, 2H), 2.11 (s, 3H), 1.99-1.94 (m, 4H), 1.80-1.60 (m, 2H). 27.81

Pd₂(dba)₃, BINAP, Cs₂CO₃, 1.4- dioxane, 120° C. 7.97 (dd, J = 1.6 Hz, 4.8 Hz, 1H); 7.55-7.52 (m, 1H); 7.49-7.44 (m, 1H); 6.92-6.89 (m, 1H); 6.71 (d, J = 8.4 Hz, 1H); 6.58 (d, J = 7.2 Hz, 1H), 5.37-5.35 (m, 1H); 4.68-4.62 (m, 1H); 4.06-4.02 (m, 1H); 3.89-.3.84 (m, 2H); 3.52- 3.52 (m, 2H); 3.30-3.05 (m, 2H); 2.72-2.68 (m, 1H), 2.11-2.04 (m, 5H), 1.93-1.81 (m, 4H), 1.70- 1.60 (m, 2H). 27.82

Cs₂CO₃, MeCN, MW, 120° C. 8.03 (d, J = 2.0 Hz, 1H); 7.98 (dd, J = 2.0 Hz, 4.2 Hz, 1H); 7.76 (dd, J = 2.8 Hz, 9.6 Hz, 1H); 7.55 (dd, J = 1.6 Hz, 7.6 Hz, 1H); 7.16 (d, J = 9.6 Hz, 1H); 6.91 (dd, J = 4.2 Hz, 7.6 Hz, 1H); 5.45-5.38 (m, 1H); 4.68-4.62 (m, 1H); 4.08- 4.02 (m, 1H); 3.89-.3.85 (m, 2H); 3.69-3.63 (m, 2H); 3.30-3.08 (m, 2H); 2.72-2.68 (m, 1H), 2.18- 2.11 (m, 6H), 1.96-1.85 (m, 4H), 1.73-1.60 (m, 1H). 27.83

Pd₂(dba)₃, BINAP, Cs₂CO₃, 1.4- dioxane, 120° C. 7.99 (dd, J = 1.6 Hz, 4.8 Hz, 1H); 7.93 (dd, J = 0.4 Hz, 6.8 Hz, 1H); 7.57-7.54 (m, 2H); 6.99 (dd, J = 2.0 Hz, 6.8 Hz, 1H); 6.93 (dd, J = 1.2 Hz, 7.6 Hz, 1H) 5.48-5.46 (m, 1H); 4.68- 4.62 (m, 1H); 4.08-4.02 (m, 1H); 3.92-3.80 (m, 2H); 3.79-3.75 (m, 2H); 3.30-3.08 (m, 2H); 2.72- 2.68 (m, 1H), 2.22-2.18 (m, 2H), 2.12 (s, 3H), 2.04- 2.01 (m, 2H), 1.98-1.90 (m, 2H), 1.80-1.60 (m, 2H). 27.84

Cs₂CO₃, MeCN, MW, 120° C. 8.16 (dd, J = 1.6 Hz, 4.8 Hz, 1H); 7.97 (dd, J = 2.0 Hz, 5.2 Hz, 1H); 7.72 (dd, J = 1.6 Hz, 8.0 Hz, 1H); 7.53 (dd, J = 1.6 Hz, 7.2 Hz, 1H); 6.96-6.88 (m, 2H), 5.35-5.33 (m, 1H); 4.68-4.62 (m, 1H); 4.05- 4.01 (m, 1H); 3.58-.3.53 (m, 2H); 3.33-3.11 (m, 4H); 2.72-2.70 (m, 1H); 2.19-2.16 (m, 2H), 2.11 (s, 3H), 1.99-1.87 (m, 4H), 1.78-1.60 (m, 2H).

Example 28.1 Benzyl 3-(3-(1-Acetyl-4-Hydroxypiperidin-4-yl)Pyrazin-2-yloxy)Azetidine-1-Carboxylate Step1: Benzyl 3-((3-(4-Chloropiperidin-4-yl)Pyrazin-2-yl)Oxy)Azetidine-1-Carboxylate Trihydrochloride Salt

To a stirred solution of tert-butyl 4-(3-(1-(benzyloxycarbonyl) azetidin-3-yloxy)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (see PREPARATION P28.3; 0.72 g, 1.543 mmol) in DCM (5 ml) was added hydrogen chloride (3.09 mL, 12.35 mmol). The reaction mixture was stirred for 3 hours, concentrated to dryness and used in the next step. The mixture also contained 1:1 ratio of benzyl 3-((3-(1,2,3,6-tetrahydropyridin-4-yl)pyrazin-2-yl)oxy)azetidine-1-carboxylate trihydrochloride salt. MS (m+2): 404.

Step 2: Benzyl 3-((3-(1-Acetyl-4-Hydroxypiperidin-4-yl)Pyrazin-2-yl)Oxy)Azetidine-1-Carboxylate

A mixture of benzyl 3-((3-(4-chloropiperidin-4-yl)pyrazin-2-yl)oxy)azetidine-1-carboxylate trihydrochloride salt, 1-acetylimidazole (0.204 g, 1.851 mmol), DIEA (1.58 mL, 9.25 mmol), and 1-acetylimidazole (0.204 g, 1.851 mmol) in DCM (10 mL) was stirred at room temperature for 16 hours. H₂O was added, and layers were separated. The organic extracts were dried over Na₂SO₄, concentrated and purified by silica gel chromatography using ISCO™ (0-60% EtOAc/Hexanes) to give the title compound. MS (M+1): 427 calc.

IC₅₀ (uM): 0.083; ¹H NMR (CD₃OD, 400 MHz) δ (ppm): 7.59 (1H, br. s.), 7.17-7.50 (6H, m), 5.09 (2H, s), 4.14-4.38 (3H, m), 4.01 (1H, m), 3.61-3.84 (3H, m), 3.23-3.34 (4H, m), 2.71 (1H, br. s.), 2.62 (1H, br. s.), 2.14 (3H, s).

Example 29.1 Benzyl 4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Quinoxalin-2-yl)Piperidine-1-Carboxylate Step 1: Benzyl 4-Iodopiperidine-1-Carboxylate

Iodine (17.6 g, 69.2 mmol) was added dropwise as a solution in THF (40 mL) over 1 hour to an ice cold solution of benzyl 4-hydroxypiperidine-1-carboxylate (15.5 g, 65.9 mmol), imidazole (4.71 g, 69.2 mmol), and triphenylphosphine (18.2 g, 69.2 mmol) in THF (40 mL). This resulting red solution was stirred overnight with warming to room temperature, then cooled back to 0° C. before being quenched with 10% aqueous sodium sulfite. The resulting biphasic mixture was separated and the aqueous layer was extracted with ethyl acetate (1×). The combined extracts were dried over magnesium sulfate (MgSO₄), filtered, and concentrated in vacuo to give an oil that was purified by silica gel chromatography (10% EtOAc/hexane) to give benzyl 4-iodopiperidine-1-carboxylate as a colorless oil (9.50 g, 42% yield).

Step 2: Benzyl 4-(3-((1-(Quinolin-2-yl)Azetidin-3-yl)Oxy)Quinoxalin-2-yl)Piperidine-1-Carboxylate

A premixed mixture of TMSCl and 1,2-dibromoethane (7:5, v/v, 0.80 mL total volume added) was added dropwise over 5 minutes to a suspension of zinc (1.62 g, 24.8 mmol) in DMA (12 mL) under argon atmosphere. The mixture was stirred for 15 minutes before benzyl 4-iodopiperidine-1-carboxylate (7.13 g, 20.67 mmol) was added dropwise over 15 minutes as a solution in DMA (6 mL). This mixture was stirred for an additional 15 min before it was added slowly to a suspension of 2-chloro-3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxaline (see PREPARATION P2.8; 5.0 g, 13.8 mmol), copper(I) iodide (0.26 g, 1.38 mmol), and Pd(dppf)Cl₂ dichloromethane adduct (0.56 g, 0.69 mmol) in DMA (15 mL) under argon. This mixture was stirred at 80° C. for 2 hours, then cooled to room temperature. Ethyl acetate was added and the suspension was filtered through CELITE® to remove insoluble material. The filtrate was diluted with more ethyl acetate and then washed with water (3×), brine(1×), dried (MgSO₄), filtered, and concentrated in vacuo to give an oil. This oil was purified by silica gel chromatography (0 to 100% EtOAc/hexane gradient) to give benzyl 4-(3-(1-(quinolin-2-yl)azetidin-3-yl)oxy)quinoxalin-2-yl)piperidine-1-carboxylate as an off-white solid (6.93 g, 92% yield).

TABLE 19A EXAMPLES 29.1-29.2 PREPARED ANALOGOUS TO SCHEME 29 Ex. # Structure Chemical Name M + 1 IC₅₀ (uM) 29.1

benzyl 4-(3-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)quinoxalin-2- yl)piperidine-1- carboxylate 546.2 0.05110 29.2

tert-butyl 4-(3-((1- (quinolin-2-yl)azetidin- 3-yl)oxy)quinoxalin-2- yl)piperidine-1- carboxylate 512.2 0.115

TABLE 19B PREPARATION AND NMR DATA OF EXAMPLES 29 Reaction ¹H NMR (CD₃OD, 400 Ex. # Starting material (1) and (2) Condition MHz) δ (ppm) 29.1

 

Zn, TMSCl, 1,2- dibromoethane, DMA; Pd(dppf)Cl₂, CuI, DMA, 80° C. (DMSO-d₆) 1.66-1.81 (m, 2H) 1.94-2.03 (m, 2H) 3.05 (br. s, 2H) 3.47 (s, 1H) 4.18 (d, J = 13.11 Hz, 2H) 4.25 (dd, J = 9.88, 4.01 Hz, 2H) 4.67 (dd, J = 9.68, 6.55 Hz, 2H) 5.12 (s, 2H) 5.71-5.79 (m, 1H) 6.85 (d, J = 8.80 Hz, 1H) 7.25 (td, J = 7.34, 1.37 Hz, 1H) 7.30- 7.37 (m, 1H) 7.37- 7.42 (m, 4H) 7.52- 7.58 (m, 1H) 7.59- 7.63 (m, 1H) 7.63- 7.69 (m, 1H) 7.71- 7.78 (m, 2H) 7.85 (dd, J = 8.22, 1.17 Hz, 1H) 7.99 (dd, J = 8.22, 1.17 Hz, 1H) 8.08 (d, J = 8.80 Hz, 1H) 29.2

 

Zn, TMSCl, 1,2- dibromoethane, DMA; Pd(dppf)Cl₂, CuI, DMA, 80° C. (DMSO-d₆) 1.42 (s, 9H) 1.62-1.76 (m, 2H) 1.90-1.98 (m, 2H) 2.93 (br. s., 2H) 3.38- 3.47 (m, 1H) 4.09 (d, J = 11.54 Hz, 2H) 4.23 (dd, J = 9.98, 4.11 Hz, 2H) 4.66 (dd, J = 9.49, 6.75 Hz, 2H) 5.69- 5.78 (m, 1H) 6.84 (d, J = 8.80 Hz, 1H) 7.20- 7.28 (m, 1H) 7.50- 7.57 (m, 1H) 7.58- 7.62 (m, 1H) 7.62- 7.68 (m, 1H) 7.70- 7.77 (m, 2H) 7.84 (dd, J = 8.22, 0.98 Hz, 1H) 7.98 (dd, J = 8.22, 0.98 Hz, 1H) 8.07 (d, J = 8.80 Hz, 1H)

The following examples nos. 30.1 to 30.29 can be prepared by those skilled in the art according to the above preparations and schemes by using commercially available starting materials.

TABLE 20 EXAMPLES 30.1-30.29 Ex. # Structure Chemical Name 30.1 

2-(3-((3-(2-methylpyridin-4-yl)- 1,6-naphthyridin-2- yl)oxy)azetidin-1- yl)benzo[d]thiazole 30.2 

1-(5-((1-(7-chloroquinazolin-2- yl)azetidin-3-yl)oxy)-6-(4- (hydroxymethyl)piperidin-1- yl)pyrazin-2-yl)ethanone 30.3 

1-(3-((1-(1,6-naphthyridin-2- yl)azetidin-3-yl)oxy)-5-fluoro- 5′,6′-dihydro-[2,4′-bipyridin]- 1′(2′H)-yl)ethanone 30.4 

1-(4-(2-(3- (hydroxymethyl)azetidin-1-yl)- 4-((1-(3-methylquinolin-2- yl)azetidin-3-yl)oxy)pyrimidin- 5-yl)piperidin-1-yl)-2- methoxyethanone 30.5 

5-(5-((1-(benzo[d]oxazol-2-yl)- 3-fluoroazetidin-3-yl)oxy)-1H- pyrrolo[3,2-b]pyridin-6- yl)picolinamide 30.6 

4-(5-fluoro-2-((4-methyl-1-(3- methyl-3H-imidazo[4,5- b]pyridin-5-yl)piperidin-4- yl)oxy)pyridin-3-yl)tetrahydro- 2H-pyran-4-carbonitrile 30.7 

methyl (1-(3-((1-(8- fluoroquinolin-2-yl)-2- methylpiperidin-4- yl)oxy)pyridin-4-yl)pyrrolidin- 3-yl)carbamate 30.8 

1-(4-(3-((1-(1H- benzo[d]imidazol-2-yl)azetidin- 3-yl)oxy)-6-chloropyridazin-4- yl)tetrahydrofuran-2-yl)ethanol 30.9 

N-(2-((1-(6-bromoquinolin-2- yl)azetidin-3-yl)oxy)-2′- methoxy-[3,3′-bipyridin]-5- yl)acetamide 30.10

1-(3-(4-((1-(7,8-dihydro-6H- cyclopenta[g]quinolin-2- yl)azetidin-3-yl)oxy)-2-(4- (hydroxymethyl)piperidin-1- yl)pyrimidin-5-yl)-3- hydroxypyrrolidin-1- yl)ethanone 30.11

5-(5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)-6-((1-(quinoxalin-2- yl)azetidin-3-yl)oxy)pyrazine- 2-carbonitrile 30.12

2-fluoro-1-(4-(4-((1- (isoquinolin-3-yl)azetidin-3- yl)oxy)pyridin-3-yl)piperidin-1- yl)propan-1-one 30.13

N-(1-(benzo[d]thiazol-2- yl)azetidin-3-yl)-3′-methyl- [3,4′-bipyridin]-2-amine 30.14

1-(3-((1-(7-chloroquinolin-2- yl)azetidin-3-yl)amino)pyrazin- 2-yl)piperidine-4-carbonitrile 30.15

1-(5-chloro-3-((1-(7-chloro-1,6- naphthyridin-2-yl)azetidin-3- yl)amino)-5′,6′-dihydro-[2,4′- bipyridin]-1′(2′H)-yl)-2- methoxyethanone 30.16

1-(4-(2-(4- (hydroxymethyl)phenyl)-4-((1- (quinoxalin-2-yl)azetidin-3- yl)amino)pyrimidin-5- yl)piperidin-1-yl)ethanone 30.17

N-(cyclopropylmethyl)-5-(5- ((3-fluoro-1-(imidazo[1,2- a]pyridin-2-yl)azetidin-3- yl)oxy)-1H-pyrrolo[3,2- b]pyridin-6-yl)picolinamide 30.18

4-(2-((1-(3H-imidazo[4,5- b]pyridin-5-yl)-4- methylpiperidin-4-yl)amino)-5- fluoropyridin-3-yl)tetrahydro- 2H-pyran-4-ol 30.19

3-(1-(3-((1-(8-fluoroquinazolin- 2-yl)-2-methylpiperidin-4- yl)amino)pyridin-4- yl)pyrrolidin-3- yl)oxazolidin-2-one 30.20

6-chloro-N-methyl-N-(1-(1- methyl-1H-benzo[d]imidazol-2- yl)azetidin-3-yl)-4-(pyrrolidin- 3-yl)pyridazin-3-amine 30.21

1-(2-((1-(6-bromo-1,5- naphthyridin-2-yl)azetidin-3- yl)amino)-6′-methoxy-[3,3′- bipyridin]-5-yl)ethanone 30.22

1-(3-(4-((1-(7,8-dihydro-6H- cyclopenta[g]quinolin-2- yl)azetidin-3-yl)amino)-2-(4- (hydroxymethyl)piperidin-1- yl)pyrimidin-5-yl)-3- hydroxypyrrolidin-1-yl)propan- 1-one 30.23

5-(6,7-dihydropyrazolo[1,5- a]pyrazin-5(4H)-yl)-6-((1-(3- methylquinolin-2-yl)azetidin-3- yl)amino)pyrazine-2- carbonitrile 30.24

1-(4-(4-((1-(1H- benzo[d]imidazole-2- carbonyl)azetidin-3- yl)amino)pyridin-3- yl)piperidin-1-yl)-2- fluoropropan-1-one 30.25

(1-(3-((1-(quinolin-2- yl)azetidin-3- yl)methyl)pyrazin-2- yl)piperidin-4-yl)methanol 30.26

(1-(5-fluoro-2-((1-(quinolin-2- yl)azetidin-3-yl)methyl)pyridin- 3-yl)piperidin-4-yl)methanol 30.27

1-(4-(3-((1-(quinolin-2- yl)azetidin-3- yl)methyl)quinoxalin-2- yl)piperidin-1-yl)ethanone 30.28

(1-(5-(3-methoxyphenyl)-4-((1- (quinolin-2-yl)azetidin-3- yl)methyl)pyrimidin-2- yl)piperidin-4-yl)methanol 30.29

(1-(5-(6-methylpyridin-3-yl)-4- ((1-(quinolin-2-yl)azetidin-3- yl)methyl)pyrimidin-2- yl)piperidin-4-yl)methanol

BIOLOGICAL EXAMPLES Example A MPDE10A7 Enzyme Activity and Inhibition

Enzyme Activity. An IMAP TR-FRET assay was used to analyze the enzyme activity (Molecular Devices Corp., Sunnyvale Calif.). 5 μL, of serial diluted PDE10A (BPS Bioscience, San Diego, Calif.) or tissue homogenate was incubated with equal volumes of diluted fluorescein labeled cAMP or cGMP for 60 min in 384-well polystyrene assay plates (Corning, Corning, N.Y.) at room temperature. After incubation, the reaction was stopped by adding 60 μL, of diluted binding reagents and was incubated for 3 hours to overnight at room temperature. The plates were read on an Envision (Perkin Elmer, Waltham, Mass.) for time resolved fluorescence resonance energy transfer. The data were analyzed with GraphPad Prism (La Jolla, Calif.).

Enzyme Inhibition. To check the inhibition profile, 5 μL of serial diluted compounds were incubated with 5 μL of diluted PDE10 enzyme (BPS Bioscience, San Diego, Calif.) or tissue homogenate in a 384-well polystyrene assay plate (Corning, Corning, N.Y.) for 30 min at room temperature. After incubation, 10 μL of diluted fluorescein labeled cAMP or cGMP substrate were added and incubated for 60 min at room temperature. The reaction was stopped by adding 60 μL of diluted binding reagents and plates were read on an Envision (Perkin Elmer, Waltham, Mass.) for time resolved fluorescence resonance energy transfer. The data were analyzed with GraphPad Prism (La Jolla, Calif.).

Example B Apomorphine Induced Deficits in Prepulse Inhibition of the Startle Response in Rats, an In Vivo Test for Antipsychotic Activity

The thought disorders that are characteristic of schizophrenia may result from an inability to filter, or gate, sensorimotor information. The ability to gate sensorimotor information can be tested in many animals as well as in humans. A test that is commonly used is the reversal of apomorphine-induced deficits in the prepulse inhibition of the startle response. The startle response is a reflex to a sudden intense stimulus such as a burst of noise. In this example, rats can be exposed to a sudden burst of noise, at a level of 120 db for 40 msec, e.g., the reflex activity of the rats can be measured. The reflex of the rats to the burst of noise may be attenuated by preceding the startle stimulus with a stimulus of lower intensity, at 3 db to 12 db above background (65 db), which attenuates the startle reflex by 20% to 80%.

The prepulse inhibition of the startle reflex, described above, may be attenuated by drugs that affect receptor signaling pathways in the CNS. One commonly used drug is the dopamine receptor agonist apomorphine. Administration of apomorphine reduces the inhibition of the startle reflex produced by the prepulse. Antipsychotic drugs such as haloperidol prevents apomorphine from reducing the prepulse inhibition of the startle reflex. This assay can be used to test the antipsychotic efficacy of PDE10 inhibitors, as they reduce the apomorphine-induced deficit in the prepulse inhibition of startle.

Example C Conditioned Avoidance Responding (Car) in Rats, an In Vivo Test for Antipsychotic Activity

Conditioned avoidance responding (CAR) occurs, for instance, when an animal learns that a tone and light predict the onset of a mild foot shock. The subject learns that when the tone and light are on, it must leave the chamber and enter a safe area. All known antipsychotic drugs reduce this avoidance response at doses which do not cause sedation. Examining the ability of test compounds to suppress the conditioned avoidance has been widely used for close to fifty years to screen for drugs with useful antipsychotic properties.

In this example, an animal can be placed in a two-chambered shuttle box and presented with a neutral conditioned stimulus (CS) consisting of a light and tone, followed by an aversive unconditioned stimulus (US) consisting of a mild foot shock through a floor grid in the shuttle box chamber. The animal can be free to escape the US by running from one chamber to the other, where the grid is not electrified. After several presentations of the CS-US pair, the animal typically learns to leave the chamber during the presentation of the CS and avoid the US altogether. Animals treated with clinically-relevant doses of antipsychotic drugs have a suppression of their rate of avoidances in the presence of the CS even though their escape response to the shock itself is unaffected.

Specifically, conditioned avoidance training can be conducted using a shuttle box (Med Associates, St. Albans, Vt.). The shuttle box is typically divided into 2 equal compartments that each contain a light source, a speaker that emits an 85 dB tone when activated and an electrified grid that can deliver a scrambled foot shock. Sessions can consist of 20 trials per day (intertrial interval of 25-40 sec) during which a 10 sec illumination and a concurrent 10 sec tone signals the subsequent delivery of a 0.5 mA shock applied for a maximum of 10 sec. Active avoidance, defined as the crossing into the opposite compartment during the 10 sec conditioning stimuli (light and tone) prevents the delivery of the shock. Crossing over to the other compartment after the delivery of the shock terminates shock delivery and may be recorded as an escape response. If an animal does not leave the conditioning chamber during the delivery of the shock it is recorded as an escape failure. Training can be continued daily until the avoidance of 16 or more shocks out of 20 trials (80% avoidance) on 2 consecutive days is achieved. After this criterion is reached the rats may be given one day of pharmacological testing. On test day, rats can be randomly assigned to experimental groups, weighed and injected intraperitoneally (i.p.) (1 cc tuberculin syringe, 26⅜ gauge needle) or per os (p.o.) (18 gauge feeding needle) with either control or compound solutions. Compounds can be injected at 1.0 ml/kg for i.p. and 10 mL/kg for p.o. administration. Compounds can be administered either acutely or chronically. For testing, each rat may be placed in the shuttle box, and given 20 trials with the same parameters as described above for training trials. The number of avoidances, escapes, and escape failures can be recorded.

Example D PCP-Induced Hyperactivity (PCP-LMA)

Equipment Used: 4×8 home cage photobeam activity system (PAS) frame from San Diego Instruments. Open PAS program and prepare an experimental session using the following variables:

Multiphase Experiment

300 sec/interval (5 min)

12 intervals (1 h)

Individual on screen switches.

Start recording after first beam break.

End session after end of interval.

Cage Preparation:

Techniplast™ rat cage with filter top, but no wire lid. Place ˜400 mL bedding and one food pellet in cage and place 250 mL techniplast water bottle in holder on filter top. Place the prepped cage in the PAS frame. Make sure bedding or pellet doesn't block the photobeams.

Animal Preparation:

Mark rats and record their weights. Bring rats to testing room.

Phase I: Habituation

Start the experiment session. Place the rat in the enclosure. The computer should start recording when it detects the rat breaking the beam. The computer will record for 1 h. During the habituation phase, prepare risperidone (positive control): Measure out risperidone, calculate final volume at 1 mg/mL concentration and add 1% glacial acetic acid of the final volume to dissolve risperidone. When risperidone is dissolved, add saline to final volume to make a concentration of 1 mg/mL. Fill syringes (3 mL syringes with 23 g½ needle or oral gavage needle) with Amgen compound solution (5 mL/kg) or risperidone (1 mL syringe with 23 g½ needle) control (1 mL/kg) s.c.

Phase II: Compound Pre-Treatment

Make sure Phase I has ended. Remove rat from enclosure, start the next phase using on-screen individual switch, administer compound p.o or i.p. and control s.c. and place rat back in the enclosure. The computer should start recording when it detects the rat breaking the beam. The computer will record for 1 h.

During phase II, prepare pcp: Dissolve pcp in saline to a concentration of 5 mg/mL.

Fill syringes (1 mL syringes with 26 g⅜ needle) with pcp solution (1 mL/kg).

Phase III: Pcp Administration.

Make sure phase II is ended. Remove rat from enclosure, start the next phase using on-screen individual switch, administer pcp s.c. and place rat back in the enclosure. The computer will record for 1 h.

Clean-Up:

End-session to terminate experiment and so that computer will compile data. Export raw data to excel file for data analysis. Euthanize rats and take necessary tissue/sample for PK.

Data Generation:

Export raw data to excel file for data analysis. Total time of movement is recorded as the number of photobeam breaks by the computer. Total time of movement (seconds) is combined into 5 minute bins and averaged for each treatment group for an N of 7-10 animals. Data are analyzed for statistical significance using a two-way ANOVA followed by a Bonferroni's post-hoc test for multiple comparisons.

The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

The compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles, for the treatment of PDE10-related diseases, such as acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

Treatment of diseases and disorders herein is intended to also include the prophylactic administration of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of preventative treatment, such as, for example, pain, inflammation and the like.

The dosage regimen for treating PDE10-receptor-mediated diseases, cancer, and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known are using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

Likewise, the compounds of this invention may exist as isomers, that is compounds of the same molecular formula but in which the atoms, relative to one another, are arranged differently. In particular, the alkylene substituents of the compounds of this invention, are normally and preferably arranged and inserted into the molecules as indicated in the definitions for each of these groups, being read from left to right. However, in certain cases, one skilled in the art will appreciate that it is possible to prepare compounds of this invention in which these substituents are reversed in orientation relative to the other atoms in the molecule. That is, the substituent to be inserted may be the same as that noted above except that it is inserted into the molecule in the reverse orientation. One skilled in the art will appreciate that these isomeric forms of the compounds of this invention are to be construed as encompassed within the scope of the present invention.

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids that may be employed to from pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

Also encompassed in the scope of the present invention are pharmaceutically acceptable esters of a carboxylic acid or hydroxyl containing group, including a metabolically labile ester or a prodrug form of a compound of this invention. A metabolically labile ester is one which may produce, for example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound. A prodrug form is one which is not in an active form of the molecule as administered but which becomes therapeutically active after some in vivo activity or biotransformation, such as metabolism, for example, enzymatic or hydrolytic cleavage. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use. Esters of a compound of this invention, may include, for example, the methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety. Metabolically labile esters, may include, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl, α-methoxyethyl, groups such as α-((C₁-C₄)alkyloxy)ethyl, for example, methoxyethyl, ethoxyethyl, propoxyethyl, iso-propoxyethyl, etc.; 2-oxo-1,3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo-1,3,dioxolen-4-ylmethyl, etc.; C₁-C₃ alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylthiomethyl, etc.; acyloxymethyl groups, for example, pivaloyloxymethyl, α-acetoxymethyl, etc.; ethoxycarbonyl-1-methyl; or α-acyloxy-α-substituted methyl groups, for example α-acetoxyethyl.

Further, the compounds of the invention may exist as crystalline solids which can be crystallized from common solvents such as ethanol, N,N-dimethyl-formamide, water, or the like. Thus, crystalline forms of the compounds of the invention may exist as polymorphs, solvates and/or hydrates of the parent compounds or their pharmaceutically acceptable salts. All of such forms likewise are to be construed as falling within the scope of the invention.

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. 

What is claimed is:
 1. A compound of formula I:

X¹ is N; X² is CR⁶; X³ is CR³; X⁴ is N; X⁵ is CR⁶; 2 of X¹, X², X³, X⁴ and X⁵ are N; the ring containing X¹, X², X³, X⁴, and X⁵ can be fused to ring A, ring B, or ring C; each having the formula:

wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms; and is substituted by 0, 1, or 2 R¹⁰ groups; which are oxo, C₁₋₆alkyl, C₁₋₃haloalkyl, —OH, —OC₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, —OC(═O)C₁₋₄alkyl, or —N(C₁₋₄alkyl,)C₁₋₄alkyl; W is —O—; —NH—; —NC₁₋₆alkyl; —CH₂—; —CH(CH₃)—; or C(CH₃)₂—; m is 0, 1, 2, 3, or 4; each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6; the ring containing p and q contains 0 or 1 double bond; R¹ is —OR^(c), —N(R^(a))C(═O)R^(b), —C(═O)R^(a), —C(═O)R^(c), —C(═O)—O—R^(a), —NR^(a)R^(c), —N(R^(c))C(═O)R^(b), —N(R^(a))C(═O)R^(c), —C(═O)NR^(a)R^(b), —C(═O)NR^(a)R^(c), or C₀₋₄alkyl-L¹; wherein said C₁₋₈alkyl group is substituted by 0, 1, 2 or 3 groups which are halo, C₁₋₃haloalkyl, —OH, —OC₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, —OC(═O)C₁₋₄alkyl, or —N(C₁₋₄-alk)C₁₋₄alkyl; R² is quinolinyl independently substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alkyl, C₁₋₄-haloalkyl, —OR^(a), —OC₁₋₄haloalkyl, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₁₋₆alkylNR^(a)R^(a), —OC₁₋₆alkylOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₁₋₆alkylOR^(a), —C₁₋₆alkylNR^(a)R^(a), —C₁₋₆alkylOR^(a), —C₁₋₆alkylN(R^(a))C(═O)R^(b), —C₁₋₆alkylOC(═O)R^(b), —C₁₋₆alkylC(═O)NR^(a)R^(a), —C₁₋₆alkylC(═O)OR^(a), or oxo; each of R³ and R⁶ is independently R¹, H, halo, CN, OH, OC₁₋₄alkyl, C₁₋₄-alkyl, or C₁₋₄haloalkyl; wherein 1 or 2 of R³ and R⁶ must be R¹; R^(4a) is H, C₁₋₄-alkyl, or C₁₋₄haloalkyl; each R^(4b) is independently F, Cl, Br, CN, OH, OC₁₋₄alkyl, C₁₋₄alkyl, or C₁₋₄haloalkyl; R⁵ is H, C₁₋₈alkyl, or C₀₋₈alkyl-L³; R^(a) is independently H or R^(b); R^(b) is independently phenyl, benzyl, or C₁₋₆alkyl, wherein said phenyl, benzyl, and C₁₋₆alkyl are being substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OH, —OC₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl, —OC(═O)C₁₋₄alkyl, or —N(C₁₋₄-alkyl)C₁₋₄alkyl; R^(c) is C₀₋₄alkyl-L⁴; and each of L¹, L³, and L⁴ is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring; each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; each L¹, L³, and L⁴ is independently substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alkyl, C₁₋₄haloalkyl, —OR^(a), —OC₁₋₄haloalkyl, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₁₋₆alkylNR^(a)R^(a), —OC₁₋₆alkylOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₁₋₆alkylOR^(a), —C₁₋₆alkylNR^(a)R^(a), —C₁₋₆alkylOR^(a), —C₁₋₆alkylN(R^(a))C(═O)R^(b), —C₁₋₆alkylOC(═O)R^(b), —C₁₋₆alkylC(═O)NR^(a)R^(a), —C₁₋₆alkylC(═O)OR^(a), or oxo.
 2. The compound as in claim 1, or a pharmaceutically acceptable salt thereof, wherein W is —O—.
 3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is a saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alkyl, C₁₋₄haloalkyl, —OR^(a), —OC₁₋₄haloalkyl, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), or —C₁₋₆alkylOR^(a).
 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is a saturated, partially-saturated or unsaturated 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 R⁷ groups which are independently F, Cl, Br, C₁₋₆alkyl, C₁₋₄haloalkyl, —OR^(a), —OC₁₋₄haloalkyl, CN, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —NR^(a)R^(a), —NR^(a)R^(c), or —C₁₋₆alkylOR^(a).
 5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is azepanyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, morpholinyl, piperidinyl, piperazinyl, dihydropyranyl dihydropyridyl, tetrahydropyranyl, benzothiazolinyl, quinolinyl, or quinazolinyl; each R¹ is independently substituted by 0, 1, or 2 R⁷ groups which are independently F, Cl, Br, methyl, methoxy, —CN, —C(═O)CH₃, —C(═O)OC(CH₃)₃, —C(═O)NH(CH₃), —C(═O)N(CH₃)₂, —NH₂, —CH₂OH, or —CH₂CH₂OH.
 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R³ is R¹ or H.
 7. The compound as in claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring containing X¹, X², X³, X⁴, and X⁵ is pyrazin, or quinoxalinyl.
 8. The compound as in claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring containing X¹, X², X³, X⁴, and X⁵ is


9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each of p and q is independently
 1. 10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein m is
 0. 11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the group

is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl.
 12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^(4a) is H or C₁₋₄alkyl; and m is
 0. 13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is

wherein each R² is substituted by 0, 1 or 2 R⁷ groups.
 14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein W is —O—; R¹ is azepanyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, morpholinyl, piperidinyl, piperazinyl, dihydropyranyl dihydropyridyl, tetrahydropyranyl, benzothiazolinyl, quinolinyl, or quinazolinyl; each R¹ is independently substituted by 0, 1, or 2 R⁷ groups which are independently F, Cl, Br, methyl, methoxy, —CN, —C(═O)CH₃, —C(═O)OC(CH₃)₃, —C(═O)NH(CH₃), —C(═O)N(CH₃)₂, —NH₂, —CH₂OH, or —CH₂CH₂OH; R² is quinolinyl, or; each of p and q is independently 1 or 2; and R³ is R¹ or H.
 15. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
 16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is: 1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yloxy)pyrazin-2yl)-5,6-dihydropyridin-1(2H)-yl)ethanone; 1-(4-(3-1-(quinolin-2-yl)azetidin-3yloxy)pyrazin-2-yl)piperidin-1-yl)ethanone; 2-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)piperidin-1-yl)quinoline; (R)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; (S)-2-(3-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)pyrrolidin-1-yl)quinoline; 2-(4-((3-(2-methoxypyridin-3yl)pyrazin-2yl)oxy)piperidin-1-yl)quinoline; 2-(4-((3-(pyridin-3-yl)pyrazin-2yl)oxy)piperidin-1-yl)quinoline; 2-(4-((3-(pyridin-4-yl)pyrazin-2yl)oxy)piperidin-1-yl)quinoline; 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-ol; 2-(4-((3-(4-methoxypiperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 1-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperazin-2-one; (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-3-yl)methanol; (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; 2-(1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-4-piperidinyl)ethanol; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-4-carbonitrile; ((2S)-1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-2-pyrrolidinyl)methanol; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; 2-(4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-1-piperazinyl)ethanol; 2-(3-((3-(4-(1-pyrrolidinyl)-1-piperidinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; N,N-dimethyl-1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-4-piperidinamine; 2-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholine; (4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholin-2-yl)methanol; 2-(3-((3-(4-(trifluoromethyl)piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 1-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-3-azetidinol; quinolin-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)methanone; (S)-1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; (R)-1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)pyrrolidin-3-ol; 2-{4-[3-(2-Methyl-pyridin-4-yl)-pyrazin-2-yloxy]-piperidin-1-yl}-quinoline; 2-(3-((3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(5-benzyl-1-benzofuran-2-yl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 6-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)-2-quinazolinamine; 2-(3-((3-(6-methoxy-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(1,3-benzothiazol-5-yl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(6-chloro-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(3-bromophenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; (3-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)phenyl)methanol; (4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)phenyl)methanol; 2-(3-((3-(5-quinolinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(5-phenyl-2-thiophenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(3-quinolinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; methyl 4-(3-((1-(2-quinolinyl)-3-azetidinyl)oxy)-2-pyrazinyl)benzoate; 2-(3-((3-(3-fluoro-5-(1-methylethoxy)phenyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(5-pyrimidinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(2-methyl-4-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(6-(cyclopropylmethoxy)-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-((3-(6-methyl-3-pyridinyl)-2-pyrazinyl)oxy)-1-azetidinyl)quinoline; 2-(3-(3-((3-methyloxetan-3-yl)ethynyl)pyrazin-2-yloxy)azetidin-1-yl)quinoline; 4-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)morpholine; 2-(4-((3-(azetidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 4-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 1-(4-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperazin-1-yl)ethanone; 2-(4-((3-(piperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 2-(4-((3-(pyrrolidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 2-(4-((3-(3-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 6-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)azetidin-3-ol; 2-(4-((3-(3-chloropyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 6-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)-2-oxa-6-azaspiro[3.3]heptane; (1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; 1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperazin-1-yl)ethanone; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-ol; 2-(3-((3-(piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)morpholine; 7-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 8-methyl-2-(4-((3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; (4-((3-morpholinopyrazin-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; (4-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)(quinolin-2-yl)methanone; 1-(6-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl)ethanone; 1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-one; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-one; 2-(3-((3-(p-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(1-(3-((1-(quinolin-2-yl)piperidin-4-yl)oxy)pyrazin-2-yl)piperidin-4-yl)propan-2-ol; 2-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)propan-2-ol; 2-(3-((3-(4-(methoxymethyl)piperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(2-methoxypyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(o-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(2-methoxyphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(4-((3-(4-(methoxymethyl)piperidin-1-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 2-(3-((3-(pyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(4-fluoro-2-methylphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-phenylpyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(3-chloropyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; 2-(3-((3-(m-tolyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; 2-(3-((3-(3-methylpyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(pyridin-2-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(2-fluoropyridin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzonitrile; N,N-dimethyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; 2-(3-((3-(4-methylpiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(5,6-dihydropyridin-1(2H)-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 7-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-2-oxa-7-azaspiro[3.5]nonane; 2-methoxy-1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-1-yl)ethanone; 2-(3-((3-(2-azabicyclo[2.2.1]heptan-2-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(3,3-difluoropyrrolidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(azetidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(azepan-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(pyrrolidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; (R)-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-2-yl)methanol; 2-(3-((3-(3,3-difluoropiperidin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 1-(3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanone; (S)-(1-(3-((1-(quinolin-2-yl)pyrrolidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; (R)-(1-(3-((1-(quinolin-2-yl)pyrrolidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; 1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanone; N,N-dimethyl-3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; 2-(3-((3-(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; methyl 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-1-carboxylate; 1-(3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanol; 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-1,4-oxazepane; (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)pyrrolidin-3-yl)methanol; 2-(3-((3-(3-(methoxymethyl)phenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; N-methyl-4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)benzamide; (S)-(1-(3-((1-(quinolin-2-yl)piperidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; (R)-(1-(3-((1-(quinolin-2-yl)piperidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; 2-(3-((3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)-1,4-diazepan-1-yl)ethanone; 1-(4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)phenyl)ethanol; (S)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline; (R)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)piperidin-1-yl)quinoline-; 2-(3-((3-chloropyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-chloropyrazin-2-yl)oxy)piperidin-1-yl)quinoline; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)azepan-4-ol; (R)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)pyrrolidin-1-yl)quinoline; (S)-2-(3-((3-(2-methylpyridin-4-yl)pyrazin-2-yl)oxy)pyrrolidin-1-yl)quinoline; 4-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)but-3-yn-2-ol; 2-(3-((3-(3-methoxyprop-1-yn-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 3-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)prop-2-yn-1-ol; (1-(6-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)methanol; (1-(3-((1-(quinolin-2-yl)azetidin-3-yl)amino)pyrazin-2-yl)piperidin-4-yl)methanol; 5-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)picolinonitrile; 1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidine-4-carboxamide; 1-(1-(3-((1-(quinolin-2-yl)azetidin-3-yl)oxy)pyrazin-2-yl)piperidin-4-yl)ethanol; 2-(3-((3-(4-methylpiperazin-1-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(6-fluoropyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(2-methylpyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; 2-(3-((3-(3-methoxyphenyl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline; or 2-(3-((3-(4-methylpyridin-3-yl)pyrazin-2-yl)oxy)azetidin-1-yl)quinoline. 